ࡱ> \ ^ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ [ R_bjbjnΐΐ\@|I& FJKKKuM NDON$$$ 4mk N(WVQbVE&Ot0l_0lĉ@b6R[vĉThQ-NJRQb Rd0 110;Sf[xvz^(W=\ϑQ\sX_c[v`Q NۏL0 120mSN{|SՋv;Sf[xvz_{1uSǏS_&OtTyf[W NwQYD(vNXTeg_U\0[`beP^_?avxvzBl1uN T܀Nvv^wQYD(v;SubkSuOePNNNXT#vcw{t0 130^:NN(W;Sf[xvz-Nl gEQRNhvSOcOS_v:gO ONNYSN0RxvzKN-N0 140S_;Su\;Sf[xvzN4N^;Suv~Te SSvQ`\O:NxvzSՋSRNN\o(W20ʋebluN

kI{0 4N^Ջ-N xvzeHh؏_{cՋTYUO~NS_v[c0 xvz&OtYXTO 230xvz_YMR xvzeHh_{cN~vsQxvz&OtYXTOۏLϑ0ċ0O0c[TybQ0YXTO_{fЏ\O _{rzNxvz03uReSvQNNUO NS_q_TKNY v^N_{ gck_D(0YXTO_{Q0R,gVbxvzyv_U\TVvl_0lĉ NS(uvVEĉThQ FO/f,g 0[ 0:NSՋ@b6R[vObag>kQ NAQJRQb Rd0 YXTO_{ gCgvcwxvzv_U\ xvz_{TvQcOvcwvOo` yr+R/fsQN%N͑ NoNNvOo`0*g~YXTOv[gTybQ NS[xvzeHhۏLO9e0xvz~_gT xvz_{TYXTOcN~bJT Sb[xvzSsT~v;`~0 yTO[ 240_{ǑSNRceObSՋvyv^[*NNOo`ۏLO[0 w` Ta 250*NNNSՋNSN;Sf[xvz_{/f?av0=\{N[Nb>y:S#NۏLFUS/fp`S_v FO/fd^ gw` TaRv*NN1u0Wh Ta N6qN/yY NbRۏeQxvzyv0 260mSN{|SՋv;Sf[xvz kMO\o(WSՋ_{_0RYvOo` Sbxvzvv0el0Dёegn0NUOSv)RvQz0xvz~~^\0gvT\o(WΘi0xvzS bv NI{NUONxvzvsQvOo`0SՋ_{JTwvQb gb~SRxvzvCg)R NS(WNUOeP6eV TaQxvz Nb YvCg)R0yr+R^la:NSՋ*NNcONN@bvwQSOOo` NScOOo`vel0 (WnxOSՋtvsQOo`T ;SubvQNTv0 gD(vN^勾l_SՋ1uhvw` Ta g}YNfNbb__0Yg Ta NNfNbb__h HN^fNbv Ta_{ۏLck_U_v^ gfN(W:W0 _{T@b g;Sf[xvzvSՋcO_xvz~gvsQOo`v bCg0 270Yg\o(WSՋN;Su gOVsQ| b gh:y TavS (Wl_vQSNxvzyvvw` Tae ;Su_{yr+R(Na0(Wُy`Q N w` Ta_{1uNMOTv0 gD(v0N[hQrzNُysQ|KNYvNegS0 280Yg\o(WSՋ NwQYw` TavR ;Su_{NvQl[NtNYl__w` Ta0ُN NwQYw` TaRvSՋQ N~eQ0R[NNl gvSvxvzKN-N d^xvzvvv/f:NNOۏSՋ@bNhNveP^ TexvzS N1uwQYw` TaRvNXTNfSN v^NxvzSSOSՋbSg\ΘiTg\b0 290S_N*N:N NwQYw` TaRv\o(WSՋYh/f&TSNxvzvQ[e ;Su(Wl__vQl[NtNv TaKNY ؏_{_SՋ,gNvُyh0SՋv_^_0R \͑0 300S_xvzmSSOb|^y N NwQYw` TaRvSՋekYeaƋv` S g(W;xw` TavSOb|^yrQck/fxvzvhNvN*N_yrpv`Q N xvzeS_U\0(Wُy`Q N ;Su_{l__l[NtNvw` Ta0Yg:\dk{|NtN v^Nxvz N^ HNxvz(Wl g_w` Tav`Q NNS_U\ MRc/fSNxvzvSՋel~Nw` TavwQSOSV](WxvzeHh-Nc v^Nxvz]_&OtYXTOybQ0sSOYdk N^=\eNSՋbvQl[NtN̑_~~SNxvzv Taa0 310;Su_{[hQ0WJTw`(W;Subt-NNxvzyv gsQvR0`b~SNxvzb-NQxvzvQ[ ~ NYx`N;SuKNvsQ|0 320[NO(uSƋvNSOPgebpencv;Sf[xvz 8^`Q N;Su_{l__[6eƖ0Rg0X[>eT/bQO(uُNPgebpencv Ta0 gN`Q N TaSNbel_ b:N_0R TaSO[xvzv gHe'` bZ0(WُN`Q N xvzS g(W_0RN*N&OtYXTOv[gTybQTeSۏL0 [paBRO(u 330Nyer^cevv0Θi0bT gHe'` _{N]fvgsOr^ceۏL[gqՋ d^(W NR`Q N (W:ON]f gHevr^cev`Q N (Wxvz-NO(u[paBRber^Yt/fSNcSvb g:_ gRv0yf[Ttvel/ecvt1uvO O(uNUOks ggsOr^NOHevr^ce0bO(u[paBR0ber^Yt[Nnx[Nyr^cev gHe'`T[hQ'`/f_v v^NcSNUOks ggsOr^NOHevr^ce0bO(u[paBR0ber^Ytv` NOV*gcS]fvgsOr^ce mSYv0%N͑b NS$O[vΘi0 yr+Rla [ُy b_{gvQ(NaNMQn(u0 ՋTĉ[ 340(W4N^Ջ_U\MR 3uRe0xvzT;NRV?e^^6R[ՋTĉ[ Ngq~@b gSRՋ v^N_(WՋ-Nnx[ gvvr^cevSՋ0dkOo`_{(Ww` TaǏ z-NTSՋlQ_0 xvzvlQ0QHrT~gS^ 350kymSN{|SՋvxvz(WbR,{N*NSՋKNMR _{(WSlQ_vpenc^ۏL{v0 360xvz0\O03uRe0TQHr[NxvzbgvQHrTS^ g&OtINR0xvz g#NlQ_NNmSN{|SՋvxvz~g v^[vQbJTv[te'`TQnx'`#0NNvbJT^u[^lSv&OtcWS0bv0 Nnx[v~g_{Tygv~gNwSh bǏvQN_OlQOwSf0Dёegn0:gg^\T)RvQz_{(WQHrir NlQ^0 Nu[,g 0[ 0SRvxvzbJT N^cSSh0 4N^[-N*g~fvr^ce 370[*NSOv`ۏLlue Ygf gHevr^ce NX[(WbvQ[]wr^ceeHe ;Su(W__N[av^_0R`bvQl[NtNvw` TaT SNO(u\*gf gHevr^ce MRc/f9hnc;Suv$Reُyr^ce g ^g=cQeu}T0͑^eP^bQ\u0T ^\ُyr^ce\O:Nxvz[a v^[ċ0OvQ[hQ'`T gHe'`ۏL0(WNUO`Q N eOo`_{U_ v^(WS_vePlQKNNO0 NSOuir;Sf[xvzVE&OtcWSCIOMS  HYPERLINK "file:///F:\\?Qz&Ot\\13%20NSOuir;Sf[xvzVE&OtcWS.doc" International Ethical Guidelines for Biomedical Research Involving Human Subjects, CIOMS2002 (VE;Sf[yf[~~YXTO2002t^8gO) ,gcWS/f1982t^Negv,{ N*NHr,g, 1ueg^2m0N2m0bN2m0'k2m0VTCIOMS yfNYv10 TN[qQ TFUwI, 1u21agc[SRSvQlʑ~b0N1982t^T1993t^v$N*NHr,gN7h,2002HrcWSe(WĉTVvNSOuir;Sf[xvz?eV{,9hncT0W`Q^(u&OthQ,NSnxzT[U&Ot[g:g6R0 ,{1ag:NSOuir;Sf[xvzv&OtTt'`Nyf['` ffffNSOuir;Sf[xvzv&OtTt'`(WN ggSs gvNN{|eP^veel0S g(Wxvzv[e-N \͑0ObTlQs^0W[_SՋ,v^N&{Txvz[e@b(W>yOvS_ĉe,vQxvzMbwQ g&Otf[ NvTt'`0dkY,\SՋf2NΘi l gSSvv^yf[vxvz/f NS_v0VdkxvzT3uR_{O@bcvmSNSOSՋvxvz,&{TlQvyf[St,v^ gEQRvvsQyf[e.s\O:NOnc0 ,{2ag:&Ot[gYXTO ffff@b gmSN{|SՋvxvzR,_{cN~N*NbN*NN Nvyf[T&Ot[gYXTO,N[gvQyf[Ny:Sbte*N>yOvgSv,b[yf[wƋv!.s 12. SՋ(WSR[bxvzT,NN&T0UOe0YUO_0Rxvzf/f[hQT gHevoTbr^el,NN/f&T:NdkN>k 13. NUOs gv0SfNvr^cebluce 14. \(uNO \leSՋy0SƋ+RSՋNU_v:g['`vĉ[ 15. xvzO[:g[RS0Rl_TvQNĉ[vP6R,NSl2:g[vSTg 16. sQN)R(uW OՋ~gT[eW OOo`v?eV{,NS(Wl gSՋ Tav`Q N,2bk\SՋvW OՋ~gb2~v|N^\bvQNN(YOilQSbǖ;N) vS_v2ce 17. xvzv3uR,xvz^\v:gg,xvzDёv'`(Tegn 18. SۏLvxvzvcbN!k)R(uSՋvuSU_T4N^ʋuǏ z-NSvuirh,g 19. xvz~_ge/f&TR\xvz-N6eƖvuirh,gk,Yg N/f,sQN[N.X[v~(0Wp,YUOX[,X[YEN,TgTvYn) T\egSv)R(u,NSSՋ gCgZPQsQN\egvO(u0b~.X[TvQkvQ[ 20. /f&TONuirh,g-N_SQFUNNT,xvzSR/f&TONdk{|NTv_S-N_bvQ[6ev 21. xvz/fN\O:Nxvz,؏/feZPxvz0SZPSՋv;Su 22. xvz:NxvzSRcO;Su gRvL#V 23. Nxvz gsQvwQSO{|Wv_c[0bv^Su\cOvMQ9lu,ُyluv'`(Tc~e,cOluv~~b*NN Ty,NSsQNُyluvDё/f&TX[(WNUO Nnx[V } 24. Vdk{|_c[_wvkub{kN,SՋbSՋv[^\bSa{QN\NUOye_,ǏNHN~~_0RTP(b,cfl gcOdk{|TPvR)  25. SSRxvzvSvSՋ[a@b(WV[[TPvCg)R/f&T gl_ NvO 26. &Ot[gYXTO]~ybQbSNxvzeHh0 ,{6ag:Sw` Ta:3uRNxvzvL# 3uRTxvz g#NZP0R: 1. MQO(u NckS_v:kKbk,eR NckS_q_T,bP`T 2. S g(Wnx[SvSՋ[aEQRN㉆NSRxvzv gsQ[`TTg,v^ gEQRv:gOQ/f&TSRNT,Mb_Bl Ta 3. cN,ĉR,^SkNMOSՋv~{ TfN\O:Nw` Tavnc---[ُagĉRvNUOOY,xvz^ gckS_t1uv^_&Ot[gYXTOvybQ 4. YgxvzvagNb z^SuN>fWvSS,b_0RNSq_TSՋ~~SRxvza?aveOo`,͑eSkMOSՋvw` Ta 5. gxvzyv,sSOxvzvbvhl gSS,_N cNHQnx[ve,͑eSkMOSՋvw` Ta0 ,{7ag:bRSՋ SՋ(WSRNyxvz-NSuv6eeQ_c1Y090SvQN_/eS_0RePNN؏_0RMQ9;Su0SՋ,$\vQ/fN NNxvz-NvcSvv,_NSV&^egv NOT9ve N~blb_0RvQ[eP06q ,bl N^Ǐ'Y,bcOv;Su gR N^ǏY,&TROSՋ N/f9hncNN]vfsO$Re TaSRxvz("Ǐ^R") 0@b gcO~SՋvbl0ePT;Su gR_{_0R&Ot[gYXTOvybQ0 ,{8ag:SRxvzvSvTΘi [N@b gNSOuir;Sf[xvz,xvz_{O\o(Wv)RvTΘi_0RNTt0Ws^a,v^Ng\SNΘi0 1. cO~SՋvwQ gvcʋe0lub2vYvr^cebluǏ zvTt'`(WN,NSvΘiTSvv҉^,NNUOS_0RvfNelvk\/f T7h g)Rv0ُy" gvv"r^cebluǏ zvΘiv[NSՋgvSv _{/fTtv0 2. [SՋl gvcʋe0lu0b2vYvr^cevΘi,v[N>yOvgSv(Sib:NwƋ) _{/fTtv0ُyr^cevΘiv[N\_vwƋv͑'` ,_{/fTtv0 ,{9ag:xvz-NmS N~Nw` TavSՋ,sQNΘivyrkP[ ggggS_X[(W&OtTyf[vTt'`,[ N~Nw` Tav*NSO[exvze,[SՋl gvcSvMRofvxvz,r^cevΘi^ Nk[NN8^ĉSOyO-Nvxvz (WN*NDn gPvNb>yO_YxvzKNMR,3uRTxvz_{=\NRRRO: 1. xvz/f[[exvz@b(W0WNb>yOveP^TOHQSRv 2. NUOr^ceb_SvNT,b_vwƋ,\Tt0W(uNO勺Nb>yOSv0 ,{11ag:4N^Ջ-N[gqv b N, ,ʋe0lub2'`r^Ջ-N[gq~vSՋ,^_0RlQ gHevr^0 gN`Q N,O(uN*NfNv[gq,Y[paBRb" Nlu",(W&Otf[ N/fScSv0[paBRS(uN: 1. S_l glQv gHevr^e 2. S_ NǑ(ulQ gHevr^,YOSՋa0Rfev N0b^ߏurve 3. S_Ǒ(uN*NlQ gHevr^\O:N[gq,\ONuyf[ N NS`v~g, O(u[paBR NOXRSՋNUO%N͑v0b NS_c[vΘi0 ,{12ag:(Wxvz-NSՋN bebT)RvvlQs^RM gggg^ǏlQs^RMxvzbT)Rvve_, bSb:NxvzSՋvN0cdSSvNSRxvzvN_{/fTtv0 ,{13ag:mS1_RNvxvz gggg1_R*NSO\O:NSՋyrkvt1u,Yg bNN,_{R[e\LObNNCg)RTeP^vce0 ,{14ag:mS?Qzvxvz (WۏLmS?QzvxvzKNMR,xvz_{nxO: 1. NbN:NSՋ[a,xvz N T7h gHe0WۏL 2. xvzvvv/f_ gsQ?QzeP^vwƋ 3. kMO?Qzv6rkbl[NtN~NNS 4. ]_kMO?Qz(WvQRVQ@b~Nv Ta(^b)  5. ?Qzb~SR0bb~~~SRxvz\_0R \͑0 ,{15ag:1uNSՋzfRbL:Nx N~NEQRw` Tavxvz 1uNSՋzfRbL:Nx N~NEQRw` Tavxvz(W_U\MR,xvz_{O: 1. (Ww` TaRl gS_cvNSO T7h gHe0WۏLxvz, NN1\ Nb:NSՋ 2. xvzvvv/f:N_ gsQzfRbL:Nxyr gveP^vwƋ 3. ]_NkMOSՋR z^v^v Ta,SvSՋ[ab~SRxvz^Y~S0R \͑,d^(Wyrk`Q N,l gTtv;SufNel,v^NS_0Wl_AQ NQb~ 4. YgSvSՋ[al gR Ta,^_#v[^bXTb&{TsLl_vl[NtNvS0 ,{16ag:YsY\O:NSՋ xvz03uRb&Ot[gYXTO N^cdgYsYSRuir;Sf[xvz0xvzg g`U[vS,vQ,g N\O:NcdbP6RSRxvzvt1u06q ,=\[U[YT΀?QvΘi,/fYsYZPQSR4N^xvzt'`Q[vHQQagN0ُNSb,Yg`U[,SRxvzSqS[0R΀?QbyY,gN,3uRPxvz^NY ZՋnxSvSՋ[a*gSU[,v^(Wxvz_YKNMRǑS gHevU[el0Yg1uNl_vb[YevSV, Nُ7hZP,xvz N^bRS`U[vYsYۏLS gُ{|Θivxvz0 ,{17ag:U[Y\O:NSՋ ^GP[U[Y gDe__TPvCgR0 ,{20ag:R:_&OtTyf[[gRNSuir;Sf[xvzvR YV[l gRċ[bnxO(WvQ{VQ@bcvbۏLvuir;Sf[xvzvyf['`b&OtvScS'`01uVY:ggSwvT\Oxvz,3uRTxvz(W&Ot N gINRO,(WُNV[-N1uNN#vuir;Sf[xvzyv\[Vb0Wevuir;Sf[xvzvT[eRw0R gHevOۏ\O(u,v^:Nُ{|xvzcOyf[T&Ot[gTvg0RW{QSb,FO NPNN N]\O: 1. ^zTR:_rzv0 gRv&Otf[[gǏ zPYXTO 2. R:_xvzR 3. SU\(uNkSuOePNSuir;Sf[xvzvb/g 4. WxvzTkSuOePNXT 5. [N-N[{ SՋvNۏLYe0 ,{21ag:VY3uRcOeP^;Su gRvS_INR VY3uR(W&Ot N gINRnxOS_: 1. [hQ0WۏLxvz@b_{vkSuOeP gR 2. lu1uNxvzr^ce S0R_c[vSՋ 3. 3uRb-NvN*N_{R,O\O:Nxvzbgv gvr^cebNTTt0W(uN gsQNb>yO@b\Ov gR0 uir;Sf[xvz[g&OtYXTOd\OcWS2000t^ WHO NLukSu~~Operational Guidelines for Ethics Committees That Review Biomedical Research, 2000, World Health Organization MR [NSOۏLuir;Sf[xvzՋv&OtTyf[hQ](WNNVE'`vcWS-N6R[Tnxz Sb 0k\W[ 00VE;Sf[yf[~~YXTOCIOMS v 0NSOuir;Sf[xvzVE&OtcWS 0SNLukSu~~WHO TN(uoirlQb/gBlVEOSOICH [oT4N^Ջ{tĉvcWS0u_ُNcWS gRNOSՋv \%N0CgR0[hQTy)R NSxvz~gvSO'`_0RO0 @b gvVEcWSdBl gw` Ta NS[ N TaNNS_ObY ؏Bl[uir;Sf[xvzۏL&OtTyf[v[g N\O:NObSRxvzv*NNT>y:Sv_ce0NُNcWSvvveg w uir;Sf[xvzSb[oT0;SuNhV0;Sf[>e\Tq_P0YyKb/g0uSTuirh,g NSAmLuf[0>yOT_tf[vxvz0 WHOcWSvvv(WNOۏT/ecNLuTVv&Ot[g0NNWN[VEcWS]nxzv&Ot[gBlv%NyO@b gVSOT6B\-NvlQs^RM TeQt^0'`+R0~NmrQ0eSTye0 &OtYXTO^[xvzyvv&Otf[ۏLrzv0yLvTSev[g0&OtYXTOv~b0Џ\OTQ[^ NS?el0:gg0LNT^:Wvq_T0 T7h NN^(W]v]\O-NfvQ]\ORTHes0 &OtYXTO#(Wxvz_YMR[xvzyvۏL[g0 Te؏^[]Ǐ[g0ck(WۏLvxvzyv[L[gv&OtċN0 &OtYXTO g#N9hncSvSՋT gsQ>y:SvteSO)RvLN TeQ0RxvzNXTv)RvTBl v^[ gsQvL?e:ggTsLl_vBlOc^ gv \͑0 N0&Ot[g|~v^z V[0:ggT>yOVSO^RR^z&OtYXTOT&Ot[g|~ Ng'YP^0WObSՋ v^:Nuir;Sf[xvz(Wyf[T&OtebS0Rvgؚ(ϑZPQ!.s0?e^^S_0WOۏV[0:ggT0We^zrzv0Yf[yv0Y蕄v0bXT/f|QLv&OtYXTO0&OtYXTOL?e NT"?e Nv/ec0 ^zT~&Ot[gvNT|v z^ NO[gvN'`TOۏT\O0V[0:ggT0WeYXTOKN^zT\OTNAmv:g6R NOEu0 gHe0WNAm v^OۏVQ&Ot[gvSU\T&OtYXTObXTv~~Ye0dkY [N*NV[QY0WpbY*NV[ۏLvuir;Sf[xvzeHh ؏^z[g z^0^^z:SW0V[T0WeYB\!kv&Ot[gQ~ NOS%cuir;Sf[[gvg'Y\O(u Te_NOcS>yOTebva0 V0&OtYXTOv~b &OtYXTOv~b^OvQ gR[3uxvzyvv@b g&OtۏL[gTċN v^O(Wl gOPPTq_TvQrz'`v`Q NۏL]\O0 &OtYXTOv~b^/fYf[yTY蕄v SbvsQvyf[b/gN GWavt^T'`+RR^ ؏ gNh>y:S)Rvv^NNNXSR0 &OtYXTOv^z^&{TV[sLvl_Tĉ[ v^&{TvQ@b gR>yOvNy:S0uNbyr[)RvVSOvNh0^ĉ[rz~vcCgV0 N &OtYXTObXTvYe &OtYXTObXT gsQuir;Sf[xvzv&OtS_Tyf[ebvRYWT~~Ye0N}TagN^ĉ[&OtYXTObXT gcS&OtYXTO]\OvRYWT~~Wv:gO NcؚNN&Ot[gR0N}TagN-N؏^SbRYWT~~YevBlTgvh0ُyYeSNN T0W:S0V[TWQvvQN&OtYXTOT\O[c NSN[&OtYXTObXTRYT~~YevvQN:gOvT| N0cN3u &OtYXTO#[cNuir;Sf[xvzR[gv3uhĉ[~vBl03u^_[f_0RُNBl0 N 3u ^1u[yxvzv&OtTyf[L:N#v0 gDNLO0OBlY N 109hnc]\Oϑvw[cO 20OMR &OtYXTObXT^ gYe[gvsQeN 30O^ gU_^ gybQOU_v z^ 403u03uRTb xvzNXTS^eHhb1\gyr[\O~f 509hncuHevO[OS[ rz~S^NObcOfNba0 N [gv } &OtYXTOv;NNR(WN[gxvzeHhT[eN ^yr+Rla~{rw` TafNvǏ z0eN0eHhv['`TSL'`0&OtYXTOQHQMRvyf[[gYg gv݋ NSsLl_TlĉvBl0Y(u ^QN NQp 10xvzvyf[T[e 1 Nxvzvv gsQvxvzvTt'`0~elSb7h,gϑ{ T(ug\vSՋNpe_S`~vS'` 2 CgaSՋTvsQSOvg)RvNvqSiT NO/f&TTt 3 ^(u[gq~vt1u 4 SՋcMRQvhQ 5 f\Pb~bkte*NxvzvhQ 6 [xvz[eǏ zvvKmT[gvS_vĉ[ Sbbzpenc[hQvgYXTO 7 Tv:W0W SbRNXT0S(uveT^%`ce 8 bJTTQHrxvz~gve_0 20bRSՋ 1 SՋvNyr_Sb'`+R0t^0eS z^0eS̀of0~NmrQTye  2 R!kc扌TbRSՋQYǑSve_ 3 b@b gOo` O~SvSՋbNNvNhve_ 4 SՋv~eQhQ 5 SՋvcdhQ0 30SՋv;SuTOb 1 [@bcvxvz xvzNXTDyO/ecv/f&T[Y 5 YgxvzǏ z-NSՋ?aQe\ǑSvce 6 ^O(u0'}%`O(u0T/bQN T` O(uxvzNTvhQ 7 Y_ TSՋvhQy;Su[^;Su cOOo`v[c Sb__SՋ[ُ*NZPl Tav z^ 8 xvz~_gT SՋS_xvzNTvRvf 9 [SՋvNUO9(u/eQvf 10 [SՋvVYRNePSbё0 gR0T/by:SvQ 1 [NS_0W>y:ST gsQ>y:S-NbSSՋ xvzvq_TTsQT 2 xvz6k@bǑSvT gsQ>y:ST⋄vek 3 >y:S[*NN Tavq_T 4 xvzǏ z-N@bcv>y:ST 5 xvz[X:_S_0WRv!.s z^ OYX:_S_0W;SuOeP0xvz0NS[lQqQkSuBlv^[R 6 xvz~_gT bRvxvzNT(W gsQ>y:SvS_'`TSb'` 7 SՋT gsQ>y:S_xvz~gve_0  N R_[g &OtYXTO^^z[xvzeHhR_[gv z^0ُN z^^~f NRTp 10&{TR_[gv3u0O9eTvQNQvNyv{|W 20R_[gvl[0RONpevBl 30Q[CgY/f&ThQSO&OtYXTObXTnx 0 N0&Ot[gvQ[ (W[uir;Sf[xvz&Ot[gv3u\OQ[e &OtYXTO^Q NRTp N YgX[(W)RvQz bXT^NO[3u[gvQ[ z^-NQ)RvQz^(W[gMR^T;N-^f v^(WO~-NU_ N S gS_ gEQRveۏL[g0d&OtYXTObXTT]\ONXTNYvvQNNXTYxvzNXT03uRNh0rz~ y:Wv`Q N MbS\OQQ[  N S g(W0Rl[SONpe&{T&OtYXTOfNbd\O z^vĉ[ e OMb\OQ[ V [3uۏL~[g@bBlveN^QYPhQ v^N(W\OQ[MR^Q Nbc0Rv gsQ }mQ0N [gv }  N S gSN[gvNXTMbSNQ[ mQ ^ cNHQnx[vel\OQQ[YN Ta bhyhQ ^(WSv`Q N NN Tave_\OQQ[ NSN Ta ^&OtYXTObhyhQ N ^ck_v^S\O:NQ[vDN kQ Yg/fagN'`vQ[ R^cQO9evfnx^ NS[3u͑e[g z^v~f ]N ^fnxHt1uNf[3uv&T['`Q[0 kQ0 OQ[ Q[^NfNbb__0 c&OtYXTOvsQ z^ O~3u g}Y(W\OQQ[vOT$N*NfgQ0Q[^SbFO NPN NRQ[ N @b[gvxvzeHhvQnxvv N fnxhlQ[@bWNv0cvxvzeHhbvQO9e?z0egTHr,gSY g   N [geNv Ty0TY g NƋ+RSHr,gS/eg SbSՋOo`h/PgeSw` TafN V 3uNY TT4YT N xvz:W@b Ty mQ Q[vegT0Wp N ZPQ[v&OtYXTOv Ty kQ @bbQ[vfnx ]N &OtYXTOvNUO^ AS Y^\agN'`Q[ &OtYXTOvNUOBl SbO9ev^T[3u͑e[gv z^ ASN Y/f['`Q[ R gNy3u#NvXfY nxcStYXTOcQvNUOBlcNۏ^bJTۏLeHhO9eew&OtYXTOd^SmSxvzTRTL?e{tebvO9e RPge0SvSՋOo`0bw` TafNۏLO9eew&OtYXTObJTNxvz gsQv%N͑vTaYv NoNNbJTelev`Q0~bkxvz0bvQN&OtYXTOv͑Q[:NN[ck(WۏLvxvz[g &OtYXTO_0RvOo`gTv;`~bbJT ASN &OtYXTO[ck(WۏLvxvz[gveh/R AS N Y:N&T['`Q[ fnxf\OQ&T['`Q[vt1u ASV &OtYXTO;N-^bvQNcCgN v~{ Teg 0 ]N0ߍ*[g &OtYXTO^^zߍ*[g z^ ߍ*@b g\OQybQQ[vxvzvۏU\ N\OQQ[_Yv0Rxvz~bk0^c[&OtYXTOT3uKNvT|p~0ߍ*[g z^^QN NTp N l[NONpeBl0[g z^0Tߍ*[gvT| z^ ُNSN[3u@b\OgR[gvBlT z^ N T N =\{xvzeHhkt^^\ۏLN!kߍ*[g FO/f ߍ*[gv^1uxvzeHhv'`(TNN@bQ[  N N N`QTNNBl[xvzۏLߍ*[g 10[eHhvNUOO9e vQSq_TSՋCg)R0[hQTb y)R bq_Txvzv[e 20Nxvz[eTxvzNT gsQv0%N͑vTaYv NoNN NSxvz03uRT{t:gg@bǑSvce 30Sq_TxvzSv/ΘikvNUONNbeOo` V ߍ*[gvQ[^lQ^v^ O~3u cQ[&OtYXTOgRQ[vf9e0f\Pb~bk bnxSQ[N6q gHe N (WxvzcMRf\P/~bkv`Q N 3u^w&OtYXTOf\P/~bkvSVcMRf\P/~bkvxvz@bS_v~gv;`~^N&OtYXTO mQ xvz~_g 3u^w&OtYXTO N xvzvgT;`~bbJTvoR,g^N&OtYXTO0 AS0eNTchHh &OtYXTOv@b geNT_egON cfNb z^^lfeg0^chv^X[ch0_fsQNeN0echTchHhvX[STԏV z^SbcCg 0 ^eNX[ch\0Rxvz~_gT3t^0 ^^zechv^X[chveNSbFO NPN  N &OtYXTOv~b0fNbhQd\Oĉ z NS8^ĉt^^ bJT N @b g&OtYXTObXTvNNe\S  N &OtYXTOhQ6eeQT_/evU_ Sb[yfNYT&OtYXTObXTv%m4TeP V &OtYXTO6R[0lQ^v3ucWS N &OtYXTOvOe z mQ &OtYXTOOvU_ N 3ucNv@b gPgevNNoR,g kQ &OtYXTObXTN3ub gsQNXT1\3u0Q[Tߍ*[gv_egON ]N N3uvQ[0^bBlvoR,g AS ߍ*[gg6e0Rv@b gfNbPge ASN xvz[b0cMRf\PbcMR~bkvw ASN xvzvgT;`~bbJT0 ICH-GCP International Conference on Harmonization of technical requirements for registration of pharmaceuticals for human use. GUIDELINE FOR CILINICAL PRACTICE A standard for the design, conduct, performance, monitoring, auditing, recording, analyses, and reporting of clinical trials that provides assurance that the data and reported results are credible and accurate, and that the rights, integrity, and confidentiality of trial subjects are protected. Ethical and scientific quality standards for designing, conducting, recording and reporting trials that involve participation of human subjects to ensure that the RIGHTS, SAFETY and WELLBEING of the trial subjects are protected. Ensure the CREDIBILITY of clinical trial data. TABLE OF CONTENT INTRODUCTION 1. GLOSSARY 1.1 Adverse Drug Reaction (ADR) 1.2 Adverse Event (AE) 1.3 Amendment (to the protocol) 1.4 Applicable Regulatory Requirement(s) 1.5 Approval (in relation to Institutional Review Boards) 1.6 Audit 1.7 Audit Certificate 1.8 Audit Report 1.9 Audit Trail 1.10 Blinding/Masking 1.11 Case Report Form (CRF) 1.12 Clinical Trial/Study 1.13 Clinical Trial/Study Report 1.14 Comparator (Product) 1.15 Compliance (in relation to trials) 1.16 Confidentiality 1.17 Contract 1.18 Coordinating Committee 1.19 Coordinating Investigator 1.20 Contract Research Organization (CRO) 1.21 Direct Access 1.22 Documentation 1.23 Essential Documents 1.24 Good Clinical Practice (GCP) 1.25 Independent Data-Monitoring Committee (IDMC) (Data and Safety Monitoring Board, Monitoring Committee, Data Monitoring Committee) 1.26 Impartial Witness 1.27 Independent Ethics Committee (IEC) 1.28 Informed Consent 1.29 Inspection 1.30 Institution (medical) 1.31 Institutional Review Board (IRB) 1.32 Interim Clinical Trial/Study Report 1.33 Investigational Product 1.34 Investigator 1.35 Investigator / Institution 1.36 Investigator's Brochure 1.37 Legally Acceptable Representative 1.38 Monitoring 1.39 Monitoring Report 1.40 Multicentre Trial 1.41 Nonclinical Study 1.42 Opinion (in relation to Independent Ethics Committee) 1.43 Original Medical Record 1.44 Protocol 1.45 Protocol Amendment 1.46 Quality Assurance (QA) 1.47 Quality Control (QC) 1.48 Randomization 1.49 Regulatory Authorities 1.50 Serious Adverse Event (SAE) or Serious Adverse Drug Reaction (Serious ADR) 1.51 Source Data 1.52 Source Documents 1.53 Sponsor 1.54 Sponsor-Investigator 1.55 Standard Operating Procedures (SOPs) 1.56 Subinvestigator 1.57 Subject/Trial Subject 1.58 Subject Identification Code 1.59 Trial Site 1.60 Unexpected Adverse Drug Reaction 1.61 Vulnerable Subjects 1.62 Well-being (of the trial subjects) 2. THE PRINCIPLES OF ICH GCP 3. INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC) 3.1 Responsibilities 3.2 Composition, Functions and Operations 3.3 Procedures 3.4 Records 4. INVESTIGATOR 4.1 Investigator's Qualifications and Agreements 4.2 Adequate Resources 4.3 Medical Care of Trial Subjects 4.4 Communication with IRB/IEC 4.5 Compliance with Protocol 4.6 Investigational Product(s) 4.7 Randomization Procedures and Unblinding 4.8 Informed Consent of Trial Subjects 4.9 Records and Reports 4.10 Progress Reports 4.11 Safety Reporting 4.12 Premature Termination or Suspension of a Trial 4.13 Final Report(s) by Investigator 5. SPONSOR 5.1 Quality Assurance and Quality Control 5.2 Contract Research Organization (CRO) 5.3 Medical Expertise 5.4 Trial Design 5.5 Trial Management, Data Handling, and Record Keeping 5.6 Investigator Selection 5.7 Allocation of Responsibilities 5.8 Compensation to Subjects and Investigators 5.9 Financing 5.10 Notification/Submission to Regulatory Authority(ies) 5.11 Confirmation of Review by IRB/IEC 5.12 Information on Investigational Product(s) 5.13 Manufacturing, Packaging, Labelling, and Coding Investigational Product(s) 5.14 Supplying and Handling Investigational Product(s) 5.15 Record Access 5.16 Safety Information 5.17 Adverse Drug Reaction Reporting 5.18 Monitoring 5.19 Audit 5.20 Noncompliance 5.21 Premature Termination or Suspension of a Trial 5.22 Clinical Trial/Study Reports 5.23 Multicentre Trials 6. CLINICAL TRIAL PROTOCOL AND PROTOCOL AMENDMENT(S) 6.1 General Information 6.2 Background Information 6.3 Trial Objectives and Purpose 6.4 Trial Design 6.5 Selection and Withdrawal of Subjects 6.6 Treatment of Subjects 6.7 Assessment of Efficacy 6.8 Assessment of Safety 6.9 Statistics 6.10 Direct Access to Source Data/Documents 6.11 Quality Control and Quality Assurance 6.12 Ethics 6.13 Data Handling and Record Keeping 6.14 Financing and Insurance 6.15 Publication Policy 6.16 Supplements 7. INVESTIGATORS BROCHURE 7.1 Introduction 7.2 General Considerations 7.3 Contents of the Investigators Brochure 7.4 APPENDIX 1: 7.5 APPENDIX 2: 8. ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL 8.1 Introduction 8.2 Before the Clinical Phase of the Trial Commences 8.3 During the Clinical Conduct of the Trial 8.4 After Completion or Termination of the Trial INTRODUCTION Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the participation of human subjects. Compliance with this standard provides public assurance that the rights, safety and well-being of trial subjects are protected, consistent with the principles that have their origin in the Declaration of Helsinki, and that the clinical trial data are credible. The objective of this ICH GCP Guideline is to provide a unified standard for the European Union (EU), Japan and the United States to facilitate the mutual acceptance of clinical data by the regulatory authorities in these jurisdictions. The guideline was developed with consideration of the current good clinical practices of the European Union, Japan, and the United States, as well as those of Australia, Canada, the Nordic countries and the World Health Organization (WHO). This guideline should be followed when generating clinical trial data that are intended to be submitted to regulatory authorities. The principles established in this guideline may also be applied to other clinical investigations that may have an impact on the safety and well-being of human subjects. 1. GLOSSARY 1.1 Adverse Drug Reaction (ADR) In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions. The phrase responses to a medicinal product means that a causal relationship between a medicinal product and an adverse event is at least a reasonable possibility, i.e. the relationship cannot be ruled out. Regarding marketed medicinal products: a response to a drug which is noxious and unintended and which occurs at doses normally used in man for prophylaxis, diagnosis, or therapy of diseases or for modification of physiological function (see the ICH Guideline for Clinical Safety Data Management: Definitions and Standards for Expedited Reporting). 1.2 Adverse Event (AE) Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event (AE) can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product (see the ICH Guideline for Clinical Safety Data Management: Definitions and Standards for Expedited Reporting). 1.3 Amendment (to the protocol) See Protocol Amendment. 1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products. 1.5 Approval (in relation to Institutional Review Boards) The affirmative decision of the IRB that the clinical trial has been reviewed and may be conducted at the institution site within the constraints set forth by the IRB, the institution, Good Clinical Practice (GCP), and the applicable regulatory requirements. 1.6 Audit A systematic and independent examination of trial related activities and documents to determine whether the evaluated trial related activities were conducted, and the data were recorded, analyzed and accurately reported according to the protocol, sponsor's standard operating procedures (SOPs), Good Clinical Practice (GCP), and the applicable regulatory requirement(s). 1.7 Audit Certificate A declaration of confirmation by the auditor that an audit has taken place. 1.8 Audit Report A written evaluation by the sponsor's auditor of the results of the audit. 1.9 Audit Trail Documentation that allows reconstruction of the course of events. 1.10 Blinding/Masking A procedure in which one or more parties to the trial are kept unaware of the treatment assignment(s). Single-blinding usually refers to the subject(s) being unaware, and double-blinding usually refers to the subject(s), investigator(s), monitor, and, in some cases, data analyst(s) being unaware of the treatment assignment(s). 1.11 Case Report Form (CRF) A printed, optical, or electronic document designed to record all of the protocol required information to be reported to the sponsor on each trial subject. 1.12 Clinical Trial/Study Any investigation in human subjects intended to discover or verify the clinical, pharmacological and/or other pharmacodynamic effects of an investigational product(s), and/or to identify any adverse reactions to an investigational product(s), and/or to study absorption, distribution, metabolism, and excretion of an investigational product(s) with the object of ascertaining its safety and/or efficacy. The terms clinical trial and clinical study are synonymous. 1.13 Clinical Trial/Study Report A written description of a trial/study of any therapeutic, prophylactic, or diagnostic agent conducted in human subjects, in which the clinical and statistical description, presentations, and analyses are fully integrated into a single report (see the ICH Guideline for Structure and Content of Clinical Study Reports). 1.14 Comparator (Product) An investigational or marketed product (i.e., active control), or placebo, used as a reference in a clinical trial. 1.15 Compliance (in relation to trials) Adherence to all the trial-related requirements, Good Clinical Practice (GCP) requirements, and the applicable regulatory requirements. 1.16 Confidentiality Prevention of disclosure, to other than authorized individuals, of a sponsor's proprietary information or of a subject's identity. 1.17 Contract A written, dated, and signed agreement between two or more involved parties that sets out any arrangements on delegation and distribution of tasks and obligations and, if appropriate, on financial matters. The protocol may serve as the basis of a contract. 1.18 Coordinating Committee A committee that a sponsor may organize to coordinate the conduct of a multicentre trial. 1.19 Coordinating Investigator An investigator assigned the responsibility for the coordination of investigators at different centres participating in a multicentre trial. 1.20 Contract Research Organization (CRO) A person or an organization (commercial, academic, or other) contracted by the sponsor to perform one or more of a sponsor's trial-related duties and functions. 1.21 Direct Access Permission to examine, analyze, verify, and reproduce any records and reports that are important to evaluation of a clinical trial. Any party (e.g., domestic and foreign regulatory authorities, sponsor's monitors and auditors) with direct access should take all reasonable precautions within the constraints of the applicable regulatory requirement(s) to maintain the confidentiality of subjects' identities and sponsors proprietary information. 1.22 Documentation All records, in any form (including, but not limited to, written, electronic, magnetic, and optical records, and scans, x-rays, and electrocardiograms) that describe or record the methods, conduct, and/or results of a trial, the factors affecting a trial, and the actions taken. 1.23 Essential Documents Documents which individually and collectively permit evaluation of the conduct of a study and the quality of the data produced (see 8. Essential Documents for the Conduct of a Clinical Trial). 1.24 Good Clinical Practice (GCP) A standard for the design, conduct, performance, monitoring, auditing, recording, analyses, and reporting of clinical trials that provides assurance that the data and reported results are credible and accurate, and that the rights, integrity, and confidentiality of trial subjects are protected. 1.25 Independent Data-Monitoring Committee (IDMC) (Data and Safety Monitoring Board, Monitoring Committee, Data Monitoring Committee) An independent data-monitoring committee that may be established by the sponsor to assess at intervals the progress of a clinical trial, the safety data, and the critical efficacy endpoints, and to recommend to the sponsor whether to continue, modify, or stop a trial. 1.26 Impartial Witness A person, who is independent of the trial, who cannot be unfairly influenced by people involved with the trial, who attends the informed consent process if the subject or the subjects legally acceptable representative cannot read, and who reads the informed consent form and any other written information supplied to the subject. 1.27 Independent Ethics Committee (IEC) An independent body (a review board or a committee, institutional, regional, national, or supranational), constituted of medical professionals and non-medical members, whose responsibility it is to ensure the protection of the rights, safety and well-being of human subjects involved in a trial and to provide public assurance of that protection, by, among other things, reviewing and approving / providing favourable opinion on, the trial protocol, the suitability of the investigator(s), facilities, and the methods and material to be used in obtaining and documenting informed consent of the trial subjects. The legal status, composition, function, operations and regulatory requirements pertaining to Independent Ethics Committees may differ among countries, but should allow the Independent Ethics Committee to act in agreement with GCP as described in this guideline. 1.28 Informed Consent A process by which a subject voluntarily confirms his or her willingness to participate in a particular trial, after having been informed of all aspects of the trial that are relevant to the subject's decision to participate. Informed consent is documented by means of a written, signed and dated informed consent form. 1.29 Inspection The act by a regulatory authority(ies) of conducting an official review of documents, facilities, records, and any other resources that are deemed by the authority(ies) to be related to the clinical trial and that may be located at the site of the trial, at the sponsor's and/or contract research organizations (CROs) facilities, or at other establishments deemed appropriate by the regulatory authority(ies). 1.30 Institution (medical) Any public or private entity or agency or medical or dental facility where clinical trials are conducted. 1.31 Institutional Review Board (IRB) An independent body constituted of medical, scientific, and non-scientific members, whose responsibility is to ensure the protection of the rights, safety and well-being of human subjects involved in a trial by, among other things, reviewing, approving, and providing continuing review of trial protocol and amendments and of the methods and material to be used in obtaining and documenting informed consent of the trial subjects. 1.32 Interim Clinical Trial/Study Report A report of intermediate results and their evaluation based on analyses performed during the course of a trial. 1.33 Investigational Product A pharmaceutical form of an active ingredient or placebo being tested or used as a reference in a clinical trial, including a product with a marketing authorization when used or assembled (formulated or packaged) in a way different from the approved form, or when used for an unapproved indication, or when used to gain further information about an approved use. 1.34 Investigator A person responsible for the conduct of the clinical trial at a trial site. If a trial is conducted by a team of individuals at a trial site, the investigator is the responsible leader of the team and may be called the principal investigator. See also Subinvestigator. 1.35 Investigator / Institution An expression meaning "the investigator and/or institution, where required by the applicable regulatory requirements". 1.36 Investigator's Brochure A compilation of the clinical and nonclinical data on the investigational product(s) which is relevant to the study of the investigational product(s) in human subjects (see 7. Investigators Brochure). 1.37 Legally Acceptable Representative An individual or juridical or other body authorized under applicable law to consent, on behalf of a prospective subject, to the subject's participation in the clinical trial. 1.38 Monitoring The act of overseeing the progress of a clinical trial, and of ensuring that it is conducted, recorded, and reported in accordance with the protocol, Standard Operating Procedures (SOPs), Good Clinical Practice (GCP), and the applicable regulatory requirement(s). 1.39 Monitoring Report A written report from the monitor to the sponsor after each site visit and/or other trial-related communication according to the sponsors SOPs. 1.40 Multicentre Trial A clinical trial conducted according to a single protocol but at more than one site, and therefore, carried out by more than one investigator. 1.41 Nonclinical Study Biomedical studies not performed on human subjects. 1.42 Opinion (in relation to Independent Ethics Committee) The judgement and/or the advice provided by an Independent Ethics Committee (IEC). 1.43 Original Medical Record See Source Documents. 1.44 Protocol A document that describes the objective(s), design, methodology, statistical considerations, and organization of a trial. The protocol usually also gives the background and rationale for the trial, but these could be provided in other protocol referenced documents. Throughout the ICH GCP Guideline the term protocol refers to protocol and protocol amendments. 1.45 Protocol Amendment A written description of a change(s) to or formal clarification of a protocol. 1.46 Quality Assurance (QA) All those planned and systematic actions that are established to ensure that the trial is performed and the data are generated, documented (recorded), and reported in compliance with Good Clinical Practice (GCP) and the applicable regulatory requirement(s). 1.47 Quality Control (QC) The operational techniques and activities undertaken within the quality assurance system to verify that the requirements for quality of the trial-related activities have been fulfilled. 1.48 Randomization The process of assigning trial subjects to treatment or control groups using an element of chance to determine the assignments in order to reduce bias. 1.49 Regulatory Authorities Bodies having the power to regulate. In the ICH GCP guideline the expression Regulatory Authorities includes the authorities that review submitted clinical data and those that conduct inspections (see 1.29). These bodies are sometimes referred to as competent authorities. 1.50 Serious Adverse Event (SAE) or Serious Adverse Drug Reaction (Serious ADR) Any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect (see the ICH Guideline for Clinical Safety Data Management: Definitions and Standards for Expedited Reporting). 1.51 Source Data All information in original records and certified copies of original records of clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial. Source data are contained in source documents (original records or certified copies). 1.52 Source Documents Original documents, data, and records (e.g., hospital records, clinical and office charts, laboratory notes, memoranda, subjects' diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions certified after verification as being accurate copies, microfiches, photographic negatives, microfilm or magnetic media, x-rays, subject files, and records kept at the pharmacy, at the laboratories and at medico-technical departments involved in the clinical trial). 1.53 Sponsor An individual, company, institution, or organization which takes responsibility for the initiation, management, and/or financing of a clinical trial. 1.54 Sponsor-Investigator An individual who both initiates and conducts, alone or with others, a clinical trial, and under whose immediate direction the investigational product is administered to, dispensed to, or used by a subject. The term does not include any person other than an individual (e.g., it does not include a corporation or an agency). The obligations of a sponsor-investigator include both those of a sponsor and those of an investigator. 1.55 Standard Operating Procedures (SOPs) Detailed, written instructions to achieve uniformity of the performance of a specific function. 1.56 Subinvestigator Any individual member of the clinical trial team designated and supervised by the investigator at a trial site to perform critical trial-related procedures and/or to make important trial-related decisions (e.g., associates, residents, research fellows). See also Investigator. 1.57 Subject/Trial Subject An individual who participates in a clinical trial, either as a recipient of the investigational product(s) or as a control. 1.58 Subject Identification Code A unique identifier assigned by the investigator to each trial subject to protect the subject's identity and used in lieu of the subject's name when the investigator reports adverse events and/or other trial related data. 1.59 Trial Site The location(s) where trial-related activities are actually conducted. 1.60 Unexpected Adverse Drug Reaction An adverse reaction, the nature or severity of which is not consistent with the applicable product information (e.g., Investigator's Brochure for an unapproved investigational product or package insert/summary of product characteristics for an approved product) (see the ICH Guideline for Clinical Safety Data Management: Definitions and Standards for Expedited Reporting). 1.61 Vulnerable Subjects Individuals whose willingness to volunteer in a clinical trial may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate. Examples are members of a group with a hierarchical structure, such as medical, pharmacy, dental, and nursing students, subordinate hospital and laboratory personnel, employees of the pharmaceutical industry, members of the armed forces, and persons kept in detention. Other vulnerable subjects include patients with incurable diseases, persons in nursing homes, unemployed or impoverished persons, patients in emergency situations, ethnic minority groups, homeless persons, nomads, refugees, minors, and those incapable of giving consent. 1.62 Well-being (of the trial subjects) The physical and mental integrity of the subjects participating in a clinical trial. 2. THE PRINCIPLES OF ICH GCP Clinical trials should be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki, and that are consistent with GCP and the applicable regulatory requirement(s). Before a trial is initiated, foreseeable risks and inconveniences should be weighed against the anticipated benefit for the individual trial subject and society. A trial should be initiated and continued only if the anticipated benefits justify the risks. The rights, safety, and well-being of the trial subjects are the most important considerations and should prevail over interests of science and society. The available nonclinical and clinical information on an investigational product should be adequate to support the proposed clinical trial. Clinical trials should be scientifically sound, and described in a clear, detailed protocol. A trial should be conducted in compliance with the protocol that has received prior institutional review board (IRB)/independent ethics committee (IEC) approval/favourable opinion. The medical care given to, and medical decisions made on behalf of, subjects should always be the responsibility of a qualified physician or, when appropriate, of a qualified dentist. Each individual involved in conducting a trial should be qualified by education, training, and experience to perform his or her respective task(s). Freely given informed consent should be obtained from every subject prior to clinical trial participation. All clinical trial information should be recorded, handled, and stored in a way that allows its accurate reporting, interpretation and verification. The confidentiality of records that could identify subjects should be protected, respecting the privacy and confidentiality rules in accordance with the applicable regulatory requirement(s). Investigational products should be manufactured, handled, and stored in accordance with applicable good manufacturing practice (GMP). They should be used in accordance with the approved protocol. Systems with procedures that assure the quality of every aspect of the trial should be implemented. 3. INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC) 3.1 Responsibilities An IRB/IEC should safeguard the rights, safety, and well-being of all trial subjects. Special attention should be paid to trials that may include vulnerable subjects. The IRB/IEC should obtain the following documents: trial protocol(s)/amendment(s), written informed consent form(s) and consent form updates that the investigator proposes for use in the trial, subject recruitment procedures (e.g. advertisements), written information to be provided to subjects, Investigator's Brochure (IB), available safety information, information about payments and compensation available to subjects, the investigators current curriculum vitae and/or other documentation evidencing qualifications, and any other documents that the IRB/IEC may need to fulfil its responsibilities. The IRB/IEC should review a proposed clinical trial within a reasonable time and document its views in writing, clearly identifying the trial, the documents reviewed and the dates for the following: approval/ favourable opinion; modifications required prior to its approval/favourable opinion; disapproval / negative opinion; and termination/suspension of any prior approval/favourable opinion. The IRB/IEC should consider the qualifications of the investigator for the proposed trial, as documented by a current curriculum vitae and/or by any other relevant documentation the IRB/IEC requests. The IRB/IEC should conduct continuing review of each ongoing trial at intervals appropriate to the degree of risk to human subjects, but at least once per year. The IRB/IEC may request more information than is outlined in paragraph 4.8.10 be given to subjects when, in the judgement of the IRB/IEC, the additional information would add meaningfully to the protection of the rights, safety and/or well-being of the subjects. When a non-therapeutic trial is to be carried out with the consent of the subjects legally acceptable representative (see 4.8.12, 4.8.14), the IRB/IEC should determine that the proposed protocol and/or other document(s) adequately addresses relevant ethical concerns and meets applicable regulatory requirements for such trials. Where the protocol indicates that prior consent of the trial subject or the subjects legally acceptable representative is not possible (see 4.8.15), the IRB/IEC should determine that the proposed protocol and/or other document(s) adequately addresses relevant ethical concerns and meets applicable regulatory requirements for such trials (i.e. in emergency situations). The IRB/IEC should review both the amount and method of payment to subjects to assure that neither presents problems of coercion or undue influence on the trial subjects. Payments to a subject should be prorated and not wholly contingent on completion of the trial by the subject. The IRB/IEC should ensure that information regarding payment to subjects, including the methods, amounts, and schedule of payment to trial subjects, is set forth in the written informed consent form and any other written information to be provided to subjects. The way payment will be prorated should be specified. 3.2 Composition, Functions and Operations The IRB/IEC should consist of a reasonable number of members, who collectively have the qualifications and experience to review and evaluate the science, medical aspects, and ethics of the proposed trial. It is recommended that the IRB/IEC should include: a) At least five members. b) At least one member whose primary area of interest is in a nonscientific area. c) At least one member who is independent of the institution/trial site. Only those IRB/IEC members who are independent of the investigator and the sponsor of the trial should vote/provide opinion on a trial-related matter. A list of IRB/IEC members and their qualifications should be maintained. The IRB/IEC should perform its functions according to written operating procedures, should maintain written records of its activities and minutes of its meetings, and should comply with GCP and with the applicable regulatory requirement(s). An IRB/IEC should make its decisions at announced meetings at which at least a quorum, as stipulated in its written operating procedures, is present. Only members who participate in the IRB/IEC review and discussion should vote/provide their opinion and/or advise. The investigator may provide information on any aspect of the trial, but should not participate in the deliberations of the IRB/IEC or in the vote/opinion of the IRB/IEC. An IRB/IEC may invite nonmembers with expertise in special areas for assistance. 3.3 Procedures The IRB/IEC should establish, document in writing, and follow its procedures, which should include: Determining its composition (names and qualifications of the members) and the authority under which it is established. Scheduling, notifying its members of, and conducting its meetings. Conducting initial and continuing review of trials. Determining the frequency of continuing review, as appropriate. Providing, according to the applicable regulatory requirements, expedited review and approval/favourable opinion of minor change(s) in ongoing trials that have the approval/favourable opinion of the IRB/IEC. Specifying that no subject should be admitted to a trial before the IRB/IEC issues its written approval/favourable opinion of the trial. Specifying that no deviations from, or changes of, the protocol should be initiated without prior written IRB/IEC approval/favourable opinion of an appropriate amendment, except when necessary to eliminate immediate hazards to the subjects or when the change(s) involves only logistical or administrative aspects of the trial (e.g., change of monitor(s), telephone number(s)) (see 4.5.2). Specifying that the investigator should promptly report to the IRB/IEC: Deviations from, or changes of, the protocol to eliminate immediate hazards to the trial subjects (see 3.3.7, 4.5.2, 4.5.4). Changes increasing the risk to subjects and/or affecting significantly the conduct of the trial (see 4.10.2). All adverse drug reactions (ADRs) that are both serious and unexpected. New information that may affect adversely the safety of the subjects or the conduct of the trial. Ensuring that the IRB/IEC promptly notify in writing the investigator/institution concerning: Its trial-related decisions/opinions. The reasons for its decisions/opinions. Procedures for appeal of its decisions/opinions. 3.4 Records The IRB/IEC should retain all relevant records (e.g., written procedures, membership lists, lists of occupations/affiliations of members, submitted documents, minutes of meetings, and correspondence) for a period of at least 3 years after completion of the trial and make them available upon request from the regulatory authority(ies). The IRB/IEC may be asked by investigators, sponsors or regulatory authorities to provide its written procedures and membership lists. 4. INVESTIGATOR 4.1 Investigator's Qualifications and Agreements The investigator(s) should be qualified by education, training, and experience to assume responsibility for the proper conduct of the trial, should meet all the qualifications specified by the applicable regulatory requirement(s), and should provide evidence of such qualifications through up-to-date curriculum vitae and/or other relevant documentation requested by the sponsor, the IRB/IEC, and/or the regulatory authority(ies). The investigator should be thoroughly familiar with the appropriate use of the investigational product(s), as described in the protocol, in the current Investigator's Brochure, in the product information and in other information sources provided by the sponsor. The investigator should be aware of, and should comply with, GCP and the applicable regulatory requirements. The investigator/institution should permit monitoring and auditing by the sponsor, and inspection by the appropriate regulatory authority(ies). The investigator should maintain a list of appropriately qualified persons to whom the investigator has delegated significant trial-related duties. 4.2 Adequate Resources The investigator should be able to demonstrate (e.g., based on retrospective data) a potential for recruiting the required number of suitable subjects within the agreed recruitment period. The investigator should have sufficient time to properly conduct and complete the trial within the agreed trial period. The investigator should have available an adequate number of qualified staff and adequate facilities for the foreseen duration of the trial to conduct the trial properly and safely. The investigator should ensure that all persons assisting with the trial are adequately informed about the protocol, the investigational product(s), and their trial-related duties and functions. 4.3 Medical Care of Trial Subjects A qualified physician (or dentist, when appropriate), who is an investigator or a sub-investigator for the trial, should be responsible for all trial-related medical (or dental) decisions. During and following a subject's participation in a trial, the investigator/institution should ensure that adequate medical care is provided to a subject for any adverse events, including clinically significant laboratory values, related to the trial. The investigator/institution should inform a subject when medical care is needed for intercurrent illness(es) of which the investigator becomes aware. It is recommended that the investigator inform the subject's primary physician about the subject's participation in the trial if the subject has a primary physician and if the subject agrees to the primary physician being informed. Although a subject is not obliged to give his/her reason(s) for withdrawing prematurely from a trial, the investigator should make a reasonable effort to ascertain the reason(s), while fully respecting the subject's rights. 4.4 Communication with IRB/IEC Before initiating a trial, the investigator/institution should have written and dated approval/favourable opinion from the IRB/IEC for the trial protocol, written informed consent form, consent form updates, subject recruitment procedures (e.g., advertisements), and any other written information to be provided to subjects. As part of the investigator's/institutions written application to the IRB/IEC, the investigator/institution should provide the IRB/IEC with a current copy of the Investigator's Brochure. If the Investigator's Brochure is updated during the trial, the investigator/institution should supply a copy of the updated Investigators Brochure to the IRB/IEC. During the trial the investigator/institution should provide to the IRB/IEC all documents subject to review. 4.5 Compliance with Protocol The investigator/institution should conduct the trial in compliance with the protocol agreed to by the sponsor and, if required, by the regulatory authority(ies) and which was given approval/favourable opinion by the IRB/IEC. The investigator/institution and the sponsor should sign the protocol, or an alternative contract, to confirm agreement. The investigator should not implement any deviation from, or changes of the protocol without agreement by the sponsor and prior review and documented approval/favourable opinion from the IRB/IEC of an amendment, except where necessary to eliminate an immediate hazard(s) to trial subjects, or when the change(s) involves only logistical or administrative aspects of the trial (e.g., change in monitor(s), change of telephone number(s)). The investigator, or person designated by the investigator, should document and explain any deviation from the approved protocol. The investigator may implement a deviation from, or a change of, the protocol to eliminate an immediate hazard(s) to trial subjects without prior IRB/IEC approval/favourable opinion. As soon as possible, the implemented deviation or change, the reasons for it, and, if appropriate, the proposed protocol amendment(s) should be submitted: to the IRB/IEC for review and approval/favourable opinion, to the sponsor for agreement and, if required, to the regulatory authority(ies). 4.6 Investigational Product(s) Responsibility for investigational product(s) accountability at the trial site(s) rests with the investigator/institution. Where allowed/required, the investigator/institution may/should assign some or all of the investigator's/institutions duties for investigational product(s) accountability at the trial site(s) to an appropriate pharmacist or another appropriate individual who is under the supervision of the investigator/institution. The investigator/institution and/or a pharmacist or other appropriate individual, who is designated by the investigator/institution, should maintain records of the product's delivery to the trial site, the inventory at the site, the use by each subject, and the return to the sponsor or alternative disposition of unused product(s). These records should include dates, quantities, batch/serial numbers, expiration dates (if applicable), and the unique code numbers assigned to the investigational product(s) and trial subjects. Investigators should maintain records that document adequately that the subjects were provided the doses specified by the protocol and reconcile all investigational product(s) received from the sponsor. The investigational product(s) should be stored as specified by the sponsor (see 5.13.2 and 5.14.3) and in accordance with applicable regulatory requirement(s). The investigator should ensure that the investigational product(s) are used only in accordance with the approved protocol. The investigator, or a person designated by the investigator/institution, should explain the correct use of the investigational product(s) to each subject and should check, at intervals appropriate for the trial, that each subject is following the instructions properly. 4.7 Randomization Procedures and Unblinding The investigator should follow the trial's randomization procedures, if any, and should ensure that the code is broken only in accordance with the protocol. If the trial is blinded, the investigator should promptly document and explain to the sponsor any premature unblinding (e.g., accidental unblinding, unblinding due to a serious adverse event) of the investigational product(s). 4.8 Informed Consent of Trial Subjects In obtaining and documenting informed consent, the investigator should comply with the applicable regulatory requirement(s), and should adhere to GCP and to the ethical principles that have their origin in the Declaration of Helsinki. Prior to the beginning of the trial, the investigator should have the IRB/IEC's written approval/favourable opinion of the written informed consent form and any other written information to be provided to subjects. The written informed consent form and any other written information to be provided to subjects should be revised whenever important new information becomes available that may be relevant to the subjects consent. Any revised written informed consent form, and written information should receive the IRB/IEC's approval/favourable opinion in advance of use. The subject or the subjects legally acceptable representative should be informed in a timely manner if new information becomes available that may be relevant to the subjects willingness to continue participation in the trial. The communication of this information should be documented. Neither the investigator, nor the trial staff, should coerce or unduly influence a subject to participate or to continue to participate in a trial. None of the oral and written information concerning the trial, including the written informed consent form, should contain any language that causes the subject or the subject's legally acceptable representative to waive or to appear to waive any legal rights, or that releases or appears to release the investigator, the institution, the sponsor, or their agents from liability for negligence. The investigator, or a person designated by the investigator, should fully inform the subject or, if the subject is unable to provide informed consent, the subject's legally acceptable representative, of all pertinent aspects of the trial including the written information and the approval/ favourable opinion by the IRB/IEC. The language used in the oral and written information about the trial, including the written informed consent form, should be as non-technical as practical and should be understandable to the subject or the subject's legally acceptable representative and the impartial witness, where applicable. Before informed consent may be obtained, the investigator, or a person designated by the investigator, should provide the subject or the subject's legally acceptable representative ample time and opportunity to inquire about details of the trial and to decide whether or not to participate in the trial. All questions about the trial should be answered to the satisfaction of the subject or the subject's legally acceptable representative. Prior to a subjects participation in the trial, the written informed consent form should be signed and personally dated by the subject or by the subject's legally acceptable representative, and by the person who conducted the informed consent discussion. If a subject is unable to read or if a legally acceptable representative is unable to read, an impartial witness should be present during the entire informed consent discussion. After the written informed consent form and any other written information to be provided to subjects, is read and explained to the subject or the subjects legally acceptable representative, and after the subject or the subjects legally acceptable representative has orally consented to the subjects participation in the trial and, if capable of doing so, has signed and personally dated the informed consent form, the witness should sign and personally date the consent form. By signing the consent form, the witness attests that the information in the consent form and any other written information was accurately explained to, and apparently understood by, the subject or the subject's legally acceptable representative, and that informed consent was freely given by the subject or the subjects legally acceptable representative. Both the informed consent discussion and the written informed consent form and any other written information to be provided to subjects should include explanations of the following: That the trial involves research. The purpose of the trial. The trial treatment(s) and the probability for random assignment to each treatment. The trial procedures to be followed, including all invasive procedures. The subject's responsibilities. Those aspects of the trial that are experimental. The reasonably foreseeable risks or inconveniences to the subject and, when applicable, to an embryo, fetus, or nursing infant. The reasonably expected benefits. When there is no intended clinical benefit to the subject, the subject should be made aware of this. The alternative procedure(s) or course(s) of treatment that may be available to the subject, and their important potential benefits and risks. The compensation and/or treatment available to the subject in the event of trial-related injury. The anticipated prorated payment, if any, to the subject for participating in the trial. The anticipated expenses, if any, to the subject for participating in the trial. That the subject's participation in the trial is voluntary and that the subject may refuse to participate or withdraw from the trial, at any time, without penalty or loss of benefits to which the subject is otherwise entitled. That the monitor(s), the auditor(s), the IRB/IEC, and the regulatory authority(ies) will be granted direct access to the subject's original medical records for verification of clinical trial procedures and/or data, without violating the confidentiality of the subject, to the extent permitted by the applicable laws and regulations and that, by signing a written informed consent form, the subject or the subject's legally acceptable representative is authorizing such access. That records identifying the subject will be kept confidential and, to the extent permitted by the applicable laws and/or regulations, will not be made publicly available. If the results of the trial are published, the subjects identity will remain confidential. That the subject or the subject's legally acceptable representative will be informed in a timely manner if information becomes available that may be relevant to the subject's willingness to continue participation in the trial. The person(s) to contact for further information regarding the trial and the rights of trial subjects, and whom to contact in the event of trial-related injury. The foreseeable circumstances and/or reasons under which the subject's participation in the trial may be terminated. The expected duration of the subject's participation in the trial. The approximate number of subjects involved in the trial. Prior to participation in the trial, the subject or the subject's legally acceptable representative should receive a copy of the signed and dated written informed consent form and any other written information provided to the subjects. During a subject's participation in the trial, the subject or the subjects legally acceptable representative should receive a copy of the signed and dated consent form updates and a copy of any amendments to the written information provided to subjects. When a clinical trial (therapeutic or non-therapeutic) includes subjects who can only be enrolled in the trial with the consent of the subjects legally acceptable representative (e.g., minors, or patients with severe dementia), the subject should be informed about the trial to the extent compatible with the subjects understanding and, if capable, the subject should sign and personally date the written informed consent. Except as described in 4.8.14, a non-therapeutic trial (i.e. a trial in which there is no anticipated direct clinical benefit to the subject), should be conducted in subjects who personally give consent and who sign and date the written informed consent form. Non-therapeutic trials may be conducted in subjects with consent of a legally acceptable representative provided the following conditions are fulfilled: The objectives of the trial can not be met by means of a trial in subjects who can give informed consent personally. The foreseeable risks to the subjects are low. The negative impact on the subjects well-being is minimized and low. The trial is not prohibited by law. The approval/favourable opinion of the IRB/IEC is expressly sought on the inclusion of such subjects, and the written approval/ favourable opinion covers this aspect. Such trials, unless an exception is justified, should be conducted in patients having a disease or condition for which the investigational product is intended. Subjects in these trials should be particularly closely monitored and should be withdrawn if they appear to be unduly distressed. In emergency situations, when prior consent of the subject is not possible, the consent of the subject's legally acceptable representative, if present, should be requested. When prior consent of the subject is not possible, and the subjects legally acceptable representative is not available, enrolment of the subject should require measures described in the protocol and/or elsewhere, with documented approval/favourable opinion by the IRB/IEC, to protect the rights, safety and well-being of the subject and to ensure compliance with applicable regulatory requirements. The subject or the subject's legally acceptable representative should be informed about the trial as soon as possible and consent to continue and other consent as appropriate (see 4.8.10) should be requested. 4.9 Records and Reports The investigator should ensure the accuracy, completeness, legibility, and timeliness of the data reported to the sponsor in the CRFs and in all required reports. Data reported on the CRF, that are derived from source documents, should be consistent with the source documents or the discrepancies should be explained. Any change or correction to a CRF should be dated, initialed, and explained (if necessary) and should not obscure the original entry (i.e. an audit trail should be maintained); this applies to both written and electronic changes or corrections (see 5.18.4 (n)). Sponsors should provide guidance to investigators and/or the investigators' designated representatives on making such corrections. Sponsors should have written procedures to assure that changes or corrections in CRFs made by sponsor's designated representatives are documented, are necessary, and are endorsed by the investigator. The investigator should retain records of the changes and corrections. The investigator/institution should maintain the trial documents as specified in Essential Documents for the Conduct of a Clinical Trial (see 8.) and as required by the applicable regulatory requirement(s). The investigator/institution should take measures to prevent accidental or premature destruction of these documents. Essential documents should be retained until at least 2 years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or at least 2 years have elapsed since the formal discontinuation of clinical development of the investigational product. These documents should be retained for a longer period however if required by the applicable regulatory requirements or by an agreement with the sponsor. It is the responsibility of the sponsor to inform the investigator/institution as to when these documents no longer need to be retained (see 5.5.12). The financial aspects of the trial should be documented in an agreement between the sponsor and the investigator/institution. Upon request of the monitor, auditor, IRB/IEC, or regulatory authority, the investigator/institution should make available for direct access all requested trial-related records. 4.10 Progress Reports The investigator should submit written summaries of the trial status to the IRB/IEC annually, or more frequently, if requested by the IRB/IEC. The investigator should promptly provide written reports to the sponsor, the IRB/IEC (see 3.3.8) and, where applicable, the institution on any changes significantly affecting the conduct of the trial, and/or increasing the risk to subjects. 4.11 Safety Reporting All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports. The immediate and follow-up reports should identify subjects by unique code numbers assigned to the trial subjects rather than by the subjects' names, personal identification numbers, and/or addresses. The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC. Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol. For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports). 4.12 Premature Termination or Suspension of a Trial If the trial is prematurely terminated or suspended for any reason, the investigator/institution should promptly inform the trial subjects, should assure appropriate therapy and follow-up for the subjects, and, where required by the applicable regulatory requirement(s), should inform the regulatory authority(ies). In addition: If the investigator terminates or suspends a trial without prior agreement of the sponsor, the investigator should inform the institution where applicable, and the investigator/institution should promptly inform the sponsor and the IRB/IEC, and should provide the sponsor and the IRB/IEC a detailed written explanation of the termination or suspension. If the sponsor terminates or suspends a trial (see 5.21), the investigator should promptly inform the institution where applicable and the investigator/institution should promptly inform the IRB/IEC and provide the IRB/IEC a detailed written explanation of the termination or suspension. If the IRB/IEC terminates or suspends its approval/favourable opinion of a trial (see 3.1.2 and 3.3.9), the investigator should inform the institution where applicable and the investigator/institution should promptly notify the sponsor and provide the sponsor with a detailed written explanation of the termination or suspension. 4.13 Final Report(s) by Investigator Upon completion of the trial, the investigator, where applicable, should inform the institution; the investigator/institution should provide the IRB/IEC with a summary of the trials outcome, and the regulatory authority(ies) with any reports required. 5. SPONSOR 5.1 Quality Assurance and Quality Control The sponsor is responsible for implementing and maintaining quality assurance and quality control systems with written SOPs to ensure that trials are conducted and data are generated, documented (recorded), and reported in compliance with the protocol, GCP, and the applicable regulatory requirement(s). The sponsor is responsible for securing agreement from all involved parties to ensure direct access (see 1.21) to all trial related sites, source data/documents , and reports for the purpose of monitoring and auditing by the sponsor, and inspection by domestic and foreign regulatory authorities. Quality control should be applied to each stage of data handling to ensure that all data are reliable and have been processed correctly. Agreements, made by the sponsor with the investigator/institution and any other parties involved with the clinical trial, should be in writing, as part of the protocol or in a separate agreement. 5.2 Contract Research Organization (CRO) A sponsor may transfer any or all of the sponsor's trial-related duties and functions to a CRO, but the ultimate responsibility for the quality and integrity of the trial data always resides with the sponsor. The CRO should implement quality assurance and quality control. Any trial-related duty and function that is transferred to and assumed by a CRO should be specified in writing. Any trial-related duties and functions not specifically transferred to and assumed by a CRO are retained by the sponsor. All references to a sponsor in this guideline also apply to a CRO to the extent that a CRO has assumed the trial related duties and functions of a sponsor. 5.3 Medical Expertise The sponsor should designate appropriately qualified medical personnel who will be readily available to advise on trial related medical questions or problems. If necessary, outside consultant(s) may be appointed for this purpose. 5.4 Trial Design The sponsor should utilize qualified individuals (e.g. biostatisticians, clinical pharmacologists, and physicians) as appropriate, throughout all stages of the trial process, from designing the protocol and CRFs and planning the analyses to analyzing and preparing interim and final clinical trial reports. For further guidance: Clinical Trial Protocol and Protocol Amendment(s) (see 6.), the ICH Guideline for Structure and Content of Clinical Study Reports, and other appropriate ICH guidance on trial design, protocol and conduct. 5.5 Trial Management, Data Handling, and Record Keeping The sponsor should utilize appropriately qualified individuals to supervise the overall conduct of the trial, to handle the data, to verify the data, to conduct the statistical analyses, and to prepare the trial reports. The sponsor may consider establishing an independent data-monitoring committee (IDMC) to assess the progress of a clinical trial, including the safety data and the critical efficacy endpoints at intervals, and to recommend to the sponsor whether to continue, modify, or stop a trial. The IDMC should have written operating procedures and maintain written records of all its meetings. When using electronic trial data handling and/or remote electronic trial data systems, the sponsor should: Ensure and document that the electronic data processing system(s) conforms to the sponsors established requirements for completeness, accuracy, reliability, and consistent intended performance (i.e. validation). Maintains SOPs for using these systems. Ensure that the systems are designed to permit data changes in such a way that the data changes are documented and that there is no deletion of entered data (i.e. maintain an audit trail, data trail, edit trail). Maintain a security system that prevents unauthorized access to the data. Maintain a list of the individuals who are authorized to make data changes (see 4.1.5 and 4.9.3). Maintain adequate backup of the data. Safeguard the blinding, if any (e.g. maintain the blinding during data entry and processing). If data are transformed during processing, it should always be possible to compare the original data and observations with the processed data. The sponsor should use an unambiguous subject identification code (see 1.58) that allows identification of all the data reported for each subject. The sponsor, or other owners of the data, should retain all of the sponsor-specific essential documents pertaining to the trial (see 8. Essential Documents for the Conduct of a Clinical Trial). The sponsor should retain all sponsor-specific essential documents in conformance with the applicable regulatory requirement(s) of the country(ies) where the product is approved, and/or where the sponsor intends to apply for approval(s). If the sponsor discontinues the clinical development of an investigational product (i.e. for any or all indications, routes of administration, or dosage forms), the sponsor should maintain all sponsor-specific essential documents for at least 2 years after formal discontinuation or in conformance with the applicable regulatory requirement(s). If the sponsor discontinues the clinical development of an investigational product, the sponsor should notify all the trial investigators/institutions and all the regulatory authorities. Any transfer of ownership of the data should be reported to the appropriate authority(ies), as required by the applicable regulatory requirement(s). The sponsor specific essential documents should be retained until at least 2 years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or at least 2 years have elapsed since the formal discontinuation of clinical development of the investigational product. These documents should be retained for a longer period however if required by the applicable regulatory requirement(s) or if needed by the sponsor. The sponsor should inform the investigator(s)/institution(s) in writing of the need for record retention and should notify the investigator(s)/institution(s) in writing when the trial related records are no longer needed. 5.6 Investigator Selection The sponsor is responsible for selecting the investigator(s)/institution(s). Each investigator should be qualified by training and experience and should have adequate resources (see 4.1, 4.2) to properly conduct the trial for which the investigator is selected. If organization of a coordinating committee and/or selection of coordinating investigator(s) are to be utilized in multicentre trials, their organization and/or selection are the sponsor's responsibility. Before entering an agreement with an investigator/institution to conduct a trial, the sponsor should provide the investigator(s)/institution(s) with the protocol and an up-to-date Investigator's Brochure, and should provide sufficient time for the investigator/institution to review the protocol and the information provided. The sponsor should obtain the investigator's/institution's agreement: to conduct the trial in compliance with GCP, with the applicable regulatory requirement(s) (see 4.1.3), and with the protocol agreed to by the sponsor and given approval/favourable opinion by the IRB/IEC (see 4.5.1); to comply with procedures for data recording/reporting; to permit monitoring, auditing and inspection (see 4.1.4) and to retain the trial related essential documents until the sponsor informs the investigator/ institution these documents are no longer needed (see 4.9.4 and 5.5.12). The sponsor and the investigator/institution should sign the protocol, or an alternative document, to confirm this agreement. 5.7 Allocation of Responsibilities Prior to initiating a trial, the sponsor should define, establish, and allocate all trial-related duties and functions. 5.8 Compensation to Subjects and Investigators If required by the applicable regulatory requirement(s), the sponsor should provide insurance or should indemnify (legal and financial coverage) the investigator/the institution against claims arising from the trial, except for claims that arise from malpractice and/or negligence. The sponsor's policies and procedures should address the costs of treatment of trial subjects in the event of trial-related injuries in accordance with the applicable regulatory requirement(s). When trial subjects receive compensation, the method and manner of compensation should comply with applicable regulatory requirement(s). 5.9 Financing The financial aspects of the trial should be documented in an agreement between the sponsor and the investigator/institution. 5.10 Notification/Submission to Regulatory Authority(ies) Before initiating the clinical trial(s), the sponsor (or the sponsor and the investigator, if required by the applicable regulatory requirement(s)) should submit any required application(s) to the appropriate authority(ies) for review, acceptance, and/or permission (as required by the applicable regulatory requirement(s)) to begin the trial(s). Any notification/submission should be dated and contain sufficient information to identify the protocol. 5.11 Confirmation of Review by IRB/IEC The sponsor should obtain from the investigator/institution: The name and address of the investigator's/institutions IRB/IEC. A statement obtained from the IRB/IEC that it is organized and operates according to GCP and the applicable laws and regulations. Documented IRB/IEC approval/favourable opinion and, if requested by the sponsor, a current copy of protocol, written informed consent form(s) and any other written information to be provided to subjects, subject recruiting procedures, and documents related to payments and compensation available to the subjects, and any other documents that the IRB/IEC may have requested. If the IRB/IEC conditions its approval/favourable opinion upon change(s) in any aspect of the trial, such as modification(s) of the protocol, written informed consent form and any other written information to be provided to subjects, and/or other procedures, the sponsor should obtain from the investigator/institution a copy of the modification(s) made and the date approval/favourable opinion was given by the IRB/IEC. The sponsor should obtain from the investigator/institution documentation and dates of any IRB/IEC reapprovals/re-evaluations with favourable opinion, and of any withdrawals or suspensions of approval/favourable opinion. 5.12 Information on Investigational Product(s) When planning trials, the sponsor should ensure that sufficient safety and efficacy data from nonclinical studies and/or clinical trials are available to support human exposure by the route, at the dosages, for the duration, and in the trial population to be studied. The sponsor should update the Investigator's Brochure as significant new information becomes available (see 7. Investigator's Brochure). 5.13 Manufacturing, Packaging, Labelling, and Coding Investigational Product(s) The sponsor should ensure that the investigational product(s) (including active comparator(s) and placebo, if applicable) is characterized as appropriate to the stage of development of the product(s), is manufactured in accordance with any applicable GMP, and is coded and labelled in a manner that protects the blinding, if applicable. In addition, the labelling should comply with applicable regulatory requirement(s). The sponsor should determine, for the investigational product(s), acceptable storage temperatures, storage conditions (e.g. protection from light), storage times, reconstitution fluids and procedures, and devices for product infusion, if any. The sponsor should inform all involved parties (e.g. monitors, investigators, pharmacists, storage managers) of these determinations. The investigational product(s) should be packaged to prevent contamination and unacceptable deterioration during transport and storage. In blinded trials, the coding system for the investigational product(s) should include a mechanism that permits rapid identification of the product(s) in case of a medical emergency, but does not permit undetectable breaks of the blinding. If significant formulation changes are made in the investigational or comparator product(s) during the course of clinical development, the results of any additional studies of the formulated product(s) (e.g. stability, dissolution rate, bioavailability) needed to assess whether these changes would significantly alter the pharmacokinetic profile of the product should be available prior to the use of the new formulation in clinical trials. 5.14 Supplying and Handling Investigational Product(s) The sponsor is responsible for supplying the investigator(s)/institution(s) with the investigational product(s). The sponsor should not supply an investigator/institution with the investigational product(s) until the sponsor obtains all required documentation (e.g. approval/favourable opinion from IRB/IEC and regulatory authority(ies)). The sponsor should ensure that written procedures include instructions that the investigator/institution should follow for the handling and storage of investigational product(s) for the trial and documentation thereof. The procedures should address adequate and safe receipt, handling, storage, dispensing, retrieval of unused product from subjects, and return of unused investigational product(s) to the sponsor (or alternative disposition if authorized by the sponsor and in compliance with the applicable regulatory requirement(s)). The sponsor should: Ensure timely delivery of investigational product(s) to the investigator(s). Maintain records that document shipment, receipt, disposition, return, and destruction of the investigational product(s) (see 8. Essential Documents for the Conduct of a Clinical Trial). Maintain a system for retrieving investigational products and documenting this retrieval (e.g. for deficient product recall, reclaim after trial completion, expired product reclaim). Maintain a system for the disposition of unused investigational product(s) and for the documentation of this disposition. The sponsor should: Take steps to ensure that the investigational product(s) are stable over the period of use. Maintain sufficient quantities of the investigational product(s) used in the trials to reconfirm specifications, should this become necessary, and maintain records of batch sample analyses and characteristics. To the extent stability permits, samples should be retained either until the analyses of the trial data are complete or as required by the applicable regulatory requirement(s), whichever represents the longer retention period. 5.15 Record Access The sponsor should ensure that it is specified in the protocol or other written agreement that the investigator(s)/institution(s) provide direct access to source data/documents for trial-related monitoring, audits, IRB/IEC review, and regulatory inspection. The sponsor should verify that each subject has consented, in writing, to direct access to his/her original medical records for trial-related monitoring, audit, IRB/IEC review, and regulatory inspection. 5.16 Safety Information The sponsor is responsible for the ongoing safety evaluation of the investigational product(s). The sponsor should promptly notify all concerned investigator(s)/institution(s) and the regulatory authority(ies) of findings that could affect adversely the safety of subjects, impact the conduct of the trial, or alter the IRB/IEC's approval/favourable opinion to continue the trial. 5.17 Adverse Drug Reaction Reporting The sponsor should expedite the reporting to all concerned investigator(s)/institutions(s), to the IRB(s)/IEC(s), where required, and to the regulatory authority(ies) of all adverse drug reactions (ADRs) that are both serious and unexpected. Such expedited reports should comply with the applicable regulatory requirement(s) and with the ICH Guideline for Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. The sponsor should submit to the regulatory authority(ies) all safety updates and periodic reports, as required by applicable regulatory requirement(s). 5.18 Monitoring Purpose The purposes of trial monitoring are to verify that: The rights and well-being of human subjects are protected. The reported trial data are accurate, complete, and verifiable from source documents. The conduct of the trial is in compliance with the currently approved protocol/amendment(s), with GCP, and with the applicable regulatory requirement(s). Selection and Qualifications of Monitors Monitors should be appointed by the sponsor. Monitors should be appropriately trained, and should have the scientific and/or clinical knowledge needed to monitor the trial adequately. A monitors qualifications should be documented. Monitors should be thoroughly familiar with the investigational product(s), the protocol, written informed consent form and any other written information to be provided to subjects, the sponsors SOPs, GCP, and the applicable regulatory requirement(s). Extent and Nature of Monitoring The sponsor should ensure that the trials are adequately monitored. The sponsor should determine the appropriate extent and nature of monitoring. The determination of the xtent and nature of monitoring should be based on considerations such as the objective, purpose, design, complexity, blinding, size, and endpoints of the trial. In general there is a need for on-site monitoring, before, during, and after the trial; however in exceptional circumstances the sponsor may determine that central monitoring in conjunction with procedures such as investigators training and meetings, and extensive written guidance can assure appropriate conduct of the trial in accordance with GCP. Statistically controlled sampling may be an acceptable method for selecting the data to be verified. Monitor's Responsibilities The monitor(s) in accordance with the sponsors requirements should ensure that the trial is conducted and documented properly by carrying out the following activities when relevant and necessary to the trial and the trial site: Acting as the main line of communication between the sponsor and the investigator. Verifying that the investigator has adequate qualifications and resources (see 4.1, 4.2, 5.6) and remain adequate throughout the trial period, that facilities, including laboratories, equipment, and staff, are adequate to safely and properly conduct the trial and remain adequate throughout the trial period. Verifying, for the investigational product(s): That storage times and conditions are acceptable, and that supplies are sufficient throughout the trial. That the investigational product(s) are supplied only to subjects who are eligible to receive it and at the protocol specified dose(s). That subjects are provided with necessary instruction on properly using, handling, storing, and returning the investigational product(s). That the receipt, use, and return of the investigational product(s) at the trial sites are controlled and documented adequately. That the disposition of unused investigational product(s) at the trial sites complies with applicable regulatory requirement(s) and is in accordance with the sponsor. Verifying that the investigator follows the approved protocol and all approved amendment(s), if any. Verifying that written informed consent was obtained before each subject's participation in the trial. Ensuring that the investigator receives the current Investigator's Brochure, all documents, and all trial supplies needed to conduct the trial properly and to comply with the applicable regulatory requirement(s). Ensuring that the investigator and the investigator's trial staff are adequately informed about the trial. Verifying that the investigator and the investigator's trial staff are performing the specified trial functions, in accordance with the protocol and any other written agreement between the sponsor and the investigator/institution, and have not delegated these functions to unauthorized individuals. Verifying that the investigator is enrolling only eligible subjects. Reporting the subject recruitment rate. Verifying that source documents and other trial records are accurate, complete, kept up-to-date and maintained. Verifying that the investigator provides all the required reports, notifications, applications, and submissions, and that these documents are accurate, complete, timely, legible, dated, and identify the trial. Checking the accuracy and completeness of the CRF entries, source documents and other trial-related records against each other. The monitor specifically should verify that: The data required by the protocol are reported accurately on the CRFs and are consistent with the source documents. Any dose and/or therapy modifications are well documented for each of the trial subjects. Adverse events, concomitant medications and intercurrent illnesses are reported in accordance with the protocol on the CRFs. Visits that the subjects fail to make, tests that are not conducted, and examinations that are not performed are clearly reported as such on the CRFs. All withdrawals and dropouts of enrolled subjects from the trial are reported and explained on the CRFs. Informing the investigator of any CRF entry error, omission, or illegibility. The monitor should ensure that appropriate corrections, additions, or deletions are made, dated, explained (if necessary), and initialled by the investigator or by a member of the investigator's trial staff who is authorized to initial CRF changes for the investigator. This authorization should be documented. Determining whether all adverse events (AEs) are appropriately reported within the time periods required by GCP, the protocol, the IRB/IEC, the sponsor, and the applicable regulatory requirement(s). Determining whether the investigator is maintaining the essential documents (see 8. Essential Documents for the Conduct of a Clinical Trial). Communicating deviations from the protocol, SOPs, GCP, and the applicable regulatory requirements to the investigator and taking appropriate action designed to prevent recurrence of the detected deviations. Monitoring Procedures The monitor(s) should follow the sponsors established written SOPs as well as those procedures that are specified by the sponsor for monitoring a specific trial. Monitoring Report The monitor should submit a written report to the sponsor after each trial-site visit or trial-related communication. Reports should include the date, site, name of the monitor, and name of the investigator or other individual(s) contacted. Reports should include a summary of what the monitor reviewed and the monitor's statements concerning the significant findings/facts, deviations and deficiencies, conclusions, actions taken or to be taken and/or actions recommended to secure compliance. The review and follow-up of the monitoring report with the sponsor should be documented by the sponsors designated representative. 5.19 Audit If or when sponsors perform audits, as part of implementing quality assurance, they should consider: Purpose The purpose of a sponsor's audit, which is independent of and separate from routine monitoring or quality control functions, should be to evaluate trial conduct and compliance with the protocol, SOPs, GCP, and the applicable regulatory requirements. Selection and Qualification of Auditors The sponsor should appoint individuals, who are independent of the clinical trials/systems, to conduct audits. The sponsor should ensure that the auditors are qualified by training and experience to conduct audits properly. An auditors qualifications should be documented. Auditing Procedures The sponsor should ensure that the auditing of clinical trials/systems is conducted in accordance with the sponsor's written procedures on what to audit, how to audit, the frequency of audits, and the form and content of audit reports. The sponsor's audit plan and procedures for a trial audit should be guided by the importance of the trial to submissions to regulatory authorities, the number of subjects in the trial, the type and complexity of the trial, the level of risks to the trial subjects, and any identified problem(s). The observations and findings of the auditor(s) should be documented. To preserve the independence and value of the audit function, the regulatory authority(ies) should not routinely request the audit reports. Regulatory authority(ies) may seek access to an audit report on a case by case basis when evidence of serious GCP non-compliance exists, or in the course of legal proceedings. When required by applicable law or regulation, the sponsor should provide an audit certificate. 5.20 Noncompliance Noncompliance with the protocol, SOPs, GCP, and/or applicable regulatory requirement(s) by an investigator/institution, or by member(s) of the sponsor's staff should lead to prompt action by the sponsor to secure compliance. If the monitoring and/or auditing identifies serious and/or persistent noncompliance on the part of an investigator/institution, the sponsor should terminate the investigator's/institutions participation in the trial. When an investigator's/institutions participation is terminated because of noncompliance, the sponsor should notify promptly the regulatory authority(ies). 5.21 Premature Termination or Suspension of a Trial If a trial is prematurely terminated or suspended, the sponsor should promptly inform the investigators/institutions, and the regulatory authority(ies) of the termination or suspension and the reason(s) for the termination or suspension. The IRB/IEC should also be informed promptly and provided the reason(s) for the termination or suspension by the sponsor or by the investigator/institution, as specified by the applicable regulatory requirement(s). 5.22 Clinical Trial/Study Reports Whether the trial is completed or prematurely terminated, the sponsor should ensure that the clinical trial reports are prepared and provided to the regulatory agency(ies) as required by the applicable regulatory requirement(s). The sponsor should also ensure that the clinical trial reports in marketing applications meet the standards of the ICH Guideline for Structure and Content of Clinical Study Reports. (NOTE: The ICH Guideline for Structure and Content of Clinical Study Reports specifies that abbreviated study reports may be acceptable in certain cases.) 5.23 Multicentre Trials For multicentre trials, the sponsor should ensure that: All investigators conduct the trial in strict compliance with the protocol agreed to by the sponsor and, if required, by the regulatory authority(ies), and given approval/favourable opinion by the IRB/IEC. The CRFs are designed to capture the required data at all multicentre trial sites. For those investigators who are collecting additional data, supplemental CRFs should also be provided that are designed to capture the additional data. The responsibilities of coordinating investigator(s) and the other participating investigators are documented prior to the start of the trial. All investigators are given instructions on following the protocol, on complying with a uniform set of standards for the assessment of clinical and laboratory findings, and on completing the CRFs. Communication between investigators is facilitated. 6. CLINICAL TRIAL PROTOCOL AND PROTOCOL AMENDMENT(S) The contents of a trial protocol should generally include the following topics. However, site specific information may be provided on separate protocol page(s), or addressed in a separate agreement, and some of the information listed below may be contained in other protocol referenced documents, such as an Investigators Brochure. 6.1 General Information Protocol title, protocol identifying number, and date. Any amendment(s) should also bear the amendment number(s) and date(s). Name and address of the sponsor and monitor (if other than the sponsor). Name and title of the person(s) authorized to sign the protocol and the protocol amendment(s) for the sponsor. Name, title, address, and telephone number(s) of the sponsor's medical expert (or dentist when appropriate) for the trial. Name and title of the investigator(s) who is (are) responsible for conducting the trial, and the address and telephone number(s) of the trial site(s). Name, title, address, and telephone number(s) of the qualified physician (or dentist, if applicable), who is responsible for all trial-site related medical (or dental) decisions (if other than investigator). Name(s) and address(es) of the clinical laboratory(ies) and other medical and/or technical department(s) and/or institutions involved in the trial. 6.2 Background Information Name and description of the investigational product(s). A summary of findings from nonclinical studies that potentially have clinical significance and from clinical trials that are relevant to the trial. Summary of the known and potential risks and benefits, if any, to human subjects. Description of and justification for the route of administration, dosage, dosage regimen, and treatment period(s). A statement that the trial will be conducted in compliance with the protocol, GCP and the applicable regulatory requirement(s). Description of the population to be studied. References to literature and data that are relevant to the trial, and that provide background for the trial. 6.3 Trial Objectives and Purpose A detailed description of the objectives and the purpose of the trial. 6.4 Trial Design The scientific integrity of the trial and the credibility of the data from the trial depend substantially on the trial design. A description of the trial design, should include: A specific statement of the primary endpoints and the secondary endpoints, if any, to be measured during the trial. A description of the type/design of trial to be conducted (e.g. double-blind, placebo-controlled, parallel design) and a schematic diagram of trial design, procedures and stages. A description of the measures taken to minimize/avoid bias, including: Randomization. Blinding. A description of the trial treatment(s) and the dosage and dosage regimen of the investigational product(s). Also include a description of the dosage form, packaging, and labelling of the investigational product(s). The expected duration of subject participation, and a description of the sequence and duration of all trial periods, including follow-up, if any. A description of the "stopping rules" or "discontinuation criteria" for individual subjects, parts of trial and entire trial. Accountability procedures for the investigational product(s), including the placebo(s) and comparator(s), if any. Maintenance of trial treatment randomization codes and procedures for breaking codes. The identification of any data to be recorded directly on the CRFs (i.e. no prior written or electronic record of data), and to be considered to be source data. 6.5 Selection and Withdrawal of Subjects Subject inclusion criteria. Subject exclusion criteria. Subject withdrawal criteria (i.e. terminating investigational product treatment/trial treatment) and procedures specifying: When and how to withdraw subjects from the trial/ investigational product treatment. The type and timing of the data to be collected for withdrawn subjects. Whether and how subjects are to be replaced. The follow-up for subjects withdrawn from investigational product treatment/trial treatment. 6.6 Treatment of Subjects The treatment(s) to be administered, including the name(s) of all the product(s), the dose(s), the dosing schedule(s), the route/mode(s) of administration, and the treatment period(s), including the follow-up period(s) for subjects for each investigational product treatment/trial treatment group/arm of the trial. Medication(s)/treatment(s) permitted (including rescue medication) and not permitted before and/or during the trial. Procedures for monitoring subject compliance. 6.7 Assessment of Efficacy Specification of the efficacy parameters. Methods and timing for assessing, recording, and analysing of efficacy parameters. 6.8 Assessment of Safety Specification of safety parameters. The methods and timing for assessing, recording, and analysing safety parameters. Procedures for eliciting reports of and for recording and reporting adverse event and intercurrent illnesses. The type and duration of the follow-up of subjects after adverse events. 6.9 Statistics A description of the statistical methods to be employed, including timing of any planned interim analysis(ses). The number of subjects planned to be enrolled. In multicentre trials, the numbers of enrolled subjects projected for each trial site should be specified. Reason for choice of sample size, including reflections on (or calculations of) the power of the trial and clinical justification. The level of significance to be used. Criteria for the termination of the trial. Procedure for accounting for missing, unused, and spurious data. Procedures for reporting any deviation(s) from the original statistical plan (any deviation(s) from the original statistical plan should be described and justified in protocol and/or in the final report, as appropriate). The selection of subjects to be included in the analyses (e.g. all randomized subjects, all dosed subjects, all eligible subjects, evaluable subjects). 6.10 Direct Access to Source Data/Documents The sponsor should ensure that it is specified in the protocol or other written agreement that the investigator(s)/institution(s) will permit trial-related monitoring, audits, IRB/IEC review, and regulatory inspection(s), providing direct access to source data/documents. 6.11 Quality Control and Quality Assurance 6.12 Ethics Description of ethical considerations relating to the trial. 6.13 Data Handling and Record Keeping 6.14 Financing and Insurance Financing and insurance if not addressed in a separate agreement. 6.15 Publication Policy Publication policy, if not addressed in a separate agreement. 6.16 Supplements (NOTE: Since the protocol and the clinical trial/study report are closely related, further relevant information can be found in the ICH Guideline for Structure and Content of Clinical Study Reports.) 7. INVESTIGATORS BROCHURE 7.1 Introduction The Investigator's Brochure (IB) is a compilation of the clinical and nonclinical data on the investigational product(s) that are relevant to the study of the product(s) in human subjects. Its purpose is to provide the investigators and others involved in the trial with the information to facilitate their understanding of the rationale for, and their compliance with, many key features of the protocol, such as the dose, dose frequency/interval, methods of administration: and safety monitoring procedures. The IB also provides insight to support the clinical management of the study subjects during the course of the clinical trial. The information should be presented in a concise, simple, objective, balanced, and non-promotional form that enables a clinician, or potential investigator, to understand it and make his/her own unbiased risk-benefit assessment of the appropriateness of the proposed trial. For this reason, a medically qualified person should generally participate in the editing of an IB, but the contents of the IB should be approved by the disciplines that generated the described data. This guideline delineates the minimum information that should be included in an IB and provides suggestions for its layout. It is expected that the type and extent of information available will vary with the stage of development of the investigational product. If the investigational product is marketed and its pharmacology is widely understood by medical practitioners, an extensive IB may not be necessary. Where permitted by regulatory authorities, a basic product information brochure, package leaflet, or labelling may be an appropriate alternative, provided that it includes current, comprehensive, and detailed information on all aspects of the investigational product that might be of importance to the investigator. If a marketed product is being studied for a new use (i.e., a new indication), an IB specific to that new use should be prepared. The IB should be reviewed at least annually and revised as necessary in compliance with a sponsor's written procedures. More frequent revision may be appropriate depending on the stage of development and the generation of relevant new information. However, in accordance with Good Clinical Practice, relevant new information may be so important that it should be communicated to the investigators, and possibly to the Institutional Review Boards (IRBs)/Independent Ethics Committees (IECs) and/or regulatory authorities before it is included in a revised IB. Generally, the sponsor is responsible for ensuring that an up-to-date IB is made available to the investigator(s) and the investigators are responsible for providing the up-to-date IB to the responsible IRBs/IECs. In the case of an investigator sponsored trial, the sponsor-investigator should determine whether a brochure is available from the commercial manufacturer. If the investigational product is provided by the sponsor-investigator, then he or she should provide the necessary information to the trial personnel. In cases where preparation of a formal IB is impractical, the sponsor-investigator should provide, as a substitute, an expanded background information section in the trial protocol that contains the minimum current information described in this guideline. 7.2 General Considerations The IB should include: Title Page This should provide the sponsor's name, the identity of each investigational product (i.e., research number, chemical or approved generic name, and trade name(s) where legally permissible and desired by the sponsor), and the release date. It is also suggested that an edition number, and a reference to the number and date of the edition it supersedes, be provided. An example is given in Appendix 1. Confidentiality Statement The sponsor may wish to include a statement instructing the investigator/recipients to treat the IB as a confidential document for the sole information and use of the investigator's team and the IRB/IEC. 7.3 Contents of the Investigators Brochure The IB should contain the following sections, each with literature references where appropriate: Table of Contents An example of the Table of Contents is given in Appendix 2 Summary A brief summary (preferably not exceeding two pages) should be given, highlighting the significant physical, chemical, pharmaceutical, pharmacological, toxicological, pharmacokinetic, metabolic, and clinical information available that is relevant to the stage of clinical development of the investigational product. Introduction A brief introductory statement should be provided that contains the chemical name (and generic and trade name(s) when approved) of the investigational product(s), all active ingredients, the investigational product (s ) pharmacological class and its expected position within this class (e.g. advantages), the rationale for performing research with the investigational product(s), and the anticipated prophylactic, therapeutic, or diagnostic indication(s). Finally, the introductory statement should provide the general approach to be followed in evaluating the investigational product. Physical, Chemical, and Pharmaceutical Properties and Formulation A description should be provided of the investigational product substance(s) (including the chemical and/or structural formula(e)), and a brief summary should be given of the relevant physical, chemical, and pharmaceutical properties. To permit appropriate safety measures to be taken in the course of the trial, a description of the formulation(s) to be used, including excipients, should be provided and justified if clinically relevant. Instructions for the storage and handling of the dosage form(s) should also be given. Any structural similarities to other known compounds should be mentioned. Nonclinical Studies Introduction: The results of all relevant nonclinical pharmacology, toxicology, pharmacokinetic, and investigational product metabolism studies should be provided in summary form. This summary should address the methodology used, the results, and a discussion of the relevance of the findings to the investigated therapeutic and the possible unfavourable and unintended effects in humans. The information provided may include the following, as appropriate, if known/available: Species tested Number and sex of animals in each group Unit dose (e.g., milligram/kilogram (mg/kg)) Dose interval Route of administration Duration of dosing Information on systemic distribution Duration of post-exposure follow-up Results, including the following aspects: Nature and frequency of pharmacological or toxic effects Severity or intensity of pharmacological or toxic effects Time to onset of effects Reversibility of effects Duration of effects Dose response Tabular format/listings should be used whenever possible to enhance the clarity of the presentation. The following sections should discuss the most important findings from the studies, including the dose response of observed effects, the relevance to humans, and any aspects to be studied in humans. If applicable, the effective and nontoxic dose findings in the same animal species should be compared (i.e., the therapeutic index should be discussed). The relevance of this information to the proposed human dosing should be addressed. Whenever possible, comparisons should be made in terms of blood/tissue levels rather than on a mg/kg basis. Nonclinical Pharmacology A summary of the pharmacological aspects of the investigational product and, where appropriate, its significant metabolites studied in animals, should be included. Such a summary should incorporate studies that assess potential therapeutic activity (e.g. efficacy models, receptor binding, and specificity) as well as those that assess safety (e.g., special studies to assess pharmacological actions other than the intended therapeutic effect(s)). Pharmacokinetics and Product Metabolism in Animals A summary of the pharmacokinetics and biological transformation and disposition of the investigational product in all species studied should be given. The discussion of the findings should address the absorption and the local and systemic bioavailability of the investigational product and its metabolites, and their relationship to the pharmacological and toxicological findings in animal species. Toxicology A summary of the toxicological effects found in relevant studies conducted in different animal species should be described under the following headings where appropriate: Single dose Repeated dose Carcinogenicity Special studies (e.g. irritancy and sensitisation) Reproductive toxicity Genotoxicity (mutagenicity) Effects in Humans Introduction: A thorough discussion of the known effects of the investigational product(s) in humans should be provided, including information on pharmacokinetics, metabolism, pharmacodynamics, dose response, safety, efficacy, and other pharmacological activities. Where possible, a summary of each completed clinical trial should be provided. Information should also be provided regarding results of any use of the investigational product(s) other than from in clinical trials, such as from experience during marketing. Pharmacokinetics and Product Metabolism in Humans A summary of information on the pharmacokinetics of the investigational product(s) should be presented, including the following, if available: Pharmacokinetics (including metabolism, as appropriate, and absorption, plasma protein binding, distribution, and elimination). Bioavailability of the investigational product (absolute, where possible, and/or relative) using a reference dosage form. Population subgroups (e.g., gender, age, and impaired organ function). Interactions (e.g., product-product interactions and effects of food). Other pharmacokinetic data (e.g., results of population studies performed within clinical trial(s). Safety and Efficacy A summary of information should be provided about the investigational product's/products' (including metabolites, where appropriate) safety, pharmacodynamics, efficacy, and dose response that were obtained from preceding trials in humans (healthy volunteers and/or patients). The implications of this information should be discussed. In cases where a number of clinical trials have been completed, the use of summaries of safety and efficacy across multiple trials by indications in subgroups may provide a clear presentation of the data. Tabular summaries of adverse drug reactions for all the clinical trials (including those for all the studied indications) would be useful. Important differences in adverse drug reaction patterns/incidences across indications or subgroups should be discussed. The IB should provide a description of the possible risks and adverse drug reactions to be anticipated on the basis of prior experiences with the product under investigation and with related products. A description should also be provided of the precautions or special monitoring to be done as part of the investigational use of the product(s). Marketing Experience The IB should identify countries where the investigational product has been marketed or approved. Any significant information arising from the marketed use should be summarised (e.g., formulations, dosages, routes of administration, and adverse product reactions). The IB should also identify all the countries where the investigational product did not receive approval/registration for marketing or was withdrawn from marketing/registration. Summary of Data and Guidance for the Investigator This section should provide an overall discussion of the nonclinical and clinical data, and should summarise the information from various sources on different aspects of the investigational product(s), wherever possible. In this way, the investigator can be provided with the most informative interpretation of the available data and with an assessment of the implications of the information for future clinical trials. Where appropriate, the published reports on related products should be discussed. This could help the investigator to anticipate adverse drug reactions or other problems in clinical trials. The overall aim of this section is to provide the investigator with a clear understanding of the possible risks and adverse reactions, and of the specific tests, observations, and precautions that may be needed for a clinical trial. This understanding should be based on the available physical, chemical, pharmaceutical, pharmacological, toxicological, and clinical information on the investigational product(s). Guidance should also be provided to the clinical investigator on the recognition and treatment of possible overdose and adverse drug reactions that is based on previous human experience and on the pharmacology of the investigational product. 7.4 APPENDIX 1: TITLE PAGE (Example) SPONSOR'S NAME Product: Research Number: Name(s): Chemical, Generic (if approved) Trade Name(s) (if legally permissible and desired by the sponsor) INVESTIGATOR'S BROCHURE Edition Number: Release Date: Replaces Previous Edition Number: Date: 7.5 APPENDIX 2: TABLE OF CONTENTS OF INVESTIGATOR'S BROCHURE (Example) - Confidentiality Statement (optional)........................................................................... - Signature Page (optional)............................................................................................. 1. Table of Contents ....................................................................................................... 2. Summary ................................................................................................................... 3. Introduction ............................................................................................................... 4. Physical, Chemical, and Pharmaceutical Properties and Formulation ...................... 5. Nonclinical Studies .................................................................................................... 5.1 Nonclinical Pharmacology ....................................................................................... 5.2 Pharmacokinetics and Product Metabolism in Animals .......................................... 5.3 Toxicology ................................................................................................................ 6. Effects in Humans ...................................................................................................... 6.1 Pharmacokinetics and Product Metabolism in Humans .......................................... 6.2 Safety and Efficacy .................................................................................................... 6.3 Marketing Experience .............................................................................................. 7. Summary of Data and Guidance for the Investigator ................................................ NB: References on 1. Publications 2. Reports These references should be found at the end of each chapter Appendices (if any) 8. ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL 8.1 Introduction Essential Documents are those documents which individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced. These documents serve to demonstrate the compliance of the investigator, sponsor and monitor with the standards of Good Clinical Practice and with all applicable regulatory requirements. Essential Documents also serve a number of other important purposes. Filing essential documents at the investigator/institution and sponsor sites in a timely manner can greatly assist in the successful management of a trial by the investigator, sponsor and monitor. These documents are also the ones which are usually audited by the sponsor's independent audit function and inspected by the regulatory authority (ies) as part of the process to confirm the validity of the trial conduct and the integrity of data collected. The minimum list of essential documents which has been developed follows. The various documents are grouped in three sections according to the stage of the trial during which they will normally be generated: 1) before the clinical phase of the trial commences, 2) during the clinical conduct of the trial, and 3) after completion or termination of the trial. A description is given of the purpose of each document, and whether it should be filed in either the investigator/institution or sponsor files, or both. It is acceptable to combine some of the documents, provided the individual elements are readily identifiable. Trial master files should be established at the beginning of the trial, both at the investigator/institutions site and at the sponsor's office. A final close-out of a trial can only be done when the monitor has reviewed both investigator/institution and sponsor files and confirmed that all necessary documents are in the appropriate files. Any or all of the documents addressed in this guideline may be subject to, and should be available for, audit by the sponsors auditor and inspection by the regulatory authority(ies). 8.2 Before the Clinical Phase of the Trial Commences During this planning stage the following documents should be generated and should be on file before the trial formally starts Title of DocumentPurposeLocated in Files ofInvestigator/ InstitutionSponsor8.2.1 INVESTIGATORIS BROCHURE To document that relevant and current scientific information about the investigational product has been provided to the investigator XX8.2.2 SIGNED PROTOCOL AND AMENDMENTS, IF ANY, AND SAMPLE CASE REPORT FORM (CRF)To document investigator and sponsor agreement to the protocol/amendment(s) and CRF XX8.2.3INFORMATION GIVEN TO TRIAL SUBJECT - INFORMED CONSENT FORM (including all applicable translations) To document the informed consent XXANY OTHER WRITTEN INFORMATIONTo document that subjects will be given appropriate written information (content and wording) to support their ability to give fully informed consent XX-ADVERTISEMENT FOR SUBJECT RECRUITMENT (if used)To document that recruitment measures are appropriate and not coercive X8.2.4FINANCIAL ASPECTS OF THE TRIATo document the financial agreement between the investigator/institution and the sponsor for the trial XXTitle of DocumentPurposeLocated in Files ofInvestigator/ InstitutionSponsor8.2.5INSURANCE STATEMEN where required To document that compensation to subject(s) for trial-related injury will be available XX8.2.6SIGNED AGREEMENT BETWEEN INVOLVED PARTIES, e.g.: - investigator/institution and sponsor - investigator/institution and CRO - sponsor and CRO - investigator/institution and authority(ies) (where required)To document agreements X X X X X (where required) X X8.2.7DATED, DOCUMENTED APPROVAL/FAVOURABLE OPINION OF INSTITUTIONAL REVIEW BOARD (IRB) /INDEPENDENT ETHICS COMMITTEE (IEC) OF THE FOLLOWING: - protocol and any amendments - CRF (if applicable) - informed consent form(s) - any other written information to be provided to the subject(s) - advertisement for subject recruitment (if used) - subject compensation (if any) - any other documents given approval/ favourable opinionTo document that the trial has been subject to IRB/IEC review and given approval/favourable opinion. To identify the version number and date of the document(s) XXTitle of DocumentPurposeLocated in Files ofInvestigator/ InstitutionSponsor8.2.8INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE COMPOSITION To document that the IRB/IEC is constituted in agreement with GCPXX (where required)8.2.9AUTHORISATION/APPROVAL/ NOTIFICATION OF PROTOCOL (where required)To document appropriate authorisation/approval/notification by the regulatory authority(ies) has been obtained prior to initiation of the trial in compliance with the applicable regulatory requirement(s) X (where required)X (where required)8.2.10CURRICULUM VITAE AND/OR OTHER RELEVANT DOCUMENTS EVIDENCING QUALIFICATIONS OF INVESTIGATOR(S) AND SUB-INVESTIGATOR(S)To document qualifications and eligibility to conduct trial and/or provide medical supervision of subjects XX8.2.11NORMAL VALUE(S)/RANGE(S) FOR MEDICAL/ LABORATORY/TECHNICAL PROCEDURE(S) AND/OR TEST(S) INCLUDED IN THE PROTOCOTo document normal values and/or ranges of the tests XX8.2.12MEDICAL/LABORATORY/TECHNICAL PROCEDURES /TEST - certification or - accreditation or - established quality control and/or external quality assessment or - other validation (where required) To document competence of facility to perform required test(s) , and support reliability of results X (where required)XTitle of DocumentPurposeLocated in Files ofInvestigator/ InstitutionSponsor8.2.13SAMPLE OF LABEL(S) ATTACHED TO INVESTIGATIONAL PRODUCT CONTAINER(S)To document compliance with applicable labelling regulations and appropriateness of instructions provided to the subjectsX8.2.14INSTRUCTIONS FOR HANDLING OF INVESTIGATIONAL PRODUCT(S) AND TRIAL-RELATED MATERIALS(if not included in protocol or Investigators Brochure)To document instructions needed to ensure proper storage, packaging, dispensing and disposition of investigational products and trial-related materialsXX8.2.15SHIPPING RECORDS FOR INVESTIGATIONAL PRODUCT(S) AND TRIAL-RELATED MATERIALSTo document shipment dates, batch numbers and method of shipment of investigational product(s) and trial-related materials. Allows tracking of product batch, review of shipping conditions, and accountabilityXX8.2.16CERTIFICATE(S) OF ANALYSIS OF INVESTIGATIONAL PRODUCT(S) SHIPPEDTo document identity, purity, and strength of investigational product(s) to be used in the trialX8.2.17DECODING PROCEDURES FOR BLINDED TRIALSTo document how, in case of an emergency, identity of blinded investigational product can be revealed without breaking the blind for the remaining subjects' treatment XX (third party if applicable)Title of DocumentPurposeLocated in Files ofInvestigator/ InstitutionSponsor8.2.18MASTER RANDOMISATION LISTTo document method for randomisation of trial populationX (third party if applicable)8.2.19PRE-TRIAL MONITORING REPORTTo document that the site is suitable for the trial (may be combined with 8.2.20)X8.2.20TRIAL INITIATION MONITORING REPORTTo document that trial procedures were reviewed with the investigator and the investigators trial staff ( may be combined with 8.2.19)XX 8.3 During the Clinical Conduct of the Trial In addition to having on file the above documents, the following should be added to the files during the trial as evidence that all new relevant information is documented as it becomes available Title of DocumentPurposeLocated in Files ofInvestigator/ Institution  Sponsor8.3.1 INVESTIGATORS BROCHURE UPDATESTo document that investigator is informed in a timely manner of relevant information as it becomes available XX8.3.2ANY REVISION TO: - protocol/amendment(s) and CRF - informed consent form - any other written information provided to subjects - advertisement for subject recruitment (if used) To document revisions of these trial related documents that take effect during trialXX8.3.3DATED, DOCUMENTED APPROVAL/FAVOURABLE OPINION OF INSTITUTIONAL REVIEW BOARD (IRB) /INDEPENDENT ETHICS COMMITTEE (IEC) OF THE FOLLOWING: - protocol amendment(s) - revision(s) of: - informed consent form - any other written information to be provided to the subject -advertisement for subject recruitment (if used) - any other documents given approval/favourable opinion - continuing review of trial (where required) To document that the amendment(s) and/or revision(s) have been subject to IRB/IEC review and were given approval/favourable opinion. To identify the version number and date of the document(s).XXTitle of DocumentPurposeLocated in Files ofInvestigator/ InstitutionSponsor8.3.4REGULATORY AUTHORITY(IES) AUTHORISATIONS/APPROVALS/NOTIFICATIONS WHERE REQUIRED FOR: - protocol amendment(s) and other documents To document compliance with applicable regulatory requirementsX (where required)X8.3.5CURRICULUM VITAE FOR NEW INVESTIGATOR(S) AND/OR SUB-INVESTIGATOR(S) (see 8.2.10)XX8.3.6UPDATES TO NORMAL VALUE(S)/RANGE(S) FOR MEDICAL/ LABORATORY/ TECHNICAL PROCEDURE(S)/TEST(S) INCLUDED IN THE PROTOCOL To document normal values and ranges that are revised during the trial (see 8.2.11)XX8.3.7UPDATES OF MEDICAL/LABORATORY/ TECHNICAL PROCEDURES/TESTS - certification or - accreditation or - established quality control and/or external quality assessment or - other validation (where required) To document that tests remain adequate throughout the trial period (see 8.2.12)X (where required)XTitle of DocumentPurposeLocated in Files ofInvestigator/ InstitutionSponsor8.3.8DOCUMENTATION OF INVESTIGATIONAL PRODUCT(S) AND TRIAL-RELATED MATERIALS SHIPMENT(see 8.2.15.)XX8.3.9CERTIFICATE(S) OF ANALYSIS FOR NEW BATCHES OF INVESTIGATIONAL PRODUCTS(see 8.2.16)X8.3.10MONITORING VISIT REPORTS To document site visits by, and findings of, the monitor X8.3.11RELEVANT COMMUNICATIONS OTHER THAN SITE VISITS - letters - meeting notes notes of telephone callsTo document any agreements or significant discussions regarding trial administration, protocol violations, trial conduct, adverse event (AE) reportingXX8.3.12SIGNED INFORMED CONSENT FORMSTo document that consent is obtained in accordance with GCP and protocol and dated prior to participation of each subject in trial. Also to document direct access permission (see 8.2.3)X8.3.13SOURCE DOCUMENTSTo document the existence of the subject and substantiate integrity of trial data collected. To include original documents related to the trial, to medical treatment, and history of subjectXTitle of DocumentPurposeLocated in Files ofInvestigator/ InstitutionSponsor8.3.14CASE REPORT FORMS (CRF)To document that the investigator or authorised member of the investigators staff confirms the observations recorded X (copy)X (original)8.3.15DOCUMENTATION OF CRF CORRECTIONSTo document all changes/additions or corrections made to CRF after initial data were recorded X (copy)X (original)8.3.16NOTIFICATION BY ORIGINATING INVESTIGATOR TO SPONSOR OF SERIOUS ADVERSE EVENTS AND RELATED REPORTSNotification by originating investigator to sponsor of serious adverse events and related reports in accordance with 4.11 XX8.3.17NOTIFICATION BY SPONSOR AND/OR INVESTIGATOR, WHERE APPLICABLE, TO REGULATORY AUTHORITY(IES) AND IRB(S)/IEC(S) OF UNEXPECTED SERIOUS ADVERSE DRUG REACTIONS AND OF OTHER SAFETY INFORMATIONNotification by sponsor and/or investigator, where applicable, to regulatory authorities and IRB(s)/IEC(s) of unexpected serious adverse drug reactions in accordance with 5.17 and 4.11.1 and of other safety information in accordance with 5.16.2 X (where required)x8.3.18NOTIFICATION BY SPONSOR TO INVESTIGATORS OF SAFETY INFORMATIONNotification by sponsor to investigators of safety information in accordance with 5.16.2 XXTitle of DocumentPurposeLocated in Files ofInvestigator/ InstitutionSponsor8.3.19INTERIM OR ANNUAL REPORTS TO IRB/IEC AND AUTHORITY(IES)Interim or annual reports provided to IRB/IEC in accordance with 4.10 and to authority(ies) in accordance with 5.17.3 XX (where required)8.3.20SUBJECT SCREENING LOGTo document identification of subjects who entered pre-trial screening XX (where required)8.3.21SUBJECT IDENTIFICATION CODE LISTTo document that investigator/institution keeps a confidential list of names of all subjects allocated to trial numbers on enrolling in the trial. Allows investigator/institution to reveal identity of any subjectX8.3.22SUBJECT ENROLMENT LOGTo document chronological enrolment of subjects by trial number X8.3.23INVESTIGATIONAL PRODUCTS ACCOUNTABILITY AT THE SITETo document that investigational product(s) have been used according to the protocol XX8.3.24SIGNATURE SHEETTo document signatures and initials of all persons authorised to make entries and/or corrections on CRFs XX8.3.25RECORD OF RETAINED BODY FLUIDS/ TISSUE SAMPLES (IF ANY)To document location and identification of retained samples if assays need to be repeated XX8.4 After Completion or Termination of the Trial After completion or termination of the trial, all of the documents identified in sections 8.2 and 8.3 should be in the file together with the following Title of DocumentPurposeLocated in Files ofInvestigator/ Institution  Sponsor8.4.1 INVESTIGATIONAL PRODUCT(S) ACCOUNTABILITY AT SITETo document that the investigational product(s) have been used according to the protocol. To documents the final accounting of investigational product(s) received at the site, dispensed to subjects, returned by the subjects, and returned to sponsorXX8.4.2DOCUMENTATION OF INVESTIGATIONAL PRODUCT DESTRUCTIONTo document destruction of unused investigational products by sponsor or at siteX (if destroyed at site)X8.4.3COMPLETED SUBJECT IDENTIFICATION CODE LISTTo permit identification of all subjects enrolled in the trial in case follow-up is required. List should be kept in a confidential manner and for agreed upon timeX8.4.4AUDIT CERTIFICATE (if available)To document that audit was performedX8.4.5FINAL TRIAL CLOSE-OUT MONITORING REPORTTo document that all activities required for trial close-out are completed, and copies of essential documents are held in the appropriate files XTitle of DocumentPurposeLocated in Files ofInvestigator/ InstitutionSponsor8.4.6TREATMENT ALLOCATION AND DECODING DOCUMENTATIONReturned to sponsor to document any decoding that may have occurredX8.4.7FINAL REPORT BY INVESTIGATOR TO IRB/IEC WHERE REQUIRED, AND WHERE APPLICABLE, TO THE REGULATORY AUTHORITY(IES)To document completion of the trialX8.4.8CLINICAL STUDY REPORTTo document results and interpretation of trialX (if applicable)X  4N^Ջ{tĉ vU_ MR 1.0/g 2.0ICH GCP vSR 3.0:ggċ[YXTO/rzv&OtYXTO(IRB/IEC) 3.10L# 3.20~b0L#Td\O 3.30 z^ 3.40U_ 4.0xvz 4.10xvzvDmv[c NSsQN"Rv[c0ՋeHhSN\O:NT TvW@x0 1.18 OSYXTO 3uR~~vOS[eY-N_ՋvYXTO0 1.19 OSxvz Sc>m#OSSRNyY-N_ՋvT-N_xvzvN Txvz0 1.20 T Txvz~~CRO N3uRzQY~[bN*NbY*N gsQ3uRevՋNRTRv*NNb~~FUN'`v f[/gvbvQN 0 1.21 vc AQv[0Rg08h[T Y6RNUO[NċN4N^Ջ g͑aINvU_TbJT0vcvNUONeYVQTVYv{tS_@\ 3uRevv[XTT=zgXT ^S_S(u{tBlv:fN ǑSNRTtv2ce~b[aNT3uRDevO['`0 1.22 eN cbU_Ջvel0[eT/b~g q_TՋvV } NSǑSvceI{vNUOb__vU_SbFO NPNfNb05uP[0x'`TIQf[vU_ NSkbc0X\~T_5uV 0 1.23 _eN cTꁌTT(WNwAQċNN*NxvzvgbL`QT@b_pencv(ϑeN8.[e4N^Ջv_eN 0 1.24 4N^Ջ{tĉGCP /f4N^Ջ0[e0gbL0v[0=zg0U_0RgTbJTvhQ [:NpencT@bbJT~gvSO'`TQnx'`cONO v^ObՋ[avCg)R0[te'`T:g['`0 1.25 rzvpencv[YXTOIDMC pencT[hQv[YXTO v[YXTO pencv[YXTO 1u3uRzN*Nrzvpencv[YXTO [[g[xvzۏU\0[hQ'`pencT gHe'`~pۏLċ0O T3uR^/f&T~~0teb\PbkՋ0 1.26 lQs^vN rzN4N^Ջ0 NSNՋ gsQNXTv NlQckq_Tv*NN0Yg[ab[avTlcSNhN N N/yY\SNw` TaǏ z v^T[acO~yYNvw` TafNTvQNfNbDe0 1.27 rzv&OtYXTOIEC N*N1u;Sf[NNNXTT^;Sf[NNNXT~bvrz:ggxvz:ggv00W:Sv0V[vbV[v[ċ:ggbYXTO vQL#/fOSRՋ[avCgv0[hQ'`TeP^v^Ǐ[ՋeHh0xvzNXT0eNS(uN_TU_Ջ[aw` TavelTPgevTt'`ۏL[ċTybQ/cOwOۏ\O(uvaN[ُyObcOlQOO0 (W N TvV[ rzv&OtYXTOvl_0WMO0~b0L#0d\OT(uv{tBlS N(u FO/f^S_Y,gc[SR@b AQrzv&OtYXTO cGCPۏL]\O0 1.28 w` Ta N*N[a(WJTwNvQ\OQQ[ gsQv@b gՋOo`T DnnxNbyYSRN*Nyr[Ջva?aǏ z0w` TaǑ(ufNbv0~{W[v^lfegvw` TafN0 1.29 Ɖ[ {tS_@\(WՋUSMO03uRT/bT Txvz~~b{tS_@\:NUOevvQN:gg[vQ:NN4N^Ջ gsQveN0Y0U_TvQNDnۏLv[e[gv;mR0 1.30 ;Sf[ xvz:gg [e4N^ՋNUObyNv[SO0Nt:gg0;Sf[bye0 1.31 :gg[ċYXTOIRB 1u;Sf[0yf[T^yf[bXT~bvN*Nrz:gg vQL#/fǏ[ՋeHhSvQO,g _SՋ[aw` Ta@b(uvelTDeۏL[ċ0ybQT~~[ċ nxONyՋvSՋ[avCg)R0[hQTeP^_0ROb0 1.32 4N^Ջ/xvz-NgbJT 9hncՋۏLǏ z-N@bZPvRgQQv-Ng~gTċNvbJT 1.33 Ջ(uoT Ny(W4N^Ջ-NOՋvb\O:N[gqv;m'`bRb[paBRvoir6RBR0SbN*N] N^oTN N TN@bybQve_(ub~T6RBRbSň b(uNN*N*g~ybQv^ b(uN6eƖN*N]ybQ(ulvfYDe0 1.34 xvz #(WN*NՋUSMO[e4N^ՋvN0Yg(WN*NՋUSMO/f1uN~NXT[eՋ xvzcُ*N~v#N _Ny:N;Nxvz0!k~xvzNXT0 1.35 xvz/xvz:gg h:y &{T(u{tBlvxvzT/bxvz:gg 1.36 xvzKbQ NՋoT(WN{|[a-Nvxvz gsQv4N^T^4N^DevGl7.xvzKbQ 1.37 l_ NScSvNh (W(ul_ NcCgNhNMO*gegv[a TaSR4N^Ջv*NN bSlNXTbvQN:gsQ0 1.38 v[ vcwN*N4N^ՋvۏU\ O4N^Ջ cgqՋeHh0hQd\O z^SOP 04N^Ջ{tĉGCP T(uv{tBl[e0U_TbJTv;mR0 1.39 v[bJT v[XT(WkN!ks:WT/bvQNNՋ gsQvNAmT 9hnc3uRvSOPQ~3uRvfNbbJT0 1.40 Y-N_Ջ cgqN*NՋeHh (WN*NN NՋUSMO[e Vdk1uN TN Nxvz[bv4N^Ջ0 1.41 ^4N^Ջ N/f(WN{|[aۏLvuir;Sf[xvz0 1.42 aNrzv&OtYXTOvsQ 1urzv&OtYXTOIEC ~QvċNT/b^ 1.43 SY;Sf[U_ neN0 1.44 ՋeHh N*NfՋvvv00elf[0~f[QT~~veN0ՋeHh8^_N~QՋv̀ofTtW@x FOُSNQ(WNeHh gsQvvQNSeN-N0(WICHc[SR-N ՋeHhُN/gcՋeHhTeHhvO9e0 1.45 ՋeHhvO9e [ՋeHhv9eSbonvfNbc0 1.46 (ϑOQA :NOՋvۏLTpencNu0U_NSbJT&{T4N^Ջ{tĉGCP T(u{tBl@b^zv gRv|~;mR0 1.47 (ϑc6RQC (W(ϑO|~Q@bǑSvd\Ob/gT;mR NgNՋvsQv;mR&{T(ϑBl0 1.48 :gS :NNQ\OPP Ǒ(u:gGQ[RMvSt\Ջ[aRMPlu~b[gq~vǏ z0 1.49 {tS_@\ gCgۏL{tvWg0(WICH GCPc[SR-N {tS_@\N͋Sb[ċ@bcNv4N^pencT[eƉ[v:gg1.29 0ُN:gg gec;N{S_@\0 1.50 %N͑ NoNNSAE b%N͑oT NoS^ Su(WNUOBRϑvNUO Nx^;Sf[NN [{kN qSSu}T OOblub^OObe [8lENb%N͑vku/R'N1Y b HQ)Y'`_8^/Qu:w ICH4N^[hQ'`penc{tc[SR _bJTv[INThQ 1.51 npenc 4N^Ջ-Nv4N^Ss0‰[bvQN;mRvSYU_SvQS`oR,g-NvhQDe NN[N͑^TċNՋ/f_v0npencS+T(WneN-NSYU_bS`oR,g 0 1.52 neN SYeN0pencTU_Y;SbU_ 4N^TRlQ[Vh [[{ Y_U_ [aeaSbċNh o?bSoU_ ꁨRNhVvU_penc (W8h[TZP:NQnxoR,gvS` YpSNbbN >f_Gr Ddq_Gr )_wSbxN( X~ [aeN NSOX[(Wo?b0[[TNSN4N^Ջv;Sf[b/g-NvU_0 1.53 3uR [N*N4N^ՋvSw0{tT/b"R#v*NN0lQ(u0:ggb~~0 1.54 3uR xvz USrNvQNNNw Swv^[eN*N4N^Ջv*NN0(WNN vvcc:y N ~[a g(u0S~[ab1u[aO(uՋoT0/gv^ NSbdN*NNNYvNUONY NSbN*NlQSbN*N:gg 0N*N3uR xvzvINRSbN*N3uRTN*Nxvz$NvINR0 1.55 hQd\O z^SOP :N0RGWN'`[bN*Nyr[L#c[v~fNbf0 1.56 !k~xvzNXT (WN*NՋUSMO (W;Nxvzc[Tvcw Nv4N^Ջ~-N[bNՋ gsQv͑ z^T/b\OQN gsQՋv͑'YQ[vbXTY TN OOb;Su yr+R/fxvzu 0xvz0 1.57 [a/Ջ[a SRN*N4N^Ջ\O:NՋoTvcSb\O:N[gqv*NN0 1.58 [aƋ+Rx xvz:NkN TSՋ[ac[vryrƋ+RSx NOb[avNv^(WxvzbJT NoNNT/bvQNNՋ gsQpenceNf[aY T0 1.59 ՋUSMO wck_U\N4N^Ջ gsQ;mRv0We0 1.60 ^gvoT NoS^ Ny NoS^ vQ'`(b%N͑ z^Ns gvNTDeYNy*gybQՋ(uoTvxvzKbQ bSňceQu/N*N]~ybQoirvNT'`Xd N&{v NoS^ICH4N^[hQ'`penc{tc[SR_bJTv[INThQ 0 1.61 1_R[a cS0R NckS_vq_T y:NN*N4N^_?avN NNS1uNggeckS_N&T SRՋ 4Ov)Rv bb~SROS0RI{~-NDmbXTvb Y0 gI{~~gvVSOvbXT Y;Sf[0of[0ybbtNNvf[u D^\;SbT[[NXT 6RolQSvǖXT QN NSvyvN0vQN1_R[aSbeSQeov` OO(Wy)Rb)RvN 1YNbwzN YNqS%`rQvuN \pele e[SR_ Amjm *gbt^ TNeR~Qw` TavN0 1.62Ջ[av eP^ SR4N^Ջ[avSOyOvSΘi0 NeOTgvSv0S gS_gvSv'YNΘie Mb_YT~~N*N4N^Ջ0 2.30Ջ[avCg)R0[hQTeP^/fg͑vQ ^S_܀Ǐyf[T>yOv)Rv0 2.40sQNՋ(uoTS_0Rv^4N^T4N^De^N/ec@bcv4N^Ջ0 2.504N^Ջ^S_ gZW[vyf[W@x gfnx0~cvՋeHh0 2.604N^Ջv[e^S_u_NHQ]~_0Rxvz:gg[gYXTO)2" /rzv&OtYXTO)%# ybQ/^bvՋeHh0 2.70N TTkTeP xvzNXTvge{S/bvQNfvQDkyvpeϑTe_ Nnxl g[Ջ[avb NckS_q_T0~[av/eN^S_ ckORM N/f[hQN[a[bՋ [0 3.1.90IRB/IEC^S_O sQN/eN~[avDe Sb/eNe_0peϑT/eN~Ջ[aveh]RNw` TafNT\cO~[aNUOvQNfNbDe N ^lf ckO/eNve_0 3.20~b0L#Td\O 3.2.10IRB/IEC^1uTtpevvbXT~b NNhQSO g[ċTċNyf[0;Sf[TT@bcՋv&Otf[ebvDeT~0^IRB/IEC^Sb A 0\ TbXT B 0\N TbXTsQ_v͑We^yf[W C 0\N TbXTrzNxvz:gg/ՋUSMO0 S gNrzNՋxvzT3uRvIRB/IECbXTMb[N*NՋvvsQNybhy/cQ^0 ^S_cONNIRB/IECbXTv TUSTNNvDNLO0 3.3.3 [ՋۏLRY[ċT~~[ċ0 3.3.4 L`nx[~~[ċv^0 3.3.5Ogq(uv{tBl :N]~_IRB/IECybQ/^bvck(WۏLvՋv\O9ecO_[ċTybQ/^ba0 3.3.6 f(WIRB/IECfNb~{r[ՋvybQ/^baKNMR N_c~[aۏeQՋ0 3.3.7f(WeHhvS_O9eHQ_0RIRB/IECvfNbybQ/^bKNMR NOPyb9eSՋeHh d^ g_cd[N[avvcqS[ beHhv9eSSmSՋvTRb{tebYfbcv[XT 9eS5u݋Sx 4.5.2 0 3.3.8 fxvzNXT^S_zsSbJTIRB/IECvNy A OPyb9eSeHhNmdՋ[avvcqS[3.3.7 4.5.2 4.5.4  B XR[aΘiv9eST/bf>fq_TՋ[ev9eS4.10.2  (C)0@b g%N͑vT^gvoT NoS^!$2  D [ՋvۏLb[av[hQS N)Rq_TveDe0 3.3.9 nxOIRB/IECŏwxvz/xvz:ggvNy A NՋ gsQvQ[/^ B IRB/IECQ[/avt1u C BlIRB/IECQ[/av z^0 3.4U_ IRB/IEC^S_OYuhQ gsQU_YfNbv z^ bXT TUS bXTvLN/T|h cNveN OU_ NS_egON [bՋT\3t^ v^(W{tS_@\eSNcOvQfNb z^TbXT TUS0 4.0xvz 4.10xvzvDm~NNNՋvsQvT;`NRvNXT TUS0 4.20YvDn 4.2.10xvz^fY9hncW_vpenc (WOSvbRgQc~@bpevvT[avS'`0 4.2.20xvz(WOSvՋgQ^S_ gYve[eT[bՋ0 4.2.30(WSvՋgQ xvz^S_ gYpeϑvTm~(Wxvz/xvz:ggvcw NvTvo^bvQNS_vNXT0 4.6.30xvz/xvz:ggT/bSxvz/xvz:ggc>mvN To^bvQNTv*NN ^S_OX[Ջ(uoTN0RՋUSMOvU_ (WՋUSMOvX['nUS kMO[avO(uU_ T*gO(uvoTN؏~3uRbSlYnvU_0ُNU_^S+Teg0peϑ0ybS/|RS0eHegY g 0TRM~Ջ(uoTTՋ[avyr+Rx0xvz^Oc} g ceHhf~N[aoϑvU_ v^^NN3uRY6e0RvՋ(uoT;`peN0 4.6.40Ջ(uoT^ c3uRvfPX[5.13.2T5.14.3 v^&{T(uv{tBl0 4.6.50xvz^S_OՋ(uoTS c]ybQveHhO(u0 4.6.60xvzbxvz/xvz:ggc[vN ^S_TkNMO[aʑՋ(uoTv%Zcknx(ul v^^(WTNՋvN[hgkNMO[a[hQugqO(uf(uo0 4.7 :gS z^T4xv xvz^S_u_Ջv:gS z^Yg g v^^OOgqeHhSb_:gSx0YgՋǑ(uvl xvz^S_zsSU_v^T3uRʑՋ(uoTvNUOcMR4xvYNY4xv V%N͑ NoNN4xv 0 4.8 Ջ[avw` Ta 4.8.1 (W_Tfw` TaǏ z-N xvz^S_u_(uv{tĉ[ ^S_&{T'#0Tnk\Wt^[v&OtSR0(W_YՋMR xvz^S_ gIRB/IEC[NfNbvw` TafNTcO~[avvQNeW[DevfNbybQ/^ba0 4.8.2 eUOe_0RN[avw` TaSvsQvevDeT cO~[avfNbw` TafNTvQNeW[De^S_ۏLO9e0O9eTvfNbw` TafNTvQNeW[De(W(uMR^S__0RIRB/IECvybQ/^b0Yg gN[a~~SRՋv?agSvsQveDe ^Sew[aT[avTlScSNh0ُyDevNAm^S_U_ Neg0 4.8.3 eՋ1\NXT؏/fՋLXT N^:_b NckS_0Wq_TN*N[aSRb~~SRN*NՋ0 4.8.4 sQNՋvSbfNbvDe SbfNbvw` TafN N^S+TO_w[ab[avTlScSNh>e_b wega/f>e_NUOTl)RvvbMQdb wega/fMQdxvz0:gg03uRbNNvNt1uNu_^#Nv0 4.8.5 xvzb1uxvzc[vN \^S_JTɋ[a bYg[a NcOw` TaeJTɋ[avTlScSvNh @b gNՋvsQveb SbeW[DeTIRB/IECvybQ/^ba0 4.8.6 sQNՋvSTfNbDe SbfNbw` TafN @b(uv^S_/f^b/g/g'`v[(u [N[ab[avTlScSNhblQckvN^S_/ffav0 4.8.7(WS_0Rw` TaKNMR xvzbxvzc[vN^S_[ab[avTlcSNh gEQveT:gOsQNՋv~`QTQ[/f&TSRՋ0^S_VT{@b g [ab[avTlScSNhna0 4.8.8 (W[aSRՋKNMR [ab[avTlScSNhNSgbLw` TavN^NMRw` TafNv^lfeg0 4.8.9 YgN T[a N bNMOTlScSvNh N (Wte*Nw` Tag_ gNMOTlScSvNh N(WfNbvw` TafNTvQNeNDeN~[aT T[ab[avTlScSNhۏLv^ʑ (W[ab[avTlScSNh]~S4Y Ta[aSRՋ0v^NYgS](Ww` TafN N~{W[v^lfeg0NǏ~{rw` TafNf w` TafNTvQNeW[De]QnxvT[ab[avTlScSNh\ONʑ [ab[avTlScSNh>f6qa_ُNʑ w` Ta/f[ab[avTlScSNh1uv~Qv0 4.8.10 w` TaTcO~[avfNbvw` TafNNSvQNeW[De^S_SbN Nvʑ (a)ՋmSvxvz (b)Ջvv (c)ՋluT:gRM0RTyluvS'` (d)Ջ1\Lv z^ Sb@b gO'` z^ (e)[av#N (f)Ջv['`eb (g)&^~[a0Se&^~ڀ΀0΀?QbTsNtZ?QvTtvqSib NeO (h)STtvSv0 NX[(Wgv4N^Sve [a^S_wSُNp (i)[aS_0RvSfNlu z^bǏ z NSُNluv͑\o(WSvTΘi (j)(WNՋvsQv$O[NN-N[aS_vePT/blu (k)~SRՋ[avg ckORMv/eNYg g  (l)[aVSRՋvg9Yg g  (m)[aSRՋ/f?av [aSNb~SRՋ b(WNUOePQՋ NO6e0RQSb_c1Y,geg[a gCg)R_0Rv)Rv0 (n)v[XT0=zgXT0IRB/IECT{tS_@\\QN(W NݏS[avO['`0(W(ul_Nĉ[Qv z^vc[avSY;Sf[U_Ng4N^Ջ z^T/bpenc [ab[avTlScSvNhǏ~{rfNbvw` TafNcCgُy0 (o)(W(ul_T/bĉ[AQvV t+R[avU_^O[ N_lQ_ُNU_0YgՋ~gSh [at+RN6q/fO[v0 (p)Yg_0RN[a~~SRՋv?agSvsQvDe [ab[avTlScSNh\_0RSeb0 (q)ۏNekN gsQՋDeTՋ[avCg)RevT|N NS(WSuNՋ gsQv$O[evT|N0 (r)[aSRՋS~bkvS`QT/bt1u (s)[aSRՋvgc~e (t)SRՋ[av'Y~Npe 4.8.11 (WSRՋMR [ab[avTlScSNh^6e0RNN]~{rv^lfegvfNbw` TafNv YpSNTvQNcO~[avfNbDe0[aSRՋg [ab[avTlScSNh^6e0R]~{rv^lfegvw` TafNvfev YpSNTcO~[avfNbDevO9ee,g0 4.8.12 S_N*N4N^Ջluvb^luv SbNL1uvQTlScSNhh:yۏeQՋv[aeY*gbt^N b%N͑uFTuN ^S_(W[at㉄v z^JTw[asQNՋvOo`0YgS [a^S_N~{rfNbvw` Tav^lfeg0 4.8.13 d^Y4.8.14@bcv`QY N*N^luՋY[N[al gSgvvc4N^}YYvՋ ^S_(WNN Tav^(WfNbvw` TafN N~{W[Tlfegv[a-NۏL0 4.8.14 S&{T NRagN ^luՋSN(W1uTlScSNh Tav[a-NۏL (a)Ջvvv NǏ(WN~Qw` Tav[a-NۏLvՋ0R0 (b) [avSΘi_NO (c)[N[aeP^vbq_TQ0Rg\ v^N/fgNOv (d) l_ NybkՋ (e)fnxv[BlIRB/IEC[c~ُN[avybQ/^bafNbvybQ/^ba Tac~ُN[a0 d^f/fN*NOY ُ{|Ջ^S_(WwQ gg(uՋ(uoTvuubrQvuN-NۏL0ُNՋ-N[a^S_S0Ryr+Rv[Rhg YgNN>f_ǏRu ^S_QՋ0 4.8.15 (W'}%``Q N NSNHQ_0R[avw` Tae ^Bl[avTlScSNhYg(W:W v Ta0S_[avc~ ceHhT/bvQNeN-Ncv0_0RIRB/IECvfNbybQ/^bavelۏL NOb[avCg)R0[hQTeP^ v^OON(uv{tBl0^=\S0Ww[ab[a0WTlScSNhsQNՋ0WN v^^_0RNN~~SRՋTvQNNy4.8.10 vw` Ta0 4.9U_TbJT 4.9.1 xvz^S_O~3uRvuSbJTh#2& T@b gvbJT-NvpencvQnx'`0[te'`0f'`TSe'`0 4.9.2 #2&-NegꁐneNvpenc^S_NneNN Y1u NN^\OQʑ0 4.9.3 #2&-NpencvNUO9eSbSf ^S_lfeg0Y TW[kTfY g_ v^^S_OSegvU_O6qSsS^OYu8hgu ُ T7h(uNeW[T5uP[v9eSbfck5.18.4N 03uR^S_TxvzT/bxvzc[vNhcOsQNۏLُyfckvcWS03uR^S_ gfNbv z^NO(WCRF-N1u3uRc[vNh\OQv9eSbfck/f gU_v0 g_v v^_0RxvzvS0xvz^S_OYu9eSTfckvU_0 4.9.4 xvz/xvz:gg^S_ c 0[e4N^ՋvW,geN 08. @bT(u{tBlOX[ՋeN0xvz/xvz:gg^S_ǑSce2bkُNeNvNYbǏe4xOW0 4.9.5 W,geN^S_OYu0RgTybQ(WN*N)#(0W:S N^T\2t^ Tv0RgT(WN*N)#(0W:Sl g*gQvbN(WQv N^^(u bՋ(uoTv4N^xvzck_\PbkT\]ǏS2t^0FO/f Yg(uv{tBlb3uR~{rvOS ُNeN^S_OX[fe03uR g#N~6Rxvz/xvz:gg 0RNHNePُNeN N_QOX[5.5.12 4.9.6 Ջv"RebN[^(W3uRNxvz/xvz:ggvOSfN-Nf0 4.9.7 9hncv[XT0=zgXT0IRB/IECb{tS_@\vBl xvz/xvz:gg^S_cONNg@bvNՋ gsQvhQ萰U_0 4.10ۏU\bJT 4.10.1 xvz^S_kt^N!k b^IRB/IECBlv^TIRB/IECcNfNbvՋ`QXd0 4.10.2 xvz^S_ŏT3uR0IRB/IEC3.3.8 TYgT Txvz:ggcOsQNf>fq_TՋ[eT/bXR[aΘivNUO9eSvfNbbJT0 4.11 [hQ'`bJT 4.11.1 dNՋeHhbvQNeNYxvzKbQ :N N_sSebJTvN%N͑ NoNN3!% NY @b g3!%^S_zsST3uRbJT0sSebJT^t:Nŏv~fNbbJT0sSeTbJT-Nv[at+R^S_Ǒ(uǑ(uc[~Ջ[avryrSx N/f[aY T0*NNNSxT/b0W@W0 4.11.2 xvz؏^S_ gNsQN{tS_@\TIRB/IECbJT^gvoir%N͑ NoS^v(u{tBl0 4.11.3 (WՋeHh-Nnx[:N[[hQ'`ċN/fsQ.v NoNNT/b[[_8^^S_ cgqbJTBlT3uR(WeHh-NfvePQT3uRbJT0 [N@bbJTv{kNNN xvz^S_T3uRTIRB/IECcO@bvhQDRDeYVRbJTTg~;Sf[bJT 0 4.12 Ջv-Nbkbf\P YgN*NՋV:NNUOt1uǏev\Pbkbf\P xvz/xvz:gg^S_ŏwՋ[a ^S_O[avTluT T9hnc(uv{tBl^S_w{tS_@\0SY 4.12.1 Ygxvz*gN3uRNHQOSO-Nbkbf\PN*NՋ xvz^S_wxvz:gg xvz/xvz:gg^S_zsSw3uRTIRB/IECcO-Nbkbf\PՋv~fNbʑ0 4.12.2 Yg3uR-Nbkbf\PN*NՋ5.21 xvz^S_zsSwxvz:gg xvz/xvz:gg^zsSwIRB/IECv^TIRB/IECcO-NbkTf\Pv~fNbʑ0 4.12.3 YgIRB/IEC~bkbf\P[[N*NՋvybQ/^ba3.12T3.3.9 xvz^S_wxvz:gg xvz/xvz:gg^S_zsSb3uRv^cO~bkbf\Pv~fNbʑ0 4.13 xvzvg~bJT (WՋ[bT xvz^S_wxvz:gg xvz/xvz:gg^S_TIRB/IECcOՋ~gvXd T{tS_@\cO@bv@b gbJT0 5.3uR 5.1 (ϑOT(ϑc6R 5.1.1 3uR# cgqfNb3/0gbLT~c(ϑOT(ϑc6R|~ OՋv[eTpencvNu0U_TbJTՋeHh0'#00S(uv{tBl0 5.1.2 3uR g#NObT gsQebvOS O3uRNhgT=zg:Nvvvvc1.21 T gsQՋUSMO0npenc/eN0bJT NSOVQTVY{tS_@\vƉ[0 5.1.3 (WpencYtvkN6k^S_ g(ϑc6R NO@b gvpenc/fS`vv^]~_0RcknxYt0 5.1.4 3uRTxvz/xvz:ggNSSR4N^ՋvvQNe^S_zfNbOSOSSN/feHhvNR _NSN NUSrvOS0 5.2 T Txvz:gg#2/ 5.2.1 3uRSN\NՋ gsQv#NTNRRbhQly~N*N#2/ FO/fՋpencv(ϑT[te'`vg~#N8l܏(W3uR0#2/^S_^z(ϑOT(ϑc6R0 5.2.2 ly~#2/vb#2/bbvNUONՋ gsQv#NTL^S_ gfNbf0 5.2.3 l gfnxly~#2/b1u#2/bbvNUONՋ gsQ#NTLN6q1u3uRbb0 5.2.4 ,gc[SR-NmS3uRvNR_N(uNN*N#2/ 1\P#2/]~bbNN*N3uRvNՋvsQ#NTL0 5.3 ;Sf[N[ 3uR^S_c[ gTDf9eS ^S_(We6RBR(uN4N^ՋKNMR_6RBRNTvDRxvz~gY3z['`0nQs uir)R(u^ NċNُN9eS/f&Tf>f9eSNToNRRf[yr_0 5.14 xvzNTO^T{t 5.14.1 3uR#Txvz/xvz:ggcOՋ(uoT 5.14.2 3uR(W_0RhQYeNYIRB/IECT{tS_@\vybQ/^ba KNMR N_Txvz/xvz:ggcOՋoir0 5.14.3 3uR^S_nxOfNbd\O z^S+Txvz/xvz:gg^S_u_vsQNՋ(uoTvYtTPX[vfSvQeN0 z^^S_fS_T[hQvcS0Yt0PX[0RS0N[aYSV*gO(uvoirNS\*gO(uvՋ(uoTԏV~3uRb~3uRcCgv^ugq(u{tBlk 0 5.14.43uR^S_ (a)nxO ce\Ջ(uoTxvz (b)OX[fЏ0c6e0RS06eVTkՋ(uoTvU_8.[e4N^ՋvW,geN (c) gN*NSVՋ(uoTTU_SVvĉ[Y g:wNTv6eV (WՋ~_gTR_؏ ǏgoTR_؏ 0 (d) gN*NYn*gO(uxvzoTTU_ُyYnvĉ[0 3uR^S_ (a)ǑSekNOՋoT(Wte*NO(ugQv3z['`0 (b)~cYpeϑv(uNՋ-NvՋ(uoT N(WNN g_eQnxvQĉm~*g~cCgvN0 (i)8h[xvzSbRTfW'`4ls^ 6.9.4 ~bkՋvhQ 6.9.5 Yt:1Ypenc0*g(upencT NTtpencv z^ 6.9.6 bJTOPyS[~Rv z^S[~RvNUOSf^S_(WeHh-NT/b(Wg~bJT-Nfv^~Qt1u 6.9.7 ReQRg[av bY@b g:gSv[a @b g~ov[a @b gTNO O['`HO b ~{W[uO b 1 vU_ 2 i 3 _ 4 irt0Sf[Sof[yr'`TYe 5 ^4N^xvz 5.1 ^4N^otf[ 5.2 RirSOQoirRRf[ToirN" 5.3 ktf[ 6 NSOQ\O(u 6.1 NSOQvoirRRf[ToirN" 6.2 [hQ'`T gHe'` 6.3 N^~ 7 penciTxvzQR laSDe01.0lQ_Shir 000000002.0bJT SDe^(WkNz+gRQ DU_ g 8. 4N^Ջ_eN 8.1_ _eN_cNSUSrTTweg(uNċNՋv[eS@bNuvpenc(ϑveN0ُNeNS fxvz03uRTv[XT[GCPT@b gvsL{tBlvON'`0 _eN_N(uNvQNNNvv0(Wxvz/xvz:ggT3uR{0Ws:WSev\_eNR_ch Yg'Y0W.^Rxvz03uRTv[XT[ՋۏLbRv{t0\O:NnxՋ[ev gHe'`T@b6eƖpenc[te'`vǏ zvNR ُNeN_N~8^S3uRY>mvrz=zgXT=zgv^c6e{tS_@\Ɖ[0 Nb{RQgNOP^v_eN09hncvQ(WՋv N T6kv_ zNu S\ N TeNR:N N*NR(1)(W4N^Ջ_YKNMR(2)4N^ՋۏLg(3)[bb~bk4N^ՋT0kNeNfvQvv NS/f&T\勇eNReQxvz/xvz:ggb3uRbSevchHh-N0Ygk*NRfNv HN\NNeNTv^_N/fSNcSv0 Ջ_Ye (Wxvz/xvz:gg{0WS3uRRlQ[^zՋ;`chHh0S gS_v[XT[8hNxvz/xvz:ggS3uRSevchHhv^nx[@b g_veN(W[vchHhwS[Q ՋMbgT~_g0 (Wc[SRQcSvNUOb@b geNSS0R _N^S_cO3uRe=zgXTv=zgT;N{蕄vƉ[0 8.2 4N^Ջ_YKNMR (Wc[xvzR6k ^Nu NReNv^(WՋck__YKNMRR_ch0 eNhvvR_ch(Wxvz/xvz:gg3uR8.2.10xvzKbQf gsQՋoTvvsQOo`TgeyxR`]~cO~xvzXX8.2.2]~{W[vՋeHhTO9e( g)SuObJTh(CRF)7h,gfxvzT3uR TaՋeHh/O9eTCRFXX8.2.30SՋ[a^wOo`XX w` TafNSb@b g[(uvыe NUOvQNfNbOo` bR[av^JTO(u fw` Ta fSՋ[a_p`S_vfNbOo`Q[Sc N/ecNNcO[hQw` TavR fbRKbk/fT[vNeZu X X X8.2.4 Ջv"RrQU_xvz/xvz:ggT3uRKNsQNՋv"ROSXX8.2.5 OiH_e fSՋ[amSNՋvsQ$O[e\_ePXX8.2.6SNՋTeKN~{rvOS OY xvz/xvz:ggT3uR xvz/xvz:ggTCRO 3uRTCRO xvz/xvz:ggT;N{ _e fN Ta X X X X X(e) X X8.2.7 IRB/IEC[N NTyQ[vfNbybQ/^bav^lfeg ՋeHhTNUOO9e CRF(Y(u) w` TafN NUOvQNcO~SՋ[avfNbDe bR_?a^JTO(u [SՋ[aveP g NUOvQN_ybQ/^baveNfՋ]~ǏIRB/IECċ0Ov^_ybQ/^ba0nxeNvHr,gSTb_begXX8.2.8 IRB/IECv~bfIRB/IECv~b&{TGCPBlXX(_e)8.2.9;N{[ՋeHhvS/ybQ/b_e f(WՋ_YKNMR]~ cgqsLv{tBl_N;N{[vNUO/ybQ/bX(_e)X(_e)8.2.100xvzT!k~xvzNXTe\ST/bfvQDeMOnThƋXX 8.4 4N^Ջ[bb~bkKNT (WՋ[bb-NbkKNT 8.2S8.3@bReNS NReNv^R_ch08.4.10ՋoT(WՋpvSpe'`fՋoT/f9hncՋeHhO(u0f(Wxvzs:W6e0Rv0S>e~SՋ[av0SՋ[a؏v0ԏ؏~3uRvՋoTvgTpeXX8.4.2ՋoTkU_f*gO(uvՋoT1u3uRb(Wxvzs:Wkv`QX(Wxvzs:Wkv݋ X8.4.3[tevSՋ[aNt+Rxh(WeAQt+RbRۏeQՋv@b gSՋ[avN0xh_O[v^X[>e~[eX8.4.4=zgfY f]ۏLǏ=zgX8.4.5Ջ~_gv[bJTf@b gՋ~_g@b_v;mR][b _eNvoR,gOX[(WTvchHh-NX8.4.6luRMhSxU_ԏ؏~3uRNfNUOSuǏvxd\OX8.4.7_exvzTIRB/IECSTeT;N{cNv;`~bJTfՋv[bXX8.4.84N^xvzbJTcOՋv~gTʑXYT X mSNvuir;Sf[xvz&Ot[gRl ՋL 2007t^ kSu kSyYeS02007017S N%%Nt^NgASNe ,{Nz0;`00R ,{Nag0:NĉmSNvuir;Sf[xvzTvsQb/gv^(u ObNvu}TTeP^ ~bNv \%N \͑TObN{|SՋvTlCgv Onc 0-NNSNlqQT VgbN;S^l 0T 0;Su:gg{tagO 0v gsQĉ[ 6R[,gRl0 00 ,{Nag0mSNvuir;Sf[xvz&Ot[g]\OGW cgq,gRl~~ۏL0 00 ,{ Nag0,gRl@bymSNvuir;Sf[xvzTvsQb/g^(uSbN N;mR 00N Ǒ(usNirtf[0Sf[Tuirf[el(WNSO N[Nvut0utsaNSuuvʋe0luT2elۏLxvzv;mR 00N Ǐuir;Sf[xvzb_bv;SukSub/gbNT(WNSO NۏLՋ'`^(uv;mR0(W,gRleLMR](W4N^[-N^(uǏ$Nt^v b(W,gRleLMR]~_kSuL?eybQ4N^^(uvb/g N^\N,gRlĉ[v[gV0 ,{Vag0&Ot[g^S_u[V[l_0lĉTĉzvĉ[NSlQvu}T&O tSR &Ot[gǏ z^S_rz0[‰0lQckTf0 ,{Nz0&OtYXTO 00,{Nag0kSu萾z;Sf[&OtN[YXTO0w~kSuL?e蕾z,gL?e:SWv&Ot[gc[T~~0kSu萌Tw~kSuL?e蕾zvYXTO/f;Sf[&OtN[T~~ ;N[͑'Y&OtۏLxvz cQ?eV{Ta _eS~~[͑'Yyxyvv&Ot[g[:SQ:gg&OtYXTOv&Ot[g]\OۏLc[0vcw0kSu萌Tw~kSuL?e蕾zv&OtN[YXTO 0z z 0 SL6R[0 00 ,{mQag0_U\mSNvuir;Sf[xvzTvsQb/g^(u;mRv:gg Sb;SukSu:gg0yxb@b0uu2c6RTY|^OeP:ggI{ z:gg&OtYXTO0:gg&OtYXTO;Nbb&Ot[gNR [,g:ggb@b^\:ggmSNvuir;Sf[xvzTvsQb/g^(uyvۏL&Ot[gTvcw_NS9hnc>yOBl StYXb[g Te~~_U\vsQ&OtW0 00 ,{Nag0:gg&OtYXTOvYXT1uz&OtYXTOvb:gg(W^l_BlavW@x N Nuir;Sf[WT{tf[0&Otf[0lf[0>yOf[I{>yOyf[WvN[-Nc>NNu Npe N_\N5N v^N^S_ g N T'`+RvYXT0\pele0W:S^Q\peleYXT0 00 ,{kQag0:gg&OtYXTOYXTNg5t^ SNޏN0&OtYXTO;NNYXTNN oR;NNYXTr^N 1u&OtYXTOYXTOSFUc>NNu SNޏN0z:gg&OtYXTOvb:gg^S_9hnc&OtYXTOYXTv]\O`Q~NS_vbl0 ,{]Nag0:gg&OtYXTOv[gL#/f[gxvzeHh ~bTObSՋv \%NTCgvnxOxvz NO\SՋf2N NTtvqSiKN-N Te[]ybQvxvzۏLvcwThg SeYtSՋvbɋT NoNN0 00 ,{ASag0:gg&OtYXTOSNLO NRCgP 00N BlxvzNXTcOw` TafN b9hncxvzNXTvBl ybQMQdw` Ta z^ 00N BlxvzNXTO9exvzeHh 00 N BlxvzNXT-Nbkb~_gxvz;mR 00V [xvzeHhZPQybQ0 NybQbO9eTQ[gvQ[0 00 ,{ASNag0&OtYXTOYXT^S_:NcS&Ot[gvxvzyvO[0 00 ,{ASNag0&OtYXTO cgq&OtSR;NZPQQ[ NSNUOr^pb~ g^S_Se ObS^0 00 ,{AS Nag0&OtYXTOcS,gL?e:SWTV[kSuL?e蕄vvcwT{t0 ,{ Nz0[g z^ ,{ASVag0mSNvuir;Sf[xvz&Ot[gSR/f 00N \͑TOSՋ;NQ[ Tab N TaSՋvCg)R %NyO)RvvQ RBlOSՋg'Y z^SvT=\SMQ$O[ 00 N Q{bMQdSՋ(WSՋǏ z-NVSv bbv~Nmb 00V \͑TObSՋvy Y[\mSSՋyvDePX[TO(u`QSO[ceJTwSՋ N_\mSSՋyvDeT`QTesQv,{ Nb OdZSO2 00N nxOSՋVSՋS0R_c$Oe_0RSeMQ9luv^_0Rv^vTP 00mQ [N'N1Yb:ONR~bꁫCg)RT)RvvSՋ1_N Sb?Qz0U[Y0zfRNO N0|^yuN0VrNS~NmagN]TeS z^_NO ^S_NNyr+ROb0 00 ,{ASNag0ۏL&Ot[gvxvzyv^T&OtYXTOcN NRPge 00N &Ot[g3uh 00N xvzbvsQb/g^(ueHh 00 N SՋw` TafN0 00 ,{ASmQag0yv3uN_{NHQ_0RSՋ?avfNbw` Ta0el_fNbw` Tav ^S_NHQ_S4Yw` Ta v^cN_S4Yw` TavfPge0[NeL:NR0el]ZPQQ[vSՋ_{_0RvQvbNbNtNvfNbw` Ta0 ,{ASNag0(W_SՋw` Tae 3uN_{TSՋcO[tefav_Oo` w` TafN^S_NOfaveW[h \pele0W:SSNǑ(uS_0WeW[h v^:NSՋ@bt Te~NSՋEQRveQ/f&T TaSՋ0 ,{ASkQag0S_yvv[e z^bagNSuSSe _{͑e_SՋvw` Ta v^͑eT&OtYXTOcQ&Ot[g3u0 00 ,{AS]Nag0&OtYXTO N_StݏSV[l_0lĉvyxyvcQv&Ot[g3u0&OtYXTOYXTN3uyv g)RvQzv ^S_;NRV0elVv ^S_T3uNlQ_ُy)Rv0 00 ,{NASag0&OtYXTO[3u&Ot[gvyvۏL NR[g 00N xvzvDNbmSNvuir;Sf[xvz-Nݏĉb NzvL:N0 00 ,{NAS]Nag0xvzNXTSuݏS&OtSRvL:N xvzyv#N@b^\USMONSkSuL?eGW gCg~Nv^YZ v^ۏLlQ_ybċ Sm_VYRvDyO)RvvQ0&OtYXTONw` TafN/fOSՋCgvv;Nce0 00 ,{]Nag0:NnxO4N^Ջ-NSՋvCgv {bzrzv&OtYXTO v^TV[ߘToTvcw{t@\YHh0&OtYXTO^ gNN;SovsQNNNXT0^;SoNNNXT0l_N[SegvQNUSMOvNXT \NN~b v^ g N T'`+RvYXT0&OtYXTOv~bT]\O N^SNUOSNՋvq_T0 00 ,{ASag0ՋeHh~&OtYXTO[ Tav^~{rybQaTeS[e0(WՋۏLg ՋeHhvNUOO9eGW^~&OtYXTOybQՋ-NSu%N͑ NoNN ^SeT&OtYXTObJT0 00 ,{ASNag0&OtYXTO[4N^ՋeHhv[ga^(WTNbhye_\OQQ[ SN4N^ՋvYXT^S_V0V]\OS^YXTvN[Q-^O FO Nbhy0&OtYXTO^^z]\O z^ @b gOSvQQGW^ gfNbU_ U_OX[4N^Ջ~_gTNt^0 00 ,{ASNag0&OtYXTO^NOSՋCgvv҉^%NmcvvgXTb=zgXTvvgT=zgSoTvcw{t蕄v=zgTƉ[ nxO4N^Ջv(ϑ0 00 ,{NAS]Nag0xvz^N3uRFU[ gsQ4N^Ջv9(u v^(WT T-NQf0xvz(W4N^ՋǏ z-N N_TSՋ6eSՋ(uo@bv9(u0 00 ,{ NASag04N^Ջ[bT xvz_{QQ;`~bJT ~{ Tv^lfegT3uR0 00,{ NASNag0xvz-NbkNy4N^Ջ_{wSՋ03uR0&OtYXTOToTvcw{t v^ft1u0 ,{mQz03uRvL# 00,{ NASNag03uR#Sw03u0~~0vgT=zgNy4N^Ջ v^cOՋ~903uR cV[l_0lĉI{ gsQĉ[ TV[ߘToTvcw{t@\N4N^Ջv3u _NSYXbT Txvz~~gbL4N^Ջ-NvgN]\OTNR0 00 ,{ NAS Nag03uR b4N^Ջv:ggTxvz SvQDfWOPyb(W4N^ScSVNYvpenc{RN8h[0hKmyv_{lf@bǑ(uvϑUSMO0 00 ,{NASag0:NObSՋy uObJTh N N^QsSՋvY T0xvz^ cSՋvNxnxvQNv^U_0 00 ,{NASNag04N^Ջ;`~bJTQ[^NՋeHhBlN Sb 00N :gۏeQT~v[EuOpe 1=TTRdvuOSvQt1u 00N N T~vW~yr_k Nnx[Sk'` 00 N [@b guHeċNchۏL~RgT4N^aINRg0~~gvʑ^@w͑QvQ4N^aIN 00V [hQ'`ċN^ g4N^ NoNNT[[chTtv~Rg [%N͑ NoNN^~cTċN 00N Y-N_ՋċNuHe ^Q-N_X[(Wv]_SvQq_T 00mQ [ՋoirvuHeT[hQ'`NSΘiTSvKNvsQ|\OQ{iT0 00 ,{NASNag04N^Ջ-NvDeGW{ cĉ[OX[DU_2 S{t0xvz^OX[4N^ՋDe4N^Ջ~bkTNt^03uR^OX[4N^ՋDeՋoirybQ N^TNt^0 ,{]Nz0penc{tN~Rg ,{NAS Nag0penc{tvvv(WNbՋpencŏ0[te0e0W~eQbJT @b gmSpenc{tvTyekGWU_(WHh NO[penc(ϑSՋ[eۏLhg0(uS_v z^Openc^vO['` ^wQ g{:gpenc^v~bT/ec z^0 00 ,{NASVag04N^Ջ-NSՋRM_{ cՋnx[v:gRMeHhۏL k TSՋvYtR~x^\O:Nv^1u3uRTxvzR+ROX[0vՋ^(WeHh-Nĉ[cvvagNTgbLcvv z^ v^M gv^Ytxv^%`ON0(W'}%``Q N AQ[*N+RSՋ'}%`4xv NvQ@bcSvlu FO_{(WuObJTh Nft1u0 00 ,{NASNag04N^ՋDev~RgǏ zSvQ~gvh_{Ǒ(uĉv~f[el04N^ՋT6kGW guir~f[NNNXTSN04N^ՋeHh-N g~RgR v^(Wck_~RgMRRNnxT~S0\O-NgRg ^ft1uSd\Oĉ z0[lu\O(uvċN^\SO:SNGPhv~gNv^Q0@b (u~RgpencƖRNf0[NWo0*g(ubYYOvDe{RNf 4N^Ջv~bJT_{N4N^Ջ;`~bJTv&{0 ,{ASz0Ջ(uoTv{t 00,{NASmQag04N^Ջ(uoT N_.U0 00 ,{NASNag03uR#[4N^Ջ(uoT\OS_vSňNh~{ v^hf:N4N^ՋN(u0(WSv4N^Ջ-N ՋoirN[gqoTb[paBR(WYb_0lsT0Sň0h~{TvQNyr_ NGW^N0 00 ,{NASkQag0Ջ(uoTvO(uU_^Sbpeϑ0ňЏ00cS0RM0^(uTiRYOoirvV6eNkI{ebvOo`0 00 ,{NAS]Nag0Ջ(uoTvO(u1uxvz# xvz_{O@b gՋ(uoTN(uN4N^ՋvSՋ vQBRϑN(ul^ugqՋeHh iRYOvՋ(uoTV3uR NǏ z1uNN#v^U_(WHh Ջ(uoT{ gNN{t0xvz N_bՋ(uoTlNNUO^4N^ՋSR0 00 ,{mQASag0Ջ(uoTvO~0O(u0PυSiRYOoirvYtǏ z^cSvsQNXTvhg0 ,{ASNz0(ϑO 00,{mQASNag03uRSxvzGW^e\LTL# v^%NNNu0 00 ,{]Nag0&OtYXTOYXT^ TalQ_vQY T0LNT^\sQ| ~{r gsQ[gyv0SՋOo`TvsQN[vO[OS ~{r)RvQzXf0 00 ,{ASag0&OtYXTOSNXrz~bYN8^Nrz~0rz~^&OtYXTOv 1\ՋeHh-NvNNT&OtYXTOcOTa FOrz~ NwQ g&Ot[ghQCg0rz~SN/f&Otbl_ebv0yr[uubelf[vN[ b/fyrkuuN0yr[0W:SN/ebvQNyr[)RvVSOvNh0 00 ,{ASNag0&OtYXTO^[eYXTTYXTv~~Ye^zW:g6R ~~GCPI{vsQl_lĉ0oir4N^Ջ&Ot[gb/gNS&OtYXTOhQd\Oĉ zvW0 00 ,{ASNag0&OtYXTO^6R[hQd\Oĉ zT6R^ NnxO&Ot[g]\Ovĉ'`NN'`0Q[\SbN NQ*Neb 00N hQd\Oĉ zN&Ot[g3ucWSv6R[ 00N &OtYXTOv~~N{t&OtYXTOv~^ &Ot[gvO[ce )RvQzv{t YXTN]\ONXTvW rz~v X 00 N &Ot[gve_O[gN'}%`O[g _[g 00V &Ot[gvAm z[g3uvStNYt RY[g ߍ*[g [gQ[v O 00N O{tOQY O z^ OU_ 00mQ eNNchHh{t^ch OX[ gN YpS0 ,{ Nz0&OtYXTOvL#Bl 00,{AS Nag0&OtYXTO^9hnc&Ot[g]\Ov Ne[U~~{tT6R^^ e\LObSՋv[hQTCgvvL#0 00 ,{ASVag0&OtYXTO^S_[3uNcNvoir4N^Ջyvv&OtۏLrz0lQck0lQs^TSev[g0&OtYXTOd[,g:gg@bbb[ev@b goir4N^ՋyvۏL[gvcwY _NS[vQN:ggYXbv4N^ՋyvۏL[g0 00 ,{ASNag0&OtYXTO[oir4N^ՋۏL[gvcwSNLOY NCgR 00N ybQ/ NybQNyoir4N^Ջ 00N [ybQv4N^ՋۏLߍ*[g 00 N ~bkbf\P]~ybQv4N^Ջ0 00 ,{ASmQag0&OtYXTObzT^SeTV[ߘToTvcw{t@\T@b(W0Ww~ߘToTvcw{tYHh0YHhe^cNY NDe&OtYXTO;NNYXTTYXT TUSD{S 0&OtYXTOz z0&OtYXTOvsQ]\O z^T6R^0 00 ,{ASNag0&OtYXTO^TV[ߘToTvcw{t@\T@b(W0Ww~ߘToTvcw{t蕥bJTt^^&Ot[g]\O`Q0 ,{Vz0&Ot[gv3uNSt 00,{ASkQag0&OtYXTO^:N&Ot[g3uNcOmS&Ot[gNyvT gR cO[g3u@bv3uhyOvSv0 002.4 ՋΘiNSvvTt'``$[SՋ gvcSvMRofvՋ gSvNΘi^\NvMRS_vfNluvSvNΘivS_0ՋΘiv[NSՋgvSv _{/fTtva$[SՋl gvcSvMRofvՋ Θiv[N>yOgSv _{/fTtv0 003. SՋvbR 003.1 SՋvNyr_Sb'`+R0t^0yeI{ 0 003.2 ՋvSvTΘi(WvhuuN-NlQs^TlQckRM0 003.3 bǑSvbRe_Tel0 003.4 TSՋbvQNhJTw gsQՋOo`ve_0 003.5 SՋv~eQNcdhQ0 004. w` TafNJTwvOo` 004.1 Ջvv0^u_vՋekSb@b gOeQ'`d\O 0ՋgP0 004.2 gvSՋvΘiT NO0 004.3 gvSv0S_SՋl gvcSve ^JTwSՋ0 004.4 SՋS_vY lu NSY lu͑v\o(WΘiTSv0 004.5 SՋSRՋ/f&T_bl0 004.6 SՋSRՋ/f&Tbb9(u0 004.7 Ƌ+RSՋNv gsQU_vO[ z^ v^f_e Ջyv3uR0&OtYXTO0?e^{t cĉ[SNgSRՋvSՋDe0 004.8 YSuNՋvsQv_c[e SՋSN_vluTv^veP0 004.9 fSRՋ/f?av SNb~SRb gCg(WՋvNUO6keQՋ NOm0RgkƉbb Y vQ;Su_GNCgv NOS0Rq_T0 004.10 S_X[(W gsQՋTSՋCg)Rv NSSuՋvsQ$O[e gT|NST|e_0 005. w` TavǏ z 005.1 w` Ta^&{T[hQJTw0EQRt0;N bvSR0 005.2 w` Tavh^Ofa TSՋSOt㉄v4ls^0 005.3 [YUO_w` Ta g~vc Sbfnx1u#Sw` Ta NS~{rw` TafNvĉ[0 005.4 R~eQ Nhw` Ta\O:NSՋe t1uEQRckS_ [YUO_w` TabcCg Ta g~f0 005.5 (WxvzǏ z-N,TSv^T{ YSՋbvQNhvuTavĉ[0 006. SՋv;SuTOb 006.1 xvzNXTDyO/ec0 006.5 SՋ?aQՋebǑSvce0 006.6 ^O(u0'}%`O(ubQN T` cOՋ(uovhQ0 006.7 Ջ~_gT /f&T~~TSՋcOՋ(uovf0 006.8 SՋ/eNv9(uf0 006.9 cOSՋvePSbsё0 gR0T/byOsQ|ebv)RvsQ|0 00penc[hQv[YXTO(Data and Safety Monitoring Board): 1u3uR#^zvN*Nrzvpenc[hQv[YXTO vQL#/f[gċ0OՋۏU\ Rg[hQ'`pencNS͑vHe^ch v^T3uRcQՋ~~ۏL0bۏLOck0bcMR~bkv^0 00&OtYXTOEthics Committee Institutional Review Board 1u;Sf[NNNXT0l_N[S^;SRNXT~bvrz~~ vQL#:N8hg4N^ՋeHhSDN/f&TTNNS_ v^:NKNcOlQOO nxOSՋv[hQ0eP^TCgvS0ROb0YXTOv~bTNR;mR N^S4N^Ջ~~T[evr^pbbq_T0 00w` TaInformed Consent cTSՋJTwNyՋvTeb`QT SՋ?anxvQ TaSRy4N^ՋvǏ z {N~{ TTlfegvw` TafN\O:NeNf0 00w` TafNInformed Consent Form /fkMOSՋh:y?aSRgNՋveNf0xvzTSՋfՋ'`(0Ջvv0SvSvTΘi0SO (uvvQNluelNS&{T 0k\W[ 0ĉ[vSՋvCg)RTINRI{ OSՋEQRNThvQ Ta0 00g\ΘiMinimal Risk cՋ-NgΘivS'`T z^ N'YNe8^u;m0bۏL8^ĉSOkvĉ[gbL0 00VRboTvcw{t蕁^v 0-NNSNlqQTVoxQ 0ToThQ:NV[oThQ0 00VRboTvcw{t~~oxQYXTO #V[oThQv6R[TO0 00VRboTvcw{t蕄voTh:gg#h[V[oThQT0[gqT0 00 ,{ NAS Nag00VRboTvcw{t~~of[0;Sf[TvQNb/gNXT [eoۏL[ċ []~ybQuNvoTۏLQċN0 00 ,{ NASVag00oTuNON0oT~%ON0;Su:gg_{NwQ goTuN0~%De\'`oT [Lyrk{t0{tRl1uVRb6R[0 00 ,{ NASmQag00V[[L-NoTyOb6R^0wQSORl1uVRb6R[0 00 ,{ NASNag00V[[oT[LYeoN^YeoR{|{t6R^0wQSORl1uVRb6R[0 00 ,{ NASkQag00ybkۏSuHe Nnx0 NoS^'YbvQNSVqS[NSOeP^voT0 00 ,{ NAS]Nag00oTۏS {~VRboTvcw{t~~[g ~[gnx&{T(ϑhQ0[hQ gHev eSybQۏS v^S~ۏSoTlQfN0 ;SuUSMO4N^%`b*NN(uۏSv\ϑoT cgqV[ gsQĉ[RtۏSKb~0 00 ,{VASag00oT_{NAQoTۏSvS\ۏS v^1uۏSoTvONTS\@b(W0WoTvcw{t{vYHh0wmsQQoTvcw{tQwQv 0ۏSoTsQUS 0>eL0e 0ۏSoTsQUS 0v wmsQ N_>eL0 00S\@b(W0WoTvcw{t蕔^S_woTh:gg cgqVRboTvcw{t蕄vĉ[[ۏSoTۏLbgh v^Ogq,gl,{VASNag,{N>kvĉ[6eSh90 00AQoTۏSvS\1uVRboTvcw{tO TwmsQ;`rcQ bVRbybQ0 00 ,{VASNag00VRboTvcw{t[ NRoT(W.UMRbۏSe c[oTh:ggۏLhh NTk@bRoTvh9yvT6e9hQ1uVRb"?eO TVRbNe\'`oT0Y(uoTT^Yeovh~{ _{pS gĉ[vh_0 ,{Nz00oTNyOs^GWb,g0^:WOBlrQT>yObSRTt6R[TteNkgbrjv OlvzRN#N0 00 ,{NASVag00uN0.UGPov l6eݏluN0.UvoTTݏl@b_ v^YݏluN0.UoT'k goTybQfeNvNNd v^#N\PN0\PNte`%N͑v T 0oTuNS 00 0oT~%S 0b 0;Su:gg6RBRS 0gbrjv OlvzRN#N0 00 ,{NASNag00uN0.URov l6eݏluN0.UvoTTݏl@b_ v^YݏluN0.UoT'k`%N͑v #N\PN0\PNtebdoTybQfeN0 T 0oTuNS 00 0oT~%S 0b 0;Su:gg6RBRS 0gbrjv OlvzRN#N0 00 ,{NASmQag00NNuN0.UGPoSuN0.URo`%N͑vONbvQNUSMO vQvc#v;N{NXTTvQNvc#NNXTASt^Q N_NNoTuN0~%;mR0 [uNN(uNuNGPo0RovSPge0SňPge0uNY NNl6e0 00,{NASNag00wSb^S_wS^\NGPRoT :NvQcOЏ0O{0NPI{O)RagNv l6ehQЏ0O{0NPv6eeQ v^Yݏl6eeQ~vRKNNASN N N PN NvZ>kgbrjv OlvzRN#N0 00 ,{NASkQag00[GPo0RovYZw _{}foTh:ggv(ϑh~gFO/f ,gl,{VASkQag,{ N>k,{N 0N 0N 0mQ yT,{VAS]Nag,{ N>kĉ[v`b_dY0 00 ,{NAS]Nag00oTvuNON0~%ON0oir^4N^[hQ'`ċNxvz:gg0oir4N^Ջ:gg*g cgqĉ[[e 0oTuN(ϑ{tĉ 00 0oT~%(ϑ{tĉ 00oir^4N^xvz(ϑ{tĉ0oir4N^Ջ(ϑ{tĉv ~NfJT #NPg9eck>g N9eckv #N\PN0\PNte v^YNCSCQN NNNCQN NvZ>k`%N͑v T 0oTuNS 00 0oT~%S 0Toir4N^Ջ:ggvDk gݏl@b_v l6eݏl@b_`%N͑v T 0oTuNS0 0oT~%S 0b;Su:gggbNSfN0 00 ,{kQASNag00ۏS]_oTۏSlQfNvoT *g cgq,glĉ[TAQoTۏSvS\@b(W0WvoTvcw{t{vYHhv ~NfJT #NPg9eck>g N9eckv dۏSoTlQfN0 00 ,{kQASNag00*O 0S 0pNVS0Qy0QPSboTybQfeNv l6eݏl@b_ v^Yݏl@b_N PN N N PN NvZ>kl gݏl@b_v YNNCQN NASNCQN NvZ>k`%N͑v v^ TVSe0Qye0QPev 0oTuNS 00 0oT~%S 00 0;Su:gg6RBRS 0bdoTybQfeNgbrjv OlvzRN#N0 00 ,{kQAS Nag00ݏS,glĉ[ cOZGPvf0eNDe7hTbǑSvQN:kKbkS_ 0oTuNS 00 0oT~%S 00 0;Su:gg6RBRS 0boTybQfeNv T 0oTuNS 00 0oT~%S 00 0;Su:gg6RBRS 0bdoTybQfeN Nt^Q NStvQ3u v^YNNCQN N NNCQN NvZ>k0 00 ,{kQASVag00;Su:gg\vQM6Rv6RBR(W^:W.Uv #N9eck l6eݏl.Uv6RBR v^Yݏl.U6RBR'k gݏl@b_v l6eݏl@b_0 00 ,{kQASNag00oT~%ONݏS,gl,{ASkQag0,{AS]Nagĉ[v #N9eck ~NfJT`%N͑v T 0oT~%S 00 00 ,{kQASmQag00oThƋ N&{T,gl,{NASVagĉ[v dOl^S_ cgqGPo0RoYvY #N9eck ~NfJT`%N͑v doTvybQfeN0 00 ,{kQASNag00oTh:ggQwQZGPhbJT gbrjv OlvzRN#N Ngbrjv #N9eck ~NfJT [USMOv^Y NNCQN NNNCQN NvZ>kc#v;N{NXTTvQNvc#NNXTOl~NM~0dL0_dvYR v^Y NNCQN NvZ>k gݏl@b_v l6eݏl@b_`%N͑v dvQhDk gݏl@b_v NNl6e`%N͑v 1u]FUL?e{t ToTuNON0oT~%ONv%Ngbgq v^woTvcw{t 1uoTvcw{t TvQ 0oTuNS 00 0oT~%S 0gbrjv OlvzRN#N0 00 ,{]NASNag00oTvuNON0~%ONv#N0Ǒ-NXTI{ gsQNXT(WoT--N6eSvQNuNON0~%ONbvQNtN~Nv"irbvQN)Rvv Ol~NYR l6eݏl@b_gbrjv OlvzRN#N0 00;Su:ggv#N0oTǑ-NXT0;S^I{ gsQNXT6eSoTuNON0oT~%ONbvQNtN~Nv"irbvQN)Rvv 1ukSuL?eb,gUSMO~NYR l6eݏl@b_[ݏlL:N`%N͑vgbN;S^ 1ukSuL?e TvQgbNfNgbrjv OlvzRN#N0 00 ,{]NASNag00ݏS,gl gsQoT^JTv{tĉ[v Ogq 0-NNSNlqQTV^JTl 0vĉ[YZ v^1uS~^JTybQeSvoTvcw{t蕤d^JTybQeS Nt^Q NStTyv^JT[yb3ugbrjv OlvzRN#N0 00oTvcw{t[oT^JT NOle\L[gL# ybQS^v^JT gZGPbvQNݏSl_0L?elĉvQ[v [vc#v;N{NXTTvQNvc#NNXTOl~NL?eYRgbrjv OlvzRN#N0 00 ,{]NAS Nag00oTvuNON0~%ON0;Su:ggݏS,glĉ[ ~oTO(u b_c[v OlbbTP#N0 00 ,{]NASVag00oTvcw{tݏS,glĉ[ g NRL:NKNNv 1uvQ N~;N{:gsQbv[:gsQ#N6eVݏlS~vfN0doTybQfeN [vc#v;N{NXTTvQNvc#NNXTOl~NL?eYRgbrjv OlvzRN#N 00N [ N&{T 0oTuN(ϑ{tĉ 00 0oT~%(ϑ{tĉ 0vONS~&{T gsQĉvfNv b[S_fNvON*g cgqĉ[e\Lߍ*hgvL# [ N&{TagNvON*gOl#NvQ9eckbdvQfNv 00N [ N&{Tl[agNvUSMOS~ 0oTuNS 00 0oT~%S 0b 0;Su:gg6RBRS 0v 00 N [ N&{TۏSagNvoTS~ۏSoTlQfNv 00V [ NwQY4N^ՋagNbuNagN ybQۏL4N^Ջ0S~eofN0S~oTybQeSv0 00 ,{]NASNag00oTvcw{tbvQnvoTh:ggbvQnx[vNNNNoThv:ggSNoTuN~%;mRv 1uvQ N~:gsQbv[:gsQ#N9eck gݏl6eeQvNNl6e`%N͑v [vc#v;N{NXTTvQNvc#NNXTOl~NL?eYR0 00oTvcw{tbvQnvoTh:ggbvQnx[vNNNNoThv:ggv]\ONXTSNoTuN~%;mRv Ol~NL?eYR0 00 ,{]NASmQag00oTvcw{tbvQn0nx[voTh:gg(WoTvcwh-Nݏl6eSh9(uv 1u?e^ gsQ#N؏ [vc#v;N{NXTTvQNvc#NNXTOl~NL?eYR0[ݏl6eSh9(u`%N͑voTh:gg dvQhDg N9eckv gCgNN9eSbd0 00 ,{]NAS]Nag00oTvcw{tNXTn(uLCg0_y _0s_L[ gbrjv OlvzRN#N\ Ngbrjv Ol~NL?eYR0 00 ,{N~vag00Ogq,gl T 0oTuNS 00 0oT~%S 0v 1uoTvcw{tw]FUL?e{t蕞RtSfbl{v0 00 ,{N~vNag ,gzĉ[v'e\'`oT0@n0uׂ0@m6RTTʋeoTI{0 00e /fcuNoTTMYee@b(uvKb_BRTDRBR0 00oTuNON /fcuNoTvN%ONb|Q%ON0 00oT~%ON /fc~%oTvN%ONb|Q%ON0 00 ,{N~v Nag00-NoPgvy i0ǑƖTr{Qv{tRl 1uVRbSL6R[0 00 ,{N~vVag00V[[2'`uir6RTvAm[Lyrk{t0wQSORl1uVRb6R[0 00 ,{N~vNag00-NVNl>eQgbL,glvwQSORl 1uVRb0-N.YQNYXTOOnc,gl6R[0 00 ,{N~vmQag00,gl2001t^12g1eweL0 DU_ 1 -NNSNlqQTVoT{tl-NsQNoir4N^ՋvageTʑIN ,{NAS]Nag0x6Reo _{ cgqVRboTvcw{t蕄vĉ[Y[bx6Rel0(ϑch0otSktՋ~gI{ gsQDeT7hT ~VRboTvcw{tybQT eSۏL4N^Ջ0oir4N^Ջ:ggDkvĉ[ (W[beov4N^Ջv^Ǐ[ybveo 1uVRboTvcw{tybQ v^S~eofN0sLv 0eo[ybRl 0\eov4N^ՋR:N`!0a!0b!0c!g v^[T{|eoۏL`!0a!0b!0c!g4N^ՋSuirI{He'`ՋvwQSOBl\ONĉ[0(W cĉ[[beo4N^Ջ ~VRboTvcw{t蕝Ogq,gl,{ NAS Nagvĉ[~~of[0;Sf[TvQNb/gNXTۏL[ċ :N&{T[hQ0 gHeBlv 1uVRboTvcw{t蕝OlybQ S~eofN0lav/f S_eofN S/fS_Nb g勰eovvsQCgv(SN3uۏLuNbb/gl)vl[Dkvĉ[ GLP1uVRbnx[v6R[0ۏLoirv^4N^[hQ'`ċN _{gbLVRb gsQ蕝Ol6R[vGLP0 00N0@boir4N^Ջ /fcNUO(WNSOuNbeP^_?a ۏLvoir|~'`xvz N[bc:yՋ(uoirv\O(u0 NoS^SՋ(uoirv8T6e0R^0N"Tcl vv/fnx[Ջ(uoirvuHeN[hQ'`0oir4N^Ջ:gg/fcNNoir4N^ՋvUSMO0:NOoir4N^ՋǏ zĉ0yf[ ~gw[S` OSՋv[hQT)Rv 20N~60t^Nw YV[6R[N gsQoir4N^Ջv{tĉ("Good Clinical Practice" )Q:NGCP NLukSu~~_NN1994t^^NGCPcWS ^gb:NvQ@b gbXTVqQ Tu[vhQ0GCP/f4N^ՋhQǏ zvhQĉ[ SbeHh0~~0[e0v[0=zg0U_0Rg;`~TbJTI{0bVvGCPN_eQ0cR0R[e~ǏNяASt^ve0dk!kOvoT{tl S\GCP\O:Noir4N^Ջ:gg_{gbLvl[Bl ُ[NObVoir4N^Ջv(ϑ ONlv(uo[hQ gHe ObSՋvCgvI{ wQ g͑aIN0 N0Ogq,gag,{N>kvĉ[ GLP0GCP1uVRbnx[v6R[0ۏLoirv^4N^[hQ'`ċNToirv4N^Ջ _{R+RgbLVRb gsQ蕝Ol6R[vGLP0GCP0 -NNSNlqQTVoT{tl[eagO VRbN,{360S 2002t^08g15e S^ ,{Nz ;` R ,{Nag 9hnc 0-NNSNlqQTVoT{tl 0N N{y 0oT{tl 0 6R[,gagO0 ,{Nag VRboTvcw{t蕾nV[oTh:gg0 w0ꁻl:S0v^Nl?e^oTvcw{tSN(W,gL?e:SWQnoTh:gg00WeoTh:ggvnĉR1uw0ꁻl:S0v^Nl?e^oTvcw{tcQ bw0ꁻl:S0v^Nl?e^ybQ0 VRbTw0ꁻl:S0v^Nl?e^voTvcw{tSN9hnc nx[&{ToThagNvh:ggbboTh]\O0 ,{Nz oTuNON{t ,{ Nag _RoTuNON ^S_ cgq NRĉ[Rt 0oTuNS 0 N 3uRN^S_TbRON@b(W0Ww0ꁻl:S0v^Nl?e^oTvcw{tcQ3u0w0ꁻl:S0v^Nl?e^oTvcw{t蕔^S_6e0R3uKNew30*N]\OeQ cgqV[S^voTLNSU\ĉRTNN?eV{ۏL[g v^\OQ/f&T Tay{^vQ[0 N 3uRN[bbRONy{^T ^S_TS[yb3u6e0S[yb蕔^S_6e0R3uKNew30*N]\OeQ Onc 0oT{tl 0,{kQagĉ[v_RagN~~6e6eTe\'`oTTVRboTvcw{tĉ[vuir6RTvoTuNONv]\O 1uVRboTvcw{t#0 0oTuN(ϑ{tĉ 0fNvkĉ[Rt 0;Su:gg6RBRS 0Sf{v0 ,{NASNag 0;Su:gg6RBRS 0 gHeg:N5t^0 gHegJ\n ~~M6R6RBRv ;Su:gg^S_(WS gHegJ\nMR6*Ng cgqVRboTvcw{t蕄vĉ[3ubcS 0;Su:gg6RBRS 00 ;Su:gg~bkM6R6RBRbsQ필v 0;Su:gg6RBRS 01uSS:gsQ40 ,{NAS Nag ;Su:ggM6R6RBR _{ cgqVRboTvcw{t蕄vĉ[b gsQDeT7hT ~@b(W0Ww0ꁻl:S0v^Nl?e^oTvcw{tybQ v^S~6RBRybQeST eSM6R0 ,{NASVag ;Su:ggM6Rv6RBR N_(W^:W N.UbSv.U N_S^;Su:gg6RBR^JT0 Su~p`0u`0zSNNb4N^%` ^:Wl gO^e ~VRbbw0ꁻl:S0v^Nl?e^voTvcw{tybQ (Wĉ[gPQ ;Su:ggM6Rv6RBRSN(Wc[v;Su:ggKNBRO(u0 VRboTvcw{tĉ[vyrk6RBRvBRO(uNSw0ꁻl:S0v^KN;Su:gg6RBRvBRO(u _{~VRboTvcw{tybQ0 ,{NASNag ;Su:gg[8hTMYevoBRNXT_{/fOl~Dkpenc3uuN0.UeWSf[bNoTSv oTvcw{t NNSFO/f vQN3uNcNLS_pencvdY0 d NR`b_Y oTvcw{t N_b2,gag,{N>kĉ[vpenc N lQqQ)Rv N ]ǑScenxO{|penc NO NckS_0WۏLFUN)R(u0 ,{ NASmQag 3uۏSvoT ^S_/f(WuNV[b0W:S_ N^SvoT*g(WuNV[b0W:S_ N^Sv ~VRboTvcw{tnxoTTy[hQ0 gHe N4N^v SNOgq 0oT{tl 0S,gagOvĉ[ybQۏS0 ۏSoT ^S_ cgqVRboTvcw{t蕄vĉ[3ulQ0VYONuNvoTS_ 0ۏSoTlQ 0 -NV/n0o蕌TS~n0W:SONuNvoTS_ 0;SoNTlQ 0T eSۏS0 ,{ NASNag ;Su:ggV4N^%`ۏS\ϑoTv ^S_c 0;Su:gggbNS 0TVRboTvcw{tcQ3u~ybQT eSۏS0ۏSvoT^S_(Wc[;Su:ggQ(uNyr[;Suvv0 ,{ NASkQag ۏSoT0R\T ۏSUSMO^S_c 0ۏSoTlQ 0b 0;SoNTlQ 0NSN0WfSN0-'T ToR,g0ň{US0ЏUS0'ЏShy0QShbJTfN0ffNI{Pge TS\@b(W0WoTvcw{tYHh0S\@b(W0WoTvcw{t~[g cNvPge&{TBlv S~ 0ۏSoTsQUS 00ۏSUSMOQ 0ۏSoTsQUS 0TwmsQRtbsQ>eKb~0 S\@b(W0WoTvcw{t蕔^S_woTh:gg[ۏSoTybۏLbghFO/f g 0oT{tl 0,{VASNagĉ[`b_vdY0 ,{ NAS]Nag uׂ{|6RT0@m6RT0(uN@n[{gvSOYʋeՋBRNSVRboTvcw{tĉ[vvQNuir6RT(W.UMRbۏSe ^S_ cgqVRboTvcw{t蕄vĉ[ۏLhb[8hybQh NTyOs^GW.U9(us0.U)RmsTAm]svc6R0wQSO[NRl1uVRbNkĉ[TۏSoTNt:gg@b(W0Ww0ꁻl:S0v^Nl?e^oTvcw{t3uoT^JTybQeS0 (WoTuNON@b(W0WTۏSoTNt:gg@b(W0WNYvw0ꁻl:S0v^S^oT^JTv S^^JTvON^S_(WS^MRTS^0Ww0ꁻl:S0v^Nl?e^oTvcw{tYHh0cSYHhvw0ꁻl:S0v^Nl?e^oTvcw{tSsoT^JTybQQ[ N&{ToT^JT{tĉ[v ^S_N1uS8hSYt0 ,{NASVag ~VRbbw0ꁻl:S0v^Nl?e^voTvcw{t蕳Q[ #Nf\PuN0.UTO(uvoT (Wf\Pg N_S^TyoT^JT]~S^^JTv _{zsS\Pbk0 ,{NASNag *g~w0ꁻl:S0v^Nl?e^oTvcw{tybQvoT^JT O(u*O 0Q(u01YHevoT^JTybQeSv^JT bVvQN^JTݏl;mRdoT^JTybQeSv^JT S^^JTvON0^JT~%0^JTS^_{zsS\PbkoT^JTvS^0 [ݏlS^oT^JT `%N͑v w0ꁻl:S0v^Nl?e^oTvcw{tSNNNlQJT0 ,{kQz oTvcw ,{NASmQag oTvcw{t+Tw~Nl?e^oTvcw{t蕝OlzvoTvcw{t:gg N T Ol[oTvx6R0uN0~%0O(u[evcwhg0 ,{NASNag oTb7h_{1u$N TN NoTvcwhgNXT[e v^ cgqVRboTvcw{t蕄vĉ[ۏLb7hbhe^S_cObh7hT N_b~0 oTbhUSMOl gckS_t1u b~bghv VRboTvcw{t蕌TbhUSMO@b(W0Ww0ꁻl:S0v^Nl?e^oTvcw{tSN[^\PbkUSMOb~bhvoT N^.UTO(u0 ,{NASkQag [ gcBg0cGPZuvoT (WV[oThQĉ[vhelThyv Nhe oTh:ggSNeEQhelThyvۏLoTh~VRboTvcw{tybQT O(ueEQhelThyv@b_Qvh~g SN\O:NoTvcw{t蕤[oT(ϑvOnc0 ,{NAS]Nag VRbTw0ꁻl:S0v^Nl?e^voTvcw{t蕔^S_9hncoT(ϑbgh~g [gS^oT(ϑlQJT0oT(ϑlQJT^S_SbboTvT T0hTegn0uNON0uNybS0oTĉg NeRv [^vQ 0oTuNS 00 0oT~%S 0T 0;Su:gg6RBRS 0eHeNNNoTuN~%;mRv Ogq 0oT{tl 0,{NAS Nagvĉ[~NYZ0 ,{NASNag ݏS,gagO,{VASkQag0,{VAS]Nag0,{NASag0,{NASNag0,{NASNagsQNoTNg N9eckv \PbkoTTy(WS^0Wv^JTS^;mR0 ,{NASkQag *g~w0ꁻl:S0v^Nl?e^oTvcw{tybQ dS^oT^JTv oTvcw{tSsT ^S_w^JTvcw{t蕝OlgY0 ,{NAS]Nag ݏS 0oT{tl 0T,gagOvĉ[ g NRL:NKNNv 1uoTvcw{t(W 0oT{tl 0T,gagOĉ[vYZE^^QN͑YZ N NoT0|^yoT0;Su(uk'`oT0>e\'`oTQEQvQNoT bNvQNoTQEQ NoTv N uN0.UNU[NY0tZ|^?QS?Qz:N;NO(u[avGPo0Rov  N uN0.Uvuir6RT0@m6RT^\NGPo0Rov V uN0.U0O(uGPo0Ro bNXT$O[Tgv N uN0.U0O(uGPo0Ro ~YtT͑rv mQ b~0vcwhg b*O 0k0?S gsQncPgev bdꁨR(ug\0cbbirTv0 ,{kQASag oTvcw{t蕾nv>mQ:gg gCg\OQ 0oT{tl 0T,gagOĉ[vfJT0Z>k0l6eݏluN0.UvoTTݏl@b_vL?eYZ0 ,{kQASNag oT~%ON0;Su:gg*gݏS 0oT{tl 0T,gagOv gsQĉ[ v^ gEQRncfvQ NwS@b.UbO(uvoT/fGPo0Rov ^S_l6evQ.UbO(uvGPo0RoTݏl@b_FO/f SNMQdvQNL?eYZ0 ,{kQASNag Ogq 0oT{tl 0T,gagOvĉ[l6evirT 1uoTvcw{t cgqĉ[vcwYt0 ,{ASz D R ,{kQAS Nag ,gagO NR(u틄v+TIN oTTk ybkoTvuNON0~%ONbvQNtNNNUO TIN~NO(uvQoTv;Su:ggv#N0oTǑ-NXT0;S^I{ gsQNXTN"irbvQN)Rv -Nv "irbvQN)Rv /fcoTvuNON0~%ONbvQNtNT;Su:ggv#N0oTǑ-NXT0;S^I{ gsQNXTcOvvv(WNq_TvQoTǑ-boTYeL:Nv NckS_)Rv0 ,{kQASmQag ,gagO2002t^9g15eweL0 oTxvz:gg{vYHh{tRlՋL Vo{[[1999]324S 1999t^10g15e S^ 00,{Nag :NR:_[oTxvzvvcw{t cؚoTxvz(ϑ ONl(uo[hQ gHe 9hnc 0-NNSNlqQTVoT{tl 0SvsQlĉ 6R[,gRl0 ,{Nag Q(WbV:N3uoT4N^ՋTuN N^ NNxvzv:gg ^Ogq,gRl{vYHh0 ,{ Nag ,gRl@byoTxvz:gg|coT4N^MRxvz:ggT4N^xvz:gg Sbxvzb@b0f[!h0;Su:gg0ONTT Txvz~~I{0 00 ,{Vag V[oTvcw{t@\;N{hQVoTxvz:gg{vYHh]\OTw0ꁻl:S0v^oTvcw{t#,g:SQoTxvz:gg{vYHh]\O0 00 ,{Nag 3u{vYHhvoTxvz:gg ^wQY NRagN 1.wQ glNDm1 Tvcw{tNXTSR,gL?e:SWQDm1 TNXTOSRhg~]\O0 00 ,{ASNag00s:Whg_Ye^1uhg~nx[hg z^TV =[hgvۏ^[c [^hg~_TlaNy0 00 ,{ASkQag00hgNXT^%NeQ;`TRkSu#Q@b^\;Su:ggD @ ^ h νqνbνbνbνbνbνhtbhfCJOJQJaJhM|CJOJQJmHo(sHhfCJOJQJmHo(sHhtbhfCJOJQJo(hrFPhf5CJOJQJo(htbhfCJOJQJaJo(!hM|CJOJQJaJmHo(sH!hfCJOJQJaJmHo(sHhlhfCJOJQJaJo(hlhlCJOJQJaJo($ . ^ @ v 8\(d < r JdHgdrFP & r JdHgdrFPh j l p t v  .068RTZ\xzȶזtetetזtethtbhfCJOJQJaJ!hM|CJOJQJaJmHo(sH!hfCJOJQJaJmHo(sHhtbhfCJOJQJaJo(hrFPhf5CJOJQJo(#htbhfCJOJQJmHo(sHhM|CJOJQJmHo(sHhfCJOJQJmHo(sHhtbhfCJOJQJo(hlCJOJQJo(' &(Z\bd 26:<HLPR|ϾϾϾϾϾϾϾϾϾϾϾϾhrFPhf5CJOJQJo(hC&hfCJOJQJaJo(htbhfCJOJQJaJ!hCJOJQJaJmHo(sH!hfCJOJQJaJmHo(sHhtbhfCJOJQJaJo(hfCJOJQJmHo(sH3RH~ dh`gd dhWD`gduN $dha$gddhgddpgdy r dHgdrFP & r JdHgdrFPǼ}obUA/#huNh`5CJKHOJPJQJ&huNh`5CJKHOJPJQJo(h3h`CJOJQJhuNh`OJQJaJhuNh`OJQJaJo(h3h5CJOJQJo( hO15CJ,OJPJQJaJ,o(&huNh`5CJ,OJPJQJaJ,o(h6CJOJQJhfCJOJQJo(he"CJOJQJo(htbhfCJOJQJ hC&hfCJOJQJmHsHhCJOJQJmHo(sH|~ FHfhfhln "(*,.bdhjFHLN  FHNPRT>@huNh3KHOJQJaJo(huNh`OJQJaJ!jhuNh`OJQJUaJhuNh`KHOJQJaJM~d X,v T( !""f##gdO1dhgdO1 WD`gdO1 dhWD`gduNdhgd<>BDVXx*,bdxz|*,:žߙr&hO1hO15CJKHOJPJQJo(h5hO1aJo(h5hO1aJ#hO1hO15CJKHOJPJQJhO1hO1aJh2hO1aJo( hO1aJo(h`KHOJQJaJo(huNh`OJQJaJhuNh`KHOJQJaJ!jhuNh`OJQJUaJ,:<LNhj (6:<LPRTVXpt      & , 4 6 : < D H L R T b d h l !"!N!P!V!j!n!v!x!~!!!!!!!!!!!!!!!"$"h7hO1aJo(hhO17aJ hO1aJo(h5hO1aJh5hO1aJo(R$"*"."<"P"Z"f"r"v"z"|""""""""""""",#.#4#6#:#>#D#F#V#d#l#~###############$$&$4$6$R$V$f$$$$$$$$$$$%%%%% %0%2%6%&hO1hO15CJKHOJPJQJo(h7hO1aJo(h7hO1aJ hO1aJo(h5hO1aJo(h5hO1aJK#p$$$$%l%&Z&&L'N'`'''(((>))j****+,, WD`gdO1dhgdO1gdO16%D%F%`%d%j%v%%%%%%%%%%%%%%%%%%%& &&`&d&f&j&l&x&~&&&&&&&&&&&&&&&&&&&&' '''''('<'@'D'J'N'`'f'j't'x'~'''''ɿɿh,cYhO1aJo(h,cYhO1aJ&hO1hO15CJKHOJPJQJo( hO1aJo(h5hO1aJo(h5hO1aJK''''''''''((( (F(T(\(^(f(~((((((((((((() )))<)D)l)n)r)x)|))))))))))))))))* **(*,*2*6*>*@*D*F*J*P*X*Z*h*v*z*ȾȾȾȾȾȾȾȾȾȾȾȾȾȾȾȾȾȾȾȾȾȾh5hO1aJo(h5hO1aJ&hO1hO15CJKHOJPJQJo( hO1aJo(h,cYhO1aJh,cYhO1aJo(Kz*~******************+++"+,+.+0+<+L+`+t+z++++++++++++++,,,,,,<,@,Z,^,p,t,~,,,,,,--- -&-*-,-2-6-f-j-t-x--#hO1hO15CJKHOJPJQJ&hO1hO15CJKHOJPJQJo(h5hO1aJ hO1aJo(h5hO1aJo(K,,-- --.//,00*224>5P6R6^66$77T8888D9F9b9 WD`gdO1gdO1dhgdO1---------------..D.F.P.X.^.`.v.x.|..........// / /,/./>/B/T/X/Z/\/^/b/f/r//////////////20T0V0b0d0l0v000000000000000000111h5hO1aJo(h5hO1aJ hO1aJo(Z1,1@1D1t1v111111111111111112222(202Z2f2|222222222222222223333"3$3P3X3f3x33333333333333333334444484@4D4F4L4N4R4Z4^4n4z444 hO1aJo(h5hO1aJo(h5hO1aJ[4444444445 555*5,50565<5D5N5R5r5x5555555555555555555555$6,66686<6>6B6N6R6^6d6t6x6z6~6666666666666667 77$7&7074787:7F7T7&hO1hO15CJKHOJPJQJo(h5hO1aJo( hO1aJo(h5hO1aJST7|7777777777777777778888 8,8:8L8T8V8^8`88888F9b999999999999999999 ::2:8:\:^:j:r:x:|::::::::::::::::$;(;&hO1hO15CJKHOJPJQJo( hO1aJh5hO1aJo(h5hO1aJ hO1aJo(Pb99&;(;F;<<<<<<<<<<<<<<<<<<<<<<<dhgddhgdO1gdO1(;F;L;N;X;\;|;;;;;;;;;;;;;< < <8<><@<B<D<F<V<Z<\<`<d<f<t<x<<<<<<<<<<<<<<<<<徳h3hO1CJOJQJo(hO1CJOJQJo(huNCJOJQJo(hCJOJQJo(hO1hCJOJQJo( hO1aJh5hO1aJh5hO1aJo( hO1aJo(&hO1hO15CJKHOJPJQJo(3<<<<<<<=R>>???HAJAbABBBCCCDDE dhWD`gd) $dha$gdxS $dha$gddhgd<== ="===6>8>P>R>>???ؿxcP>))hxShB* CJKHOJPJQJph! "hB* CJKHOJQJo(ph! %h)hB* KHOJQJaJph! )hxShB* CJKHOJPJQJph! 'hxShCJKHOJPJQJ^Jo(-hxShB*CJKHOJPJQJ^Jph6jhxShB*CJKHOJPJQJU^Jph0hxShB*CJKHOJPJQJ^Jo(ph&hO1h5CJ,OJPJQJaJ,o(&hO1h`5CJ,OJPJQJaJ,o(??HAJAbAjABBBBCCCCCDDEdEfEEEFFfFjFFFhGlGGG"H&HHHhIlIIįįٝsaaaaaaaaaa"h)B* KHOJQJaJo(ph! )hUhB* CJKHOJPJQJph! (h)h)B* KHOJQJaJo(ph! "hB* KHOJQJaJo(ph! )hxShB* CJKHOJPJQJph! (h)hB* KHOJQJaJo(ph! %h)hB* KHOJQJaJph! %h3hB*CJKHOJQJph&EfEEFjFFlGG&HHlIIINJJJKKLVL MMMMN&OvOO dh`gd)IIIIJJNJ|JJJJKKKKKLRLVLM M|MMMMMMNN"O&OrOvOOOOOO*P.PPP&Q*QQQRRR,RƱۜ$h)hB* OJQJaJo(ph! (h)hB* KHOJQJaJo(ph! )hs>8hB* CJKHOJPJQJph! (h)hB* KHOJQJaJo(ph! %h)hB* KHOJQJaJph! "h)B* KHOJQJaJo(ph! 0OOOO.PP*QQRR,RSSS&TUUU VWWBWWW$X&XFXX dhWD`gd)dhgd,RlRnRSSS$T&TUUUU VVWWBWWWWW$X&XFXXX YY\Y`YYYZ"ZZZZZZ[[2[\[˶˶˶˶˶˶shB* CJOJQJo(ph! !hxhB* OJQJaJph! !hxhB*OJQJaJph!h3hB*CJOJQJph)hs>8hB* CJKHOJPJQJph! $h)hB* OJQJaJo(ph! h)B* OJQJaJo(ph! !h)hB* OJQJaJph! *XY`YYYZZZZ[[2[^[[[[*\^\`\\\D]]&^^^ dhWD`gdxdhgd dhWD`gd)\[^[[[[[[[&\*\^\`\\\\@]D]]]"^&^^^^\`^`z`aaa`bbbbvcxccdd0e2eDeFeteveeeeeeff>fBfnfrfff̷̷̷̷̷̷̷ߢ(hxhB* KHOJQJaJo(ph! )hs>8hB* CJKHOJPJQJph! $hxhB* OJQJaJo(ph! !hxhB* OJQJaJph! hxB* OJQJaJo(ph! 8^^\`^`z`aaa`bbbbvcxccd2eFeveeeeefBfrffff dhWD`gdxdhgdfffffff&g(ghhxijtkVlXlblmmmmnopp dhWD`gd# $dha$gdn $dha$gddhgdfffff$g&g(ghhvixijjrktkTlʵgSE:E:E:Eh#OJQJaJo(h#hOJQJaJo(&h#h5CJKHOJPJQJo(0hnhB*CJKHOJPJQJ^Jo(phh5CJOJQJo(&hnh5CJ,OJPJQJaJ,o(&hnh`5CJ,OJPJQJaJ,o((h3hnB* CJKHOJQJo(ph! "hB* CJKHOJQJo(ph! "hB* CJKHOJQJo(ph! "hB* CJKHOJQJo(ph! TlXlblmmmmnnoopppppqqBsDsXsZsssRtTtttrutuuuuDvϰϰϰϰݜϰψψψr^&h'h5CJKHOJPJQJo(*h'h5CJKHOJPJQJaJo(&h#h'5KHOJPJQJaJo(&h#h'5CJKHOJPJQJo(h#h'OJQJaJo( hnt5CJKHOJPJQJo(h#hOJQJaJo(&h#h5CJKHOJPJQJo(h#hOJQJaJo(!pppqBsDsZssTtttuuuFv`vvvPw\wxwwwwwwwx:x dhWD`gd#dhgdDvFv^v`vvvvvPw\wvwxwwwwwwwwwwwwxx8x:xxxyyyy zzPzRzhzzzzz{|||R~T~ҳҳ}h#hOJQJaJo(&h#h5KHOJPJQJaJo(&h#h'5KHOJPJQJaJo( h'5CJKHOJPJQJo(h#h'OJQJaJo(&h'h5CJKHOJPJQJo(h#hOJQJaJo(h#OJQJaJo(/:xxyyzRzhzzz{|||R~T~b~~~"2| dhWD`gdntdhgd'dhgd dhWD`gd#T~b~~~~~ "2z|24\^`lāƁ$&VXϽޫޝhnth'OJQJaJo(hnthOJQJaJo(h#h'OJQJaJo("h#h5OJPJQJaJo("h'h5CJOJPJQJo(h'5CJOJPJQJo(h#hOJQJaJo(&h#h5CJKHOJPJQJo(24^`lƁ&XpȄDtHJdhgd dhWD`gdntރnpƄȄBDrtHJTֆ؆,.XZˆڈ܈HJ‰ĉ02hjNPhj΋Ћ"h'h5CJOJPJQJo("hnth5CJOJPJQJo(hnthOJQJaJo(hnth'OJQJaJo(hnthOJQJaJo(FJT؆.Zˆ܈Jĉ2jPj dhWD`gdntdhgdЋL\<\rDT2V dhWD`gdntJLZ\:<Z\prBDRT02TV$4z|ؒڒ hCJOJQJo("h'h5CJOJPJQJo(h'CJOJQJo(h3hCJOJQJo(hnthOJQJaJo(hnth'OJQJaJo(@$4|ڒ "fnĔ8`r*P2Ldhgd dhWD`gdnt"dfޓln”Ĕ68^`pr(*NP02JLlnޚRTbjlΜМNPRT؞ڞhnth0@)OJQJaJo(hnthOJQJaJo(hnth'OJQJaJo(hnthOJQJaJo("hnth5CJOJPJQJo(HLnRTblМPTڞ8:JʟZdhgd dhWD`gdnt8:JȟʟXZ~РҠ46\^֡ء,.NVXbptv㵪zh#h|h55CJ,OJPJQJaJ,hnt5CJOJQJo(h0@)5CJOJQJo(h0@)CJOJQJo(hCJOJQJo(hCJOJQJo(h3hCJOJQJo("hnth5CJOJPJQJo(hnthOJQJaJo(hnthOJQJaJo(hnth0@)OJQJaJo((ZҠ6^ء.NPRTVXZ\^`bdfhjlndhgd dhWD`gdntnprtvvx+9Fgʦ xdhWD2`xgdv3 $dha$gd.[ dhWD`gdv3 $dha$gd $dha$gd0@)dhgd0@)dhgdvx+9IJ *+NOڧۧ()efӨw|lylhv3h-#&CJOJQJhL;CJOJQJo(hv3CJOJQJo(hv3CJOJQJhv3h-#&CJOJQJo(hv3h5CJOJQJhv3h55CJPJhv3h5CJaJhv3h5OJQJaJhv3h55CJaJhKh55CJOJQJhKh5CJOJQJ)'9Ja~֧$AaΨwϩ#Mk~ xdhWD2`xgdv3~&>zݫ )yˬ (J[ŭ xdhWD2`xgdv3lxĭŭ ')+,-;hi !&'();<|h!hK5CJOJQJh!h5CJOJQJhL;hKOJQJaJhL;h!OJQJaJo(hL;hOJQJaJhL;h5CJPJhKh5CJOJQJhv3hqzCJOJQJhv3h5CJOJQJhv3hCJOJQJ0ŭ(>iyɮ%Ccѯ4ZfӰ: xdhWD2`xgdv3dhgd:^ر0Ͳ )=r;Mwȴشdhgd xdhWD2`xgdv3ش1>eʵܵ%6G˶,-;i dhWD`gdL;dhgd xdhWD2`xgdv3!B'()Sx; dhWD`gdL; idhWD2`igdL;dhgd;<MABX dhWD`gdL; idhWD2`igdL;dhgdABgh 12 01RSuvlm7hL;hL;OJQJaJhOJQJaJo(hL;h!OJQJaJo(hL;hKOJQJaJo(hL;hKOJQJaJhL;hOJQJaJD ghBdhgd dhWD`gdL; idhWD2`igdL; 6 12Y 4dhgd dhWD`gdL; idhWD2`igdL;01DRSt uv7dhgdL; idhWD2`igdL;dhgd dhWD`gdL;7lm3B478S#dhgdL; idhWD2`igdL;dhgd dhWD`gdL;78pq&'*+PQ+,()UVLM78D٥hWhxbeOJQJaJo(hWhOJQJaJhxbeh5CJOJQJhL;hL;OJQJaJhOJQJaJo(hL;h!OJQJaJo(hL;hKOJQJaJo(hL;hOJQJaJhKCJOJQJo(6>q'+Q+,:dhgd! dhWD`gdL; idhWD2`igdL;dhgd()?UVrLMt78a idhWD2`igdL;dhgd dhWD`gdL;E035   f | $ X  Ih idhWD2`igdWdhgd dhWD`gdWDE/02345    f # $ W X   HIgh{|BC\]34}~_`QRhWhxbeOJQJaJhKCJOJQJo(hxbeh5CJOJQJhWhKOJQJaJo(hWhOJQJaJhWhxbeOJQJaJo(E|C]4~`R\Z[kH idhWD2`igdWdhgd dhWD`gdW[\Z[GH\]  +!,!!!""a"b"""##$#J#K#r#s###%%%%%(&~''(((())****i+j+ ,!,,󼮼hZ<hKOJQJaJo(hZ<hxbeOJQJaJo(hZ<hOJQJaJhxbeh5CJOJQJhWhKOJQJaJo(hWhxbeOJQJaJo(hWhOJQJaJ?] ,!!"b""$#K#s####%%%%%'(( dhWD`gdZ< idhWD2`igdWdhgd dhWD`gdW()**3**j+!,,, --\/E0&1'1G123]4^4|4578c9 idhWD2`igdZ<dhgd dhWD`gdZ<,,--[/\/D0E0%1&1'12233]4^4557788b9c9999999::;;;>>J?K???@@@BBqDrDFFGGII]J^JKK?M@M@NAN7R䭠hZ<hZ<OJQJaJhZ<hOJQJaJo(hZ<hxbeOJQJaJhZ<hZ<OJQJaJo(hZ<hxbeOJQJaJo(hZ<hOJQJaJhZ<hKOJQJaJo(?c99999::;>K??@@ABBBrDFGI^JK@MAN8R idhWD2`igdZ<dhgd dhWD`gdZ<7R8RRRSS,S-SSSSSSSTTTT'U(UUUVVsVtVVVWWYYZZt[u[\\\\\\ ] ]^^``aa@bAbbbbb-c.cRcScccee-h.hhhiil ldmemoogphpqqqqrruhZ<h-vOJQJaJo(hZ<hOJQJaJhZ<hxbeOJQJaJo(T8RRS-SSSSTT(UUVtVVWYZu[\\\ ]^`aAbbb.c dhWD`gdZ<.cScce-h.hGhhi lemohpqq3qqrrruv9w:wow idhWD2`igdZ<dhgd dhWD`gdZ<uuvv9w:wowqwrwuwvwxxzz;{<{||}}}}}rdVIh\hOJQJaJhxbeh5CJOJQJhZ<hZ<OJQJaJo(h-vOJQJaJo(hZh-vOJQJaJo(hZhxbeOJQJaJo(hZhOJQJaJhZhZOJQJaJo(hZhZOJQJaJhZOJQJaJo(hZOJQJaJhZ<h-vOJQJaJo(hZ<hOJQJaJhZ<hxbeOJQJaJo(owxz<{|||}}}}}@ʀ͂> dhWD`gd\ idhWD2`igd\ idhWD2`igdZ<dhgd dhWD`gdZ< dhWD`gdZ?@ɀʀ̂͂=>UVTUZ[YZ./tucdxy  ٗڗ !ghABz{_`ߛh\h-#&OJQJaJo(h\h\OJQJaJo(h\h-vOJQJaJo(h\hOJQJaJh\hxbeOJQJaJo(IUVmTUh[Z/uddhgd\ idhWD2`igd\dhgd dhWD`gd\dy ڗ!hB{`ߛ}~ɝ&dhgd idhWD2`igd\ dhWD`gd\ߛ}~ȝɝ  OPҢӢHIͦΦ  >?̰ͰHIȻȻȻh=gh-#&OJQJaJo(h=ghOJQJaJh=gh-vOJQJaJo(h4Xh-#&OJQJaJo(h4XhOJQJaJh4Xh-vOJQJaJo(h\h-#&OJQJaJo(h\hOJQJaJh\h-vOJQJaJo(4ϡ PӢIͦΦ > dhWD`gd=g idhWD2`igd=g dhWD`gd4X idhWD2`igd4Xdhgd>?xͰI8MauxEF_޺ߺX dhWD`gd=g idhWD2`igd=gdhgd78LMwxEF޺ߺXYjqr:;־׾./ : rsBCUVȸ䫝䫝h=gh5OJQJaJh=g5OJQJaJo(h=gh-#&5OJQJaJo(h=gh-#&5OJQJaJh=gh-vOJQJaJo(h=ghOJQJaJh=gh-#&OJQJaJo(>XYjr;־׾/ : sCV dhWD`gd=gdhgd-#& idhWD2`igd=gdhgdVN$+ojlG/]dhgd dhWD`gd=gMN#$*+noijklFG/\]\]lm'󻮤ht^h-#&OJQJaJo(ht^OJQJaJht^hOJQJaJht^h5OJQJaJh=gh-vOJQJaJo(h=gh5OJQJaJh=gh-#&OJQJaJo(h=ghOJQJaJ;\]im'="#7 idhWD2`igdt^ dhWD`gdt^ idhWD2`igd=gdhgd dhWD`gd=g<="#=>  NO  \]qrBC./  89ht^ht^OJQJaJo(ht^h5OJQJaJht^h-vOJQJaJo(ht^h-#&OJQJaJo(ht^hOJQJaJH> O  $]rC dhWD`gdt^ idhWD2`igdt^dhgdC/ 9'OK[f?Q idhWD2`igdt^dhgd dhWD`gdt^NOJKZ[ef>?PQ#$>?lm#$ghlmijؼh/h-#&OJQJaJo(h/hOJQJaJh/h-vOJQJaJo(ht^h-vOJQJaJo(ht^hOJQJaJht^h-#&OJQJaJo(ht^h-#&OJQJaJ?$?m$gh dhWD`gd/ idhWD2`igd/ idhWD2`igdt^dhgd dhWD`gdt^j7U|bc dhWD`gd: idhWD2`igd: idhWD2`igd/dhgd dhWD`gd/67TU{|bcghDE` a )5?R-p[\ȻȻȻȻȻȻȻȻh:OJQJaJo(h:h5OJQJaJh:hOJQJaJh:h-vOJQJaJo(h/h-#&OJQJaJo(h/hOJQJaJh/h-vOJQJaJo(:DEc a )5?R dhWD`gd:dhgd idhWD2`igd:R-p\g$2J] D] dhWD`gdAdhgd dhWD`gd:fg#$12IJ\]b  $CD\]uv^!_! "8"9"#Ϻźźźźź䯢h}h5OJQJaJh}5OJQJaJh}hOJQJaJh}OJQJaJo(hAOJQJaJo(hAOJQJaJh:OJQJaJh:OJQJaJo(h:hOJQJaJh:h:OJQJaJo(2]v_! "9"#.$%%v&&&&& '','()[))dhgddr dhWD`gddrdhgd dhWD`gd} dhWD`gdA#.$%%u&v&&&&&&&&& ' ''+','()[)))k*l***.+/+v+w+++++//j0~00;2n24444a7b7c7t7񦘦h-vCJOJQJo(hOJQJaJo(hh5OJQJaJhhOJQJaJhdr5OJQJaJhKhCJOJQJhdrhdrOJQJaJo(hdrOJQJaJo(hdrhOJQJaJhdrh5OJQJaJ1)l**/+w+++/j00;2n244b7c7t7777777 idhWD2`igd dhWD`gd dhWD`gddhgd dhWD`gddrt7777%8=8888888809I999%:?:::';?;;;;<v<<<<W=o===5>L>>>>*?A???????/@k@|@ɼԥԥԥԥԥԥԥԥԥԥԥԥԥԥԥԚԚԌhh5OJQJaJh<fCJOJQJo(h<fCJOJQJhhOJQJaJhKhCJOJQJhCJOJQJo(hKhCJOJQJhKh56CJOJQJhKh5CJOJQJ27$8%8=8N8\8]8888888888888J99A::@;;<<< idhWD2`igddhgd<p==M>>B?????@.@/@k@}@ACRFGbHHI dhWD`gdZn dhWD`gd idhWD2`igd dhWD`gddhgd|@}@AACCQFRFGGHIIFIHIlImItIIIJJ!JjJJJJJK/K0KSKTKYKZKwKxKLLLOEP\PPQ1R2RbRRRRRRSS:SASSSTʿՑ~m~~ʿ!h<%hB*OJQJaJph%h<%hB*KHOJQJaJph%h<%hB*KHOJQJaJphh<%h5OJQJaJh<%h<%OJQJaJh<%OJQJaJo(hOJQJaJo(h<%h5OJQJ\aJh<%hOJQJ\aJh<%hOJQJaJ&%M&M'M9MAMUMrffff dh$Ifgdkdp$$IflrQ$,_7\- t7644 layt7UMVMWMXMYMgMsM{Myyyyyy dh$Ifgdzkd$$Ifl\Q$_7\ t7644 layt7{M|MMM"NNNNrffffff dh$Ifgdkd$$IflrQ$,_7\- t7644 layt7NNNLOOOOPEP\P]P^Prffffffffff dh$Ifgdkd@$$IflrQ$,_7\- t7644 layt7 ^P`PbPcPdPfPgPhPjPlP}PPP dh$Ifgd PPPQ0QGQcQQQQ2RbRrffffffffff dh$Ifgdkd$$IflrQ$,_7\- t7644 layt7 bRRRRRRRRRRRRRRRRR dh$IfgdRRRRSSrffff dh$Ifgdkd$$IflrQ$,_7\- t7644 layt7SSSSS&S2S:Syyyyyy dh$Ifgdzkd&$$Ifl\Q$_7\ t7644 layt7:S;SASSSSSSSrfffffff dh$Ifgdkd$$IflrQ$,_7\- t7644 layt7SSSST'TTTTU UUrffffffffff dh$IfgdkdT $$IflrQ$,_7\- t7644 layt7 TT&T'TTTT#UUVVVVWWWWX6X8X\XdXX-YYY]ZZ[[2\Y\]]]$]R]T]x]]]]^s^^#_$_ƹƹƹƹƹֹƹƹƹƹƹƹ{hKhCJOJQJh<%h5OJQJaJh<%OJQJaJo(h<%h<%OJQJaJhOJQJaJo(h<%hOJQJaJh<%h5OJQJ\aJ%h<%hB*KHOJQJaJph+h<%h5B*KHOJQJ\aJph.UU#UUVVV V Vrfffffff dh$Ifgdkd $$IflrQ$,_7\- t7644 layt7 V VVVVVVVVrfffffff dh$Ifgdkd $$IflrQ$,_7\- t7644 layt7VVVVWWaWWWWWWrffffffffff dh$Ifgdkd: $$IflrQ$,_7\- t7644 layt7 WWWWWWXXXXX"Xfkd $$IflrQ$,_7\- t7644 layt7 dh$Ifgd "X6X7X8X9X:XHXTX\Xyzkd~ $$Ifl\Q$_7\ t7644 layt7 dh$Ifgd\X]XdXX"Y#Y%Yrfffff dh$Ifgdkd $$IflrQ$,_7\- t7644 layt7%Y&Y-YYQZSZUZrfffff dh$Ifgdkd $$IflrQ$,_7\- t7644 layt7UZVZ]ZZy[{[}[rfffff dh$IfgdkdN$$IflrQ$,_7\- t7644 layt7}[~[[['\(\*\rfffff dh$Ifgdkd$$IflrQ$,_7\- t7644 layt7*\+\2\Y\]]]]]"]rffffffff dh$Ifgdkd$$IflrQ$,_7\- t7644 layt7 "]#]$]6]>]R]rffff dh$Ifgdkd4$$IflrQ$,_7\- t7644 layt7R]S]T]U]V]d]p]x]yyyyyy dh$Ifgdzkd$$Ifl\Q$_7\ t7644 layt7x]y]]]]]]]rffffff dh$Ifgdkdb$$IflrQ$,_7\- t7644 layt7]]]^h^i^k^rfffff dh$Ifgdkd$$IflrQ$,_7\- t7644 layt7k^l^s^^_ _"_rfffff dh$Ifgdkd$$IflrQ$,_7\- t7644 layt7"_#_R_``)`1`E`rdVJJJJ dh$Ifgd dhWD`gdZn xdhWD2`xgdZnkdH$$IflrQ$,_7\- t7644 layt7$_``E`G`v`w````aa a2aaaaa/b5bbccccddddd杌|odYLhGVhGVOJQJaJhGVOJQJaJo(hOJQJaJo(hKhCJOJQJhGVhGV5OJQJ\aJ!hGVh5OJQJ\aJo(hGVhOJQJ^J aJhGVhOJQJ\aJhGVh5OJQJ\aJhGVh5OJQJaJhGVh5OJQJaJhGVhOJQJaJhZnhOJQJaJE`F`G`H`I`W`v``vvvvvv dh$Ifgd|kd$$Ifl\&6t t76m44 layt7`````aaaaoccccccQ;dh$IfWD`;gdGV dh$Ifgdkd{$$Iflr&1.6t* t76m44 layt7aa a2aRakaaaaa*b,bocccccccccc dh$Ifgdkd"$$Iflr&1.6t* t76m44 layt7 ,b.b/b5bbbbc@cgc]QQQQQQQ dh$Ifgdkd$$Iflr&1.6t* t76m44 layt7;dh$IfWD`;gdGV gcrccccccddd;dh$IfWD`;gdGV dh$Ifgd ddddddocccc dh$Ifgdkdp$$Iflr&1.6t* t76m44 layt7ddddddddyyyyyy dh$Ifgdzkd$$Ifl\Q$_7\ t7644 layt7dddSeeeeeeerffffffff dh$Ifgdkd$$IflrQ$,_7\- t7644 layt7 dSeeee f8ffffgHgggg@hAhohphqhhhhhiiMieiiiijjkklllll㵨rrrrh,yh5OJQJaJhKhCJOJQJh,yhGVOJQJaJh,yhOJQJaJo(h,yhOJQJaJh,yh5OJQJ\aJhGVhGV5OJQJ\aJh5OJQJ\aJo(hGVhOJQJaJhGVh5OJQJ\aJ'eeef f-f/f1focccccc dh$IfgdkdE$$Iflr&1.6t* t76m44 layt71f2f8ffffgggoccccccc dh$Ifgdkd$$Iflr&1.6t* t76m44 layt7gggHg[goggggg*h,hocccccccccc dh$Ifgdkd$$Iflr&1.6t* t76m44 layt7 ,h=h?h@hAhSh[hohckd:$$Iflr&1.6t* t76m44 layt7 dh$Ifgdohphqhrhshhhhyyyyyy dh$Ifgdzkd$$Ifl\Q$_7\ t7644 layt7hhhhhhhrfffff dh$Ifgdkdm$$IflrQ$,_7\- t7644 layt7hiiMiZi[i]ioccccc dh$Ifgdkd$$Iflr&1.6t* t76m44 layt7]i^iei~iiiiiioccccccc dh$Ifgdkd$$Iflr&1.6t* t76m44 layt7iiiiij(jjjjocccccccc dh$Ifgdkd]$$Iflr&1.6t* t76m44 layt7 jjjjkkkoccccc dh$Ifgdkd$$Iflr&1.6t* t76m44 layt7kkkk}llloccccc dh$Ifgdkd$$Iflr&1.6t* t76m44 layt7llllllocccc dh$IfgdkdR$$Iflr&1.6t* t76m44 layt7llllllllyyyyyy dh$Ifgdzkd$$Ifl\Q$_7\ t7644 layt7lllllmmmomvmxmmrffffffff dh$Ifgdkd $$IflrQ$,_7\- t7644 layt7 lllmm)nnoopqqqqqqrrr"sCs#t9tttu+uuu2v3v4vw3w5wtw|wwxxZyy3zEzSzTzzz:{;{<{A{o{q{{{{|||||}ʽʽ󰠰hKh5CJOJQJ\hKhCJOJQJhfhfOJQJaJhOJQJaJo(hfh5OJQJaJhfh5OJQJ\aJhfhOJQJaJ>mmmm n n nnn!nocccccccc dh$Ifgdkd'!$$Iflr&1.6t* t76m44 layt7 !n"n)nnooo oocccccc dh$Ifgdkd!$$Iflr&1.6t* t76m44 layt7 o ooopppppoccccccc dh$Ifgdkdu"$$Iflr&1.6t* t76m44 layt7pppqxqyq{q}qocccccc dh$Ifgdkd#$$Iflr&1.6t* t76m44 layt7}q~qqqqqocccc dh$Ifgdkd#$$Iflr&1.6t* t76m44 layt7qqqqqqqqyyyyyy dh$Ifgdzkdj$$$Ifl\Q$_7\ t7644 layt7qqqrrrrrrrfffffff dh$Ifgdkd$$$IflrQ$,_7\- t7644 layt7rrrrsss ssoccccccc dh$Ifgdkd%$$Iflr&1.6t* t76m44 layt7ss"sCstttoccccc dh$Ifgdkd?&$$Iflr&1.6t* t76m44 layt7tt#t9tytzt|t}tocccccc dh$Ifgdkd&$$Iflr&1.6t* t76m44 layt7}t~tttuuuuocccccc dh$Ifgdkd'$$Iflr&1.6t* t76m44 layt7uuu+uuuuuocccccc dh$Ifgdkd4($$Iflr&1.6t* t76m44 layt7uuuu3v4v6v8vocccccc dh$Ifgdkd($$Iflr&1.6t* t76m44 layt78v9vkvwwww3woaSGGGG dh$Ifgd dhWD`gdf idhWD2`igdfkd)$$Iflr&1.6t* t76m44 layt73w4w5w6w7wEwdwtwvvvvvv dh$Ifgd|kd)*$$Ifl\&6t t76m44 layt7twuw{w|wwxxxocccccc dh$Ifgdkd*$$Iflr&1.6t* t76m44 layt7xxxx8y:yQySyocccccc dh$Ifgdkda+$$Iflr&1.6t* t76m44 layt7SyTyZyy)z+z,zoccccc dh$Ifgdkd,$$Iflr&1.6t* t76m44 layt7,z-z3zTzyzzz|zoccccc dh$Ifgdkd,$$Iflr&1.6t* t76m44 layt7|z}zzz;{<{={?{occcccc dh$IfgdkdV-$$Iflr&1.6t* t76m44 layt7?{@{A{S{[{o{occcc dh$Ifgdkd-$$Iflr&1.6t* t76m44 layt7o{p{q{r{s{{{{yyyyyy dh$Ifgdzkd.$$Ifl\Q$_7\ t7644 layt7{{{{|||rfffff dh$Ifgdkd0/$$IflrQ$,_7\- t7644 layt7|||||||occccc dh$Ifgdkd/$$Iflr&1.6t* t76m44 layt7||||||}}}occccccc dh$Ifgdkdy0$$Iflr&1.6t* t76m44 layt7}}}~~~*~H~~og\\gggg $dha$gddhgdkd 1$$Iflr&1.6t* t76m44 layt7}~~~~~~~~*ʃ̃ z &.vx lnͽ~pepepepepWh$h OJQJaJo(h yOJQJaJo(h$hOJQJaJo(h$CJOJQJo(h CJOJQJo(hp1h OJQJaJo(hp1hOJQJaJhp1hOJQJaJo(hp1hCJOJPJQJo(#h$hCJ OJPJQJaJ o(&h$h5CJ,OJPJQJaJ,o(h3hCJOJQJ!~~~~~~~"@\p*Ffxƀڀdhgd dhWDd`gdp1&Ll΁ 2Vt΂(<P^~dhgd dhWDd`gdp1΃ ,>XhzԄ dhgd dhWDd`gdp1  &.x lnx:<Vz|~Ċ idhWD2`igd y dhWD`gd y $dha$gddhgdnrx:Dz|~R\Ȍ*,8BDĹĮĹĒĒĒĒĠĒĒĒĒĒĒĒĒćhBOJQJaJo(h yhBOJQJaJo(h yh yOJQJaJo(h OJQJaJo(h yOJQJaJo(h yhOJQJaJo(h yh OJQJaJo(h yh5CJOJQJo(h yh 5CJOJQJo(5RTfҌ :,.Ldhgd dhWD`gd y idhWD2`igd yLBDb 68ZԒ idhWD2`igd ydhgd dhWD`gd y28<@JNfhޔF02ԙ֙xzКҚ֝؝<>PRğƟ,.hjƠȠ̡Ρ  ؼhS~h,bOJQJaJo(hS~OJQJaJo(hS~hOJQJaJo(h yhBOJQJaJo(h yhOJQJaJo(h yh yOJQJaJo(h yOJQJaJo(@Ɠfh|ޔFl02Fԙ֙ idhWD2`igdS~ dhWD`gdS~ idhWD2`igd ydhgdxzКҚڛ*֝؝<>\ idhWD2`igdS~dhgd dhWD`gdS~žPRfğƟܟ,.DhjƠȠ̡Ρ  dhWD`gdS~ idhWD2`igdS~dhgd*  jlFjxΤ&(:Хҥdhgd dhWD`gdS~ idhWD2`igdS~  jlhjvx̤Τ&(ХҥXZhjxz̩Ω`b@B.0tvFHDFPRXh*h,b5OJQJaJo(hS~h5OJQJaJo(hS~OJQJaJo(hS~hOJQJaJo(hS~h,bOJQJaJo(FҥXZthj֨xz̩Ω`bvdhgd dhWD`gdS~ idhWD2`igdS~@B^.0tvFH dhWD`gdS~ idhWD2`igdS~dhgdDFPR :Hδ 0 vdhWD,`vgd* dhWD`gd* idhWD2`igd* idhWD2`igdS~dhgdX 8:FH̴δ  .0 Z\̹ιbdz|ܺ޺:<prNPNX\⻭hOJQJaJo(hhOJQJaJo(hhOJQJaJo(hh,bOJQJaJo(h*OJQJaJo(h*h,bOJQJaJo(h*hOJQJaJo(h*h5OJQJaJo(:\ιd|޺<rPNP^̽ vdhWD,`vgd dhWD`gd idhWD2`igddhgd dhWD`gd*\^ʽ̽ؽ"&2HLVľƾҾ *68 PR"$&ʼʬʼʼʼʼh[OJQJaJo(h[h5OJQJaJo(h[hOJQJaJo(h[hOJQJaJo(hOJQJaJo(hhOJQJaJo(hhOJQJaJo(?&Lƾ 8F< dhWD`gd[ idhWD2`igd[dhgd vdhWD,`vgd dhWD`gd<v2<0t, idhWD2`igd[dhgd dhWD`gd[&(<,Vf dhWD`gdoI idhWD2`igdoI idhWD2`igd[dhgd vdhWD,`vgd[ dhWD`gd[&frDP`l,2@BDJRTV\$&(.jlnt,.06XZ\b,.4hoIOJQJaJo(h[hOJQJaJo(h[hOJQJaJo(UfD`,DV(n0\.(J dh^gdoI dhWD`gdoI&(.HJPhvlzR`V\ np bn<H6Djؿؿؿh[h mjOJQJaJo(h[h+OJQJaJo(h+OJQJaJo(h[hoIOJQJaJo(h[hOJQJaJo(h[hOJQJaJo(hoIOJQJaJo(@JhlRV pb dhWD`gd=A idhWD2`igd=Adhgd dhWD`gd+ vdhWD,`vgd+ vdhWD,`vgdoI dhWD`gdoI dh^gdoI<6jdf|:<X idhWD2`igd=Adhgd dhWD`gd=Ajxdp,|:F@BN (@L4@BN ȸ񟑃h[hOJQJaJo(hhOJQJaJo(hh mjOJQJaJo(hOJQJaJo(h=Ah5OJQJaJo(h=Ah mj5OJQJaJo(h=AOJQJaJo(h[hOJQJaJo(h[h mjOJQJaJo(3B @4B x idhWD2`igddhgd dhWD`gd idhWD2`igd=Adhgd=Ax"bhtv|:F\fxz(*6&(4r~ "(>@Fnpv(2<Fh?`OJQJaJo(hW{OJQJaJo(hXOJQJaJo(h[hOJQJaJo(h[hOJQJaJo(Lxbv:\z*(dhgd?` dhWD`gd?` dhWD`gdW{ vdhWD,`vgdX dhWD`gdX dhWD`gdt"@p(*><:<dhgd vdhWD,`vgd?` dhWD`gd?` dh`gd?` idhWD2`igd?`:F6B  8 D Z h   > J n | $ 2   D P   hvp|  npvʿʿh[hOJQJaJo(hhfOJQJaJo(h[h*OJQJaJo(h?`OJQJaJo(h[hOJQJaJo(h[hOJQJaJo(F<\68\ 8 : Z  > @ n $  D   vdhWD,`vgd?` & Fdhgd?`dhgd dhWD`gd?` idhWD2`igd?`hp phdhgd dhWD`gd( idhWD2`igdhf & Fdhgdhf vdhWD,`vgdhf dhWD`gdhf dhWD`gd?` idhWD2`igd?`hpv"NVZLNVX^fj0<PVlntT\` npvռռռռռձձh$OJQJaJo(h(OJQJaJo(h[huOJQJaJo(h[h*OJQJaJo(h[hOJQJaJo(h[hOJQJaJo(FNLN^p0PnTr ( vdhWD,`vgd(dhgd dhWD`gd( idhWD2`igd(p:x,LnF j  HdhWD`Hgd, vdhWD,`vgdI HdhWD`HgdI HdhWD`Hgd$ vdhWD,`vgd$8<>@vz|~*,2JLRlntDFL  & h j p      !!!F"H"N""""""h,OJQJaJo(h[h*OJQJaJo(hIOJQJaJo(h[hOJQJaJo(h$OJQJaJo(Gj   !H""" #^#h## $$$$$&%:% dhWD`gd|> idhWD2`igdj vdhWD,`vgdj & F!dhgdjdhgd dhWD`gdj vdhWD,`vgd, HdhWD`Hgd,""h#n####$ $$$$$$$$$&%4%%%%%&&&v&|&&&&''''''\(^(d(((((6)D)))***6,8,p,|,,,x---- .㴦h[h|>OJQJaJo(huOJQJaJo(h|>OJQJaJo(h[h*OJQJaJo(hjOJQJaJo(h[hOJQJaJo(h[huOJQJaJo(=:%%%&l&v&&''^((((6)))**** +v+6, idhWD2`igd|>dhgd & F#dhgd|> vdhWD,`vgd|> dhWD`gd|>6,8,N,p,,x--. .*....:/z// 0X00$1&181\1 idhWD2`igdh) dhWD`gdh) dhWD`gd|> idhWD2`igd|>dhgd ..*.....:/F/z//// 00X0d000$1.181D1\1h11111&222d2p2~222222N3Z333333(4.44464<4B4N44445H5T555556"646@6P6\666666ҹҹҹĹҹĹhh)OJQJaJo(h[huOJQJaJo(h[hOJQJaJo(hh)h5OJQJaJo(hh)hu5OJQJaJo(I\111&2d2~2222222N333(464B444H555 vdhWD,`vgdh) & F$dhgdh) idhWD2`igdh)dhgd dhWD`gdh)56646P6l666 7$7T7V7j78Z8|8~8888 idhWD2`igdM dhWD`gdM vdhWD,`vgdh) & F%dhgdh) idhWD2`igdh)dhgd dhWD`gdh)67 77"7$7*7T7^7j7v788Z8f8|888888888 99(9T9`99999999:$:::::::; ;;;;;<<<<<<==P=\===>>>ʼhwYhQ5OJQJaJo(h[hQOJQJaJo(h[hZOJQJaJo(hh)OJQJaJo(h[huOJQJaJo(h[hOJQJaJo(@8889T99999::::;;;;<<<<<< idhWD2`igdwY dhWD`gdM idhWD2`igdMdhgd<<<==.=P=R=n====>>(>6>R@2CDDDDDDEdhgdwY idhWD2`igdwYdhgd dhWD`gdwY>(>0>P@R@.C2CDDDDEE>FHFFFFFLGNGPG\G`HlHIIJJJJJJJJKK KKKK"K$K&K4K6K8KHKJKLK^K`KbKKKKKKKKKKKLL8M>M*N,NԸԭԭԭԭԭԭԭԭԭԭhxOJQJaJo(! j lh[hOJQJaJo(hwYOJQJaJo(h[hOJQJaJo(h[hQOJQJaJo(hwYh5OJQJaJo(DEE>F@FZFFFFFPGbG`HHHvIIII|JJ idhWD2`igdx dhWD`gdx vdhWD,`vgdwY idhWD2`igdwYdhgd dhWD`gdwYJJJKK$K6KJK`KxKKKKKKKL8MLM,NPNO OfO dhWD`gdx & Fdhgd1 vdhWD,`vgdx,N2NOOpOrOzO|OOOOOOOOOPPnQpQQQQQRRLRRRSSTTPWZW"X*XtXxX~XXXXXXXXXXXXXYYYY&YDYLY\YdYnYrYYY ZZ^^\^ȸhrh5OJQJaJo(hrhQ5OJQJaJo(h[hQOJQJaJo(h[hOJQJaJo(hxOJQJaJo(DfOrO|OOOOOOOP8QpQQQRLRdRSTTTUV & Fdhgd1 vdhWD,`vgdx idhWD2`igdx dhWD`gdx & Fdhgd1VPWRWdWrWtWWWWWWWWWXXX X"X4XLXbXtX~XXX idhWD2`igdrdhgd dhWD`gdxXXXXXYYDY\YnYYYYYYY ZZZ[\]^^ ^^^ dhWD`gdr idhWD2`igdrdhgd\^^^0j:j6x@x{{{{|8|:|X|Z|t|v||||||0}2}̶xxjXxJ=h"(h OJQJaJh"(h OJQJaJo(#h"(h CJ OJPJQJaJ o(h3hFFOCJOJQJo(h3h CJOJQJo(hFFOCJOJQJo( hLx5CJ,OJPJQJaJ,o(&hLxh`5CJ,OJPJQJaJ,o(hHPCJOJQJo(hCJOJQJo(hCJOJQJo(h[hQOJQJaJo(h[hOJQJaJo(h[hOJQJaJ^^`^j^p^x^z^|^~^^^Pkd1$$Ifl4\LM  8u   t0644 layt dh$Ifgd ^^^^^^^=kd2$$Ifl4rLM a 8u  n t0644 layt dh$Ifgd^^^_@_n_r_v_?kd3$$IflrLM a 8u  n t0644 layt dh$Ifgdv_x______K????? dh$Ifgdkdu4$$IflrLM a 8u  n t0644 layt________K?????? dh$IfgdkdU5$$IflrLM a 8u  n t0644 layt__```^```````````` dh$Ifgd```````K????? dh$Ifgdkd56$$IflrLM a 8u  n t0644 layt``aaFaJaNaK????? dh$Ifgdkd7$$IflrLM a 8u  n t0644 laytNaPa\aaaaaaK?????? dh$Ifgdkd7$$IflrLM a 8u  n t0644 laytaabbb bbbbbb(b,b0b dh$Ifgd 0b2b@b~bbbbbK?????? dh$Ifgdkd8$$IflrLM a 8u  n t0644 laytbbc6ccccc?kd9$$IflrLM a 8u  n t0644 layt dh$Ifgdcccccccd?kd:$$IflrLM a 8u  n t0644 layt dh$Ifgdd0d~dddddd?kdo;$$IflrLM a 8u  n t0644 layt dh$Ifgddee"e$e2ezee?kdO<$$IflrLM a 8u  n t0644 layt dh$Ifgdeeeeeeee?kd/=$$IflrLM a 8u  n t0644 layt dh$Ifgdef8ftfffff?kd>$$IflrLM a 8u  n t0644 layt dh$IfgdffffffgLg?kd>$$IflrLM a 8u  n t0644 layt dh$IfgdLggggggg(h?kd?$$IflrLM a 8u  n t0644 layt dh$Ifgd(h,h0h2hBh^hhh?kd@$$IflrLM a 8u  n t0644 layt dh$Ifgdhhhhhhii?kdA$$IflrLM a 8u  n t0644 layt dh$Ifgdii*i4iNiPihiK????? dh$IfgdkdoB$$IflrLM a 8u  n t0644 laythijixiiiiiK????? dh$IfgdkdOC$$IflrLM a 8u  n t0644 laytiiii&j*j.jK????? dh$Ifgdkd/D$$IflrLM a 8u  n t0644 layt.j0j2jLjK?-idh$IfWD2`igdr dh$IfgdkdE$$IflrLM a 8u  n t0644 laytLjjjjjkkkyyyyy dh$IfgdhkdE$$IflL & t0644 laytdh$IfWD`gdrk kk0kJkXkxkkK?????? dh$IfgdkdF$$IflrLM a 8u  n t0644 laytrkkkkkk$l4l?kdmG$$IflrLM a 8u  n t0644 layt dh$Ifgd4lFlVl|llll:m>mBm dh$Ifgd BmDmRm~mmmmmK?????? dh$IfgdkdMH$$IflrLM a 8u  n t0644 laytmmmm nnnK????? dh$Ifgdkd-I$$IflrLM a 8u  n t0644 laytnn ndnnnnK????? dh$Ifgdkd J$$IflrLM a 8u  n t0644 laytnnnnnn$o>oK?????? dh$IfgdkdJ$$IflrLM a 8u  n t0644 layt>ozooooooo?kdK$$IflrLM a 8u  n t0644 layt dh$Ifgdoooooopp?kdL$$IflrLM a 8u  n t0644 layt dh$Ifgdppp(p6pRpTpXp?kdM$$IflrLM a 8u  n t0644 layt dh$IfgdXpZphppppppK?????? dh$IfgdkdmN$$IflrLM a 8u  n t0644 laytpqqqq(qqq?kdMO$$IflrLM a 8u  n t0644 layt dh$Ifgdqqqqqq.r2r?kd-P$$IflrLM a 8u  n t0644 layt dh$Ifgd2r4r6rDrrrrrr?kd Q$$IflrLM a 8u  n t0644 layt dh$Ifgdrrrrs$s2sK????? dh$IfgdkdQ$$IflrLM a 8u  n t0644 layt2s4sBstssssK????? dh$IfgdkdR$$IflrLM a 8u  n t0644 laytsss"ttttK????? dh$IfgdkdS$$IflrLM a 8u  n t0644 layttttt,u0u4uK????? dh$IfgdkdT$$IflrLM a 8u  n t0644 layt4u6uDuxuuuuK????? dh$IfgdkdmU$$IflrLM a 8u  n t0644 laytuuuu&v*v8vK????? dh$IfgdkdMV$$IflrLM a 8u  n t0644 layt8v:vHv`vvvvK????? dh$Ifgdkd-W$$IflrLM a 8u  n t0644 laytvvvvw wwK????? dh$Ifgdkd X$$IflrLM a 8u  n t0644 laytwww:w^wbwfwK????? dh$IfgdkdX$$IflrLM a 8u  n t0644 laytfwhwvw~wwwwK????? dh$IfgdkdY$$IflrLM a 8u  n t0644 laytwwww,x0x4xK????? dh$IfgdkdZ$$IflrLM a 8u  n t0644 layt4x6x8xXxK?-idh$IfWD2`igdr dh$Ifgdkd[$$IflrLM a 8u  n t0644 laytXxxxxxByFyJyyyyyy dh$Ifgdhkdm\$$IflL & t0644 laytdh$IfWD`gdrJyLyXyjyyyyK????? dh$Ifgdkd\$$IflrLM a 8u  n t0644 laytyyyyDzHzJzK????? dh$Ifgdkd]$$IflrLM a 8u  n t0644 laytJzLzXzlz~zzzK????? dh$Ifgdkd^$$IflrLM a 8u  n t0644 laytzzzzzzzK????? dh$Ifgdkd_$$IflrLM a 8u  n t0644 laytzz{{>{@{D{K????? dh$Ifgdkd}`$$IflrLM a 8u  n t0644 laytD{F{R{{{{{K????? dh$Ifgdkd]a$$IflrLM a 8u  n t0644 layt{{{{{{{K????? dh$Ifgdkd=b$$IflrLM a 8u  n t0644 layt{{{{{{{{KCCCCCCdhgdkdc$$IflrLM a 8u  n t0644 layt{{{||||| | |||||||:|X|Z|v||||2}p}v}}} $dha$gdFFOdhgd2}t}~}}}Z\^HJZdtvx<FZd^`rDN.02FLNPƍЍ̺h"(hFFOOJQJaJo(#hRXh CJ OJPJQJaJ o(h"(h8OJQJaJh3h CJOJQJo(#hLxh CJ OJPJQJaJ o(h"(hFFOOJQJaJh"(h OJQJaJhf-OJQJaJo(h"(h OJQJaJo(2}~~\^JV\vx8>pƅV\ $dha$gdFFO dhWD`gd"(dhgd\ ^`rJ"@F02NP dhWD`gd"( $dha$gdFFOdhgdPȍx~"dJ,pޑ>:<N $dha$gd8dhgd dhWD`gd"(Ѝ|<>:<LNPT^HR 02VXZ\f˼˪~peZhRXCJOJQJo(hCJOJQJo(h3hCJOJQJo(h3h CJOJQJ hRXh CJ OJPJQJaJ h"(hRXOJQJaJo(#hRXh CJ OJPJQJaJ o(hRXCJ OJPJQJaJ o(h"(h OJQJaJh"(h8OJQJaJo(hf-OJQJaJo(h"(h OJQJaJo("<hPV ܗDJ 2VXZ\^`bdfh dhWD`gd"( $dha$gdRXdhgdhjlnprtvxz|~ԙ>Ddhgd8 $dha$gd8dhgdfxșԙǶ~eJ~5)h"(h B*KHOJQJ^JaJph4hzh B*CJ KHOJPJQJ^JaJ o(ph1hzh B*CJ KHOJPJQJ^JaJ ph)h3h B*CJKHOJQJ^Jph h8h CJKHOJQJ^J#h8h CJKHOJQJ\^J h"(CJKHOJQJ\^Jo(&hzh`5CJ,OJPJQJaJ,o(h8hf-CJOJQJo(hf-CJOJQJo(h"(CJOJQJo( ĚBL8:\^bDNğhrjtܥ68wwc&hB*KHOJQJ^JaJo(ph)h3h B*CJKHOJQJ^Jph4hzh B*CJ KHOJPJQJ^JaJ o(ph1hzh B*CJ KHOJPJQJ^JaJ ph,h"(hB*KHOJQJ^JaJo(ph)h"(h B*KHOJQJ^JaJph&hf-B*KHOJQJ^JaJo(ph#8:^@Fdjflإޥަ68 $dha$gd $dha$gddhgd8:L­޳hnƵrx*0$ dhWDd`gd"( $dha$gddhgd8:JLPʭ޳lvĵεv.8",blx>@еww`еwwwwwwwwwww`,h"(hB*KHOJQJ^JaJo(ph&hf-B*KHOJQJ^JaJo(ph)h"(h B*KHOJQJ^JaJph)h3h B*CJKHOJQJ^Jph4hqh B*CJ KHOJPJQJ^JaJ o(ph1hqh B*CJ KHOJPJQJ^JaJ ph,h"(h"(B*KHOJQJ^JaJo(ph%^dtzһ>@V28(.HN.4v| $dha$gddhgd@TV\6@,6LV2<z,6NX˶v[4hqh B*CJ KHOJPJQJ^JaJ o(ph,h"(hB*KHOJQJ^JaJo(ph&hf-B*KHOJQJ^JaJo(ph)h"(h B*KHOJQJ^JaJph)h3h B*CJKHOJQJ^Jph4hqhB*CJ KHOJPJQJ^JaJ o(ph1hqh B*CJ KHOJPJQJ^JaJ ph (.|JPhj~z $dha$gddhgdPRThj|~~ꭔydꭔ)h3h B*CJKHOJQJ^Jph4hqh B*CJ KHOJPJQJ^JaJ o(ph1hqh B*CJ KHOJPJQJ^JaJ ph,hPhB*KHOJQJ^JaJo(ph#hf-B*KHOJQJ^JaJph&hf-B*KHOJQJ^JaJo(ph)hPh B*KHOJQJ^JaJph ",Ѽ}dI4)h3h B*CJKHOJQJ^Jph4hqh B*CJ KHOJPJQJ^JaJ o(ph1hqh B*CJ KHOJPJQJ^JaJ ph,hPhf-B*KHOJQJ^JaJo(ph&hB*KHOJQJ^JaJo(ph&hf-B*KHOJQJ^JaJo(ph)hPh B*KHOJQJ^JaJph&hf-B*CJKHOJQJ^Jo(ph4hqhB*CJ KHOJPJQJ^JaJ o(ph $$*np $dha$gddhgd,(2npHRֿvbbKvbb7&h B*KHOJQJ^JaJo(ph,hPhB*KHOJQJ^JaJo(ph&hf-B*KHOJQJ^JaJo(ph)h3h B*CJKHOJQJ^Jph4hqh B*CJ KHOJPJQJ^JaJ o(ph1hqh B*CJ KHOJPJQJ^JaJ ph,hPhPB*KHOJQJ^JaJo(ph&hB*KHOJQJ^JaJo(ph)hPh B*KHOJQJ^JaJphpDJn^Pz&@ dh`gdf-dhgdf-dhgd $dha$gd  $&Ѷu^J6"&h4 B*CJKHOJQJ^Jo(ph&hmXnB*CJKHOJQJ^Jo(ph&hB*CJKHOJQJ^Jo(ph,hPhB*KHOJQJ^JaJo(ph,hPh B*KHOJQJ^JaJo(ph)hPh B*KHOJQJ^JaJph)h3h B*CJKHOJQJ^Jph4hPh B*CJ KHOJPJQJ^JaJ o(ph1hPh B*CJ KHOJPJQJ^JaJ ph)h3hf-B*CJKHOJQJ^Jph J   "$.@Vhpx dh$Ifgd $dha$gdmXndhgd&*.>@TVfhnpvxz~̰jS>S>S>/>S>S>hhh_CJKHOJQJ)hh B*CJKHOJQJ^Jph,hh B*CJKHOJQJ^Jo(ph)h3h B*CJKHOJQJ^Jph/hh B*CJKHOJQJ\^Jo(ph1hPh B*CJKHOJPJQJ^JaJph7hPh B*CJKHOJPJQJ\^JaJo(ph1hPh B*CJ KHOJPJQJ^JaJ ph4hPh B*CJ KHOJPJQJ^JaJ o(phxz~rffff dh$Ifgdkdc$$IfFFBw S006    44 layt   "&(,.04fhlnrtvz4:BDFLhhh_CJKHOJQJ)hh B*CJKHOJQJ^Jph,hh B*CJKHOJQJ^Jo(phN_SSSS dh$Ifgdkdd$$If\\FB0G S00644 layt_SSSS dh$Ifgdkdae$$If\\FB0G S00644 layt _SSSS dh$Ifgdkdf$$If\\FB0G S00644 layt"(._SSSS dh$Ifgdkdf$$If\\FB0G S00644 layt.04hnt_SSSS dh$Ifgdkdg$$If\\FB0G S00644 layttvz_SSSS dh$IfgdkdUh$$If\\FB0G S00644 layt_SSSS dh$Ifgdkdi$$If\\FB0G S00644 layt_SSSS dh$Ifgdkdi$$If\\FB0G S00644 layt_SSSS dh$Ifgdkdj$$If\\FB0G S00644 layt6:D_SSSS dh$IfgdkdIk$$If\\FB0G S00644 laytDFLbhr_SSSS dh$Ifgdkdl$$If\\FB0G S00644 laytL`bfhprtz "(*,2RTXZ^`bhzŰ)hPB*CJKHOJQJ\^Jo(phhhh_CJKHOJQJ)hh B*CJKHOJQJ^Jph,hh B*CJKHOJQJ^Jo(phErtz_SSSS dh$Ifgdkdl$$If\\FB0G S00644 layt_SSSS dh$Ifgdkdm$$If\\FB0G S00644 layt_SSSS dh$Ifgdkd=n$$If\\FB0G S00644 layt"*_SSS dh$Ifgdkdn$$If\\FB0G S00644 layt*,2TZ`rffff dh$Ifgdkdo$$IfFFBw S006    44 layt`bh|_SSSS dh$Ifgdkd^p$$If\\FB0G S00644 layt_SSSS dh$Ifgdkdq$$If\\FB0G S00644 layt_SSSS dh$Ifgdkdq$$If\\FB0G S00644 layt_SSSS dh$Ifgdkdr$$If\\FB0G S00644 layt"*2_WWWKKK dh$IfgddhgdkdRs$$IfZ\\FB0G S00644 layt "(*024:JLPRVXZ` 0268<>@F^`bdlnpvһһһҬһһһҬһһһҬһһһҬһһһҬһһһҬһһһҬһһһҬһhhh_CJKHOJQJ,hh B*CJKHOJQJ^Jo(ph)hh B*CJKHOJQJ^Jph/hh B*CJKHOJQJ\^Jo(phD24:LRXrffff dh$Ifgdkdt$$IfFFBw S006    44 laytXZ`_SSSS dh$Ifgdkdt$$If\\FB0G S00644 layt_SSSS dh$Ifgdkdsu$$If\\FB0G S00644 layt_SSSS dh$Ifgdkd0v$$If\\FB0G S00644 layt 28>_SSSS dh$Ifgdkdv$$If\\FB0G S00644 layt>@F`dn_SSSS dh$Ifgdkdw$$If\\FB0G S00644 laytnpv_SSSS dh$Ifgdkdgx$$If\\FB0G S00644 layt_SSSS dh$Ifgdkd$y$$If\\FB0G S00644 layt"$&,LNVX\^`prxz $8:>@DFHN^`dfjlnthhh_CJKHOJQJ)hh B*CJKHOJQJ^Jph,hh B*CJKHOJQJ^Jo(phN_SSSS dh$Ifgdkdy$$If\\FB0G S00644 layt$_SSSS dh$Ifgdkdz$$If\\FB0G S00644 layt$&,NX^_SSSS dh$Ifgdkd[{$$If\\FB0G S00644 layt^`rz_SSS dh$Ifgdkd|$$If\\FB0G S00644 laytrffff dh$Ifgdkd|$$IfKFFBw S006    44 layt_SSSS dh$Ifgdkd|}$$IfJ\\FB0G S00644 layt_SSSS dh$Ifgdkd9~$$If\\FB0G S00644 layt$:@F_SSSS dh$Ifgdkd~$$If\\FB0G S00644 laytFHN`fl_SSSS dh$Ifgdkd$$If\\FB0G S00644 laytlnt_SSSS dh$Ifgdkdp$$If\\FB0G S00644 layt &06>@BHTVXZbdfl~į/hh B*CJKHOJQJ\^Jo(ph)hPB*CJKHOJQJ\^Jo(phhhh_CJKHOJQJ,hh B*CJKHOJQJ^Jo(ph)hh B*CJKHOJQJ^Jph;_WWWKKK dh$Ifgddhgdkd-$$If\\FB0G S00644 laytrffff dh$Ifgdkd$$IfKFFBw S006    44 layt_SSSS dh$Ifgdkd$$If\\FB0G S00644 layt &26@_SSSS dh$IfgdkdN$$If\\FB0G S00644 layt@BHVZd_SSSS dh$Ifgdkd $$If\\FB0G S00644 laytdfl_SSSS dh$IfgdkdȄ$$If\\FB0G S00644 layt_SSSS dh$Ifgdkd$$If\\FB0G S00644 layt*.NP`bŸveVE h3hh_CJKHOJQJ^Jhh_CJKHOJQJ^Jo( h3h CJKHOJQJ^Jhh_hh_5CJOJQJo( hk u5CJ,OJPJQJaJ,o(&hk uh`5CJ,OJPJQJaJ,o(hk u5CJOJQJo(hP5CJOJQJo(hhh_CJKHOJQJ)hh B*CJKHOJQJ^Jph,hh B*CJKHOJQJ^Jo(ph_SSSS dh$IfgdkdB$$If\\FB0G S00644 layt  _WWWWWWWWWdhgdPkd$$If\\FB0G S00644 layt  "$&(*,.P`bdhgd $dha$gdh_ $dha$gdmXndhgdP", x Zd04´´{#hh CJ OJPJQJaJ o(hh OJQJaJo(h%hh_OJQJaJo(hOJQJaJo(h%h OJQJaJo(h3h CJOJQJo(#h%h CJ OJPJQJaJ o(hh_CJOJQJo(#hh_h CJKHOJQJ^Jo(0$tzV\L $dha$gdh_dhgd@j0.plLz $dha$gdh_dhgd&BzRTr6 < . 4    n    ~     $dha$gddhgdTrv: D 2 <         | HR R\.8HR    !!v"" ##N#p#t###$%&&0&&&ѸƸƸƸh CJOJQJo(h-hKh OJQJaJo(hOJQJaJo(h3h CJOJQJo(#hh CJ OJPJQJaJ o(hh OJQJaJo(>  |     0Llx~~dD $dha$gdh_dhgdTn DJZRd0dhgd TNT*0 .ZDJ0b     $dha$gdh_dhgd !!r"x"# #L#N#p###$h$$$$2%`%%"&(&&&&&&& $dha$gdh_dhgd&&&&&''''(( (((,(p7777øøѭfѢK/7hh B*CJKHOJPJQJ\^JaJo(ph4hh B*CJ KHOJPJQJ^JaJ o(ph7h-hKh B*CJKHOJPJQJ\^JaJo(ph#h-hKh CJOJPJQJaJo(h3hmXnCJOJQJo(hmXnCJOJQJo(h CJOJQJo(hOJQJaJo(h-hKh OJQJaJo(h3h CJOJQJo(#h-hKh CJ OJPJQJaJ o(h3h-hKCJOJQJo(&'''''((((( ( (((,(L((()l)))*H*p**+ $dha$gdmXndhgd+++6,\,,,,"-J----*..///0@000V11112^22dhgd223H3p333404|444 5@55.6d6667l7n7p7r7t7v7x7z7|7dhgd|7~77777778@8`888899>9X9~9999 :4:Z:::: $dha$gdmXndhgd:::::::;<=>b?@"AA"BBtC DDxEFFGGGGG $dha$gdmXndhgd7:::GGGGGGGGGGGGHHNHTHVHHHֺ񯤖n^QQFQh~PCJOJQJo(h3h CJOJQJhmXnhmXn5CJOJQJo(&hhmXn5CJ,OJPJQJaJ,o(&hh`5CJ,OJPJQJaJ,o(h3hmXnCJOJQJo(hmXnCJOJQJo(h CJOJQJo(7hh B*CJKHOJPJQJ\^JaJo(ph4hh B*CJ KHOJPJQJ^JaJ o(phh3h CJOJQJo(GGGGGGHHHHHHHHI2IPItIIIIIIdhgdmXn dh`gdmXn $dha$gddhgd $dha$gdmXndhgdHHHHIIIII6J8JJJJ,KKKLLM MMMMNNVO\OOOPpPPP~QQQ $dha$gdmXndhgdQRSSSSTT&U(UDUrVV*W0WhWWWXHXNX0YYY ZZZ[ $dha$gdmXndhgd&U(UDUHU(W*W.W8WFXHXLXVX~YYYYZ ZZZZZZ[\\\"\\\\\]]]<^>^B^L^\_^_b_l_____XaZa^ahaaaaabbbb*c,c.cBcFcdźźźźźźźźźźźźźůhhB9OJQJaJh OJQJaJo(hB9OJQJaJo(hh OJQJaJo(h3h CJOJQJo(#hh CJ OJPJQJaJ o(hh OJQJaJ@[[\\\\\ ]]]>^D^ _^_d___Za`aaabb*c,c.cBcLd $dha$gdmXndhgdLddd&exe~efffglgghhhhi"iiiiiBjHjjj2k~kkdhgdddddvexe|eeffffghhhhhhhii i*iiiiiiiii@jBjFjPjjjjj|k~kkk4m6m:mDmnnnnppp&ppppppppp~qqqqqqqqVrXr\rfrttttvvv"vvvBwhB9OJQJaJo(hh OJQJaJo(hh OJQJaJVkNll6m@źźźźźźźźźźźůӂuh2_h OJQJaJh2_h OJQJaJo(#h2_h CJ OJPJQJaJ o(hhOJQJaJh OJQJaJo(hB9OJQJaJo(hh OJQJaJo(h3h CJOJQJo(#hh CJ OJPJQJaJ o(hh OJQJaJ.xxx*y0yzyzzz|zz{{B|H||}}~~~~<>D܀ $dha$gdmXndhgd  "Є@FHNDJ dhWD`gd2_ $dha$gdmXndhgd@DNFHLVBDHRȎʎΎ؎",  ʒ̒Вڒ Z\`j",rtxǹh3h CJOJQJo(#h2_h CJ OJPJQJaJ o(h2_h OJQJaJhB9OJQJaJo(h2_h OJQJaJo(I2 ʎЎ$‘ ̒Ғ\b$tz $dha$gdmXndhgdșdfjt",lnr|VX\f֨بܨЩҩ֩TVZdޫjlpzvx#h2_h CJ OJPJQJaJ o(hFkOJQJaJo(h2_h OJQJaJo(h2_h OJQJaJKfl$lntNvRXdhgdX^TبިҩةtV\lrvxԮ DJ $dha$gdmXndhgdBDHR^`dn°jn"&㾳}rg\hSCJOJQJo(h CJOJQJo(h2_OJQJaJo(#h2_h CJOJPJQJaJo(#h2_hmXnCJ OJPJQJaJ o(#h2_h CJ OJPJQJaJ o(h2_CJOJQJo(h3h CJOJQJhFkOJQJaJo(h2_h OJQJaJh2_h OJQJaJo(h3h CJOJQJo("`f°Lt¶j" dhWD`gd2_ $dha$gdmXndhgd\  $dha$gd8u; dhWDd`gd2_dhgd dhWD`gd2_|~6:z|Ϳ||o]PPCPh8u;h8u;CJOJQJhWDh8u;OJQJaJ#hWDh CJ OJPJQJaJ o(hWDh OJQJaJhWDOJQJaJo(h>OJQJaJo(hWDh OJQJaJo(#hr}h CJ OJPJQJaJ o(h3h CJOJQJh3h CJOJQJo(h8u;h8u;5CJOJQJo(&hSh`5CJ,OJPJQJaJ,o(h3hSCJOJQJo(:~.z|N.8 dh`gdWD dhWD`gdWDdhgd $dha$gd8u;,.6@:<> NPXb*,4>$ ~>@HR^`hr "*毼h3h CJOJQJo(hWDh OJQJaJ#hWDh CJ OJPJQJaJ o(h(COJQJaJo(hWDh8u;OJQJaJhWDh OJQJaJo(h>OJQJaJo(?8<> PZ,6 $dha$gd8u; dh`gdWDdhgd@J`j",P@J*4$ $dha$gd8u;dhgd*4>@HR(*2<  (2jlt~$&.8dfnx*,4>NPXb.08B&0ǹh3h CJOJQJo(#hWDh CJ OJPJQJaJ o(hWDh OJQJaJhWDh OJQJaJo(h(COJQJaJo(I *lv&0fp,6PZ@dhgd $dha$gd8u;0:(\^x&Zd @ dh`gd(C $dha$gd8u;dhgd0\^xXZbd @H,.6@z|"$,6",&  $ .     B D X `    HJR\ǹǹǹh(Ch(COJQJaJo(h OJQJaJo(h3h CJOJQJo(#hWDh CJ OJPJQJaJ o(h(COJQJaJo(hWDh OJQJaJhWDh OJQJaJo(?@.8|$.$l   &    B D X   JTd $dha$gd8u;dhgd\bdlv\^fp " TV|~ (2VX`jjt  ^`h伫hLOJQJaJo( hWDh CJ OJPJQJaJ #hWDh CJ OJPJQJaJ o(h$OJQJaJo(h(COJQJaJo(hWDh OJQJaJhWDh OJQJaJo(?dn^h"V~ *Xbbl $dha$gdWDdhgd  `j$.r | !!!""##$$%%%&\&&' 'dhgdhr"$,6p r z  !!!$!""####~$$$$'' ''''''(((((( ),,,,d-f-n-x-....// /"/./0/R/ٺhLCJOJQJo(h8u;CJOJQJo(h CJOJQJo(h3h CJOJQJ#hWDh CJ OJPJQJaJ o(hWDh OJQJaJhWDh OJQJaJo(hLOJQJaJo(9 '''(((( )8)))$**+++ ,n,,,f-p-..// /"/ $dha$gd8u;dhgd"/$/&/(/*/,/./0/2/4/6/8/://@/B/D/F/H/J/L/N/P/R/T/z/|/ $dha$gd8u;dhgdR/T/z/|////B0D0F0000111(1111122:2t222223333X3`3333384:4>4H4444Ϳ~ssssssshJ)OJQJaJo(hJ)h8u;OJQJaJo(hLOJQJaJo(hJ)h OJQJaJhJ)h OJQJaJo(h3h CJOJQJh3h CJOJQJo(h8u;h8u;5CJOJQJo(&hJ)h`5CJ,OJPJQJaJ,o(hLhLCJOJQJo(-|////D0F0001 11112t22233T333:4@44 HdhWD`HgdJ) dh`gdJ)dhgd $dha$gd8u;44Z5`5B6H6z66667777D8J88888.9V9X9Z9\9^9`9b9 HdhWD`HgdJ)dhgd44^5h5@6B6F6P6666666 77777777B8D8H8R888888889,9.9V9X9\9^9l9n9999p&hpCh`5CJ,OJPJQJaJ,o(h3hLCJOJQJo(hLCJOJQJo(h8u;CJOJQJo(h CJOJQJo(h3h CJOJQJo(h3h CJOJQJhJ)OJQJaJo(hJ)h OJQJaJhJ)h OJQJaJo(hLOJQJaJo(,b9d9f9h9j9l9n9p9r9t9v9x9z9|9~99999999999999 $dha$gd"dhgd999999: :::::;;;;<<<&<<<<<,=.=H=L=??@"@@@@@@BBBFBPBDDEEEEHFRFFFHGRGô⦙⦎⦙⦎hT5+OJQJaJo(h=OJQJaJo(hLh OJQJaJhLh OJQJaJo(hLCJ OJPJQJaJ o(#hLh CJ OJPJQJaJ o(h3h CJOJQJh3h CJOJQJo(h"h"5CJOJQJo(39:::;;<<<<,=.=H=~===>J>>>?D???@@@ $dha$gd"dhgd $dha$gdL@@@ABBHBBDDEEEEDFJFFFDGJGGG^HdHHHrIxII $dha$gd"dhgdRGGGbHlHHHvIIlJvJKKKKKLLLLLMMVN`NNNBPDPVPZPPPPPQQQQxRzR~RRSSSSTT6UTUXUUUUUǹ櫞櫞櫞櫞櫌#h?[h CJ OJPJQJaJ o(h?[h OJQJaJh?[h OJQJaJo(h3h CJOJQJo(#hLh CJ OJPJQJaJ o(hLh OJQJaJhT5+OJQJaJo(hLh OJQJaJo(7IhJnJKKKKKKLLL~MMRNXNNN0OBPDPVPPPQQzRR $dha$gd"dhgdRSSTT6UTUUUVVW WWWWXXrYxYYYZZPZRZ\Zdhgd| $dha$gd"dhgdUVVVVWWW(WWWWWXXXXpYrYvYYYYYYZZZZPZRZXZZZ\ZǹtethCJ OJPJQJaJ o( h|h CJ OJPJQJaJ h3h"CJOJQJo(hOJQJaJo(h|h OJQJaJh|h OJQJaJo(h3h CJOJQJo(#h|h CJ OJPJQJaJ o(hT5+OJQJaJo(h?[h OJQJaJh?[h OJQJaJo(!\ZZZZZZZZZZZZZ[["[([>[B[b[h[z[~[[[[[[[[[\\"\&\J\T\Z\p\r\\zmh3h CJOJQJh3h 5CJOJQJo(h3h|5CJOJQJh|5CJOJQJo(h 5CJOJQJo(h3h 5CJOJQJ!h3h 5>*CJOJQJ\h"5CJOJQJ\o(!h3h 5CJOJQJ\o(h3h 5CJOJQJ\(\ZZZZZZZZZZZZ[Z[[[\:\<\>\r\\\\\\\\ $dha$gd|dhgd\\\\\\\\\\\\\\\P]T]]]]]^^8^:^<^>^`^d^^^^^^ƹ{{i{Y jh3h CJOJQJ#h3h CJOJQJmHnHu!jh3h CJOJQJUh3h 5CJOJQJ\h3h"5CJOJQJo(h"5CJOJQJo(h 5CJOJQJo(h3h 5CJOJQJo(h3h 5CJOJQJh3h CJOJQJh3h CJOJQJo(!\\\\P]]]`^^^_*_p________________dhgd^^^^__*_._p_t_______aaaaaaaaaabbbbbblcnceeJeʿ㡏qch3h CJOJQJo(h3h >*CJOJQJ j +h3h CJOJQJ#h3h CJOJQJmHnHu!jh3h CJOJQJUh3h"CJOJQJh"CJOJQJo(h CJOJQJo(h3h 5CJOJQJh3h CJOJQJ j bh3h CJOJQJ$___``` ` `ekd$$Ifl4F I06    4 laf4yt| dh$Ifgd ````qee dh$Ifgdkd$$Ifl4FF I06    4 laf4yt|``&`,`.`6`8`xxxxx dh$Ifgd{kd$$Ifl4[0 064 laf4yt|8`:`<`B`D`F`K???? dh$Ifgdkd1$$Ifl4Nr,  064 laf4yt|F`H`T`V`d`f`n`p`qeeeeee dh$Ifgdkd1$$Ifl4NF I06    4 laf4yt|p`r`|`~``8,,, dh$Ifgdkd$$Ifl4ֈ w,   f064 laf4yt|`````````Rkd$$Ifl4M\w f064 laf4yt| dh$Ifgd`````8,,, dh$Ifgdkdύ$$Ifl4ֈ w, Of064 laf4yt|````` dh$Ifgd````a8,,, dh$Ifgdkdʎ$$Ifl4Mֈ w, ?f064 laf4yt|a aaaa,kdŏ$$Ifl4ֈ w, Of064 laf4yt| dh$Ifgda&a(a6a8aBaDa dh$IfgdDaFaPaRa\a8,,, dh$Ifgdkd$$Ifl4ֈ w, Of064 laf4yt|\a^ahajarata dh$Ifgdtavakd$$Ifl4ִ `/, V06    4 laf4yt|vaaaaaaa dh$Ifgdaaaaa8,,, dh$Ifgdkd$$Ifl4kֈ`, W064 laf4yt|abbbb dh$Ifgdbb,b% dh$Ifgdkd$$Ifl4"֞ `/, V064 laf4yt|,b8b:bHbJbVbXb dh$IfgdXbZbrb% dh$Ifgdkd$$Ifl4֞ `/, V064 laf4yt|rbtbbbbbbbbbRkd-$$Ifl4\`, W064 laf4yt| dh$Ifgd bbbbbbbbbcx{kd$$Ifl40 FB064 laf4yt| dh$Ifgd cccc cccccaYMMMMMM dh$Ifgddhgdkd$$Iflp\G 3 un064 layt|cc"c&c*c.c2c4c6c8c:cZcncccc&d\dddddee dh$Ifgdeee&eJeLeVeXe|qq|ee dh$Ifgd $dha$gd|dhgd{kd$$Ifl430y 064 laf4yt|JeLefPg8iNiPiijjj6j8j@kFkHkJkhkkkkkkkkk{{{ dh$Ifgdxkd$$Ifl 0o o064 layt|>k@kJkhkjkpkvkkkqi^iRRRR dh$Ifgd $dha$gd"dhgdkd($$Ifl4_ F  @06    4 laf4yt|kkkkkkk^RRRRR dh$Ifgdkd$$Ifl4\q  064 laf4ytvkkkK? dh$Ifgdkdɩ$$Ifl4rq   mm 064 laf4ytvkkkkkkk dh$Ifgdfkd$$Ifl4 064 laf4ytvkkkllllPDDDDD dh$IfgdkdB$$Iflrq  mm064 laytvll&l@lBlDlFlPDDDDD dh$Ifgdkd$$Iflrq  mm064 laytvFlHlTlzl|l~llPDDDDD dh$Ifgdkd$$Iflrq  mm064 laytvlllllllPDDDDD dh$Ifgdkd$$Iflrq  mm064 laytvlllllllPDDDDD dh$Ifgdkd$$Iflrq  mm064 laytvll m,m.m0m2mPDDDDD dh$Ifgdkdk$$Iflrq  mm064 laytv2m4m$$Iflrq  mm064 laytvnnnnnnnPDDDDD dh$Ifgdkd$$Iflrq  mm064 laytvnnnnnnnPDDDDD dh$Ifgdkd$$Iflrq  mm064 laytvnnoooooPDDDDD dh$Ifgdkd$$Iflrq  mm064 laytvoo(oo@oBoPDDDDD dh$Ifgdkd$$Iflrq  mm064 laytvBoDoPohojolonoPDDDDD dh$Ifgdkdg$$Iflrq  mm064 laytvnopo|oooooPDDDDD dh$Ifgdkd<$$Iflrq  mm064 laytvoooooooPDDDDD dh$Ifgdkd$$Iflrq  mm064 laytvoooooooPDDDDD dh$Ifgdkd$$Iflrq  mm064 laytvoooppppPDDDDD dh$Ifgdkd$$Iflrq  mm064 laytvpp(pPD dh$Ifgdkd$$Iflrq  mm064 laytv(p*p2pHpJpLpNp dh$Ifgdfkde$$Ifl4 064 laf4ytvNpPp\pzp|p~ppPDDDDD dh$Ifgdkd$$Iflrq  mm064 laytvpppppppPDDDDD dh$Ifgdkdſ$$Iflrq  mm064 laytvpppppppPDDDDD dh$Ifgdkd$$Iflrq  mm064 laytvpppppppPDDDDD dh$Ifgdkdo$$Iflrq  mm064 laytvpq q"q$q&q(qPDDDDD dh$IfgdkdD$$Iflrq  mm064 laytv(q*q6qLqNqPqRqPDDDDD dh$Ifgdkd$$Iflrq  mm064 laytvRqTq`qvqxqzq|qPDDDDD dh$Ifgdkd$$Iflrq  mm064 laytv|q~qqqqqqPDDDDD dh$Ifgdkd$$Iflrq  mm064 laytvqqqqPDD dh$Ifgdkd$$Iflrq  mm064 laytvJpqqqqqrrs"s&sHsJsv.vDvzvvvvvvvvv w wwwFwHwdwfwlwnwwwwwwwwxx x:xyyyyyPDDDDD dh$Ifgdkd$$Iflrq  mm064 laytvyyyyyyyPHH<<< dh$Ifgddhgdkd$$Iflrq  mm064 laytvyyyyyyyyyzzz"z$z&z(zLzNzdzfzH{J{f{h{j{l{{{{t|||>}@}\}^}`}b}}}}}}}}}}۹۹۹۫۫۫۹u$h3h B*CJOJQJo(ph#h3h CJOJQJmHnHu!jh3h CJOJQJUh3h CJOJQJo(h3h CJOJQJ)h3h 5CJOJQJ\mHnHuh3h 5CJOJQJ\'jh3h 5CJOJQJU\.yyyyyyyzRkd$$Ifl4\"y h 76064 laf4ytv dh$IfgdzzzLzK?? dh$Ifgdkd$$Ifl4r"y h 6064 laf4ytvLzNzVzdzfzhzjzzzzzz dh$Ifgdykd$$Ifl40 064 laf4ytvjzlzxzzzzzPDDDDD dh$Ifgdkd-$$Iflr"y h 6064 laytvzzzzzzzPDDDDD dh$Ifgdkd $$Iflr"y h 6064 laytvzzz{{{{PDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytv{{&{|{~{{{PDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytv{{{{{{{PDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytv{{{{{{{PDDDDD dh$Ifgdkd~$$Iflr"y h 6064 laytv{{{||||PDDDDD dh$Ifgdkd[$$Iflr"y h 6064 laytv|||:|<|>|@|PDDDDD dh$Ifgdkd8$$Iflr"y h 6064 laytv@|B|N|l|n|p|r|PDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytvr|t|||||||PDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytv|||||||PDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytv|||}}} }PDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytv } }}6}8}:}<}PDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytv<}>}}PD dh$Ifgdkdf$$Iflr"y h 6064 laytv}}}}}}} dh$IfgdfkdC$$Ifl4 064 laf4ytv}}}~~~~PDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytv}} ~"~>~@~B~D~Xnp.0246>nrxz|́΁Ῥᘿmᘿm*h3h 5B*CJOJQJ\o(ph)h3h 5CJOJQJ\mHnHu'jh3h 5CJOJQJU\$h3h B*CJOJQJo(phh3h 5CJOJQJ\#h3h CJOJQJmHnHuh3h CJOJQJ!jh3h CJOJQJU'~~~d~f~h~j~PDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytvj~l~x~~~~~PDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytv~~~~~~~PDDDDD dh$Ifgdkde$$Iflr"y h 6064 laytv~~~~~~~PDDDDD dh$IfgdkdB$$Iflr"y h 6064 laytv~~  "$PDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytv$&2PRTVPDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytvVX`nprtPDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytvtvPDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytvPDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytvPDDDDD dh$Ifgdkdp$$Iflr"y h 6064 laytv>@BDPDDDDD dh$IfgdkdM$$Iflr"y h 6064 laytvDFRz|~PDDDDD dh$Ifgdkd*$$Iflr"y h 6064 laytvPDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytvҀԀր؀PDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytv؀ڀ  PDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytvpPD dh$Ifgdkd$$Iflr"y h 6064 laytvprz dh$Ifgdfkd{$$Ifl4 064 laf4ytv́PDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytv"$@BDFHPxzЂ҂"$@BDFHPlnͻͻͻާl*h3h 5B*CJOJQJ\o(ph)h3h 5CJOJQJ\mHnHuh3h 5CJOJQJ\'jh3h 5CJOJQJU\#h3h CJOJQJmHnHu!jh3h CJOJQJUh3h CJOJQJ'h3h B*CJOJQJ\o(ph#"dfhjPDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytvjlx‚PDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytv‚ĂЂPDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytv"nprtPDDDDD dh$Ifgdkdz$$Iflr"y h 6064 laytvnp$VXtvxz|„ބjl…ąƅϽϽϽϽϽ'jh3h 5CJOJQJU\h3h 5CJOJQJ\'h3h B*CJOJQJ\o(ph#h3h CJOJQJmHnHu!jh3h CJOJQJUh3h CJOJQJ$h3h B*CJOJQJo(ph.tvPDDDDD dh$IfgdkdW$$Iflr"y h 6064 laytvBDFHPDDDDD dh$Ifgdkd4$$Iflr"y h 6064 laytvHJVPDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytvVXZ\PDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytv\^jPDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytv…ąHPDD dh$Ifgdkd$$Iflr"y h 6064 laytv &(*,:FJPRt&BD$8:Љ҉.0LNPRV`bŽĎҎƹƹƹƹƹƃƃƹƃƃƃ$h3h B*CJOJQJo(ph#h3h CJOJQJmHnHu!jh3h CJOJQJUh3h CJOJQJh3h 5CJOJQJ\'jh3h 5CJOJQJU\)h3h 5CJOJQJ\mHnHu1HJRtzzzzzz dh$Ifgdykd$$Ifl40 064 laf4ytvPDDDDD dh$Ifgdkd&$$Iflr"y h 6064 laytvPDDDDD dh$Ifgdkd $$Iflr"y h 6064 laytv "$PDDDDD dh$Ifgdkd $$Iflr"y h 6064 laytv$&0BDFHPDDDDD dh$Ifgdkd $$Iflr"y h 6064 laytvHJV|~PDDDDD dh$Ifgdkd $$Iflr"y h 6064 laytvЇ҇ԇևPDDDDD dh$Ifgdkdw $$Iflr"y h 6064 laytvև؇ "PDDDDD dh$IfgdkdT $$Iflr"y h 6064 laytv"$,8:<>PDDDDD dh$Ifgdkd1$$Iflr"y h 6064 laytv>@Lxz|~PDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytv~PDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytv̈PDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytv$PRTVPDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytvVXdPDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytvPDDDDD dh$Ifgdkd_$$Iflr"y h 6064 laytvĉPDDDDD dh$Ifgdkd<$$Iflr"y h 6064 laytv&nprtPDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytvtvPDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytvPDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytvPDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytv&FHJLPDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytvLNV`bdfPDDDDD dh$Ifgdkdj$$Iflr"y h 6064 laytvfhtPDDDDD dh$IfgdkdG$$Iflr"y h 6064 laytvЋҋԋ֋PDDDDD dh$Ifgdkd$$$Iflr"y h 6064 laytv֋؋PDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytv>@BDPDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytvDFRPDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytv̌ΌЌҌPDDDDD dh$Ifgdkd$$Iflr"y h 6064 laytvҌԌ PDDDDD dh$Ifgdkdu$$Iflr"y h 6064 laytv DFHJPDDDDD dh$IfgdkdR $$Iflr"y h 6064 laytvJLXjlnpPDDDDD dh$Ifgdkd/!$$Iflr"y h 6064 laytvpr~PDDDDD dh$Ifgdkd "$$Iflr"y h 6064 laytvPDDDDD dh$Ifgdkd"$$Iflr"y h 6064 laytv̍PDDDDD dh$Ifgdkd#$$Iflr"y h 6064 laytv.024PDDDDD dh$Ifgdkd$$$Iflr"y h 6064 laytv46BnprtPDDDDD dh$Ifgdkd%$$Iflr"y h 6064 laytvtvPDDDDD dh$Ifgdkd]&$$Iflr"y h 6064 laytvŽĎƎȎPDDDDD dh$Ifgdkd:'$$Iflr"y h 6064 laytvȎʎ֎PDDDDD dh$Ifgdkd($$Iflr"y h 6064 laytvҎ֎FJ~ HZ\FHLNlnȑʑޑBPpܖBRVܘ<䶫Ԍ!h3h 5CJOJQJ\o(h3hvCJOJQJo(hvCJOJQJo(hACJOJQJo($h3h B*CJOJQJo(phh3h 5CJOJQJ\h3h CJOJQJh3h CJOJQJo(768:<PDDDDD dh$Ifgdkd($$Iflr"y h 6064 laytv<>JnprtPDDDDD dh$Ifgdkd)$$Iflr"y h 6064 laytvtvPDDDDD dh$Ifgdkd*$$Iflr"y h 6064 laytv֏؏ڏ܏PDDDDD dh$Ifgdkd+$$Iflr"y h 6064 laytv܏ޏ  PDDDDD dh$Ifgdkdh,$$Iflr"y h 6064 laytv@BDFPDDDDD dh$IfgdkdE-$$Iflr"y h 6064 laytvFHPZ\^`PDDDDD dh$Ifgdkd".$$Iflr"y h 6064 laytv`bnPDDDDD dh$Ifgdkd.$$Iflr"y h 6064 laytvؐڐܐސPDDDDD dh$Ifgdkd/$$Iflr"y h 6064 laytvސ  PDDDDD dh$Ifgdkd0$$Iflr"y h 6064 laytv>@BDPDDDDD dh$Ifgdkd1$$Iflr"y h 6064 laytvDFHJLNlPHHHH= $dha$gdvdhgdkds2$$Iflr"y h 6064 laytvlntzJkdP3$$Ifl4\ r 064 laf4ytv dh$Ifgddhgdȑ?kd14$$Ifl4rr r nn064 laf4ytv dh$Ifgdȑʑґޑ dh$Ifgdfkd&5$$Ifl4 064 laf4ytvPDDDDD dh$Ifgdkd5$$Iflrr ] nn064 laytv$>@BDPDDDDD dh$Ifgdkd6$$Iflrr ] nn064 laytvDFRxz|~PDDDDD dh$Ifgdkd[7$$Iflrr ] nn064 laytv~PDDDDD dh$Ifgdkd08$$Iflrr ] nn064 laytv’ΒPDDDDD dh$Ifgdkd9$$Iflrr ] nn064 laytv2468PDDDDD dh$Ifgdkd9$$Iflrr ] nn064 laytv8:BPRTVPDDDDD dh$Ifgdkd:$$Iflrr ] nn064 laytvVXdPDDDDD dh$Ifgdkd;$$Iflrr ] nn064 laytvPDDDDD dh$IfgdkdY<$$Iflrr ] nn064 laytvړܓޓPDDDDD dh$Ifgdkd.=$$Iflrr ] nn064 laytvPDDDDD dh$Ifgdkd>$$Iflrr ] nn064 laytv,.02PDDDDD dh$Ifgdkd>$$Iflrr ] nn064 laytv24@hjlnPDDDDD dh$Ifgdkd?$$Iflrr ] nn064 laytvnpPD dh$Ifgdkd@$$Iflrr ] nn064 laytv”Ĕ dh$IfgdfkdWA$$Ifl4 064 laf4ytvĔƔҔPDDDDD dh$IfgdkdA$$Iflrr ] nn064 laytv 468:PDDDDD dh$IfgdkdB$$Iflrr ] nn064 laytv:<Hz|~PDDDDD dh$IfgdkdC$$Iflrr ] nn064 laytv•PDDDDD dh$IfgdkdaD$$Iflrr ] nn064 laytv•ĕЕPDDDDD dh$Ifgdkd6E$$Iflrr ] nn064 laytv FHJLPDDDDD dh$Ifgdkd F$$Iflrr ] nn064 laytvLNZdfhjPDDDDD dh$IfgdkdF$$Iflrr ] nn064 laytvjlxPDDDDD dh$IfgdkdG$$Iflrr ] nn064 laytvԖ֖ؖږPDDDDD dh$IfgdkdH$$Iflrr ] nn064 laytvږܖPD dh$Ifgdkd_I$$Iflrr ] nn064 laytv&BDFH dh$Ifgdfkd4J$$Ifl4 064 laf4ytvHJVvxz|PDDDDD dh$IfgdkdJ$$Iflrr ] nn064 laytv|~PDDDDD dh$IfgdkdK$$Iflrr ] nn064 laytvPDDDDD dh$IfgdkdiL$$Iflrr ] nn064 laytv$&(*PDDDDD dh$Ifgdkd>M$$Iflrr ] nn064 laytv*,8dfhjPDDDDD dh$IfgdkdN$$Iflrr ] nn064 laytvjlxPDDDDD dh$IfgdkdN$$Iflrr ] nn064 laytvԘؘ֘ژPDDDDD dh$IfgdkdO$$Iflrr ] nn064 laytvژܘPD dh$IfgdkdP$$Iflrr ] nn064 laytv<BHJ dh$IfgdfkdgQ$$Ifl4 064 laf4ytvJLXPDDDDD dh$IfgdkdQ$$Iflrr ] nn064 laytv<bdԙ֙ڙܙ *,24dfҚLNjlpr›țʛ :V>LĞܟ & < 2 F ž Ğ  U!h3h 5CJOJQJ\o(#h3h CJOJQJmHnHuh3h CJOJQJ!jh3h CJOJQJUh3h CJOJQJo(DPDDDDD dh$IfgdkdR$$Iflrr ] nn064 laytvFHJLPDDDDD dh$IfgdkdS$$Iflrr ] nn064 laytvLNZPDDDDD dh$IfgdkdqT$$Iflrr ] nn064 laytvҚؚޚPDDDDD dh$IfgdkdFU$$Iflrr ] nn064 laytv.024PDDDDD dh$IfgdkdV$$Iflrr ] nn064 laytv46BPDDDDD dh$IfgdkdV$$Iflrr ] nn064 laytvܛޛPDDDDD dh$IfgdkdW$$Iflrr ] nn064 laytv2468PDDDDD dh$IfgdkdX$$Iflrr ] nn064 laytv8:BTVXZPDDDDD dh$IfgdkdoY$$Iflrr ] nn064 laytvZ\hPDDDDD dh$IfgdkdDZ$$Iflrr ] nn064 laytvPDDDDD dh$Ifgdkd[$$Iflrr ] nn064 laytv.024PDDDDD dh$Ifgdkd[$$Iflrr ] nn064 laytv46>JLNPPDDDDD dh$Ifgdkd\$$Iflrr ] nn064 laytvPR^PDDDDD dh$Ifgdkd]$$Iflrr ] nn064 laytvʝ̝ΝНPDDDDD dh$Ifgdkdm^$$Iflrr ] nn064 laytvНҝޝ"$&(PDDDDD dh$IfgdkdB_$$Iflrr ] nn064 laytv(*6bdfhPDDDDD dh$Ifgdkd`$$Iflrr ] nn064 laytvhjvPDDDDD dh$Ifgdkd`$$Iflrr ] nn064 laytvžĞƞȞPDDDDD dh$Ifgdkda$$Iflrr ] nn064 laytvȞʞ֞PDDDDD dh$Ifgdkdb$$Iflrr ] nn064 laytv68:<PDDDDD dh$Ifgdkdkc$$Iflrr ] nn064 laytv<>JprtvPDDDDD dh$Ifgdkd@d$$Iflrr ] nn064 laytvvxPDDDDD dh$Ifgdkde$$Iflrr ] nn064 laytvԟ֟؟ڟPDDDDD dh$Ifgdkde$$Iflrr ] nn064 laytvڟܟPDDDDD dh$Ifgdkdf$$Iflrr ] nn064 laytv0246PDDDDD dh$Ifgdkdg$$Iflrr ] nn064 laytv68D^`bdPDDDDD dh$Ifgdkdih$$Iflrr ] nn064 laytvdfrPDDDDD dh$Ifgdkd>i$$Iflrr ] nn064 laytvĠƠȠʠPDDDDD dh$Ifgdkdj$$Iflrr ] nn064 laytvʠ̠ؠ  PDDDDD dh$Ifgdkdj$$Iflrr ] nn064 laytvPRTVPDDDDD dh$Ifgdkdk$$Iflrr ] nn064 laytvVXdPDDDDD dh$Ifgdkdl$$Iflrr ] nn064 laytv¡ġơPDDDDD dh$Ifgdkdgm$$Iflrr ] nn064 laytvơȡԡPDDDDD dh$Ifgdkdee&{TBlgeNX[>eeC10eNX[ch[teg[gU_SxvzcNvTyeNI{DevOX[`Q oTlQ{tRl2007t^ @\N,{28S 2007t^07g10e S^ ,{Nz0;`0R 00,{Nag0:NOoTv[hQ0 gHeT(ϑSc ĉoTlQL:N 9hnc 0-NNSNlqQTVoT{tl 0N N{y 0oT{tl 0 0 0-NNSNlqQTVL?eSl 0N N{y 0L?eSl 0 0 0-NNSNlqQTVoT{tl[eagO 0N N{y 0oT{tl[eagO 0 6R[,gRl0 00 ,{Nag0(W-NNSNlqQTVXQ3uoir4N^Ջ0oTuNToTۏS NSۏLoT[yb0lQhTvcw{t (u,gRl0 00 ,{ Nag0oTlQ /fcV[ߘToTvcw{t@\9hncoTlQ3uNv3u Ogql[ z^ [b N^.UoTv[hQ'`0 gHe'`0(ϑSc'`I{ۏL[g v^Q[/f&T TavQ3uv[ybǏ z0 00 ,{Vag0V[RxvzR6Reo [R6Rveo0luuqS͑uuveo[Lyrk[yb0 00 ,{Nag0V[ߘToTvcw{t@\;N{hQVoTlQ]\O #[oir4N^Ջ0oTuNTۏSۏL[yb0 00 ,{mQag0oTlQ]\O^S_u_lQ_0lQs^0lQckvSR0 00V[ߘToTvcw{t@\[oTlQ[L;N[ƖSO#6R0vsQNXTlQ:y6RTV6R0#Nvz6R St0h0[ċ0[yb0I{scS>yOvcw0 00 ,{Nag0(WoTlQǏ z-N oTvcw{t蕤:NmSlQqQ)Rvv͑'YSNy ^S_T>yOlQJT v^>NL,T0 00L?eSvcmS3uNNNNKN͑'Y)RvsQ|v oTvcw{t(W\OQL?eSQ[MR ^S_JTw3uN0)R[sQ|NN gBl,T0HT3uvCg)R0 00 ,{kQag0oTvcw{t蕔^S_T3uNcOSg⋄voTlQSt0hg0h0[ċ0[ybvۏ^T~I{Oo`0 00oTvcw{t蕔^S_(WL?e:gsQQzblQ3uSt:W@blQ_ NROo` 00N oTlQ3uNy0 z^06e9hQTOnc0eP cNvhQPgevU_T3ufN:ye,g 00N oTlQSt0hg0h0[ċ0[ybTsNXT TUSTvsQOo` 00 N ]ybQvoTvU_I{~TOo`0 00 ,{]Nag0oTvcw{t0vsQUSMONSSNoTlQ]\OvNXT [3uNcNvb/gy[T[penc gO[vINR0 ,{Nz0W,gBl 00,{ASag0oTlQ3uNN N{y3uN /fccQoTlQ3uv^bbv^l_#Nv:gg0 00XQ3uN^S_/f(W-NVXQTl{vv^rzbblN#Nv:gg XY3uN^S_/fXYTl6RoSFU0XY3uNRtۏSoTlQ ^S_1uvQ{-NVXQvRN:ggb1uvQYXbv-NVXQNt:ggRt0 00RtoTlQ3uNRvNXT^S_wQ gv^vNNwƋ q`oTlQvl_0lĉSb/gBl0 00 ,{ASNag0oTlQ3uSbeo3u0N6Ro3u0ۏSoT3uSvQeEQ3uTQlQ3u0 00XQ3uN3uoTlQ cgqeo3u0N6Ro3uv z^TBlRt XY3uN3uۏSoTlQ cgqۏSoT3uv z^TBlRt0 00 ,{ASNag0eo3u /fc*gf(W-NVXQ N^.UvoTvlQ3u0 00[] N^oT9eSBRW09eS~o_0XRe^uvoTlQ cgqeo3uv z^3ub0 00N6Ro3u /fcuNV[ߘToTvcw{t@\]ybQ N^v] gV[hQvoTvlQ3uFO/fuir6RT cgqeo3uv z^3ub0 ۏSoT3u /fcXYuNvoT(W-NVXQ N^.UvlQ3u0 00eEQ3u /fceo3u0N6Ro3ubۏSoT3u~ybQT 9eS0XRbSmSybQNybQ[vlQ3u0 00QlQ3u /fcoTybQfeN gHegnT3uNb~~uNbۏSoTvlQ3u0 00 ,{AS Nag03uN^S_cOEQRS`vxvzpenc foTv[hQ'`0 gHe'`T(ϑSc'` v^[hQDevw['`#0 00 ,{ASVag0oTlQ@bbvDe_(ue.s^S_lfW\O Ty0 Rir TySwS0g0uI{*glQ_Shve.sDe^S_cODe@b gSO(uvfeN0YeDe^S_ cgqBlcO-Neы,g0 00 ,{ASNag0V[ߘToTvcw{t@\^S_gbLV[6R[voTLNSU\ĉRTNN?eV{ SN~~[oTv N^Ng*g[ev SybQfeNL^bkNۏL4N^Ջv ^S_͑e3u0 00 ,{VASNag04N^ՋǏ z-NSu%N͑ NoNNv xvz^S_(W24\eQbJT gsQw0ꁻl:S0v^oTvcw{t蕌TV[ߘToTvcw{t@\ w3uN v^SeT&OtYXTObJT0 00 ,{VASNag04N^Ջ g NR`b_KNNv V[ߘToTvcw{t@\SN#N3uNO9eՋeHh0f\Pb~bk4N^Ջ 00N &OtYXTO*ge\LL#v 00N N gHeOSՋ[hQv 00 N *g cgqĉ[ePbJT%N͑ NoNNv 00V gncf4N^Ջ(uoireHev 00N 4N^Ջ(uoirQs(ϑv 00mQ 4N^Ջ-N_Z\OGPv 00N vQNݏS 0oir4N^Ջ(ϑ{tĉ 0v`b_0 00,{VAS Nag04N^Ջ-NQs'YV0^gv NoS^b%N͑ NoNN b gncf4N^Ջ(uoirX[(W%N͑(ϑe V[ߘToTvcw{t@\bw0ꁻl:S0v^oTvcw{tSNǑS'}%`c6Rce #Nf\Pb~bk4N^Ջ 3uNT4N^ՋUSMO_{zsS\Pbk4N^Ջ0 00 ,{VASVag0XY3uN(W-NVۏLVEY-N_oir4N^Ջv ^S_ cgq,gRlTV[ߘToTvcw{t@\cQ3u v^ c NRBlRt 00N 4N^Ջ(uoir^S_/f](WXYlQvoTb]ۏeQIIgbIIIg4N^ՋvoirV[ߘToTvcw{t@\ NStXY3uNcQv\*g(WXYlQv2(uuׂ{|oirvVEY-N_oir4N^Ջ3u 00N V[ߘToTvcw{t@\(WybQۏLVEY-N_oir4N^Ջv Te SNBl3uN(W-NVHQۏLIg4N^Ջ 00 N (W-NVۏLVEY-N_oir4N^Ջe (WNUOV[SsNoir gsQv%N͑ NoS^T^g NoS^ 3uN^S_ cgq gsQĉ[SebJTV[ߘToTvcw{t@\ 00V 4N^Ջ~_gT 3uN^S_\[tev4N^ՋbJTbV[ߘToTvcw{t@\ 00N VEY-N_oir4N^ՋS_vpenc(uN(W-NVۏLoTlQ3uv ^S_&{T,gRl gsQ4N^Ջvĉ[v^cNVEY-N_4N^ՋvhQxvzDe0 ,{Vz0eo3uv3ubN[yb 00,{VASNag0V[ߘToTvcw{t@\[ NR3uSN[Lyrk[yb 00N *g(WVQ N^.UvN iir0Rir0wirI{ir(-NcSv gHebNSvQ6RBR eSsvoPgSvQ6RBR 00N *g(WVQYQ N^vSf[SeoSvQ6RBR0uir6RT 00 N lu~nu0v`'`$v0UuI{uuNwQ gf>f4N^luORveo 00V lu\e gHeluKbkvuuveo0 00&{TMR>kĉ[voT 3uN(WoTlQǏ z-NSNcQyrk[ybv3u 1uV[ߘToTvcw{t@\oT[ċ-N_~~N[Onx[/f&T[Lyrk[yb0 00yrk[ybvwQSORlSL6R[0 00,{VASmQag0Y*NUSMOTTx6Rveo ^S_1uvQ-NvN*NUSMO3ulQ vQNUSMO N_͑ Y3uTT3uv ^S_qQ Tr T\O:N勰eov3uN0eo3u_ybQTk*NTy Sb TNTyv N Tĉfv4N^^(uOR0 009eSBRWFO N9eS~o_ NSXRe^uvlQ3u ^S_1uwQYuNagNvONcQvT6RBR0ʑ0cʑ6RBRI{yrkBRWdY0 00 ,{VASkQag0(Weo[ybg eovlQR{|Tb/gBl NVv T;m'`bNv6RBR(WVYQ N^ SuSS0 00(Weo[ybg vQlQR{|Tb/gBl NVVQoTuNON3ubvv T;m'`bNv6RBR(WbVQ N^ SuSS0 00 ,{VAS]Nag0oTlQ3ubDe^S_N!k'`cN oTlQ3uStT N_LeEQevb/gDeۏeQyrk[yb z^vlQ3ubmSoT[hQ'`veSs NS cBleEQDevdY03uN:N_{eEQevb/gDev ^S_dVvQoTlQ3u03uN͑e3ubv ^S_&{T,gRl gsQĉ[N\e TTyۏeQeovKmg0 ,{N0eo4N^Ջ 00,{NASag03uN[b4N^MRxvzT ^S_kXQ 0oTlQ3uh 0 T@b(W0Ww0ꁻl:S0v^oTvcw{t蕂Y[b gsQDe0 00 ,{NASNag0w0ꁻl:S0v^oTvcw{t蕔^S_[3ubDeۏLb__[g &{TBlv QwQoTlQ3uStwfN N&{TBlv QwQoTlQ3u NNStwfN v^ft1u0 00 ,{NASNag0w0ꁻl:S0v^oTvcw{t蕔^S_St3uKNew5eQ~~[oirx6R`QSSYDeۏLs:W8hg [3ubDeۏLRek[g cQ[ga03ulQvoT^\Nuir6RTv ؏bS3*NuNybSvh(u7hT v^ToTh@bSQlQhw0 00 ,{NAS Nag0w0ꁻl:S0v^oTvcw{t蕔^S_(Wĉ[vePQ\[ga08hgbJTNS3ubDeNV[ߘToTvcw{t@\oT[ċ-N_ v^w3uN0 00,{NASVag0c0RlQhwvoTh@b^S_ c3uN3ubvoThQ[7hTۏLh [3ubvoThQۏL Y8h v^(Wĉ[veQ\oTlQhbJTNV[ߘToTvcw{t@\oT[ċ-N_ v^b3uN0 00 ,{NASNag0V[ߘToTvcw{t@\oT[ċ-N_6e0R3ubDeT ^(Wĉ[veQ~~of[0;Sf[SvQNb/gNXT[3ubDeۏLb/g[ċ _eSNBl3uNeEQDe v^ft1u0[bb/g[ċT cQb/g[ċa ޏ T gsQDebV[ߘToTvcw{t@\0 00V[ߘToTvcw{t@\Oncb/g[ċa\OQ[ybQ[0&{Tĉ[v S~ 0oir4N^ՋybN 0 N&{Tĉ[v S~ 0[ybawN 0 v^ft1u0 ,{N0eouN 00,{NASmQag03uN[boir4N^ՋT ^S_kXQ 0oTlQ3uh 0 T@b(W0Ww0ꁻl:S0v^oTvcw{t蕥b3uuNv3ubDe v^ TeT-NVoTuir6RTh[@bb6RYhQTvSPgeS gsQhQir(vxvzDe0 00,{NASNag0w0ꁻl:S0v^oTvcw{t蕔^S_[3ubDeۏLb__[g &{TBlv QwQoTlQ3uStwfN N&{TBlv QwQoTlQ3u NNStwfN v^ft1u0 00 ,{NASkQag0w0ꁻl:S0v^oTvcw{t蕔^S_St3uKNew5eQ~~[4N^Ջ`QS gsQSYDeۏLs:W8hg [3ubDeۏLRek[g cQ[ga0duir6RTYvvQNoT ؏bS3yb7hT ToTh@bSQhQ Y8hvw0 00w0ꁻl:S0v^oTvcw{t蕔^S_(Wĉ[vePQ\[ga08hgbJTS3ubDeNV[ߘToTvcw{t@\oT[ċ-N_ v^w3uN0 00 ,{NAS]Nag0oTh@b^[3ubvoThQۏL Y8h v^(Wĉ[veQ\ Y8haNV[ߘToTvcw{t@\oT[ċ-N_ TebwvQ Y8hvw0ꁻl:S0v^oTvcw{t蕌T3uN0 00 ,{mQASag0V[ߘToTvcw{t@\oT[ċ-N_6e0R3ubDeT ^S_(Wĉ[veQ~~of[0;Sf[SvQNb/gNXT[3ubDeۏL[ċ _eSNBl3uNeEQDe v^ft1u0 00~[ċ&{Tĉ[v V[ߘToTvcw{t@\oT[ċ-N_w3uN3uuNs:Whg v^JTwV[ߘToTvcw{t@\oT{t-N_~[ċ N&{Tĉ[v V[ߘToTvcw{t@\oT[ċ-N_\[ċaT gsQDebV[ߘToTvcw{t@\ V[ߘToTvcw{t@\Oncb/g[ċa \OQ NNybQvQ[ S~ 0[ybawN 0 v^ft1u0 00 ,{mQASNag03uN^S_6e0RuNs:WhgwKNew6*NgQTV[ߘToTvcw{t@\oT{t-N_cQs:Whgv3u0 00 ,{mQASNag0V[ߘToTvcw{t@\oT{t-N_(W6e0RuNs:Whgv3uT ^S_(W30eQ~~[7hTybϑuNǏ zI{ۏLs:Whg nx8h[vuN]zvSL'` TebS1yb7hTuir6RTbS3yb7hT ۏLoThQ Y8hvoTh@bh v^(W[bs:WhgT10eQ\uNs:WhgbJTNV[ߘToTvcw{t@\oT[ċ-N_0 00 ,{mQAS Nag07hT^S_(WS_ 0oTuN(ϑ{tĉ 0fNvfuNe_RoTuNON0oTuNONe^oTuNfbeXuNBRWv vQ7hTuNǏ z^S_&{T 0oTuN(ϑ{tĉ 0vBl0 00 ,{mQASVag0oTh@b^S_Onc8h[voThQ[bSv7hTۏLh v^(Wĉ[veQ\oTlQhbJTNV[ߘToTvcw{t@\oT[ċ-N_ TebvsQw0ꁻl:S0v^oTvcw{t蕌T3uN0 00 ,{mQASNag0V[ߘToTvcw{t@\oT[ċ-N_Oncb/g[ċa07hTuNs:WhgbJTT7hTh~g b_b~Ta ޏ T gsQDebV[ߘToTvcw{t@\0V[ߘToTvcw{t@\Onc~Ta \OQ[ybQ[0&{Tĉ[v S~eofN 3uN]c g 0oTuNS 0v^wQYuNagNv TeS~oTybQeS N&{Tĉ[v S~ 0[ybawN 0 v^ft1u0 9eSBRWFO N9eS~o_ NSXRe^uvlQ3u_ybQT NS~eofNvT6RBR0ʑ0cʑ6RBRI{yrkBRWdY0 ,{ N0eovKmg 00,{mQASmQag0V[ߘToTvcw{t@\9hncOblQOeP^vBl SN[ybQuNveoTyzvKmg0vKmgꁰeoybQuNKNew{ g N_Ǐ5t^0 00vKmgQveo V[ߘToTvcw{t@\ NybQvQNONuN09eSBRWTۏS0 00 ,{mQASNag0oTuNON^S_[YNvKmgQveovuN]z0(ϑ03z['`0uHeS NoS^I{`Q v^kt^T@b(W0Ww0ꁻl:S0v^oTvcw{t蕥bJT0oTuNON*ge\LvKmg#Nv w0ꁻl:S0v^oTvcw{t蕔^S_#NvQ9eck0 00 ,{mQASkQag0oTuN0~%0O(uSh0vcwUSMOSseoX[(W%N͑(ϑ0%N͑b^gv NoS^e ^S_SeTw0ꁻl:S0v^oTvcw{t蕥bJT0w0ꁻl:S0v^oTvcw{t6e0RbJTT^S_zsS~~g v^bJTV[ߘToTvcw{t@\0 00 ,{mQAS]Nag0oTuNON[zvKmgveoNQuNKNew2t^Q*g~~uNv V[ߘToTvcw{t@\SNybQvQNoTuNONcQvuN勰eov3u v^͑e[勰eoۏLvKm0 00 ,{NASag0eoۏeQvKmgKNew V[ߘToTvcw{t@\]~ybQvQN3uNۏLoir4N^Ջv SN cgqoTlQ3ubN[yb z^~~Rt3u &{Tĉ[v V[ߘToTvcw{t@\ybQ勰eovuNbۏS v^[XQoTuNONuNv勰eoNv^ۏLvKm0 00 ,{NASNag0eoۏeQvKmgKNew NQStvQN3uNv TTylQ3u0]~StFO\*gybQۏLoir4N^ՋvvQN3uN TTy3uNNVeovKmgnT 3uNSNcQN6Ro3ubۏSoT3u0 00 ,{NASNag0ۏSoTlQ3uHQ_ybQT ]~ybQXQ3uNۏL4N^Ջv SN cgqoTlQ3ubN[yb z^~~RtvQ3u &{Tĉ[v V[ߘToTvcw{t@\ybQvQۏLuN3uN_NSNdVy3u ͑ecQN6Ro3u0[]~StFO\*gybQۏLoir4N^ՋvvQN TTy3uNNV 3uNSNcQN6Ro3u0 ,{Nz0N6Rov3ubN[yb 00,{NAS Nag0N6Ro3uN^S_/foTuNON vQ3uvoT^S_N 0oTuNS 0}fvuNVN0 00 ,{NASVag0N6Ro^S_NN6RowQ g T7hv;m'`bN0~o_0BRW0ĉenffN0|4h~{I{0 00 ,{]NASNag03uۏSoTRSň ^S_&{T NRBl 00N oT]~S_ 0ۏSoTlQ 0b 0;SoNTlQ 0 00N oT^S_/f-NVXQ\*guNvTy b} guNFO/f Nn4N^vTy 00 N TN6RoSFUv TNTy^S_1uN*NoTuNONRSň RSňvgP N_Ǐ 0ۏSoTlQ 0b 0;SoNTlQ 0v gHeg 00V dGrBR0VY RSňvvQNBRW^S_](WXY[bQSň 00N cSRSňvoTuNON ^S_c g 0oTuNS 00ۏSGr0V3u(WVQRSňv cSRSňvoTuNON؏^S_c gNRSňvBRWvNv 0oTuN(ϑ{tĉ 0fN 00mQ 3uۏSoTRSň ^S_(WoT 0ۏSoTlQ 0b 0;SoNTlQ 0v gHegJ\n1t^MRcQ0 00 ,{]NASkQag0XY6RoSFU^S_NXQoTuNON~{ۏSoTRSňT T v^kXQ 0oTeEQ3uh 00 00 ,{]NAS]Nag03uۏSoTRSňv ^S_1ucSRSňvoTuNONT@b(W0Ww0ꁻl:S0v^oTvcw{tcQ3u cN1uYXbekXQv 0oTeEQ3uh 0 b gsQDeT7hT0w0ꁻl:S0v^oTvcw{t[3ubDeۏLb__[gT &{TBlv QwQoTlQ3uStwfN N&{TBlv QwQoTlQ3u NNStwfN v^ft1u0 00w0ꁻl:S0v^oTvcw{tcQ[8haT \3ubDeT[8habV[ߘToTvcw{t@\[yb Tew3uN0 00 ,{N~vag0V[ߘToTvcw{t@\[bvDeۏL[g &{Tĉ[v S~ 0oTeEQ3uybN 0ToTybQeS N&{Tĉ[v S~ 0[ybawN 0 v^ft1u0 00 ,{N~vNag0ۏSRSňvoT^S_gbLۏSoTlQhQ0 00 ,{N~vNag0ۏSRSňoTvffNTh~{_{NۏSoTvffNTh~{N v^N^S_hlRSňoTvybQeSTRSňoTuNONv Ty0 00 ,{N~v Nag0XY'YSň6RBRvۏSh cgqV[ߘToTvcw{t@\v gsQĉ[gbL0SňTNTvhNۏShgbL TNoThQ0 ,{N~vVag0cOoTvXY6RoSFU^S_[RSňToTv(ϑ#0RSňTvoTQs(ϑv V[ߘToTvcw{t@\SNdRSňoTvybQeS _eSNOgq 0oT{tl 0,{VASNagvĉ[ doTv 0ۏSoTlQ 0b 0;SoNTlQ 00 ,{Nz0^Yeov3ub 00,{N~vNag03uN6RvoT^\N c^Yeo{tv 3uN^S_(W 0oTlQ3uh 0v DR3uNy -Nhl^Yeoy0 00 ,{N~vmQag03uN6RvoT^\N Te cYeoT^Yeo{tv 3uNSN b cgqYeob^YeovBlcQ3u0 00 ,{N~vNag0^\NN N`Qv 3uNSN(W 0oTlQ3uh 0v DR3uNy -Nhl^Yeoy &{T^Yeo gsQĉ[v cgq^Yeo[ybT{t N&{T^Yeo gsQĉ[v cgqYeo[ybT{t0 00N ~V[ߘToTvcw{t@\nx[v^Yeo9eSBRW FO N9eS^ubR;Nl0~oBRϑNS~o_voT 00N O(uV[ߘToTvcw{t@\nx[v^Yeo;m'`bN~bvev Ye6RBR0 00 ,{N~vkQag0^YeovlQ3u vQoTffNTSňh~{^S_&{T^Yeov gsQĉ[0 00 ,{N~v]Nag0ۏSvoT^\N^Yeov (uۏSoTv3ubT[yb z^ vQb/gBlNXQuNv^Yeov T0 ,{kQz0eEQ3uv3ubN[yb 00,{N~vNASag0Sfx6Reo0uNoTTۏSoT]ybQfeNSvQDN-N}fNyv ^S_cQeEQ3u0 003uN^S_SgqvsQb/gc[SR ċ0OvQSf[oT[hQ'`0 gHe'`T(ϑSc'`vq_T v^ۏLv^vb/gxvz]\O0 00 ,{N~vNASNag03uN^S_kXQ 0oTeEQ3uh 0 T@b(W0Ww0ꁻl:S0v^oTvcw{t蕥b gsQDeTf0w0ꁻl:S0v^oTvcw{t[3ubDeۏLb__[g &{TBlv QwQoTlQ3uStwfN N&{TBlv QwQoTlQ3u NNStwfN v^ft1u0 00 ,{N~vNASNag0ۏSoTveEQ3u 3uN^S_TV[ߘToTvcw{t@\b gsQDeTf cNuNV[b0W:SoT{t:ggybQSfveN0V[ߘToTvcw{t@\[3ubDeۏLb__[g &{TBlv QwQoTlQ3uStwfN N&{TBlv QwQoTlQ3u NNStwfN v^ft1u0 00 ,{N~vNAS Nag0O9eoTlQhQ0SfoTYe-N] go(uBlve09eSq_ToT(ϑvuN]zI{veEQ3u 1uw0ꁻl:S0v^oTvcw{tcQ[8haT bV[ߘToTvcw{t@\[yb Tew3uN0 00O9eoTlQhQveEQ3u _e1uoTh@bۏLhQ Y8h0 00,{N~vNASVag09eSVQoTuNON Ty09eSVQuNoTv gHeg0VQoTuNONQ9eSoTuN:W0WI{veEQ3u 1uw0ꁻl:S0v^oTvcw{tStv^[yb &{Tĉ[v S~ 0oTeEQ3uybN 0 v^bV[ߘToTvcw{t@\YHh N&{Tĉ[v S~ 0[ybawN 0 v^ft1u0 00 ,{N~vNASNag0 cĉ[SfoTSňh~{09hncV[ߘToTvcw{t@\vBlO9effNI{veEQ3u bw0ꁻl:S0v^oTvcw{tYHh0 00 ,{N~vNASmQag0ۏSoTveEQ3u 1uV[ߘToTvcw{t@\[yb0vQ-N9eSۏSoT6RBR@b(uSeovN0W0SfۏSoTY‰FO N9eSoThQ09hncV[oThQbV[ߘToTvcw{t@\vBlO9eۏSoffN0eEQ[UۏSoffNv[hQ'`Q[0 cĉ[SfۏSoTSňh~{09eSlQNt:ggveEQ3u 1uV[ߘToTvcw{t@\YHh0 00 ,{N~vNASNag0[oTuNb/gl0SfYeTuN]zSq_TNT(ϑI{veEQ3u w0ꁻl:S0v^oTvcw{t蕔^S_9hncvQ 0oTlQybN 0DNb8h[vuN]z ~~ۏLuNs:Whg oTh@b^S_[bSv3yb7hTۏLh0 00 ,{N~vNASkQag0V[ߘToTvcw{t@\[oTeEQ3uۏL[g _eSNBl3uNeEQDe v^ft1u0&{Tĉ[v S~ 0oTeEQ3uybN 0 N&{Tĉ[v S~ 0[ybawN 0 v^ft1u0 00 ,{N~vNAS]Nag0eEQ3u_ybQT bcSoTybQfeNv SoTybQfeN1uV[ߘToTvcw{t@\NNlXSoTybQfeNv SybQfeN~~ gHe0 ,{]Nz0oTQlQ 00,{N~vNASag0V[ߘToTvcw{t@\8hSvoTybQeS0 0ۏSoTlQ 0b 0;SoNTlQ 0v gHeg:N5t^0 gHegJ\n ~~uNbۏSv 3uN^S_(W gHegJ\nMR6*Ng3uQlQ0 00 ,{N~vNASNag0(WoTybQeS0 0ۏSoTlQ 0b 0;SoNTlQ 0 gHegQ 3uN^S_[oTv[hQ'`0 gHe'`T(ϑc6R`Q YvKmgQvvsQxvz~g0 NoS^vvKm0uNc6RTNT(ϑvGWN'`I{ۏL|~ċN0 00,{N~vNASNag0oTQlQ3u1uoTybQeSvc gTw0ꁻl:S0v^oTvcw{tcQ cgqĉ[kXQ 0oTQlQ3uh 0 v^cO gsQ3ubDe0 00ۏSoTvQlQ3u1u3uNTV[ߘToTvcw{t@\cQ0 00 ,{N~vNAS Nag0w0ꁻl:S0v^oTvcw{t[3ubDeۏL[g &{TBlv QwQoTQlQ3uStwfN N&{TBlv QwQoTQlQ3u NNStwfN v^ft1u0 00 ,{N~vNASVag0w0ꁻl:S0v^oTvcw{t蕔^S_St3uKNew6*NgQ[oTQlQ3uۏL[g &{Tĉ[v NNQlQ N&{Tĉ[v bV[ߘToTvcw{t@\0 00 ,{N~vNASNag0ۏSoTvQlQ3u1uV[ߘToTvcw{t@\St v^(W6*NgQ[b[g &{Tĉ[v NNQlQ N&{Tĉ[v SQ NNQlQvw v^ft1u0 00 ,{N~vNASmQag0 g NR`b_KNNvoT NNQlQ 00N gHegJ\nMR*gcQQlQ3uv 00N *g0RV[ߘToTvcw{t@\ybQ N^ecQv gsQBlv 00 N *g cgqBl[bIVg4N^Ջv 00V *g cgqĉ[ۏLoT NoS^vKmv 00N ~V[ߘToTvcw{t@\QċN^\NuHe Nnx0 NoS^'YbvQNSVqS[NSOeP^v 00mQ cgq 0oT{tl 0vĉ[^S_doTybQfeNv 00N NwQY 0oT{tl 0ĉ[vuNagNv 00kQ *g cĉ[e\LvKmg#Nv 00]N vQN N&{T gsQĉ[v`b_0 00 ,{N~vNASNag0V[ߘToTvcw{t@\6e0Rw0ꁻl:S0v^oTvcw{taT ~[g N&{ToTQlQĉ[v SQ NNQlQvw v^ft1u0 00[ NNQlQvTy dVl[N1udoTybQfeNvY (W gHegJ\ne lvQoTybQeS0 0ۏSoTlQ 0b 0;SoNTlQ 00 ,{ASz0oTlQh 00,{N~vNASkQag0oTlQh Sb7hThToThQ Y8h0 007hTh /fcoTh@b cgq3uN3ubbV[ߘToTvcw{t@\8h[voThQ[7hTۏLvh0 00oThQ Y8h /fcoTh@b[3ubvoThQ-NhelvSL'`0yf['`0[vyvTch&Tc6RoT(ϑI{ۏLv[[hT[8h]\O0 00 ,{N~vNAS]Nag0oTlQh1u-NVoTuir6RTh[@bbw0ꁻl:S0v^oTh@bbb0ۏSoTvlQh1u-NVoTuir6RTh[@b~~[e0 00 ,{N~v NASag0 NRoTvlQh1u-NVoTuir6RTh[@bbV[ߘToTvcw{t@\c[voTh@bbb 00N ,gRl,{VASNagN 0N ĉ[voT 00N uir6RT0>e\'`oT 00 N V[ߘToTvcw{t@\ĉ[vvQNoT0 00,{N~v NASNag0QۏeQyrk[yb z^voT oTh@b^S_OHQ[c7hThToThQ Y8h0 00 ,{N~v NASNag0NNoTlQhvoTh@b ^S_ cgqoTh@b[[(ϑ{tĉTV[ϑvBl MYNoTlQhNRv^vNXTTY &{ToTlQhv(ϑOSO|Tb/gBl0 00 ,{N~v NAS Nag03uN^S_cOoTlQh@bv gsQDe0b7hTbMTbSh(u7hT0cOh(uhQir(0bbbSv7hTϑ^S_:Nh(uϑv3 Puir6RTvlQh؏^S_cOv^yb!kv6R h[U_0 00 ,{N~v NASVag0oTh@bۏLeohQ Y8he dۏL7hThY ؏^S_9hncoirvxvzpenc0VQY T{|NTvoThQTV[ gsQBl [oirvoThQ0hyvI{cQ Y8ha0 00 ,{N~v NASNag0Bl3uN͑e6RoThQv 3uN N_YXbcQS Y8havoTh@bۏLyoThQvxvz]\OoTh@b N_cSdkyYXb0 ,{ASNz0oTlQhQTffN ,{N0oTlQhQ 00,{N~v NASmQag0V[oThQ /fcV[ߘToTvcw{t@\^v 0-NNSNlqQTVoxQ 00oTlQhQTvQNoThQ vQQ[Sb(ϑch0helNSuN]zI{b/gBl0 00oTlQhQ /fcV[ߘToTvcw{t@\ybQ~3uNyr[oTvhQ uNoTvoTuNON_{gbLlQhQ0 00oTlQhQ N_NON-NVoxQvĉ[0 00 ,{N~v NASNag0oTlQhQvyvSvQhelv[ ^S_&{T-NVoxQvW,gBl0V[ߘToTvcw{t@\S^vb/gc[SRSV[oThQQSR0 00,{N~v NASkQag03uN^S_ S gNh'`v7hTۏLhQvxvz]\O0 ,{N0oThQir( 00,{N~v NAS]Nag0oThQir( /fcOoThQ-NirtTSf[KmՋSuirelՋ(u wQ gnx[yr'`ϑ

g NJTwv 6e0R3ubDeKNewsS:NSt 00N 3uNy^\N,gLCgV 3ubDePhQ0&{Tl[b__ b3uN cgqBlcNhQeckDev ^S_StoTlQ3u0 00oTvcw{tStb NNStoTlQ3u ^S_QwQRvoTlQN(upSzTlfegvfNbQ0 00 ,{N~vVASkQag0w0ꁻl:S0v^oTvcw{t蕔^S_(WSt3uT30eQ[b[x6R`QSSYDev8hg0[3ubDev[g0bS7hT0woTh@bۏLlQh0\[gaT8hgbJTޏ T3uNv3ubDeNv^bV[ߘToTvcw{t@\I{]\O Te\[gaw3uN0 00 ,{N~vVAS]Nag0oTlQhve cgqN Nĉ[gbL 00N 7hTh30e TeۏL7hThThQ Y8h60e 00N yrkoTTuׂ{|6RTv7hTh60e TeۏL7hThThQ Y8h90e0 00 cgq,gRl,{ NASmQagvĉ[1uoTh@bۏL4N^Ջ(u7hThv ^S_ cgqMR>k7hThve[b0 00 ,{N~vNASag0b/g[ċ]\Oe cgq NRĉ[gbL 00N eo4N^Ջ90eQۏeQyrk[yb z^vTy80e 00N eouN150eQۏeQyrk[yb z^vTy120e 00 N [] N^oT9eSBRWTN6Rov3u160e 00V ۏLb/g[ċveEQ3u40e0 00ۏSoTlQ3uvb/g[ċeSgqMR>kgbL0 00 ,{N~vNASNag0(Wb/g[ċǏ z-N3uNeEQDev ^S_N!k'`SQeEQDew 3uN[eEQDewQ[cQ_v SNS_b,TS3uNvHa03uN^S_(W4*NgQ cgqwBlN!k'`[beEQDe ۏeQyrk[yb z^v cgqyrk[yb z^vBlRt0 006e0ReEQDeT b/g[ċe^S_ NǏSĉ[ev1/3ۏeQyrk[yb z^v N_ǏSĉ[ev1/40 00oTlQǏ z-N3uNLcQdV3uv vQ[yb z^L~bk0 00 ,{N~vNASNag0V[ߘToTvcw{t@\^S_(W20eQ\OQ[ybQ[20eQ N\OQQ[v ~;N{@\[ybQ SN^10e v^^S_\^ePvt1uJTw3uN0 00 ,{N~vNAS Nag0V[ߘToTvcw{t@\^S_\OQoTlQ[ybQ[KNew10eQS0 gsQL?eSN0 ,{AS Nz0 Y0[ 00,{N~vNASVag0 g NR`b_KNNv V[ߘToTvcw{t@\ NNybQ 00N N T3uNcNvxvzDe0pencv Tb T NeckS_t1uv 00N (WlQǏ z-NSs3ubDe Nw[ 3uN NfvQ3ubDew[v 00 N xvzyvT[e N/ec[vQ3uoTv[hQ'`0 gHe'`0(ϑSc'`ۏLċNv 00V 3ubDe>f:yvQ3uoT[hQ'`0 gHe'`0(ϑSc'`I{X[(W'Y:wv 00N *g(Wĉ[vePQeEQDev 00mQ Seoegn N&{Tĉ[v 00N uNs:Whgb7hTh~g N&{Tĉ[v 00kQ l_lĉĉ[v N^S_ybQvvQN`b_0 00 ,{N~vNASNag0oTvcw{t蕝Ol\OQ NNStb NNybQvfNbQ[ ^S_ft1u v^JTw3uNN gOlcL?e YbcwL?eɋvCg)R0 00 ,{N~vNASmQag03uN[V[ߘToTvcw{t@\\OQv NNybQQ[ g_v SN(W6e0R NNybQvwKNew60eQkXQ 0oTlQ Y[3uh 0 TV[ߘToTvcw{t@\cQ Y[3uv^f Y[t1u0 00 Y[vQ[NPNS3uNySS3ubDe0 00 ,{N~vNASNag0V[ߘToTvcw{t@\c0R Y[3uT ^S_(W50eQ\OQ Y[Q[ v^w3uN0~cSQ[v V[ߘToTvcw{t@\ NQStQ!kv Y[3u0 00 ,{N~vNASkQag0 Y[ۏLb/g[gv V[ߘToTvcw{t@\^S_~~ gsQNNb/gNXT cgqS3uePۏL0 ,{ASVz0l_#N 00,{N~vNAS]Nag0 g 0L?eSl 0,{mQAS]Nagĉ[`b_v V[ߘToTvcw{t@\9hnc)R[sQ|NvBlbOncLCg SNd gsQvoTybQfeN0 00 ,{N~vmQASag0oTvcw{tSvQ]\ONXTݏS,glvĉ[ g NR`b_KNNv 1uvQ N~L?e:gsQbv[:gsQ#N9eck`%N͑v [vc#v;N{NXTTvQNvc#NNXTOl~NL?eYR 00N [&{Tl[agNvoTlQ3u NNStv 00N N(WSt:W@blQ:yOl^S_lQ:yvPgev 00 N (WSt0[ċ0[ybǏ z-N *gT3uN0)R[sQ|Ne\Ll[JTwINRv 00V 3uNcNv3ubDe NPhQ0 N&{Tl[b__ NN!kJTw3uN_{eckvhQ萅Q[v 00N *gOlf NStb NybQoTlQ3ut1uv 00mQ Ol^S_>NL,T N>NL,Tv0 00 ,{N~vmQASNag0oTvcw{tSvQ]\ONXT(WoTlQǏ z-N"}Sb6eSNN"irb SvQN)Rv gbrjv OlvzRN#N\ Ngbrjv Ol~NL?eYR0 00 ,{N~vmQASNag0oTvcw{t(WoTlQǏ z-N g NR`b_KNNv 1uvQ N~L?e:gsQbv[:gsQ#N9eck [vc#v;N{NXTTvQNvc#NNXTOl~NL?eYRgbrjv OlvzRN#N 00N [ N&{Tl[agNv3u\OQQNlQQ[bl[LCg\OQQNlQQ[v 00N [&{Tl[agNv3u\OQ NNlQQ[b N(Wl[gPQ\OQQNlQQ[v 00 N ݏS,gRl,{]Nagvĉ[*ge\LO[INRv0 00 ,{N~vmQAS Nag0oTh@b(WbboT[yb@bvh]\Oe QwQZGPhbJTv Ogq 0oT{tl 0,{kQASNagvĉ[YZ0 00 ,{N~vmQASVag0oTvcw{td6e9b N cgql[yvThQ6e9v 1uvQ N~L?e:gsQbv[:gsQ#N؏^l6eSv9(uc#v;N{NXTTvQNvc#NNXTOl~NL?eYR0 00 ,{N~vmQASNag0(WoTlQ-N*g cgqĉ[[e 0oir^4N^xvz(ϑ{tĉ 0b 0oir4N^Ջ(ϑ{tĉ 0v Ogq 0oT{tl 0,{NAS]Nagvĉ[YZ0 00,{N~vmQASmQag03uN(W3ub4N^Ջe bZGPoTlQ3ubDeT7hTv oTvcw{t NNStb[3uboTv4N^Ջ NNybQ [3uN~NfJT 1t^Q NSt3uNcQvoir4N^Ջ3u]ybQۏL4N^Ջv dybQoir4N^ՋvybN v^Y1NCQN N3NCQN NZ>k 3t^Q NSt3uNcQvoir4N^Ջ3u0 00oTvcw{t[bZGPDeT7hTv3uN^z NoL:NU_ v^NNlQ^0 00 ,{N~vmQASNag03uoTuNbۏSe 3uNbZGPoTlQ3ubDeT7hTv V[ߘToTvcw{t@\[3u NNStb NNybQ [3uN~NfJT 1t^Q NStvQ3u]ybQuNbۏSv doTybQfeN 5t^Q NStvQ3u v^Y1NCQN N3NCQN NZ>k0 00 ,{N~vmQASkQag09hnc,gRl,{NASNagvĉ[ ۏLoir͑ YՋ 3uNb~v V[ߘToTvcw{t@\[vQNNfJTv^#N9eck 3uNb N9eckv NNybQvQ3u0 00 ,{N~vmQAS]Nag0wQ g NR`b_KNNv 1uV[ߘToTvcw{t@\loTybQeS v^NNlQ^ 00N ybQfeNv gHeg*gn 3uNLcQloTybQeSv 00N cgq,gRl,{N~vNASmQagvĉ[ NNQlQv 00 N 0oTuNS 0Ol Tb4v 00V cgq 0oT{tl 0,{VASNagT 0oT{tl[eagO 0,{VASNagvĉ[ [ NoS^'YbvQNSVqS[NSOeP^voT dybQfeNv 00N Ol\OQdoTybQfeNvL?eYZQ[v 00mQ vQNOl^S_dbdVoTybQfeNv`b_0 ,{ASNz0D0R 00,{N~vNASag0-NoT)Y6qoir0Sf[oT0uir6RT0eEQ3u0QlQv3ubDeTBlR+R,gRlDN10DN20DN30DN40DN5 vKmgvĉ[DN60 00,{N~vNASNag0oTybQeSve\'`oTvlQ3u d cgq,gRlvĉ[RtY ؏^S_&{TV[vvQN gsQĉ[0 00 ,{N~vNASNag0[eybQeS{tv-NoPg0-NonGrNSۏS-NoPgvlQ{tĉ[ 1uV[ߘToTvcw{t@\SL6R[0 00 ,{N~vNASmQag0oTb/glTYXbuNvRlSL6R[0 00 ,{N~vNASNag0,gRl2007t^10g1eweL0V[ߘToTvcw{t@\N2005t^2g28elQ^v 0oTlQ{tRl 0V[ߘToTvcw{t@\N,{17S Te^bk0 DN1 -No0)Y6qoirlQR{|S3ubDeBl 00,gDN-Nv-No/fc(WbV O~;Sotc[ NO(uvo(uir(SvQ6RBR0 00,gDN-Nv)Y6qoir/fc(WsN;Sotc[ NO(uv)Y6qo(uir(SvQ6RBR0 00N0lQR{|Sf 00N lQR{| 001.*g(WVQ N^.UvN iir0Rir0wirI{ir(-NcSv gHebNSvQ6RBR0 002.eSsvoPgSvQ6RBR0 003.ev-NoPgN(uT0 004.oPgevo(uMOSvQ6RBR0 005.*g(WVQ N^.UvN iir0Rir0wirI{ir(-NcSv gHeMOSvQ6RBR0 006.*g(WVQ N^.Uv-No0)Y6qoir Ye6RBR0 007.9eSVQ] N^.U-No0)Y6qoir~o_v6RBR0 008.9eSVQ] N^.U-No0)Y6qoirBRWv6RBR0 009.N6Ro0 00N f 00lQR{|1^6vTy:Neo lQR{|708 ceo3u z^3ub0 001. *g(WVQ N^.UvN iir0Rir0wirI{ir(-NcSv gHebNSvQ6RBR /fcV[oThQ-N*g6e}vN iir0Rir0wirI{ir(-NcS_0Rv)Y6qvUSNbNSvQ6RBR vQUSNbNv+Tϑ^S_`S;`cSirv90%N N0 002. eSsvoPgSvQ6RBR /fc*gV[oThQbw0ꁻl:S0v^0WeoPgĉ~y l[hQ 6e}voPgSvQ6RBR0 003. ev-NoPgN(uT /fcfNV[oThQ-Nobe6RBRYe-Nvk'`oPgbYNoqSr`oPgv*gl[hQ6e}vo(uir(0 004. oPgevo(uMOSvQ6RBR /fcwQ gl[hQoPgvSR0 iirevo(uMOSvQ6RBR0 005. *g(WVQ N^.UvN iir0Rir0wirI{ir(-NcSv gHeMOSvQ6RBR /fcV[oThQ-N*g6e}vNUSN iir0Rir0wirI{ir(-NcSvN{|bpe{|bN~bv gHeMOSvQ6RBR vQ gHeMO+Tϑ^`ScSirv50N N0 006. *g(WVQ N^.Uv-No0)Y6qoir Ye6RBR Sb 006.1-No Ye6RBR 006.2)Y6qoir Ye6RBR 006.3-No0)Y6qoirTSf[oT~bv Ye6RBR0 00-No Ye6RBR^(W O~;Sotc[ N~e0;NSbegnNSN~xQ Tev-No Ye6RBR0;Nl:NPv-No Ye6RBR0;Nl:Nu~Tv-No Ye6RBRI{0 00)Y6qoir Ye6RBR^(WsN;Sotc[ N~e vQ^u(usN;Sf[/gh0 00-No0)Y6qoirTSf[oT~bv Ye6RBRSb-NoTSf[oT )Y6qoirTSf[oT NS-No0)Y6qoirTSf[oT N~bv Ye6RBR0 007. 9eSVQ] N^.U-No0)Y6qoir~o_v6RBR /fc N T~o_b8T6eMOKNvN9eSv6RBR0 008. 9eSVQ] N^.U-No0)Y6qoirBRWv6RBR /fc(W~o_ NSv`Q N9eSBRWv6RBR0 009. N6Ro /fclQ3ubV]ybQ N^.Uv-Nob)Y6qoir0 00N03ubDeyvSf 00N 3ubDeyv 00~De 001.oT Ty0 002.f'`eN0 003.zvvNOnc0 004.[;Nxvz~gv;`~SċN0 005.oTffN7h?z0wIfSgeSe.s0 006.Sň0h~{7h?z0 00of[xvzDe 007.of[xvzDe~0 008.oPgegnSt[Onc0 009.oPgu`sX0uyr_0b_`c0=hWbW iW b/g0N0WR]Tp6RelI{0 0010.oPghQIHhSwIf v^cOoThQir(S gsQDe0 0011.cO iir0wirh,g iirh,g^S_Sb0g[0yP[I{0 0012.uN]zvxvzDe0]zDeSe.sDe eegnS(ϑhQ0 0013.Sf[bNxvzvՋDeSe.sDe0 0014.(ϑxvz]\OvՋDeSe.sDe0 0015.oThQIHhSwIf v^cOoThQir(S gsQDe0 0016.7hThbJTfN0 0017.oir3z['`xvzvՋDeSe.sDe0 0018.vccoTvSňPgeT[hVv bOncS(ϑhQ0 00otktxvzDe 0019.otktxvzDe~0 0020.;NoHef[ՋDeSe.sDe0 0021.N,otxvzvՋDeSe.sDe0 0022.%`'`k'`ՋDeSe.sDe0 0023.gk'`ՋDeSe.sDe0 0024.ǏOe'`@\0hQTIQOek'` 0n@'`T@\@{0v0|0I{ :Ro'`0OV'`I{;NN@\0hQ~ovsQvyrk[hQ'`ՋDeTe.sDe0 0025.W Ok'`ՋDeSe.sDe0 0026.ukk'`ՋDeSe.sDe0 0027.LvՋDeSe.sDe0 0028.RiroNRRf[ՋDeSe.sDe0 004N^ՋDe 0029.4N^ՋDe~0 0030.4N^ՋRNeHh0 0031.4N^xvzKbQ0 0032.w` TafN7h?z0&OtYXTOybQN0 0033.4N^ՋbJT0 00N f 001.3ubDeyvf 00~De 001 Deyv1oT TySb 00`$-Ne T 00a$Ilb T 00b$}T TOnc0 002 Deyv2f'`eNSb 00`$3uNTl{vfeN0 0oTuNS 00 0oTuN(ϑ{tĉ 0fN YpSN 3ueouNe^S_cO7hT6RYfv 0oTuN(ϑ{tĉ 0fN YpSN 00a$3uvoirbO(uvYe0]z0(uI{(W-NVvN)RSvQCg^\r`vf NS[NNvN)R NgbOCgvXf 00b$oT0|^yoT0;S(uk'`oTx6Rzyyb YeN YpSN 00c$3ueouNe^S_cO 0oir4N^ՋybN 0 YpSN 00d$vccoTvSňPgeb[hV v 0oTSňPgeT[hVlQ 0b 0ۏSSňPgeT[hVlQ 0 YpSN 00e$vQNfeN0 00Y:NۏS3u ؏^cO 00`$uNV[b0W:SoT{t:ggQwQvAQoT N^.USoTuNON&{ToTuN(ϑ{tĉvfeN0lQefNQSViry;N{S_@\ TaQSvf 00a$1uXY6RoSFU8^{-NVNh:ggRtlQNRv ^S_cO 0YVON8^{-NVNh:gg{v 0 YpSN 00XY6RoSFUYXb-NVNt:ggNt3ubv ^S_cOYXbefN0lQefNNS-NVNt:ggv 0%Ngbgq 0 YpSN 00b$[hQ'`ՋDe^S_cOv^voir^4N^xvz(ϑ{tĉfeN4N^Ջ(u7hT^S_cOv^voTuN(ϑ{tĉfeN0 003 Deyv3zvvNOnc-NoPg0)Y6qoir^S_cO gsQS0sNe.sDe~0-No0)Y6qoir6RBR^S_cOYeegnT Onc VQYxvzsrbuN0O(u`Qv~ NS[TyRe'`0SL'`0BRWvTt'`T4N^O(uv_'`I{vRg SbT] gV[hQv T{|Tyvk0-No؏^cO gsQ O~;SovtOncSSM|e.sDe~I{0 004 Deyv4[xvz~gv;`~SċNSb3uN[;Nxvz~gۏLv;`~ NSN[hQ'`0 gHe'`0(ϑSc'`I{eb[@b3ubTyۏLv~TċN0 005 Deyv5oTffN7h?z0wIfSgeSe.sSb c gsQĉ[wIvoTffN7h?z0ffNTyQ[vwIf0 gsQ[hQ'`T gHe'`I{ebvgee.s0 00of[xvzDe 006 Deyv167hThbJTfN/fc[3ub7hTvhbJT04N^ՋMRbDeecO\1yb7hTvhbJT [b4N^ՋTbDeecOޏ~3yb7hTvhbJT0 00otktxvzDe 007 Deyv24ǏOe'`@\0hQTIQOek'` 0n@'`T@\@{0v0|0I{ :Ro'`0OV'`I{;NN@\0hQ~ovsQvyrk[hQ'`ՋDeTe.sDe9hncoir~o_S6RBRyrpcOv^v6RBR[hQ'`ՋDe0wQ gOV'`>PTveo ^cOoirOV'`ՋDe0 008 Deyv25W Ok'`ՋDeSe.sDeYgYe-N+T gel[hQvoPg begnNel[hQoPgv gHeMO NS(uNNv^S[uk|~Nuq_TveoYU[o0'`o }0lu'`Rxo0O|P[ubo0O΀ob g~ހk\O(uI{veo ^bW Ok'`ՋDe0 009 Deyv26ukk'`ՋDeSe.sDe(uNNv^S[uk|~Nuq_TveoYU[o0'`o }0lu'`Rxo0O|P[ubo0O΀oNSW Ok'`Ջ3'`b g~ހk\O(uI{veo ^9hncwQSO`QcOv^vukk'`xvzDe0 0010 Deyv27LvՋDeSe.sDeeo(Wgk'`Ջ-NSs g~ހk\O(ub[gNhV~~u g_8^Oۏ\O(uvNSzSՋ~g:N3'`v _{cOLvՋDeSe.sDe0 002.3ubDevwQSOBl 001 3ueo4N^Ջ N,^bDeyv1^407^310 002 [b4N^ՋT3ueouN N,^bDeyv1^33NSvQNSfTeEQvDe v^~fSfvt1uTOnc0 003 3uN6Ro-No0)Y6qoirl\BRI{ۏL4N^ՋvdY N,^bDeyv2^8012015^180 004 ۏS3ucOvuNV[b0W:S?e^feNShQ萀b/gDe^S_/f-Ne,gv^DSevQ-N(ϑhQv-Ne,g_{ c-NVV[oThQĉ[vf9eSv9eBRWTy ^S_ۏLc!g4N^Ջ 00c$uir)R(u^ՋN,:N18^24O 00d$U[o`!g4N^Ջ^S_ cgq,gRlvĉ[ۏL a!g4N^Ջ^S_[b\100[6*Ng~hTgv:g[gqՋ b!g4N^Ջ^S_[b\1000O12*Ng~hTgv_>eՋ c!g4N^Ջ^S_EQRQ{|oTvSSV } [bY7h,gϑvxvz]\O 00e$ev-NoPgN(uTvRfN ^S_NV[oThQ-N SYEQRS fN(uoPgRHeyr_v-No6RBR\O:N[gqoۏLkxvz k*NRb;Nlu~Ǐ2yN N-No6RBRۏL ky6RBR4N^vuOpe N\N100[ 00f$9eBRWTy^9hnc]zSSv`QToTvyrp MQdbۏL N\N100[v4N^Ջ 00g$N6RoƉ`Q ۏL N\N100[v4N^Ջ 00h$ۏS-No0)Y6qoir6RBR clQR{|-Nvv^BlcO3ubDe v^^cO(WVQۏLvNSOoNRRf[xvzDeT4N^ՋDe uOpe N\N100[Y*N;Nlub^uv k*N;N^uvuOpe N\N60[0 00 N03ubDeyvhSf 00N -No0)Y6qoir3ubDeyvh DeR{|DeyvlQR{|SDeyvBl1234567896.16.26.3~De1           2           3           4           5           6           of[De7           8           9    %%%%   10    %%%%   11    %%%%   12           13          DeR{|DeyvlQR{|SDeyvBl1234567896.16.26.3of[De14      15           16           17           18           otktDe19  *       20  *      21  *       22  *       23         24***********25  % *****  26  *******  27*********  28  *        4N^De29           30         * 31         * 32         * 33         *  00N f 001.  c_{bvDe 002.  cSNMQbvDe 003.  cSN(ue.s~NfՋxvzb cĉ[SQMQՋxvzvDe 004. % wQ gl[hQv-NoPg0)Y6qoirSN NcO &TR_{cODe 005. *  cgq3ubDeyvfT3ubDewQSOBl0 DN2 Sf[oTlQR{|S3ubDeBl 00N0lQR{| 001.*g(WVQY N^.UvoT 001 ǏTbbJSTbvel6R_vSeoSvQ6RBR 002 )Y6qir(-NcSbǏSucSvev gHeUSSOSvQ6RBR 003 (ubRbTbI{el6R_v]woir-NvIQf[_gSOSvQ6RBR 004 1u] N^.UvY~Noir6RY:N\~Nvoir 005 ev Ye6RBR 006 ](WVQ N^.Uv6RBRXRVQYGW*gybQve^u0 002.9eS~o_N\*g(WVQY N^.Uv6RBR0 003.](WVY N^.UFO\*g(WVQ N^.UvoT 001 ](WVY N^.Uv6RBRSvQSeo T/b9eS6RBRvBRW FO N9eS~o_v6RBR 002 ](WVY N^.Uv Ye6RBR T/b9eS6RBRvBRW FO N9eS~o_v6RBR 003 9eS~o_v^](WVY N^.Uv6RBR 004 VQ N^.Uv6RBRXR](WVYybQve^u0 004.9eS] N^.Uv{|oirvx9h0xWbё^\CQ } FO N9eSvQot\O(uvSeoSvQ6RBR0 005.9eSVQ] N^.UoTvBRW FO N9eS~o_v6RBR0 006.] gV[oThQvSeob6RBR0 00N03ubDeyv 00N ~De 001.oT Ty0 002.f'`eN0 003.zvvNOnc0 004.[;Nxvz~gv;`~SċN0 005.oTffN0wIfSvsQSe.s0 006.Sň0h~{7h?z0 00N of[xvzDe 007.of[xvzDe~0 008.SeouN]zvxvzDeSe.sDe6RBRYeS]zvxvzDeSe.sDe0 009.nxSf[~gb~NvՋDeSe.sDe0 0010.(ϑxvz]\OvՋDeSe.sDe0 0011.oThQSwIf v^cOhQTb[gqT0 0012.7hTvhbJTfN0 0013.Seo0evegnS(ϑhQ0hbJTfN0 0014.oir3z['`xvzvՋDeSe.sDe0 0015.vccoTvSňPgeT[hVv bOncS(ϑhQ0 00 N otktxvzDe 0016.otktxvzDe~0 0017.;NoHef[ՋDeSe.sDe0 0018.N,otf[vՋDeSe.sDe0 0019.%`'`k'`ՋDeSe.sDe0 0020.gk'`ՋDeSe.sDe0 0021.ǏOe'`@\0hQTIQOek'` 0n@'`T@\@{0v0|0I{ :Ro'`I{yrk[hQ'`ՋDeTe.sDe0 0022. Ye6RBR-NYybNoHe0k'`0oNRRf[vNq_TvՋDeSe.sDe0 0023.zSՋDeSe.sDe0 0024.ukk'`ՋDeSe.sDe0 0025.LvՋDeSe.sDe0 0026.OV'`ՋDeSe.sDe0 0027.^4N^oNRRf[ՋDeSe.sDe0 00V 4N^ՋDe 0028.VQYvsQv4N^ՋDe~0 0029.4N^ՋRSxvzeHh0 0030.4N^xvzKbQ0 0031.w` TafN7h?z0&OtYXTOybQN0 0032.4N^ՋbJT0 00 N03ubDeyvf 001.Deyv1oT TySb(u T0Sf[ T0e T0Ilb v^lfvQSf[~g_0RP[ϑ0RP[_I{0e6R[v Ty ^S_f}T TOnc0 002.Deyv2f'`eN 001 3uN:ggTl{vfeN%NgbgqI{ 0 0oTuNS 0SSfU_u0 0oTuN(ϑ{tĉ 0fN YpSN 3uuNe^S_cO7hT6RYfv 0oTuN(ϑ{tĉ 0fN YpSN 002 3uvoirbO(uvYe0]z0(uI{N)R`QSvQCg^\r`f NS[NNvN)R NgbOCgvXf 003 oT0|^yoTT>e\'`oTcOx6Rzyyb YeN YpSN 004 [b4N^ՋT3ubuNe^S_cO 0oir4N^ՋybN 0 YpSNS4N^Ջ(uov(ϑhQ 005 3u6RBRv ^cOSeovTlegnfeN SbSeovybQfeN0oThQ0hbJT0SeouNONv%Ngbgq0 0oTuNS 00 0oTuN(ϑ{tĉ 0fN0.UShy0O'OSI{v YpSN; 006 vccoTvSňPgeT[hVv 0oTSňPgeT[hVlQ 0b 0ۏSSňPgeT[hVlQ 0 YpSN0 003.Deyv3zvvNOncSbVQY gsQTxS0 N^.UsrSvsQe.sDebuN0O(u`Q 6RBRxvzTt'`T4N^O(u_'`v~0 004.Deyv4[xvz~gv;`~SċNSb3uN[;Nxvz~gۏLv;`~ v^N[hQ'`0 gHe'`0(ϑSc'`I{eb[@b3ubTyۏL~TċN0 005.Deyv5oTffN0wIfSvsQSe.sSb c gsQĉ[wIvoTffN0ffNTyQ[vwIf0vsQe.s0 006.Deyv7of[xvzDe~/fc@b3uoirvof[xvzTb]z0BRW b0Ye[{ 0~gnx0(ϑxvzT(ϑhQ6R[03z['`xvzI{ vՋTVQYe.sDev~0 007.Deyv8SeouN]zvxvzDeSb]zAm zTSf[S^_0wYSeT g:gnZ0S^agN)n^0SR0e0PSBRI{ Td\Oek0|6Rel0;NtS8^peS6k'`vpency/}~gI{ v^lfbeϑT6e_sNS]zǏ z-NSNub_eQvBg(bvQN-NNir \^Sb[]zvDe0 006RBRYeS]zxvzDe^SbwYire0Ye[{ 0uN]zSDe0 008.Deyv10(ϑxvz]\OvՋDeSe.sDeSbtS'`(0~^hg0nQ^0+TϑKm[Self[S6k'`vpency/}~gI{0 009.Deyv11oThQSwIf v^cOhQTb[gqT(ϑhQ^S_&{T 0-NVoxQ 0sLHrveeQDeyv2vDef'`eN TDeyv13SvDeSeo0evegnS(ϑhQ0hbJTfN -N0O(uVNSeov3uN ^S_cO募SeovoTybQfeN0hbJTfN0oThQ0SeouNONv%Ngbgq0 0oTuNS 00 0oTuN(ϑ{tĉ 0fN0N募SeouNON~{vO'OS0.UShyI{v YpSN0O(uۏSSeov ^S_cON募SeouNONbVQTlv.UNtFU~{vO'OS0 0ۏSoTlQ 0b 0;SoNTlQ 00S\oTh@bhbJTfN0oThQ YpSNI{0oTlQǏ z-N x6R6RBR@b(uvۏSSeo*gS_ 0ۏSoTlQ 0b 0;SoNTlQ 0v _{~V[ߘToTvcw{t@\ybQ0 005.[(uNNvoir ^S_9hncvQ^uT\O(uyrpI{V }bv^vukk'`xvzDe0 006.[N4N^gޏ~(uo6*NgN N+T6*Ng bluba'` YS'`uu ~8^GkO(uvoir GW^cOLv'`Ջbe.sDe NR`Qvoir 9hncvQ^uT\O(uyrpI{V }bLvՋbe.sDe 001 eobvQN"Nirv~gN]wLvir(v~gvPTveo ^S_boirOV'`ՋDe0 008.^\lQR{|1v N,^(W͑ Y~ok'`ՋǏ z-NۏLkNRRf[xvz0 009.^\lQR{|1-N (ubRbTbI{el6R_v]woir-NvIQf[_gSOSvQ6RBR ^S_bmeSONUSN_gSOkvoHef[0oNRRf[Tktf[N,:N%`'`k'` I{S fvQzTt'`vxvzDebvsQe.sDe0(WvQmeSO[hQV\0] gvsQDeSc:yUSN_gSOv^gk'`Not\O(uesQ f>fXRe ؏^S_9hncvQ4N^u zTBRϑ0^uNS(uoNI{V }~TQ cONmeSOkvUSN_gSO͑ Y~ok'`N,:N3*NgNQ bvQNktxvzDeYukk'` 0 0010.^\lQR{|1-N 1u] N^.UvY~Noir6RY:N\~Nvoir YvQ~N-N N+T,gf6@bir( SNMQbDeyv23^250 0011.^\lQR{|1-N ev Ye6RBR ^S_bDeyv220 0012.^\lQR{|1-N ev Ye6RBR N,^cONUSokv͑ Y~ok'`ՋDe Y͑ Y~ok'`Ջ>f:yvQk'` NXR k'`vhV[_N*g9eS S NcODeyv270 0013.^\lQR{|1-N ev Ye6RBR YvQRiroNRRf[xvz~g>f:ye͑'Y9eSv SMQbDeyv23^250 0014.^\lQR{|2v vQotktxvz@bǑ(uv~o_^S_N4N^b(u_N0N,`Q N^S_cONS_kvoNRRf[ՋT/bvsQvktxvzDeY͑ Y~ok'`ՋT/b@\k'`Ջ 0 0015.^\lQR{|3-N 9eS~o_ ](WXY N^.Uv6RBR ^S_͑Ɖ6RBR-Nve[oir8T6eb@\k'`vq_T _ecOvQoNRRf[ՋbvsQktxvzDe0 0016.^\lQR{|4v ^S_cON] N^.UoirkvoNRRf[0;NoHef[0N,otf[T%`'`k'`ՋDe NS f9eSMRTv]_ _e؏^S_cO͑ Y~ok'`TvQNotktxvzDe0Yg9eS] N^.Uv{|oirvx9h0xWbё^\CQ } 6Rbvoir](WVY N^.U R clQR{|3v3ubDeBlRt0 0017.@\(uod c@b^\lQR{|Syvbv^DeY ^S_bDeyv21 _e^S_ۏL@\8T6eՋ0 0018.[NX[(Wf>f[hQ'`b_Y[hQ'`Vk\0~oBRϑf>fXR v0cʑ6RBR N,^S_cON] N^cʑ6RBRb8^ʑ6RBRkvUS!k~ovRiroNRRf[xvzDe0 00N04N^ՋBl 001.^\lQR{|1T2v ^S_ۏL4N^Ջ0 001 4N^ՋvuOpe^S_&{T~f[BlTgNOuOpeBl 002 4N^ՋvgNOuOpeՋ~ Bl 00Ig:N2030O IIg:N100O IIIg:N300O IVg:N2000O0 003 U[ovIg4N^Ջ^S_ cgq,gRlvĉ[ۏLIIg4N^Ջ^S_[b\100[6*Ng~hTgv:g[gqՋIIIg4N^Ջ[b\1000O12*Ng~hTgv_>eՋIVg4N^Ջ^S_EQRQ{|oTvSSV } [bY7h,gϑvxvz]\O0 002.^\lQR{|3T4v ^S_ۏLNSOoNRRf[xvzT\100[:g[gq4N^Ջ0Y*N^uv k*N;N^uvuOpe N\N60[0U[o^S_ۏLNSOoNRRf[xvzT\500O12*Ng~hTgv_>eՋ0 00^\N NRNy`Qv SNMQNۏLNSOoNRRf[xvz 001 @\(uo NNS%c@\萻lu\O(uv6RBR 002 N8T6evS g6RBR0 003.^\lQR{|5v 4N^Ջ cgq NRSRۏL 001 S gVSO6RBR^S_ۏLuirI{He'`Ջ N,:N1824O 002 NۏLuirI{He'`ՋvS gVSO6RBRSvQN^S gVSO6RBR ^S_ۏL4N^Ջ 4N^ՋvuOpe\:N100[ 003 ʑ0cʑ6RBR^S_ۏLUS!kTY!k~ovNSOoNRRf[v[kxvzT_vluf[vsQv4N^Ջ 4N^ՋvuOpe\:N100[ 004 l\BR^S_ۏL_v4N^Ջ0ۏL4N^Ջv USN;m'`bNl\BR 4N^ՋvuOpe\:N100[Y~Nl\BR 4N^ՋvuOpe\:N300OՋo (SO0_t0_sNI{l\BR ^9hnclQR{|1T2vBlۏL4N^Ջ0 004.[NlQR{|6-NvS gVSO6RBR ^S_ۏLuirI{He'`Ջ N,:N1824O0 00(u]zThQc6RoT(ϑv ^S_ۏL4N^Ջ 4N^ՋvuOpe\:N100[0 005.QMQ4N^Ջv3u ^S_(W3uoTlQeNv^cQ v^~RQQMQ4N^Ջvt1uSvsQDe0[N]ybQۏL4N^Ջv d 0oTlQ{tRl 0ĉ[SNQMQ4N^Ջv`QY N, NQybQQMQՋ0Y[b4N^Ջnx gVv 3uN^S_cQ3u ~fQMQ4N^ՋvOncTeHh N4N^~f[0ՋeQ~uN`QI{T*NebvQTt'`0 006.4N^Ջ[gqoT^S_/f](WVQ N^.UvoT0[_{NVY-ۏvoT ~V[ߘToTvcw{t@\ybQ v^~S\oTh@bhTe\'`oT3ubDeTBl 00N 3ubDeyvBl 001.3ub>e\'`oT^S_ cgq>e\Sf[T0ovS6RBR SgqSf[oTv^{|+RS 03ubDeyv 0BlR+R~~3ubDe0vQ-NDeyv22026SNMQb0 002.3ubʋe(u>e\'`oTSMQbDe240250 003.3ub>e\Sf[T0ovSMQbDeyv1701803ubove؏^b6RBRy NBlvDe0 00N 3ubDeyvf 001.Deyv8 c NRBlb 001 >e\Sf[T^cO@b(u8h }uNe_v [0gq\agN08hS^_0gqTvPgevSf[Yt]zDSf[S^_S]zAm zV ~d\Oek SNuv>e\'`8hBg( |6R~S el @b(uSf[ՋBRyr+R/fvPge vĉe\Sf[T^S_cOvQ~gnxvՋDeV10pencS~T㉐gI{ NSVQYe.sDe0+T gV[hQ\*g6e}v>e\'`8h } ؏^cO8h }vpS~V nxvQ8h'`(vՋpencbV1 NSNVQYlQv8h }v8h'`(ۏLkvՋDeSe.sDe0 002 ov^cOovv~~NSvQ(uϑ v^fT~N(Wov-Nv\O(u0L6RYv~N ^S_cOvQ~gnxvՋDeV10pencS~T㉐gI{ NSVQYe.sDe0 003 6RBR^S_cOnxvQ~gvՋpenc0Ynx gV ^ft1u v^ۏLTtceSX[(Wv~gb_(ue.sOnc0 003.Deyv10 c NRBlb 001 >e\Sf[T^S_9hnc7hTvyr'`TwQSO`Qnx[tS8^pexvzyv0~^hgQ[0+TϑKm[elNSelnx[vOncI{0Y>e\'`8h~^S;N8hBg(v+Tϑ0>e\'`;m^0Sf[~^I{ v^cO~Km[elTKm[penc0 002 ov^cO'`r0t+R0nmvon^0pHe\'`8h~^Sb;N8hBg( 0>e\Sf[~^0>e\'`;m^0Sf[~^vKm[elSՋpencI{De0:Nl\m؏^cOẽ0~̃Qk }hgelSpenc ~̃Qk }P^ĉ[vOncI{De0 004.Deyv17 c NRBlb 001 ʋe(u>e\'`oT^S_cO[RirvvhV[ShQ>fPb!jb4N^RKm[Ջvxvzel0ՋagNT~gʑI{De Ջ‰[TePv>fPbRKm[~gvVPgqGrbvQ YpSN0 002 lu(u>e\'`oT^S_cOlu;N^uvRir!jWՋDe v^cO,gTb T{|oirVQY gsQoHef[xvzv~e.sDe0 005.Deyv19 c NRBlb 00lQR{|1T3v>e\'`oT;NSe ^S_ۏL\ %`'`k'`Ջ ovS6RBRSۏL_8^k'`Ջ0;NSevTb|6RNϑ gP 4N^(uϑSg_ _NSǑ(u_8^k'`Ջ0 006.Deyv20 c NRBlb 001 lQR{|1vlu(u>e\'`oT ^S_cO'Y Trvgk'`ՋDe ;Sf[Qgq\8T6eBRϑMIRD vՋDeSe.sDe0 002 lQR{|1vʋe0lu(u>e\'`oT ^S_cOoT-N>e\'`8h }[hQpSTvQgq\8T6eBRϑ NSOvhV[T^vhV[v8T6eBRϑv0O{bVYv Tb T{|oirve.sDe0 00 N 4N^ՋBl 00>e\'`oTv4N^Ջ N, cgqSf[oTv^{|+RvBlۏL0yrk`Q N 4N^ՋvuOpe(Wn~f[Blv`Q NSS_te0 00V [IN 00,gBl-N@bcv>e\Sf[T0ovS6RBRv[INY N 00>e\Sf[T|cvc(uN>e\'`oT6RBRv6RY +T g>e\'`8h }vir(0 00ov|cN>e\Sf[TMWYO(u 4N(uMR_M6R>e\'`oTvN~_hMSO0؏SBR0'lSBR0RyBRI{~Nv;`y0 006RBR|c>e\'`8h }NvQNSe~ǏR]T6Rbv>e\'`oT0 DN3 uir6RTlQR{|S3ubDeBl ,{NR0lu(uuir6RT 00N0lQR{| 001.*g(WVQY N^.Uvuir6RT0 002.USKQbSO0 003.WVlu0SO~ހluSvQ6RT0 004.S`S^S6RT0 005.1uNv0Rirv~~bSOmcSv bǏSu6RYvwQ guir;m'`vY~N6RT0 006.1u] N^.Uuir6RT~bev Ye6RT0 007.](WVY N^.UFO\*g(WVQ N^.Uvuir6RT0 008.+T*g~ybQ̃y6RYv_u`6RT0 009.N] N^.U6RT~g N[hQv TNVQYGW*g N^.Uv6RTSb(lWxMOpzS0:1Y Vh|~ N T Nu0mdb9eSыTOp [NirۏLSf[OpI{ 0 0010.N] N^.U6RT6RYel N Tv6RTOYǑ(u N ThSO|0[;N~ހI{ 0 0011.!kǑ(uDNA͑~b/g6RYv6RTOYN͑~b/gfNTbb/g0uir~~cSbSub/gI{ 0 0012.VQY\*g N^.Uv1u^l\_9e:Nl\_~o b1u@\(uo9e:NhQ~ov6RT0 0013.9eS] N^.U6RTvBRWFO N9eS~o_vuir6RT0 0014.9eS~o_vuir6RT NSb N12y 0 0015.] gV[oThQvuir6RT0 00N03ubDeyv 00N ~De 001.oT Ty0 002.f'`eN0 003.zvvNOnc0 004.xvz~g;`~SċN0 005.oTffN7h?z0wIfSSe.s0 006.Sň0h~{7h?z0 00N of[xvzDe 007.of[xvzDe~0 008.uN(uSPgexvzDe 001 uN(uRir0uir~~b~ހ0Se@Fmvegn06eƖS(ϑc6RI{xvzDe 002 uN(u~ހvegn0g^b[{ Ǐ zSt[I{xvzDe 003 yP[^v^z0h[0OX[S ON3z['`De 004 uN(uvQ[SPgevegnS(ϑhQ0 009.SmbSeuN]zvxvzDe nx[vtT[OncSDe0 0010.6RBRYeS]zvxvzDe evegnT(ϑhQ S gsQe.sDe0 0011.(ϑxvzDeS gsQe.s SbSTb[gqTv6RYSh[,NSNVQY] N^.Uv T{|NTkvDe0 0012.4N^Ջ3u(u7hTv6R Th[U_0 0013.6R Th[ĉ zIHh DwIfSh[elDe0 0014.Rek3z['`xvzDe0 0015.vcc6RTvSňPgeT[hVv bOncS(ϑhQ0 00 N otktxvzDe 0016.otktxvzDe~0 0017.;NoHef[ՋDeSe.sDe0 0018.N,otxvzvՋDeSe.sDe0 0019.%`'`k'`ՋDeSe.sDe0 0020.gk'`ՋDeSe.sDe0 0021.RiroNRRf[ՋDeSe.sDe0 0022.W Ok'`ՋDeSe.sDe0 0023.ukk'`ՋDeSe.sDe0 0024.LvՋDeSe.sDe0 0025.MQuk'`T/bMQuS'`xvzDeSe.sDe0 0026.n@'`T@\:Ro'`xvzDeSe.sDe0 0027. Ye6RBR-NYy~NoHe0k'`0oNRRf[vNq_TvՋDeSe.sDe0 0028.OV'`ՋDeSe.sDe0 00V 4N^ՋDe 0029.VQYvsQv4N^ՋDe~0 0030.4N^ՋRSxvzeHhIHh0 0031.4N^xvzKbQ0 0032.w` TafN7h?zS&OtYXTOybQN0 0033.4N^ՋbJT0 00N vQN 0034.4N^MRxvz]\O{;`~0 0035.4N^ՋgۏLv gsQ9eۏ]z0[U(ϑhQTotktxvzI{ebv]\O;`~SՋxvzDe0 0036.[[[v6R Th[ĉ zvO9eQ[SO9eOnc NSO9eTv6R Sh[ĉ z0 0037.3z['`ՋxvzDe0 0038.ޏ~3ybՋNT6R Sh[U_0 00 N03ubDeBl 00N lu(uuir6RT3ubDeyvhDeyv1^15 29^38 DeR{|DeyvlQR{|SDeyvBl123456789101112131415~De1++Sgqv^c[SRSgqv^c[SR+++++++++++2+++++++++++++3+++++++++++++4+++++++++++++5+++++++++++++6+++++++++++++of[xvzDe7+++++++++ + +8+++ +++++   +9+++ +++++   +10+++++++++ + +11+++++++++ + +12+++++++++ + +13+++++++++ + +14+++++++++ + +15+++++++++ + +4N^ՋDe29+++++++++++++30+++++++++++++31+++++++++++++32+++++++++++++33+++++++++++++vQN34+++++++++++++35+++++++++++++36+++++++++ + +37+++++++++ + +38+++++++++ + + 00l1. + c_{bvDe 00002.  cSNMQbvDe 00003.  c9hnc3ubTyvwQSO`QBlb NBl0 00N lu(uuir6RTotktxvzDeyvBlDeyv16^28 R{|yvlQR{|SDeyvBl123456789101112131415otktxvzDe16++Sgqv^c[SRSgqv^c[SR+++++++++++17+++++++++++++18+++++++++++++19++++++++++++20+++++++++++++21++ ++++22   23   24   25+++++ ++++ +26+++++ ++++++27   +         28         00l1. + c_{bvDe 00002.  cSNMQbvDe 00003.  c9hnc3ubTyvwQSO`QBlb NBl0 00V03ubDef 00N 3u4N^ՋbDeyv1^31[b4N^ՋTbDeyv1^6015T29^380 00N [~Devf 001.Deyv1oT Ty Sb(u T0e T0Ilb0RP[ϑI{0e6R[v Ty ^fOnc0 002.Deyv2f'`eNSb 001 3uN:ggTl{vfeN%NgbgqI{ 0 0oTuNS 0SSfU_u0 0oTuN(ϑ{tĉ 0fN YpSN 002 3uvuir6RTbO(uvYe0]zI{N)R`QSvQCg^\r`f NS[NNvN)R NgbOCgvXf 003 3ueuir6RTuNT/beofNe^S_cO 0oir4N^xvzybN 0 YpSNS4N^Ջ(uov(ϑhQ 004 vcc6RTvSňPgeT[hVv 0oTSňPgeT[hVlQ 0b 0ۏSSňPgeT[hVlQ 0 YpSN0 003.Deyv3zvvNOnc SbVQY gsQ6RTxvz0 N^.UsrSvsQe.sDebuN0O(u`Qv~yvRe'`0SL'`I{vRgDe0 004.Deyv4xvz~g;`~SċN Sbxvz~g;`~ [hQ0 gHe0(ϑScNSΘi/HevI{ebv~TċN0 005.Deyv5oTffN7h?z0wIfSSe.s Sb cgq gsQĉ[wIvoTffN7h?z0ffNTyQ[vwIf vsQe.sbSSSgeHrvffNSeSыe0 00 N [of[xvzDevf 001.uN(uSPgemS[rn'`ir(v cV[ߘToTvcw{t@\v gsQĉ[cOv^vDe0 002.1uNv0Rirv~~bSOmcSv6RT0USKQbSOSw8h~ހhv͑~6RT vQuN]z-N^S+T gHevukSd/mp;m]zek v^^cOukSd/mp;mHegDe0 003.uNǏ z-NReQ[N g\o(Wk'`vir( ^cOuN]zSdHegvDe 6R[NT-NvPϑhQv^cOOnc0 004.Deyv11(ϑxvzDe-NSb6RTvtSyr'`Rg0~gnx0t+RՋ0~^Km[0+TϑKm[T;m'`Km[I{De [~S6RT؏^cOBg(RgvxvzDe0uN]znx[NT ^9hncKm[el~gS[YybՋ6RNTvh[penc (u~f[elRgnx[(ϑhQ v^~T6RT[hQ gHe'`xvz~gS3z['`[pencI{RgċNb[hQvTt'`0 005. clQR{|153ubvuir6RT SR NvQ(ϑhQ N_NON] N^ TTy0 006.3ubuNeޏ~ NybՋNTvuNĉ!j^NvQuNRv&{ N^MRTvuNĉ!j^Ocv[vN'`Y N^TvuNĉ!j g'YE^^SS R cgqeEQ3u͑e3ub0 00V [otktxvzDevf 001.tNuir6RTvY7h'`T YBg'` otktebvDeyvBlSv^ N(uN@b gvlu(uuir6RT0lQ3uN^WN6RTv\O(u:g6RTꁫyrp SgqvsQb/gc[SR yf[0Tt0WۏLotktxvz0Yg NBl N(uN3ub6RT lQ3uN^(W3ubDe-NNNf _e^cOvQNvsQvxvzDe0 002.SR N ^Ǒ(uvsQRirۏLuir6RTvotktxvzxvzǏ z-N^sQluir6RTvMQuS'`[RirՋv0~gTċNvq_TgN8^ĉvxvzelYg N(uN3ub6RT lQ3uN^(W3ubDe-NNNf _e^cOvQNvsQvxvzDe0 003.8^ĉvW Ok'`ՋelN, N(uNuir6RT Vdk8^ NۏLdkyՋFOYg6RTX[(Wyrkv[hQ'`b_ R^bvsQvxvzDe0 004.[(uNNvuir6RT lQ3uN^~TvQ6RTyrp04N^^uI{V }[6RTvukk'`ΘiۏLċN _e^bukk'`xvzDe0 005.8^ĉvLvՋel N(uN'YRuir6RT FOlQ3uN^~T6RTvuir;m'`04N^(uoe0(uoNI{V }[6RTvLvΘiۏLċN0Yg6RTSX[(WLvS ^bvsQvxvzDe0 006.l\BR0hBR0f4'` SMQbktxvzDe v^cOvsQOnc0 003 MQuk'`xvz^[USKQbSON^v~~~Tv\o(Wk'`S^ YNN~~b~ހvNSS^'`I{0Y gTv!jW NSS^ՋdNSOYՋ ؏^(WRirSOQۏL0[wQ gn~ހ'`vMQu~TirbwQ gbSOOV~ހN[v~ހk'`\O(uADCC vbSO ؏^QۏLNyN NRir͑ YBRϑvRirk'`Ջ (Wk'`ՋT~gċN-N$\vQ^sQlvQN^v~~~Tv\o(Wk'`S^0 009.lQR{|3v6RTWVlu6RT votktxvz^sQlN NQ[ 001 xvz^Ǒ(uvsQRirۏL0SR N WVlu6RTvvsQRir[WVhNirvuirS^^NNSOvsQYg6RTǑ(uuk}SO Rir؏^[ΑuWukfa0 002 8^ĉvoNRRf[xvzelv^ N(uNWVlu6RT0dk{|6RTvoRf[xvz^͑p[[eQWVvR^0md WV/f&TteTN[;NSO~ހTuk~ހWV~WVhNirvoNRRf[L:N}SOir(vR^TmdI{0 003 ^9hnc[eQWVTWVhNirvR^Tmdpenc Te~T4N^(uoNT(uoeI{V }ċN6RTNuW Ok'`0Lv'`Tukk'`vS _e^cOvsQxvzDe0 0010.lQR{|5-NvN@m6RT YO(uBRϑ NǏutAQBRϑV N*gۏLyrk]zvYt *gO(uyrknBR (WcQvsQDebfT SMQb[hQ'`xvzDeDeyv19^28 0 0011.[lQR{|7010T15vuir6RT ^HQNkxvz҉^RgċNvQ6RY]z0(ϑhQTuirf[;m'`_eSboNRRf[yr_ N] N^.U6RTvN'`0(W NebN] N^6RTW,gv T N] N^6RTwQ gnxRv4N^[hQ'`T gHe'`vMRc N ktebN,NǑ(uNyvsQRirۏLՋxvz gk'`ՋvgPSN:NN*Ng;NoHef[ebSNcO1 2y;NRiroHef[Ջ _NS~T(ϑhQ-Nv;m'`hKmeg~TQ0lQ3uNEQRnxvQN] N^6RTvN'` _NScQt1u3uQMQv^votktxvz0 0012.[NlQR{|8v6RT ^QۏL[ck8^̃q_Tvxvz0 0013.[NlQR{|13v6RT ^S_9hncBRW9eSvyrpSSmSv gsQof[T4N^I{ebv`Q~TQ bv^vՋyv0 001 [N N9eSSBRWv4N^O(uelTBRϑv|BR0\4lBRKNvvN9eS N,NcOn@'`T@\:Ro'`Ջ9hncYeSS`Q _ecOvQNvsQk'`xvzDe 002 (SOI{S9eSS6RToNRRf[L:Nvyrk6RBR ^(WeeBRWRiroNRRf[kxvzpencvW@x N ~T6RTv'`(0[hQV04N^^uT(uoNI{V }otktxvz v^cNvsQxvzDe0 0014.[NlQR{|14v6RT Yg gEQRvՋT/be.sOnc[vQN9eS~o_MRvuir6RT(WSOQN"yr_T[hQ'`ebvfcؚvuׂ0 0010.9eSmp;mBRel b1kBRel vuׂ0 0011.9eS~o_vuׂ0 0012.9eSVQ] N^.UuׂvBRW FO N9eS~o_vuׂ0 0013.9eSMQuBRϑbMQu z^vuׂ0 0014.ib'YO(uNXRt^~ vuׂ0 0015.] gV[oThQvuׂ0 00N03ubDeyv 001.~De 001 e6RT Ty 002 f'`eN 003 vvTOnc 004 oTffN7h?z0wIfSSe.s 005 Sň0h~{7h?z0 002.xvz~g;`~SċNDe0 003.uN(ũk yxvzDe 001 ̃k yvegn0yr'`Tt[De 002 yP[ybv^zTh[De 003 ̃k y ON3z['`xvzDe 004 -NVoTuir6RTh[@b[uN(u]\OyP[ybvh[bJT0 004.uN(u~ހW(xvzDe 001 ~ހW(vegn0yr'`Tt[De 002 ~ހ^v^zTh[De 003 ~ހv ON3z['`xvzDe 004 -NVoTuir6RTh[@b[uN(u~ހW(]\O~ހ^vh[bJT 005 W{QmSmRbNvegn0(ϑhQI{0 5.uN]zxvzDe 001 uׂSmuN]zvxvzDe nx[vtT[OncSDe 002 6RBRvYeT]zSvQnx[Onc evegnS(ϑhQ0 006.(ϑxvzDe 4N^MR gHe'`S[hQ'`xvzDe 001 (ϑxvzSlQhQxvzDe 002 h[elvxvzNSDe 003 N T{|6RTkxvzDe 004 NTbS'`0MQuS'`TRirՋOb'`vRgDe 005 RirǏOeՋxvzDe 006 Rir[hQ'`ċNDe0 007.6R Sh[ĉ zIHh DwIfTvsQe.s0 008.4N^Ջ3u(u7hTv6R h[U_0 009.Rek3z['`ՋDe0 0010.uN0xvzTh[(u[RirTenb[.X[agN N kN[ehKmHeR/;m'`I{ch RgSS`Q (W͑epۏLhQbhKm0dkY \ۏLR3z['`xvz0 0010.Deyv18 003ubuNeޏ~ NybՋNTvuNĉ!j^NvQuNRv&{ N^MRTvuNĉ!j^Ocv[vN'`Y N^TvuNĉ!j g'YE^^SS R cgqeEQ3u͑e3ub0 00N0sQN4N^Ջvf 001.4N^ՋvSՋuO pe^&{T~f[BlTgNOSՋuO pevBl0 002.4N^ՋvgNOSՋuO peՋ~ Bl`!g20O a!g300O b!g500O0 003.lQR{|1^9T14vuׂ ceoBlۏL4N^Ջ0 004.lQR{|10vuׂ cOfvQmp;mb1kTv[hQ'`T gHe'`*gSuSSvxvzDe SMQZP4N^Ջ0 005.lQR{|11vuׂ N,^ ceoBlۏL4N^Ջ FO1ul\_~o9e:N^l\_vuׂSMQZP`!g4N^Ջ0 006.lQR{|12T15vuׂ N,NۏLb!g4N^Ջ0 007.lQR{|13-N9eSMQu z^vuׂ SMQZP`!g4N^Ջ0 008.^(uNtZ|^?Qv2{|6RT vQIg4N^Ջ^S_ cgqHQbN0T?Qz0gTtZ|^?QvSRۏL0 009.kgv4N^Ջ^S_(W[vMQu z^[bTۏL NNgv4N^Ջ0 0010.[N!k3u(W-NV N^vuׂ ^ۏLAmLuf[vObRՋ0 00mQ0ۏS2(uuir6RT3ubDeTBl 00N 3ubDeyvBl 003ubDe cgq 0lQ3ubDeyv 0Blb03u*g(WVQY N^.Uvuׂ cgqlQR{|1vĉ[bDe3u](WVY N^.UFO\*g(W-NV N^.Uvuׂ cgqlQR{|6ĉ[bDe3u](WVQ N^.Uvuׂ cgqlQR{|15vĉ[bDe0 00N Deyv1.2 f'`eNvBlTf 001.Deyv1.2 f'`eNSbN NDe 001 uNV[b0W:SoT{t:ggQwQvAQuׂ N^.USoTuNON&{ToTuN(ϑ{tĉvfeN0lQefNSvQ-Neы,g0 3u*g(WVQY N^.Uvuׂ ,gfeNSN[b(W-NVۏLv4N^ՋT N4N^ՋbJTNv^b0 002 1uXY6RoSFU8^{-NVNh:ggRtlQNRv ^S_cO 0YVON8^{-NVNh:gg{v 0 YpSN0 00XY6RoSFUYXb-NVNt:ggNt3ubv ^S_cOYXbefN0lQefNSvQ-Neы,g NS-NVNt:ggv 0%Ngbgq 0 YpSN0 003 3uvuir6RTbO(uvYe0]zI{N)R`QSvQCg^\r`f NS[NNvN)R NgbOCgvOfN0 002.f 001 uNV[b0W:SoT{t:ggQwQvAQuׂ N^.USoTuNON&{ToTuN(ϑ{tĉvfeN {~@b(WVlQ:gsQlQS{@b(WV-NVO 002 (WN0W[b6RBRuN1uSN0W[bSňv ^S_cO6RBRSTSňS@b(WV[b0W:SoT{t:ggQwQvoTuNON&{ToTuN(ϑ{tĉvfeN 003 *g(WuNV[b0W:SQ N^.Uv SNcO(WvQNV[b0W:S N^.UvfeN v^{~V[ߘToTvcw{t@\S0oTuNON&{ToTuN(ϑ{tĉvfeN {1uuNVb0W:SoT;N{:ggQwQ0 00 N vQNDeyvvBl 001.Deyv13^S_b6RT(WuNV[b0W:S:N3u N^.U ۏLvhQ4N^ՋvDe0 002.hQ3ubDe^S_ыb-Nev^DSe vQ-Neыe^S_NSeQ[N0 003.uׂhQv-Ne,g _{&{T-NVV[oThQve_uNv^S_cOv^eNSN0 00*11V[ߘToTvcw{t@\9hncċNSLcQBl0 00*12cOSňS@b(WV[b0W:SoT{t:ggQwQvoTSňON&{ToTuN(ϑ{tĉvfeN0 00*13NcORSň]z0oir3z['`xvzvՋDe0vccoTvSňPgeT[hVv bOncS(ϑhQ0ޏ~3*NybSv7hThbJTfN0 00*14cOۏSoTRSňT T+TO(uۏSoTFUhvcCg 0 00*15NcORSň]z0vccoTvSňPgeT[hVv bOncS(ϑhQ0 00*16cO gsQ{t:gg Taf TveN YpSN f TMRNf TTv%Ngbgq0 0oTuNS 00oTuN(ϑ{tĉfNI{v YpSN0 00*17cO gsQ{t:gg TaoTuNONSfuN:W0WvfeN0 00*18cOevV[oThQbV[ߘToTvcw{t@\BlO9eoTffNveN0 00*19ScOktxvzvՋDebe.sDe0 00*20ScOe.sDe0 00*21 cĉ[SfoTSňh~{ ^cO gsQĉ[veNQ[0 00*22NcOoT3z['`xvzvՋDeTޏ~3*NybSv7hThbJTfN0 00*23NcOSeovybQfeNSvQTlegnf06RBR1*NybSvhbJTfN0 00*24cOXY6RoSFUYXbev-NVoTlQNt:ggNt3ubvYXbefN0lQefNSvQ-Neы,g ev-NVoTlQNt:ggv%Ngbgq YpSN XY6RoSFUdSYXbNtlQsQ|vefN0lQefNSvQ-Neы,g0 00 #  V0lQNyfS gsQBl 0 00V0lQNyfS gsQBl 001lQNy1 c geofNvoTuNON3uoTvybQeS /fceox6RUSMO_eofNe NwQY勰eouNagN v^Nl gl~vQNoTuNONv (WwQYv^uNagNNT 3uuN勰eo0 002lQNy3 XR-NovR;NlbSf[oT0uir6RT] gVQ TTyO(uv^u vQotktxvzT4N^Ջ^S_ cgq NRۏL 001 XR-NoevR;Nl ^(uohTgbXRBRϑ ^S_cOotktՋDebe.sDe0~ybQT^S_ۏL4N^Ջ 4N^Ջ c-NoeoBl 002 XR-NoevR;Nl (uohTgT g(uBRϑGW NS ^S_cO;NoHef[ՋDeSe.sDe v^{ۏL\100[4N^Ջ 003 XR] gVQ TTyO(uvR;Nlb^u {ۏL\60[4N^Ջ bۏLNO(udk^uv TTy:N[gqvuirI{He'`Ջ0 003.lQNy4 Sf(ul(uϑbSf(uNVFO N9eS~o_ ^S_cO/ecy9eSv[hQ'`xvzDebe.sDe _e^S_ۏL4N^Ջ0-No0)Y6qoir^S_[;Nu ۏL\100[4N^Ջ0 004lQNy5 SfoTĉfcؚvuׂ0 10.9eSmp;mBRel b1kBRel vuׂ0 11.9eS~o_vuׂ0  oTlQs:W8hg{tĉ[2008.05.23 Vߘovl[2008]255S 2008t^05g23e S^ ,{Nz0;` R 00,{Nag0:NR:_oTlQs:W8hg{t ĉoTx6Ry^ 9hnc 0-NNSNlqQTVoT{tl 0SvQ[eagO0 0oTlQ{tRl 0 6R[,gĉ[0 00 ,{Nag0oTlQs:W8hgR:Nx6Rs:W8hgTuNs:Whg0 00oTlQx6Rs:W8hg /fcoTvcw{t[@bStoTlQ3uvx6R`QۏL[0Wnx [SYU_ۏL[g nx3ubDew['`0Qnx'`T[te'`vǏ z0 00oTlQuNs:Whg /fcoTvcw{t[@bStoTlQ3uybQ N^MRv7hTybϑuNǏ zI{ۏL[0Whg nxvQ/f&TN8h[vb3ubvuN]zv&{TvǏ z0 00,gĉ[@bcvoTlQhb7h /fcoTvcw{t(WoTlQs:W8hgǏ z-NۏLvS7h0\7hTwh0 00 ,{ Nag0oTlQs:W8hgR:N8^ĉT gV0 gV8hg;N/fc[ NR`b_ۏLvs:W8hg 00N oT[ċǏ z-NSsv 00N oTlQvsQv>Nb 00 N oTvcw{t蕤:NۏL8hgvvQN`b_0 00 ,{Vag0V[ߘToTvcw{t@\#hQVoTlQs:W8hgv~~OSTvcw{t0 Te#~~eo0uir6RTybQ N^MRvuNs:Whg#~~ۏSoTlQs:W8hg#~~[oT[ċǏ z-NSsvۏLs:W8hg#~~mSoTlQ͑'YHhNv gV8hg0 00 ,{Nag0w0ꁻl:S0v^oTvcw{t#,gL?e:SWQv NRoTlQs:W8hg 00N #@bStoTlQ3uvx6Rs:W8hg 00N #@bSt] N^oT9eSBRW09eS~o_lQ3uvuNs:Whg 00 N #@bStN6RolQ3uvuNs:Whg 00V #@bStoTuNb/gl0SfYeTuN]zSq_TNT(ϑI{eEQ3uvuNs:Whg 00N #,gL?e:SWQv gV8hg0 00x6R]\OwۏLvoTlQ3u x6Rs:W8hg]\O1uSt3uvw0ꁻl:S0v^oTvcw{t# x6Rs:W@b(W0Ww0ꁻl:S0v^oTvcw{t蕔^S_NNOSR0 ,{Nz0oTlQx6Rs:W8hg 00,{mQag0oTlQx6Rs:W8hgSboir4N^MRxvzs:W8hg0oir4N^Ջs:W8hgT3ubuNx6Rs:W8hg0 00oir4N^MRxvzs:W8hg;N/f[of[xvz0otktxvz`QۏLs:W8hg0 00oir4N^Ջs:W8hg;N/f[4N^Ջ`QۏLs:W8hg0_e S[4N^Ջ(uoir6RYagNS`QۏLs:W8hg [4N^Ջ(uoirۏLbgh0 003ubuNx6Rs:W8hg;N/f[3ubuNlQ3uv7hTՋ6R`QۏLs:W8hg03ubuNeof[0otktI{xvzN3ub4N^vkSuSS ^[SSQ[ۏLs:W8hg0 00 ,{Nag0oTlQ3uNN N{y 3uN (WcQoTlQ3ue ^cN 0oTx6R`Q3ubh 0DN2 f@b[bvՋyv0mSv;NYNhV0SeooPg egn0Ջ6R:W@b0YXbxvzbhKmvyvSbb:ggI{`Q0 ,{N0oir4N^MRxvzs:W8hg 00,{kQag0w0ꁻl:S0v^oTvcw{tStoTlQ3uT ^S_~~s:W8hg~ cgq 0oTlQs:W8hgpS$R[SR 0DN1 [of[0otktI{xvz`Q[es:W8hg0 003ulQvoT^\Nuir6RTv 8hg~(Ws:W8hge^bS3*NuNybSvh(u7hT kXQ 0oTlQb7hU_US 0S 0oTlQhwfN 0 v^\7hT0 0oTlQb7hU_US 00 0oTlQhwfN 0SvsQDeNv^NoTh@b0 00,{]Nag0w0ꁻl:S0v^oTvcw{t蕌[boir4N^MRxvzs:W8hgT ^S_(Wĉ[veQ\ 0oTlQx6Rs:W8hgbJT 0DN3 ޏ T 0oTlQ{tRl 0ĉ[vvQNDeNv^NV[ߘToTvcw{t@\oT[ċ-N_0 ,{N0oir4N^Ջs:W8hg 00,{ASag0w0ꁻl:S0v^oTvcw{tSteo0 cgqeo z^3ubvuN3uT ^S_~~s:W8hg~ cgq 0oTlQs:W8hgpS$R[SR 0[4N^Ջ`Q[es:W8hg0 00 ,{ASNag0[NN6Ro3uTeEQ3u 3uN[b4N^ՋT ^S_\4N^ՋDebV[ߘToTvcw{t@\oT[ċ-N_ v^b@b(W0Ww0ꁻl:S0v^oTvcw{t0w0ꁻl:S0v^oTvcw{t蕔^S_~~[4N^ՋۏLs:W8hg0 00 ,{ASNag0w0ꁻl:S0v^oTvcw{t蕌[boir4N^Ջs:W8hgT ^S_(Wĉ[veQ\ 0oTlQx6Rs:W8hgbJT 0ޏ T 0oTlQ{tRl 0ĉ[vvQNDeNv^NV[ߘToTvcw{t@\oT[ċ-N_0 ,{ N03ubuNx6Rs:W8hg 00,{AS Nag0w0ꁻl:S0v^oTvcw{tStoTuN3uT ^S_~~s:W8hg~ cgq 0oTlQs:W8hgpS$R[SR 0[3ubuNx6R`Q[es:W8hg0 00[Neo0 cgqeo z^3ubvuN3u duir6RTYvvQNoT 8hg~(Ws:W8hge^bS3yb7hT kXQ 0oTlQb7hU_US 0S 0oTlQhwfN 0 v^\7hT0 0oTlQb7hU_US 00 0oTlQhwfN 0SvsQDeNv^NoTh@b0 00 ,{ASVag0w0ꁻl:S0v^oTvcw{t蕌[b3ubuNx6Rs:W8hgT ^S_(Wĉ[veQ\ 0oTlQx6Rs:W8hgbJT 0ޏ T 0oTlQ{tRl 0ĉ[vvQNDeNv^NV[ߘToTvcw{t@\oT[ċ-N_0 ,{ Nz0oTlQuNs:Whg ,{N0eo0uir6RTuNs:Whg 00,{ASNag0V[ߘToTvcw{t@\oT[ċ-N_[Neo0uir6RTvlQ3u ~[ċ&{Tĉ[v w3uN3uuNs:Whg TeJTwV[ߘToTvcw{t@\oT{t-N_0 00 ,{ASmQag03uN^S_6e0RuNs:WhgwKNew6*NgQTV[ߘToTvcw{t@\oT{t-N_cQoTlQuNs:Whgv3u b 0oTlQuNs:Whg3uh 0DN4 0 00,{ASNag0V[ߘToTvcw{t@\oT{t-N_(W6e0RuNs:Whgv3uT ^S_9hnc8h[vuN]z~~[7hTybϑuNǏ zI{ۏLuNs:Whg0 00 ,{ASkQag0V[ߘToTvcw{t@\oT{t-N_^S_~~s:W8hg~ cgq 0oTlQs:W8hgpS$R[SR 0[es:Whg0 008hg~(Ws:Whge^bS1yb7hTuir6RTbS3yb7hT kXQ 0oTlQb7hU_US 0S 0oTlQhwfN 0 v^\7hT0 0oTlQb7hU_US 00 0oTlQhwfN 0SvsQDeNv^NۏLoThQ Y8hvoTh@b0 00 ,{AS]Nag0V[ߘToTvcw{t@\oT{t-N_[buNs:WhgT ^S_(Wĉ[veQ\ 0oTlQuNs:WhgbJT 0DN5 NV[ߘToTvcw{t@\oT[ċ-N_0 ,{N0] N^oT9eSBRW09eS~o_uNs:Whg 00,{NASag0V[ߘToTvcw{t@\oT[ċ-N_[N] N^oT9eSBRW09eS~o_vlQ3u ~[ċ&{Tĉ[v w3uN3uuNs:Whg TeJTwStlQ3uvw0ꁻl:S0v^oTvcw{t0 00 ,{NASNag03uN^S_6e0RuNs:WhgwKNew6*NgQTStvQlQ3uvw0ꁻl:S0v^oTvcw{tcQuNs:Whgv3u b 0oTlQuNs:Whg3uh 00 00 ,{NASNag0w0ꁻl:S0v^oTvcw{t(W6e0RuNs:Whgv3uT ^S_9hnc8h[vuN]z~~[7hTybϑuNǏ zI{ۏLuNs:Whg0 00 ,{NAS Nag0w0ꁻl:S0v^oTvcw{t蕔^S_~~s:W8hg~ cgq 0oTlQs:W8hgpS$R[SR 0[es:Whg0 008hg~(Ws:Whge^bS1yb7hT kXQ 0oTlQb7hU_US 0S 0oTlQhwfN 0 v^\7hT0 0oTlQb7hU_US 00 0oTlQhwfN 0SvsQDeNv^NۏLoThQ Y8hvoTh@b0 00 ,{NASVag0w0ꁻl:S0v^oTvcw{t蕌[buNs:WhgT ^S_(Wĉ[veQ\ 0oTlQuNs:WhgbJT 0NV[ߘToTvcw{t@\oT[ċ-N_0 ,{ N0N6RouNs:Whg 00,{NASNag03uN3uN6RolQ ^S_kXQ 0oTlQ3uh 0T 0oTlQuNs:Whg3uh 0 v^ޏ T gsQ3ubDeb@b(W0Ww0ꁻl:S0v^oTvcw{t0 00 ,{NASmQag0w0ꁻl:S0v^oTvcw{tStN6Ro3uT ^S_9hnc3uN3ubvuN]z~~[7hTybϑuNǏ zI{ۏLuNs:Whg0 00 ,{NASNag0w0ꁻl:S0v^oTvcw{t蕔^S_~~s:W8hg~ cgq 0oTlQs:W8hgpS$R[SR 0[es:Whg0 008hg~(Ws:Whge^bSޏ~uNv3yb7hT kXQ 0oTlQb7hU_US 0S 0oTlQhwfN 0 v^\7hT0 0oTlQb7hU_US 00 0oTlQhwfN 0SvsQDeNv^NoTh@b0 00 ,{NASkQag0w0ꁻl:S0v^oTvcw{t蕌[buNs:WhgT ^S_(Wĉ[veQ\ 0oTlQuNs:WhgbJT 0ޏ T 0oTlQ{tRl 0ĉ[vvQNDeNv^NV[ߘToTvcw{t@\oT[ċ-N_0 ,{V0eEQ3uuNs:Whg 00,{NAS]Nag0 cgq 0oTlQ{tRl 0,{N~vNASNagvĉ[ [NoTuNb/gl0SfYeTuN]zSq_TNT(ϑI{veEQ3u w0ꁻl:S0v^oTvcw{t蕔^S_ۏLuNs:Whg0 00 ,{ NASag0 cgq 0oTlQ{tRl 0,{N~vNASNagvĉ[ۏLuNs:WhgveEQ3u QuN]z*gSuSfv 3uN^S_kXQ 0oTeEQ3uh 0T 0oTlQuNs:Whg3uh 0 v^ޏ T gsQ3ubDeb@b(W0Ww0ꁻl:S0v^oTvcw{t0 00w0ꁻl:S0v^oTvcw{tSt3uT ^S_9hncvQ 0oTlQybN 0~~[7hTybϑuNǏ zI{ۏLuNs:Whg0 00 ,{ NASNag0 cgq 0oTlQ{tRl 0,{N~vNASNagvĉ[ۏLuNs:WhgveEQ3u QuN]zSuSfv 3uN^S_kXQ 0oTeEQ3uh 0 v^ޏ T gsQ3ubDeb@b(W0Ww0ꁻl:S0v^oTvcw{t0 00w0ꁻl:S0v^oTvcw{t\3ubDebV[ߘToTvcw{t@\oT[ċ-N_0~[ċ&{Tĉ[v cgq,gĉ[,{NAS0NASN0NASNagv z^ۏLuNs:Whg0 00 ,{ NASNag0w0ꁻl:S0v^oTvcw{t蕔^S_~~s:W8hg~ cgq 0oTlQs:W8hgpS$R[SR 0[es:Whg0 008hg~(Ws:Whge^bS3yb7hT kXQ 0oTlQb7hU_US 0S 0oTlQhwfN 0 v^\7hT0 0oTlQb7hU_US 00 0oTlQhwfN 0SvsQDeNv^NoTh@b0 00,{ NAS Nag0w0ꁻl:S0v^oTvcw{t蕌[buNs:WhgT ^S_(Wĉ[veQ\ 0oTlQuNs:WhgbJT 0ޏ T 0oTlQ{tRl 0ĉ[vvQNDeNv^NV[ߘToTvcw{t@\oT[ċ-N_0 ,{Vz0~~[e 00,{ NASVag0oTvcw{t(W[eoTlQs:W8hgMR ^6R[8hgeHh ~~8hg~ w8hgUSMO v^JTw3uN0 00 ,{ NASNag0oTlQs:W8hg1u8hg~wQSO[e08hg~N,1u2NN N~b [L~#6R 8hg~bXT1u>mQ8hg~vnx[09hnc8hgoTlQ3uv`Q SN~~vsQN[SN8hg0 00V[ߘToTvcw{t@\~~voTlQs:W8hg 8hgUSMO@b(W0Ww0ꁻl:S0v^oTvcw{t蕔^ >mN ToTvcw{tNXT\O:N‰[XTOSR8hg]\O0 00 ,{ NASmQag0oTlQs:W8hg_Ye,8hg~^S_O 1u8hg~~T8hgUSMO[^8hgQ[0BlT~_I{0 008hgUSMO^MT8hg~]\O O@bcOvDew[ v^ >mvsQNXTOSR8hg~]\O0 00 ,{ NASNag08hg~^ cgq 0oTlQs:W8hgpS$R[SR 0[e8hg v^ cBlbS7hT0 00 ,{ NASkQag08hg~^[8hg-NSsvY[U_ _e^NS0 00 ,{ NAS]Nag0[bs:W8hgT 8hg~~~~[8hg`QۏLGl;` b_b8hg~g dQ 0oTlQx6Rs:W8hgbJT 0b 0oTlQuNs:WhgbJT 00Gl;`g 8hgUSMONXT^V0 00 ,{VASag08hg~_gMR^S_O 1u~T8hgUSMO[8hg~g0 00 ,{VASNag0傫8hgUSMO[8hg~ge_ 8hg~hQSObXTS8hgUSMO#N^(W 0oTlQx6Rs:W8hgbJT 0b 0oTlQuNs:WhgbJT 0-N~{ T v^Rv8hgUSMOlQz0‰[XTSRv8hg ‰[XT_N{~{ T0 00 ,{VASNag0傫8hgUSMO[8hg~g g_ ScQ N Ta0\OQʑTf [8hgUSMOcQv 8hg~^ۏNek8h[vsQ`Q v^^ZP}YU_0U_~8hg~hQSObXTT8hgUSMO#N~{ T v^Rv8hgUSMOlQz0‰[XTSRv8hg ‰[XT_N{~{ T0 00 ,{VAS Nag08hg~[bs:W8hgT dSDeY ^\8hgUSMOcOvvQNDe؏0 00,{VASVag08hgUSMO[s:W8hgNXT0 z^08hg~gI{ g_e S(W5eQvcT>mQ8hg~vboTvcw{tcQ3uɋ0 00 ,{VASNag0s:W8hg~_gT 8hg~^b_b~Tċ[~ ~hQSONXT~{ TT cBl\ 0oTlQx6Rs:W8hgbJT 0b 0oTlQuNs:WhgbJT 0SvsQDebvQ>mQ0 00 ,{VASmQag0>mQ8hg~v蕔^[8hg~bvDeۏL[8h (W 0oTlQx6Rs:W8hgbJT 0b 0oTlQuNs:WhgbJT 0-NkXQ[8ha v^(Wĉ[veQNV[ߘToTvcw{t@\oT[ċ-N_0 00 ,{VASNag0V[ߘToTvcw{t@\oT[ċ-N_Oncb/g[ċa0oTlQx6Rs:W8hgTuNs:WhgbJT07hTh~g b_b~Ta ޏ T gsQDebV[ߘToTvcw{t@\0 ,{Nz0oTlQhb7hBl 00,{VASkQag0oTlQs:W8hgNXT(Ws:Wb7he ^SgqoTb7hvsQĉ[ۏL d\Oĉ Ob7hvNh'` b7hǏ z N^q_T@bb7hTv(ϑ0 00 ,{VAS]Nag0b7hNXT^nx[b7hybS 8h[yb7hTv;`ϑ hgSň/f&T[te0h~{ N/f&TlfoT Ty0ĉNNv^v8hgyv e(Wc:ys:W8hgv͑psTsQ. }0~T8hg~gv^Onc$R[SR [oTlQ3uvx6RTybϑuN`QۏL~Tċ[0 00000000000 oTlQx6Rs:W8hgpS$R[SR 00N0oTlQx6Rs:W8hgp 00N of[eb 001.]zSYexvz 001.1x6RNXT/f&TNNǏyx6R]\O v^N3ubDev}N0 001.2]zSYexvz/f&TwQ gNxvzyvv^v:W@b0YTNhV0 001.3]zSYexvzU_/f&T g[{ 0xd"}I{ՋǏ zvwQSOQ[ ]zxvzSvQnx[]zvՋpenc0e/f&TN3ubDeN0 002.7hTՋ6R 002.17hTՋ6Rs:W/f&TwQ gNՋ6R7hTv^v:W@b0Y v^n7hTuNvBl 4N^Ջ(u7hTT3ubuN7hTvuNagN/f&T&{T 0oTuN(ϑ{tĉ 0vBl03ubuN@b7hTvՋ6R/f&T(W,gONuNfQۏL0 002.27hTՋ6R@bvSe0oPgTcSir0vccoTvSňPgeI{/f&TwQ gTlegnYO'OS0Shy0oTybQf'`eN YpSNI{ 0 002.3Se0oPgTcSir0vccoTvSňPgeI{-eQebO'eN7hTՋ6Re/f&T[^ -eQϑ/f&Tn7hTՋ6RvBl0 002.47hTՋ6R(uvSeSvccoTvSňPge/f&T ghbJTfN0 002.57hTՋ6R/f&TwQ g6RYU_bSYybuNU_ 7hT6RYU_yvSvQQ[^PhQ YՋ6Re0Ջ6RǏ zSvsQsQ.]zSpe0-NSOhU_I{0 002.67hTՋ6Rϑ0iRYOϑNO(uϑKNvsQ|/f&T[^N0 002.7\(WۏLvg3z['`xvz/f&T gYu7h 7hT@b(uvccoTvSňPge/f&TN3ubDeN0 002.83ubuN@b7hTvSYybuNU_/f&TN3ub]z[^0 003.(ϑ03z['`xvzS7hTh 003.1xvzNXT/f&TNNǏyxvz]\O v^N3ubDev}N0 003.2(ϑ03z['`xvzShs:W/f&TwQ gNxvzyvv^v:W@b0YTNhV0 003.3xvzgvNhVY/f&T!hTe/f&TGW g~{ T0oirvcSpeϑ0O(upeϑSiRYOpeϑKNvsQ|/f&T[^N0 002.2.3Ջ(uoTv(ul(uϑSO(u;`ϑ/f&TNSՋ(uoSYU_04N^ՋbJT[^N0 002.34N^Ջpencvnn 002.3.1uObJThCRF NSYDeYSYuS0[[hg0q_Pf[hg0ECG0Holter0À\0\I{hgvSYU_I{ NS3ubDe/f&T[^N0 002.3.2SYDe-Nv4N^hgpenc/f&TYnn _e[4N^hY4N^hy0q_P[0Tyhg[I{ ۏL8hg N8h[4N^hgpencvw['`0 002.3.34N^ՋǏ z-N/f&T[Su%N͑ NoNNSAE 0Tv^(uo`QۏLU_ /f&TN4N^;`~bJTN0 002.3.43ubDe4N^Ջ;`~bJT-N[b4N^ՋvuOpeN[E4N^ՋuOpe^[^N0 002.4 oNRRf[NuirI{He'`Ջ-NSYV1/f&TYnn 002.4.1~(V1/f&TS+T[tevOo` v^Npenc^-N5uP[V1N0 002.4.2SYV1Spenc/f&TN4N^Ջ;`~bJT[^N0 002.4.3ۏ7he(bǑƖe)/f&TNՋe0NhVO(ue[^N0 002.4.4V1U_vKmՋ7hTS/f&TNv^SՋ@h,gSvU_[^N0 002.5 ~bJT/f&TN4N^Ջ;`~bJTN0 003.YXbxvz vQNbUSMOۏLvxvz0hKmI{]\O /f&T gYXbfPge0YXbfPgeS fvYXbUSMO0e0yvSeHhI{/f&TN3ubDe}N0YXb:ggQwQvbJTfNbV1/f&T:NRvvQlQzvSN0_e S[YXb:ggۏLs:W8hg NnxvQxvzagNTxvz`Q0 00N0oTlQx6Rs:W8hg$R[SR 001.x6R`QSagN~[0Wnx NS[x6RǏ z-NSYU_ۏL[g *gSsw['`0NN3ubDeNv 8hg~$R[:N Ǐ  002.Ssw['`bN3ubDe NNv 8hg~$R[:N NǏ 0 oTlQuNs:WhgpS$R[SR 00N0oTlQuNs:Whgp 001.:ggTNXT 001.1ON^zvoTuNT(ϑ{t~~:gg/f&TYnxOT~蕌TNXTcknxe\LL#0 001.2SN7hTybϑuNvT~NXT Sbire{t07hTuN0(ϑh0(ϑOI{NXT/f&TwQYe\LvQL#v[ER0 001.37hTybϑuNMR NNXT/f&TۏLǏN,gNTuNT(ϑc6R gsQvWSoTGMPW v^ gWU_0 002.S?bNe0Y 002.1uNS?bSvQe0uNY0NPagNI{/f&Tn7hTybϑuNBl0 002.2uNybϑNvQ[EuNagNTR/f&T9SM0 002.3Y N/fN(uuN~ 7hTNS gNT[hQuN&^egvΘi/f&TEQRċ0O, v^ gHe2bkNSalg0 002.4:NXR勧NTuN S gS?bNe0Y/f&T\Ov^vSf Sf/f&T~ybQv^~0Y:Ne^ONbf ybϑuNMRNNTuNvsQvS?bNe0sQ.Y/f&T~nxIQ/OQ/PQ 0 003.SeTSňPge 003.1uNǏ z@bvSeTSňPge-eQ0PX[0S>e0O(uI{/f&T6R[{t6R^v^ugqgbL0 003.2 Nire/f&TwQ gTlegnv^NlQ3ubN Y gSf /f&T~ybQ0 003.3/f&T[-eQvSe0vccoTvSňPgeI{S7hhv^&{T(ϑhQBl0 003.4/f&T[sQ.Se0vccoTvSňPgeO'FUۏL[v^~(ϑ{tybQ0 004.7hTybϑuNǏ z 004.1/f&T6R[7hTuN]zĉ z ]zĉ zvQ[N8h[vYe0]zNSybuNU_vQ[/f&TN0 004.2/f&TۏL]z penc/f&T/ecybϑuNvsQ.]zSpe0 004.3nmel/f&T~0 004.4uNs:Wd\ONXT/f&Tugq]zĉ zۏLd\O0 004.5ybU_Q[/f&Tw[0[te \SbN NQ[ 004.5.1NT Ty0ĉyOlQ^ 00V bhQVoT NoS^bJTTvKm`Q 00N ~~hgoTuN0~%ONvoT NoS^bJTTvKm]\Ov_U\`Q v^NkSuTT~~hg;Su:ggvoT NoS^bJTTvKm]\Ov_U\`Q0 00 ,{Nag0w0ꁻl:S0v^oTvcw{t#,gL?e:SWQoT NoS^bJTTvKmv{t]\O v^e\LN N;NL# 00N 9hnc,gRlN T~kSuL?eqQ T6R[,gL?e:SWQoT NoS^bJTTvKmv{tĉ[ v^vcw[e 00N N T~kSuL?eTT~~_U\,gL?e:SWQSuvq_T'YvoTSO NoNNvgTYt v^S^vsQOo` 00 N []nxSu%N͑oT NoS^boTSO NoNNvoTOlǑS'}%`c6Rce \OQL?eYtQ[ v^T>yOlQ^ 00V b,gL?e:SWQoT NoS^bJTTvKm`Q 00N ~~hg,gL?e:SWQoTuN0~%ONvoT NoS^bJTTvKm]\Ov_U\`Q v^N T~kSuL?eTT~~hg,gL?e:SWQ;Su:ggvoT NoS^bJTTvKm]\Ov_U\`Q 00mQ ~~_U\,gL?e:SWQoT NoS^bJTTvKmv[ O0W]\O0 ,{kQag0:Sv^~0S~oTvcw{t#,gL?e:SWQoT NoS^bJTTvKmv{t]\ON T~kSuL?eTT~~_U\,gL?e:SWQSuvoTSO NoNNvg v^ǑS_c6Rce~~_U\,gL?e:SWQoT NoS^bJTTvKmv[ O0W]\O0 00 ,{]Nag0S~N NkSuL?e蕔^S_R:_[;Su:gg4N^(uovvcw{t (WL#VQOl[]nxv%N͑oT NoS^boTSO NoNNǑSvsQv'}%`c6Rce0 00 ,{ASag0V[oT NoS^vKm-N_#hQVoT NoS^bJTTvKmvb/g]\O v^e\LN N;NL# 00N bbV[oT NoS^bJTTvKmDev6eƖ0ċN0ST Nb NShQVoT NoS^vKmOo`Q~v^T~b 00N 6R[oT NoS^bJTTvKmvb/ghQTĉ [0WeT~oT NoS^vKm:ggۏLb/gc[ 00 N ~~_U\%N͑oT NoS^vgTċN OSR gsQ_U\oTSO NoNNvg 00V S^oT NoS^f:yOo` 00N bboT NoS^bJTTvKmv[ O0W0xvzTVENAm]\O0 00 ,{ASNag0w~oT NoS^vKm:gg#,gL?e:SWQvoT NoS^bJTTvKmvb/g]\O v^e\LN N;NL# 00N bb,gL?e:SWQoT NoS^bJTTvKmDev6eƖ0ċN0ST Nb NSoT NoS^vKmOo`Q~v~bT{t 00N [:Sv^~0S~oT NoS^vKm:ggۏLb/gc[ 00 N ~~_U\,gL?e:SWQ%N͑oT NoS^vgTċN OSR gsQ_U\oTSO NoNNvg 00V ~~_U\,gL?e:SWQoT NoS^bJTTvKmv[ O0W]\O0 00,{ASNag0:Sv^~0S~oT NoS^vKm:gg#,gL?e:SWQoT NoS^bJTTvKmDev6eƖ08h[0ċN0ST Nb_U\,gL?e:SWQ%N͑oT NoS^vgTċNOSR gsQ_U\oTSO NoNNvgbboT NoS^bJTTvKmv[ O0WI{]\O0 00,{AS Nag0oTuN0~%ONT;Su:gg^S_^zoT NoS^bJTTvKm{t6R^0oTuNON^S_zN:ggv^MYNLNXT oT~%ONT;Su:gg^S_zbc[:ggv^MYN|Q LNXT bb,gUSMOvoT NoS^bJTTvKm]\O0 ,{ASVag0NNoT NoS^bJTTvKmv]\ONXT^S_wQ g;Sf[0of[0AmLuf[b~f[I{vsQNNwƋ wQYyf[RgċNoT NoS^vR0 ,{ Nz0bJTNYn ,{N0W,gBl 00,{ASNag0oTuN0~%ONT;Su:ggwbSsSN(uo gsQv NoS^ ^S_ǏV[oT NoS^vKmOo`Q~bJT NwQY(W~bJTagNv ^S_Ǐ~(bhb@b(W0WoT NoS^vKm:gg 1u@b(W0WoT NoS^vKm:ggN:N(W~bJT0 00bJTQ[^S_w[0[te0Qnx0 00,{ASmQag0T~oT NoS^vKm:gg^S_[,gL?e:SWQvoT NoS^bJTTvKmDeۏLċNT{t0 00,{ASNag0oTuN0~%ONT;Su:gg^S_MToTvcw{t0kSuL?e蕌ToT NoS^vKm:gg[oT NoS^bSO NoNNvg v^cOg@bvDe0 00,{ASkQag0oTuN0~%ONT;Su:gg^S_^zv^OX[oT NoS^bJTTvKmchHh0 ,{N0*NOoT NoS^ 00,{AS]Nag0oTuN0~%ONT;Su:gg^S_;NR6eƖoT NoS^ wbSsoT NoS^T^S_~U_0RgTYt kXQ 0oT NoS^/NNbJTh 0Dh1 v^bJT0 00,{NASag0eovKmgQvVNoT^S_bJToTv@b g NoS^vQNVNoT bJTevT%N͑v NoS^0 00ۏSoTꁖ!kQۏSKNew5t^Q bJTۏSoTv@b g NoS^n5t^v bJTevT%N͑v NoS^0 00,{NASNag0oTuN0~%ONT;Su:ggSsbwev0%N͑voT NoS^^S_(W15eQbJT vQ-N{kNuO{zsSbJTvQNoT NoS^^S_(W30eQbJT0 gOo`v ^S_SebJT0 00,{NASNag0oTuNON^S_[wv{kNuOۏLg ~N{kNuOvW,gOo`0oTO(u`Q0 NoS^SuSʋl`QI{ v^(W15eQ[bgbJT boTuNON@b(W0Wvw~oT NoS^vKm:gg0 00,{NAS Nag0*NNSsevb%N͑voT NoS^ SNT~l;S^bJT _NSNToTuN0~%ONbS_0WvoT NoS^vKm:ggbJT _ecOvsQvuSDe0 00,{NASVag0:Sv^~0S~oT NoS^vKm:gg^S_[6e0RvoT NoS^bJTvw['`0[te'`TQnx'`ۏL[8h0%N͑oT NoS^bJTv[8hTċN^S_6e0RbJTKNew3*N]\OeQ[b vQNbJTv[8hTċN^S_(W15*N]\OeQ[b0 00:Sv^~0S~oT NoS^vKm:gg^S_[{kNuOۏLg ~N{kNuOvW,gOo`0oTO(u`Q0 NoS^SuSʋl`QI{ 6e0RbJTKNew15*N]\OeQ[bgbJT b T~oTvcw{t蕌TkSuL?e NS NN~oT NoS^vKm:gg0 ,{NASNag0w~oT NoS^vKm:gg^S_(W6e0R NN~oT NoS^vKm:ggcNv%N͑oT NoS^ċNaKNew7*N]\OeQ[bċN]\O0 00[{kNuO NNSu0WToTuNON@b(W0Wvw~oT NoS^vKm:ggGW^S_Se9hncgbJTۏLRg0ċN _eۏLs:Wg v^\ċN~gbw~oTvcw{t蕌TkSuL?e NSV[oT NoS^vKm-N_0 ,{NASmQag0V[oT NoS^vKm-N_^S_Se[{kNuOۏLRg0ċN v^\ċN~gbV[ߘToTvcw{t@\TkSu0 ,{ N0oTSO NoNN 00,{NASNag0oTuN0~%ONT;Su:ggwbSsoTSO NoNNT ^S_zsSǏ5u݋b OwI{e_b@b(W0WvS~oTvcw{t0kSuL?e蕌ToT NoS^vKm:gg _eSN~bJT TekXQ 0oTSO NoNNW,gOo`h 0Dh2 [kNuO؏^S_SekXQ 0oT NoS^/NNbJTh 0 ǏV[oT NoS^vKmOo`Q~bJT0 00,{NASkQag0:Sv^~0S~oTvcw{t蕷woTSO NoNNT ^S_zsSN T~kSuL?eTT~~_U\s:Wg v^Se\g~g~bw~oTvcw{t蕌TkSuL?e0 00w~oTvcw{tN T~kSuL?eTT[:Sv^~0S~vgۏLcwO0c[ [oTSO NoNNۏLRg0ċN [,gL?e:SWQSuvq_T'YvoTSO NoNN ؏^S_~~s:Wg ċNTg~g^S_SebV[ߘToTvcw{t@\TkSu0 00[hQVVQq_T'Yv^ b%N͑TgvoTSO NoNN V[ߘToTvcw{t@\^S_NkSuTT_U\vsQg]\O0 00,{NAS]Nag0oTuNONwoTSO NoNNT^S_zsS_U\g ~NoTSO NoNNvSu0oTO(u0`ʋlNSoTuN0PX[0Am0e_{|kĉ[~NS^vOo` V[ߘToTvcw{t@\TkSu_NSNcCgw~oTvcw{t蕌TkSuL?eS^0 00,{NASNag0(WoT NoS^bJTTvKmǏ z-NSvFUNy[0*NNy0`TbJTOo`^S_NNO[0 00,{NASmQag0R;Su:gg0oTuNON0oT~%ONKNqQNoT NoS^Oo`0 ,{NASNag0oT NoS^bJTvQ[T~De/fR:_oTvcw{t0c[Tt(uovOnc0 ,{Nz0l_#N 00,{NASkQag0oTuNON g NR`b_KNNv 1u@b(W0WoTvcw{t~NfJT #NPg9eck SNv^YNCSCQN N NNCQN NvZ>k 00N *g cgqĉ[^zoT NoS^bJTTvKm{t6R^ beN:gg0NLNXT#,gUSMOoT NoS^bJTTvKm]\Ov 00N *g^zTOX[oT NoS^vKmchHhv 00 N *g cgqBl_U\oT NoS^bSO NoNNbJT0g0ċNTYtv 00V *g cgqBlcN[g[hQ'`febJTv 00N *g cgqBl_U\͑pvKmv 00mQ NMT%N͑oT NoS^bSO NoNNvsQg]\Ov 00N vQNݏS,gRlĉ[v0 00oTuNON gMR>kĉ[,{V y0,{N y`b_KNNv cgq 0oTlQ{tRl 0vĉ[[v^oT NNQlQ0 00,{NAS]Nag0oT~%ON g NR`b_KNNv 1u@b(W0WoTvcw{t~NfJT #NPg9eck>g N9ev Y NNCQN NvZ>k 00N eNLb|QLNXT#,gUSMOoT NoS^vKm]\Ov 00N *g cgqBl_U\oT NoS^bSO NoNNbJT0g0ċNTYtv 00 N NMT%N͑oT NoS^bSO NoNNvsQg]\Ov0 00,{mQASag0;Su:gg g NR`b_KNNv 1u@b(W0WkSuL?e~NfJT #NPg9eck>g N9ev Y NNCQN NvZ>k0`%N͑v^ b%N͑Tgv 1u@b(W0WkSuL?e[vsQ#NN~NL?eYR 00N eNLb|QLNXT#,gUSMOoT NoS^vKm]\Ov 00N *g cgqBl_U\oT NoS^bSO NoNNbJT0g0ċNTYtv 00 N NMT%N͑oT NoS^TSO NoNNvsQg]\Ov0 oTvcw{tSs;Su:gg gMR>kĉ[L:NKNNv ^S_yN T~kSuL?eYt0 00kSuL?e[;Su:gg\OQL?eYZQ[v ^S_Seb T~oTvcw{t0 00,{mQASNag0T~oTvcw{t0kSuL?e蕌ToT NoS^vKm:ggSvQ gsQ]\ONXT(WoT NoS^bJTTvKm{t]\O-NݏS,gRl b%N͑Tgv Ogq gsQĉ[~NL?eYR0 ,{mQASNag0oTuN0~%ONT;Su:ggݏSvsQĉ[ ~oTO(u b_c[v OlbbTP#N0 ,{kQz0D0R 00,{mQAS Nag0,gRl NR(u틄v+TIN 00N oT NoS^ /fcTfWvb8lENvNSO$OkbhV[Rv_c$O 005.[OObbOObe^ 006.[vQN͑;Sf[NN Y NۏLluSQs N@bR`Qv0 00V evoT NoS^ /fcoTffN-N*g}fv NoS^0ffN-N] gc FO NoS^Suv'`(0 z^0TgbsNffNc NNbf%N͑v cgqevoT NoS^Yt0 00N oTSO NoNN /fc TNoT(WO(uǏ z-N (Wv[Ɩ-Nve0:SWQ [N[peϑNvSOeP^bu}T[hQ b_c[bZ NN'}%`YnvNN0 00 TNoTc TNuNONuNv TNoT Ty0 TNBRW0 TNĉf% u z^% u`R͑% [TWu% [{kN%sQT'`ċNbJTNċN00[%0_S%0S%0SesQ%0_ċN%0 elċN%0 ~{ T0 bJTUSMOċN0[%0_S%0S%0SesQ%0_ċN%0 elċN%0 ~{ TbJTNOo`T|5u݋LN;Su%0 o^%0 bX% vQN% 5uP[{~{ TbJTUSMOOo`USMO Ty0000000 000 T|N5u݋00bJTeg 0t^00g00e uNON kXQOo`egn;Su:gg% ~%ON% *NN% e.sbS% N^Txvz% vQN% Y l %N͑oT NoS^ /fcVO(uoT_wN N_c[`b_KNNvS^ 1) [{kN 2 qSSu}T 3 Lv0xu0Qu:w 4 [>fWvb8lENvNSO$OkbhV[Rv_c$O 5 [OObbOObe^ 6 [vQN͑;Sf[NN Y NۏLluSQs N@bR`Qv0 evoT NoS^/fcoTffN-N*g}fv NoS^0ffN-N] gc FO NoS^Suv'`(0 z^0TgbsNffNc NNbf%N͑v cgqevoT NoS^Yt0 bJTeP ev0%N͑voT NoS^^NSsbwKNew15eQbJT vQ-N{kNuO{zsSbJT vQNoT NoS^ 30eQbJT0 gOo`v ^S_SebJT0 vQNf `uoT/fc`O(uv`uN NoS^Su gsQvoT0 v^(uoTcSudkoT NoS^e`d`uoTYvvQN(uo`Q Sb`L-pNvoTb-NIoI{0 (ul(uϑSbk!k(uoBRϑ0~o_0ke~o!kpe OY 5mg S g ke2!k0 bJTvYt @b gvbJT\OU_eQpenc^ NNNXTORgoTT NoS^/NNKNvsQ|09hncoTΘivnfM'`b%N͑ z^ Q[/f&TǑSvsQce Y(WoTffN-NReQf:yOo` feoTYUO[hQO(uvOo`I{0(Wg\pe`Q N S_:NoTvΘi'YNHeve oT_NOd^0 Dh2 oTSO NoNNW,gOo`h Su0W:SO(uUSMO(uoNpeSu NoNNNpe%N͑ NoNNNpe{kNNpeO(uoeg t^ g eOSueg t^ g e`uoTFUT T(u TuNONoTĉkĉ[3ufhKm QlQvNT uNON_{(WS;SuhVheQXT0beQO(uMR[blQhKm0~hKmTg NJTwv 6e0R3uPgeKNewsS:NSt 00V 3uPgePhQ0&{Tb__[gBlv b3uN cgqBlcNhQeck3uPgev NNSt0 00ߘT oTvcw{tStb NNSt;SuhVhlQ3u ^S_QwQRv,gN(upSzv^lfegv 0StwfN 0b 0 NNStwfN 00 00,{NASNag0ߘT oTvcw{tSt;SuhVhlQ3uT ^S_(W,gRl,{NASNagĉ[vgPQ[3uۏL[('`[gv^\OQ/f&T~NlQvfNbQ[0~[g&{Tĉ[ybQlQv fNbybQQ[\OQKNew10*N]\OeQS~;SuhVhlQfN0~[g N&{Tĉ[v \OQ NNlQvfNbQ[ v^ft1u TeJTw3uNN gOl3uL?e YbcwL?eɋvCg)R0 00,{NASNag0:Sv^~ߘT oTvcw{t:gg^S_St3uKNew30*N]\OeQ \OQ/f&T~NlQvQ[0 00w0ꁻl:S0v^ߘT oTvcw{t蕔^S_St3uKNew60*N]\OeQ \OQ/f&T~NlQvQ[0 00V[ߘToTvcw{t@\^S_St3uKNew90*N]\OeQ \OQ/f&T~NlQvQ[0 00(W[lQ3uۏL[gvǏ z-N hKm0N[ċ[T,Tv @be N{(W,gagĉ[vgPQ0ߘT oTvcw{t蕔^S_\@befNbJTw3uN0 00,{NAS Nag0*g_XY;SuhVh N^SvXY;SuhVh 3ulQe SgqXQ T{|NTlQvb/g[gBlgbLcNvPge,gRlDN80DN9 0 00,{NASVag0ߘT oTvcw{t(W[;SuhVhlQ3uPgeۏLb/g[ge uNONeEQPgev ^S_N!k'`SQfNbeEQPgew0 00uNON^S_(W60*N]\OeQ cgqwBl\PgeN!k'`eP eEQPgeve N{(WߘT oTvcw{tۏL[([gvgPQ0uNON*g(Wĉ[vePQeEQPgeNl gckS_t1uv ~bk[g0 00,{NASNag0lQ3u~bk[gv (W~bk[gTv6*NgQ N_Q!k3u0 00,{NASmQag0uNON[eEQPgewQ[ g_v SN(Wĉ[vePQTߘT oTvcw{tcQfNba ft1uv^cOb/g/ecPge ~ߘT oTvcw{t蕡[gT\OQQ[0 00,{NASNag0;SuhVhNTvlQUSCQSR NNb/g~g0'`chTg(u:NRROnc0 00,{NASkQag0\O:NNlQv;SuhVh 3uN^S_fNNMTO(uvcPNT0Nv Ty0WS0ĉyOlQJT v^>NL,T0 ,{Nz0;SuhVhv͑elQ 00,{ NAS Nag0;SuhVhlQfN gHegJ\n ~~.UbO(u;SuhVhv uNON^S_(W;SuhVhlQfN gHegJ\nMR6*NgQ 3u0Rg͑elQ0>gRtv ͑elQe^S_[NTۏLlQhKm0 00,{ NASVag0;SuhVhlQfN-N NRQ[SuSSv uNON^S_SuSSKNew30eQ3uSf͑elQ 00N WS0ĉ\R&^bSv f W[0 00SfTv;SuhVhlQfNv gHeg*bbkeNS;SuhVhlQfNv gHeg*bbkev T gHegn^S_3u͑elQ0 00,{VASNag0;SuhVhlQfN"N1Yb_ckv uNON^S_ cgq,gRlDN11vBlcN gsQPgeTf TSlQ[yb3ueR0 ,{Nz0vcw{t 00,{VASNag0#;SuhVhlQ[ybvߘT oTvcw{t蕔^S_ cgqĉ[ z^ۏL[yb v^\OQ/f&T~NlQvQ[0[ݏSĉ[[yblQv ^S_OlvzvQL?e#N0 00,{VAS Nag0:Sv^~N N0WeߘT oTvcw{tݏS,gRlĉ[[ev;SuhVhlQ 1uvQ N~ߘT oTvcw{t#NPg9eck>g N9eckv N~ߘT oTvcw{tSNvclQJTd;SuhVhlQfN0]~d;SuhVhlQfNv;SuhVh N_~~.UTO(u ]~.U0O(uv 1uS~N N0WeߘT oTvcw{t#vcwONۏLYt0 00,{VASVag0w~N NߘT oTvcw{t[ N^Tv;SuhVhۏLb/gQċN v^9hncb/gċNv~g[ N0RgO(uvv0 NO[hQ gHev;SuhVh \OQd;SuhVhlQfNvQ[ v^T>yOlQJT0]~d;SuhVhlQfNv;SuhVh N_~~.UTO(u ]~.U0O(uv 1uS~N N0WeߘT oTvcw{t#vcwONۏLYt0 ,{VASNag0 g 0-NNSNlqQTVL?eSl 0,{NASag`b_KNNv SlQ[yb蕔^S_Oll;SuhVhlQfN0 ,{kQz0l_#N 00,{VASmQag0ݏS,gRlĉ[ 3u;SuhVhlQe ǑScOZGPf0eN07hTI{ZGPPge bN:k0?BI{ NckS_KbkS;SuhVhlQfNv lQ[yb NNStb NNlQ,v^~NfJT 1t^Q NStvQ;SuhVhlQ3uvQ]~S_0Rv;SuhVhlQfN NNd 2t^Q NStvQ;SuhVhlQ3u v^Ogq 0;SuhVhvcw{tagO 0,{VASagvĉ[NNYZ0 00,{VASNag0m9e0PVS0Qy0QP;SuhVhlQfN bNvQNb__^ll;SuhVhlQfNv 1uS~N NߘT oTvcw{t#N9eck SNv^Y3NCQN NZ>k0 00,{VASkQag0ݏS,gRl,{ NAS Nag0,{ NASVagb,{ NASNagvĉ[ *gOlRt;SuhVh͑elQ .Uv;SuhVh b.Uv;SuhVhNlQfNP[Q[ N Tv bNTffN0h~{0SňhƋI{Q[N;SuhVhlQfNP[Q[ N Tv 1uS~N NߘT oTvcw{t蕝Ogq 0;SuhVhvcw{tagO 0sQNe;SuhVhlQfNvYZĉ[NNYZ0 00,{VAS]Nag0ݏS,gRl,{ NASkQagvĉ[ *gOlRt;SuhVhlQfNSfv 1uS~N NߘT oTvcw{t#NPg9eckb~NfJT>g N9eckv SNYN5000CQN N1NCQN NZ>k0 00,{NASag09hnc,gRl,{ASNag3ulQTQ[NTۏLlQhKmv;SuhVh *g cgqĉ[[blQhKmsS\NTbeQO(uv 1uV[ߘToTvcw{t@\d;SuhVhlQfN NNlQJT v^eQONڋOchHh0 00NT~lQhKm NTe\'`|P[\OlunvluY0XQNTcOv^ĉ[v4N^ՋDe XYNTcOXY?e^;SuhVh;N{ybQ勧NTlQ N^ev4N^ՋDe ~-NV?e^~~vN[~S0B TewQY 10XQNT*gybQ N^0XYNTXY?e^;SuhVh;N{]ybQ3uNT(W,gV0W:S N^ 20ʋeWNTb N/f(uX0_l0oIQ0X\~0=Os\~NSvQN>e\'`|P[\OlunvluY 30,gONvvQNNT(W-NV.U g4t^N Neb(`vU_0 lNT gb(`U_vgbL,gyA0XQNTcOv^ĉ[v4N^ՋDe XYNTcOXY?e^;SuhVh;N{ybQ勧NTlQ N^ev4N^ՋDe0 N0ON] gNTۏeQ-NV^:W 3uNTN]lQNT^\ T{|NT0A TewQY 10XQNT*gybQ N^0XYNTXY?e^;SuhVh;N{]ybQ3uNT(W,gV0W:S N^ 20^\Ǒ(uX0_l0oIQ0X\~0=Os\~NSvQN>e\'`|P[\OlunvluY0XQNTcOv^ĉ[v4N^ՋDe XYNTcOXY?e^;SuhVh;N{ybQ勧NTlQ N^ev4N^ՋDe ~-NV?e^~~vN[~S0B TewQY 10XQNT*gybQ N^0XYNTXY?e^;SuhVh;N{]ybQ3uNT(W,gV0W:S N^ 20,gON T{|NT(W-NV.U g4t^N Neb(`vU_ lNT gb(`U_vgbL,gyA0cO,gON T{|NTlQ N^ev4N^ՋDe0,{N{|NTN0eUOy`QXQ*gybQ N^0XYNTXY?e^;SuhVh;N{\*gybQ3uNT(W,gV0W:S N^0cO(W-NVXQۏL4N^v4N^ՋDe0N0NT,{N!kۏeQ-NV^:WAXYNTXY?e^;SuhVh;N{]ybQ3uNT(W,gV0W:S N^0cOXY?e^;SuhVh;N{ybQNT N^ev4N^ՋDe0BXQNT-NV?e^]ybQ T{|NT(W-NV N^0cN T{|NTv4N^ՋDeT[kf0CgbLV[0LNhQvh0ʋe{|;SuhVh NcO4N^ՋDe0 lʑ 10 T{|NTcW,gSt0;NR0~g0Pge0Pg( g(uv TvNT0wQSOvU_ 1uV[ߘToTvcw{t@\6R[v^^ 20 TWSc(WW,gSt0;NR0~gv TvMRc N RRvSt~gv TvNT 30 Tĉe\'`8h }hvSOYʋeՋBRNT NS,gc[SRۏL4N^xvz0 00N04N^xvzvW,gSR 00N W,gBl 001&OtQxvz^Q4N^xvz(u7h,g Y@m04l04l0y4l0~~m0ym0~~RGr0ӚI{v_bxvz~g[SՋvΘi'` ^cN&OtYXTOv[gaSSՋvw` TafN0[NOY`Q Y[‰ N NS_SՋvw` Tab4N^xvz[SՋQNNl gΘi S NcN&OtYXTOv[ċaSSՋvw` TafN FO4N^xvz^cO gsQ&OtN[vf0 002_{&{Tk\W[v&Otf[QR xvz[avCgv0[hQTa_ؚNxvzv0 003:Nxvz[aO[ \͑*NNy02bkxvz[aVhKm~g S0RgkƉb$O[0 44N^MRxvz~g/ecۏL4N^xvz0 N 4N^xvzUSMOSNXTvBl 001ʋeՋBRv4N^xvzUSMO^:NNNN{|eP^buu20ʋe0luNSAmLuf[gI{;mRvlNUSMO0 NۏLxvzvNT^(WvQ@bNNvNNVNQ0 0024N^xvzUSMO_{wQ gv^NNvb/gNXT _{wQ gNxvzՋBRv^vNhVY v^YnxOyxvzv[e0 003ʋeՋBRv4N^xvzN,^(W\$N[N N+T$N[ w~;SukSuUSMO[b [NyrkO(uvvvNT SN(W^~N Nuuc6R-N_0Ny;Sbbhhu@b0bk-N_I{USMO_U\4N^xvz0 004lQ3uN^9hncNTyrpSvQ4N^O(uvv ~T N T0W:SNy0AmLuf[̀of0uS_uirvyr'`I{V } bxvzUSMO0 005(W4N^xvz_YMR lQ3uN^N4N^xvz]\ONXTۏL4N^xvzvՋ NO[4N^xvz]\ONXTۏLW OvQq`v^cc勧NT@b(uvNhV0d\Oel0b/g'`I{ Ng'YP^0Wc6RՋ]0 006(W4N^xvzhQǏ z-N lQ3uN^Q8T6eAmLuf[0~f[04N^;Sf[0h;Sf[I{ebNNNXTbwƋ NOxvzelyf[0Tt0 00 N04N^xvzSR 00N xvzel 001eʋeՋBRNTv4N^xvz 0011[NeʋeՋBRNT bS_vxvz[a (uۏL4N^xvzvNTNʋe勾uuvёhQgoldstandard ۏLvl Tekk0 00[(uNegʋe0uHevKm0T$ReI{vʋeՋBRNT (WۏLNёhQvkxvzv Te ؏_{[xvz[aۏLߍ*xvz0(Wxvz_Ye xvz^fnxxvz[aveQ hQ0hQTe0 0012ёhQvnx[ 00ёhQ/fcvMRlQvgS`0gQnx0g}Yvʋeel _NyhQʋeel04N^ N8^(uvёhQ g~~utf[hg;mh08\h 0Kb/gSs0q_PʋeCT08hxqQ/c0i_rB 0uSSOvRyW{QNSg@b_v~0ёhQN,/fyr_'`ʋeel SNcknx:SR gu T eu 0 0013xvz[av b 00xvz[a^Sb$N~N~/f(uёhQnx[:N gguvuO~ SN~/f(uёhQ[euv`bck8^N \O:N[gq~0uO~^Sbuyv N TuO YurxQWT^xQWv u ze0-N0Zfgv u`{0-N0͑Wv N Tt^B\!kvI{ NOS fuvhQyr_0[gq~^Sbnx[euv` NfN,guvmmuuvuO0 0014 TekvlKmՋ 00~ёhQnx[vuON[gq~-NvSՋ7h,g TekcS evhyv NTvKm[ \Km[~gNёhQ$R[v~gۏLk { evhyv NTKm[~gNёhQ$Re~g&{Tb]_ z^v~f[ch Q9hncُNch[eNTۏLċN0(WՋd\OvhQǏ zT$R[Ջ~ge Ǒ(uvl=\S(uSvl /fOʋeՋ~gw[S`vsQ.0 002 ] g TTyybQ N^ NTv4N^xvz 00 b]ybQ N^NT Ǒ(uۏL4N^xvzvNTN]ybQ N^NT[4N^7h,gۏL[kՋxvz f,gTN] N^NTI{Heequivalent 0 0021[kՋBRv b 00(WǑ(u]ybQ N^NT\O:N[kՋBRvMRc N bvMR4N^nfM:N(ϑ}YvNT0 Te^EQRN@b bNTvb/gOo` Sbelf[ 4N^O(uvvTV ;N'`ch0hQTb!hQTvnn`Q0cPvSe\'`8h }hvSOYʋeՋBR4N^xvz;`7h,gpe\:N500O0 0025eʋeՋBRNT*g(WVQybQlQvNT0Kmirv TFORgOea^ch N(WV[]ybQlQNTVQ NwQ gev4N^ʋeaINvNT vQ4N^xvz7h,gϑBl T,{ N{|NT0 00V0sQN4N^xvzbJTvdQ 004N^xvzbJT^[ՋvteSOSvQsQ.p~Nnpf0[tev ^[Ջ[eǏ zۏLagtRfvc ^Sb_vW@xpencT~Rgel0 00lQ3uN{y3uN b4N^xvz#:gg^[T4N^xvzUSMOvbJTۏLGl;` v^[b4N^xvz;`~bJT04N^xvzbJTv PAGE  ,{ PAGE \* MERGEFORMAT 371u qQ429u PAGE  < >,{ PAGE \* MERGEFORMAT 429u qQ429u   & : < > @ PDDDDD dh$Ifgdkdo$$Iflrr ] nn064 laytv@ B N r t v x PDDDDD dh$Ifgdkdp$$Iflrr ] nn064 laytvx z PDDDDD dh$Ifgdkdq$$Iflrr ] nn064 laytv Ĝ PDDDDD dh$Ifgdkder$$Iflrr ] nn064 laytv  " $ & ( PDDDDD dh$Ifgdkd:s$$Iflrr ] nn064 laytv( * 2 D F H J PDDDDD dh$Ifgdkdt$$Iflrr ] nn064 laytvJ L X t v x z PDDDDD dh$Ifgdkdt$$Iflrr ] nn064 laytvz | PDDDDD dh$Ifgdkdu$$Iflrr ] nn064 laytv PDDDDD dh$Ifgdkdv$$Iflrr ] nn064 laytv " $ & PDDDDD dh$Ifgdkdcw$$Iflrr ] nn064 laytv& ( 4 P R T V PDDDDD dh$Ifgdkd8x$$Iflrr ] nn064 laytvV X d PDDDDD dh$Ifgdkd y$$Iflrr ] nn064 laytv ƞ Ȟ ʞ ̞ PDDDDD dh$Ifgdkdy$$Iflrr ] nn064 laytv̞ Ξ ڞ  PDDDDD dh$Ifgdkdz$$Iflrr ] nn064 laytv      PDDDDD dh$Ifgdkd{$$Iflrr ] nn064 laytv  * J L N P PDDDDD dh$Ifgdkda|$$Iflrr ] nn064 laytvP R ^ PDDDDD dh$Ifgdkd6}$$Iflrr ] nn064 laytv Ÿ ğ PDDDDD dh$Ifgdkd ~$$Iflrr ] nn064 laytvğ Ɵ ҟ PDDDDD dh$Ifgdkd~$$Iflrr ] nn064 laytv      PDDDDD dh$Ifgdkd$$Iflrr ] nn064 laytv  2 4 8 @ D F < @ d f     R V X \ v ν|||k[[h3h CJOJQJ^Jo(!h3h h CJOJQJo(h3h >*CJOJQJo(h3h CJOJQJ\o(h3h CJKHOJQJo(!h@'h 5CJOJQJ\o(!h%h 5CJOJQJ\o(#hvhACJ OJPJQJaJ o(!h3h 5CJOJQJ\o(h3h CJOJQJo(#  " T V X Z PDDDDD dh$Ifgdkd$$Iflrr ] nn064 laytvZ \ h PDDDDD dh$Ifgdkd_$$Iflrr ] nn064 laytv ֠ PH@5 $dha$gd%dhgdAdhgdkd4$$Iflrr ] nn064 laytv֠   * 2 dh$Ifgd $dha$gd@'2 4 6 8 < @ B F::::: dh$Ifgdkd $$Ifl4r*6!dc0644 laf4yt7B D F L d 'kd$$Ifl4ֈf*6! d c0644 laf4yt7 dh$Ifgdd f h j dh$Ifgd ̡ Ρ 8,,, dh$Ifgdkd9$$Iflֈf*6!dc0644 layt7Ρ С ҡ ,kd)$$Iflֈf*6!dc0644 layt7 dh$Ifgd < > @ B d dh$Ifgdd f l 8,,, dh$Ifgdkd$$Iflֈf*6!dc0644 layt7 ,kd $$Iflֈf*6!dc0644 layt7 dh$Ifgd  dh$Ifgd   T V 8,,, dh$Ifgdkd$$Iflֈf*6!dc0644 layt7V Z \ x z ,kd$$Iflֈf*6!dc0644 layt7 dh$Ifgdv x z У ԣ : > P R n r ؤ   & * : > B D H J Ħ ѭђхseXeMeXeh;OJQJaJo(h37h OJQJaJh37h OJQJaJo(#h37h CJ OJPJQJaJ o(h3h CJOJQJhACJOJQJo(hAhA5CJOJQJo(&h37h`5CJ,OJPJQJaJ,o(h3h >*CJOJQJo(h3h CJOJQJo(h3h CJKHOJQJo(h3h CJOJQJ^Jo(z У ң ԣ ֣ dh$Ifgd : < 8,,, dh$Ifgdkdي$$Iflֈf*6!dc0644 layt7< > @ P R ,kdɋ$$Iflֈf*6!dc0644 layt7 dh$IfgdR X n p r t dh$Ifgd 8,,, dh$Ifgdkd$$Iflֈf*6!dc0644 layt7 Ԥ ֤ ,kd$$Iflֈf*6!dc0644 layt7 dh$Ifgd֤ ؤ  & * : D J Ʀ t z ̧ ҧ 4 : p  l   r dhWD`gd;dhgdA $dha$gdAdhgdĦ Ʀ r t x z ʧ ̧ Ч ҧ 2 4 8 :          t v z |     Ʊ ȱ ̱ α > @ D F , . 2 4 v x | ~ V X \ ^ ǹhQRh OJQJaJh3h CJOJQJo(#h37h CJ OJPJQJaJ o(h37h OJQJaJh37h OJQJaJo(h;OJQJaJo(Dr  h    x : v |  ԯ F   $dha$gdA dhWD`gd;dhgd;dhgd ȱ α @ F . 4 6 x ~ X ^ l r $ * ܺ ܻ Ҽ ؼ dhgd dhWD`gd; j l p r " $ ( * ں ܺ ڻ ܻ м Ҽ ּ ؼ   " ξ о 󻪜͎ڎ͎ڎ͎ڎ͎hQRh OJQJaJo(h3h CJOJQJo( hQRh CJ OJPJQJaJ #hQRh CJ OJPJQJaJ o(hQRh OJQJaJh;OJQJaJo(h37h OJQJaJo(h37h OJQJaJ8ؼ  " | ξ о j 8 r  $dha$gdQRdhgd dhWD`gd;    Z \ ` b , . < > B D #hQRh CJ OJPJQJaJ o(hQRhQROJQJaJh;h;OJQJaJh OJQJaJo(h;OJQJaJo(hQRh OJQJaJhQRh OJQJaJo(8 t  \ b  ( N | , . > dhgd dhWD`gd;> D P  $  $dha$gdt! dhWD`gd;dhgd H N   f l d   $dha$gdt! $dha$gdQRdhgd dhWD`gd; F H L N   d f j l      B D H J T V Z \ " & ( h;OJQJaJo(hQRh OJQJaJhQRh OJQJaJo(h3h CJOJQJo( hQRh CJOJPJQJaJ#hQRh CJOJPJQJaJo(< | D J V \ " (    $dha$gdt! dh`gdt! dhWD`gd;dhgd    b d h j & ( , . \ ^ b d t v z | ѹѹѹѹѹѹƙƙƙƙƙƙhh OJQJaJhh OJQJaJo(#hQRh CJ OJPJQJaJ o(hQRh OJQJaJh;OJQJaJo(hQRh OJQJaJo(#hQRh CJOJPJQJaJo(hQRht!OJQJaJo(7 d j ( . ^ d  v | X , $dha$gdt! dhWD`gd;dhgd * , 0 2 f h l n     x z ~    4 6 : <     ǵ٧٧٧٧٧٧٧٧٧٧hh OJQJaJhh OJQJaJo(#hh CJOJPJQJaJo(#hh CJ OJPJQJaJ o(h;OJQJaJo(hh OJQJaJhh OJQJaJo(:, 2 h n   z `  6 $dha$gdt! dhWD`gd;dhgd6 < F     J P         |  $dha$gdt! dhWD`gd;dhgd  H J N P     z |   J L P R     0 2 6 8 D F H B D \ T V 6 8 < >                  ߹ҧ#h*Zh CJ OJPJQJaJ o(h3ht!CJOJQJo(h;OJQJaJo(h*Zh OJQJaJh*Zh OJQJaJo(#hh CJOJPJQJaJo(B  L R   2 8 F H B D \ P V  8 > $dha$gdt! dh`gdt!dhgd dhWD`gd;>    6           &         Z \ $dha$gdt!dhgd dhWD`gd;   $ &                 Z \ p 2 4 8 :           P R V X         D F H ^ ! ! ! ! $" &" *" ," # # ˹񮡹h*Zh*ZOJQJaJh OJQJaJo(#h*Zh CJ OJPJQJaJ o(h*Zht!OJQJaJo(h;OJQJaJo(h*Zh OJQJaJh*Zh OJQJaJo(?\ p 4 :        R X   2 ^    Z      dhWD`gd;dhgd $dha$gdt!  D F H ^ ! ! ! &" ," " " " # # # D$ J$ % % % % f& dhWD`gd"? $dha$gdt!dhgd dhWD`gd; # ~# # # # B$ D$ H$ J$ % % % % % % % % f& h& & & ' ' ' ' ( ( ( ( ( ) ) ) ) f* h* l* n* @+ B+ b+ + + + + , , , , ̺ٚ{ٚٚ{ٚ#hzV1h CJOJPJQJaJo(hzV1h OJQJaJhzV1h OJQJaJo(#h*Zh CJOJPJQJaJo(#h*Zh CJ OJPJQJaJ o(h*Zh*ZOJQJaJh"?OJQJaJo(h*Zh OJQJaJh*Zh OJQJaJo(0f& h& & & J' ' ' ' ( ( ( ( ) ) ) h* n* @+ B+ b+ + + v, , , dhWD`gdzV1 dhWD`gd"? $dha$gdt!dhgd, - - - - - - (/ */ ./ 0/ 1 1 1 2 3 3 3 3 F4 H4 L4 N4 5 5 5 5 X7 Z7 ^7 `7 7 8 8 8 r8 t8 8 8 : : : : R; T; X; Z; H< J< N< P< < < < < b= d= x= > > > > D@ F@ J@ L@ @ @ @ @ B B B B ǹh3h CJOJQJo(#hzV1h CJ OJPJQJaJ o(h"?OJQJaJo(hzV1h OJQJaJhzV1h OJQJaJo(I, - - - - . */ 0/ / / <0 0 1 1 1 2 3 3 H3 3 3 H4 N4 4 4 5 $dha$gdt!dhgd dhWD`gd"? 5 F5 v5 5 5 6 7 Z7 `7 8 8 r8 t8 8 8 9 b9 9 : 4: X: : : : T; Z; $dha$gdt! dhWD`gd"?dhgdZ; < J< P< < < b= d= x= > > > > 0? ? ? @ F@ L@ @ @ A B dB B $dha$gdt! ;dhWD`;gd"?dhgd dhWD`gd"?B B C C C C pD E F F G "G G G &H nH H H lI I I I I J :K } @} V} X} Z} ^} `} b} d} f} h} j} l} n} p} r} v} x} z} |} ~} } } } } } } } } } } } } } } } } } } } } } ǹ~~~~~~hHh KHOJQJaJ)hHh B*KHOJQJ^JaJph,hHh B*KHOJQJ^JaJo(phhHh OJQJaJo(h3h CJOJQJo(h*h OJQJaJo(h*h OJQJaJh*h 5CJOJQJo(1tQ Q Q R 6R pR R R R S S \T T 6U V LV fV V V LW W X X X .Y 0Y LY dY tY dhgdtY Y Y Y Y Z .Z BZ ^Z |Z Z [ Z[ [ [ \ D\ `\ \ \ \ ] 2] `] ] ] L^ t^ ^ dhgd^ ^ ^ _ _ @_ \_ _ _ _ _ _ ` ` &` 8` ^` a va a a \b rb b *c c d d e dhgde bf g g g g h i j k k k rl l |m n 4n "o p *q q ,r r Ds &t t t @u u dhgdu :w x Zx tx x "y y y z { { | | } ,} 6} @} X} dh$IfgddhgdX} Z} \} ^} b} f} j} n} r} v} z} ~} } } xxxxxxxxxxxsFf dh$Ifgdzkd$$Ifl4F~} +>6    44 lapyt {h } } } } } } } } } } } } } } } } } } } } } } } } } } } } FfX dh$Ifgd} } } } } } } } } } } } } } } } } } } } ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ "~ $~ (~ *~ ,~ .~ 0~ 2~ 4~ 6~ 8~ :~ <~ >~ @~ B~ D~ F~ H~ J~ L~ N~ P~ R~ T~ V~ X~ \~ ^~ `~ b~ d~ f~ h~ j~ l~ n~ p~ r~ t~ v~ hHh KHOJQJaJ,hHh B*KHOJQJ^JaJo(ph)hHh B*KHOJQJ^JaJphM} } } } } } ~ ~ ~ ~ ~ ~ ~ ~ ~ "~ $~ (~ ,~ 0~ 4~ 8~ <~ @~ D~ H~ L~ P~ Ff dh$IfgdFfP~ T~ V~ X~ \~ `~ d~ h~ l~ p~ t~ x~ |~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ FfFfJ dh$Ifgdv~ x~ z~ |~ ~~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~                hHh KHOJQJaJ,hHh B*KHOJQJ^JaJo(ph)hHh B*KHOJQJ^JaJphM~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~          Ff<Ff dh$Ifgd   " $ & ( * , . 0 4 6 8 : < > @ B D F H J L N P R T V X Z \ ^ ` b d h j l n p r t v x z | ~                                hHh KHOJQJaJ)hHh B*KHOJQJ^JaJph,hHh B*KHOJQJ^JaJo(phN  $ ( , . 0 4 8 < @ D H L P T X \ ` b d h l p t x |   FfFf dh$Ifgd                            FfFf. dh$Ifgd                                         " $ & ( * , . 0 2 4 6 8 : @ B D F H J L N P R T V X Z \ ^ ` b d f hHh KHOJQJaJ,hHh B*KHOJQJ^JaJo(ph)hHh B*KHOJQJ^JaJphM            " & * . 2 6 8 : @ D H L P T Ff Ffz dh$IfgdT X \ ` d h l n x szkd$$Ifl4F~} +>6    44 lapyt {hFf dh$Ifgd f h j l n v x € Ā ƀ Ԁ             " $ & ( * , . 0 2 4 : < > @ B D F H J L N P R T V X hHh KHOJQJaJ,hHh B*KHOJQJ^JaJo(ph)hHh B*KHOJQJ^JaJphM Ā ƀ Ȁ ʀ ̀ ΀ Ѐ Ҁ Ԁ ܀   FfKFf dh$Ifgd     $ ( , 0 2 4 : > B F J N R V Z ^ b f h j p FfFf dh$IfgdX Z \ ^ ` b d f h j p r t v x z | ~  ā Ɓ ȁ ʁ ́ ΁ Ё ҁ ԁ ց ܁ ށ hHh KHOJQJaJ,hHh B*KHOJQJ^JaJo(ph)hHh B*KHOJQJ^JaJphMp t x |  Ɓ ʁ ΁ ҁ ԁ ց FfFf= dh$Ifgdց ܁     " & * . 2 6 : > B F J L Ff/Ff dh$Ifgd        " $ & ( * , . 0 2 4 6 8 : < > @ B D F H J L N T V X Z \ ^ ` b d f h j l n p r t v x z | ~ hHh KHOJQJaJ,hHh B*KHOJQJ^JaJo(ph)hHh B*KHOJQJ^JaJphML N T X \ ` d h l p t x | Ff dh$Ifgd ‚ Ă Ƃ Ȃ ʂ ̂ ΂ Ђ ҂ Ԃ ւ ؂ ڂ ܂ ނ              " $ & , . 0 2 4 6 8 : < > @ B D F H J L N P R T V hHh KHOJQJaJ)hHh B*KHOJQJ^JaJph,hHh B*KHOJQJ^JaJo(phN Ă Ȃ ̂ Ђ Ԃ ؂ ܂        Ff! dh$IfgdFf{ " $ & , 0 4 8 < @ D H L P T X Z \ b f j n r v z ~ FfmFf  dh$IfgdV X Z \ b d f h j l n p r t v x z | ~ ƒ ă ƃ ȃ ΃ Ѓ ҃ ԃ փ ؃ ڃ ܃ ރ ,hHh B*KHOJQJ^JaJo(phhHh KHOJQJaJ)hHh B*KHOJQJ^JaJphM ă ƃ ȃ ΃ ҃ փ ڃ ރ FfFf dh$Ifgd       $ ( , 0 2 < B F J N R V Z ^ Ff#Ff_ dh$Ifgd             " $ & ( * , . 0 2 : < B D F H J L N P R T V X Z \ ^ ` b d f h j l n p r x z | ~ ,hHh B*KHOJQJ^JaJo(phhHh KHOJQJaJ)hHh B*KHOJQJ^JaJphM^ b f j n p r x | „ Ƅ FfQ,Ff' dh$Ifgd „ Ą Ƅ Ȅ ʄ ̄ ΄ Є ҄ Ԅ ք ؄ ڄ ܄ ބ            " $ & ( * , . 0 2 4 6 8 : < > @ B D F H )hHh B*KHOJQJ^JaJph,hHh B*KHOJQJ^JaJo(phhHh KHOJQJaJJƄ ʄ ΄ ҄ ք ڄ ܄ ބ        " & * . Ff5Ff0 dh$Ifgd. 2 6 : > B F H J Z | 4 n p r t v x z ܆ $dha$gdt!dhgdFfC: dh$IfgdH J L l n p r t x z , 4 6 > @ V X 㽲ugP;P;P;)h {hh B*KHOJQJ^JaJph,h {hh B*KHOJQJ^JaJo(phh {hh OJQJaJo(h {hh OJQJaJh*h 5CJOJQJo(#h*h CJ OJPJQJaJ o(h3h*CJOJQJo(ht!CJOJQJo(h CJOJQJo(h*h OJQJaJh*h OJQJaJo(h3h CJOJQJo(hHh OJQJaJo(܆  X ؇ 2 f R ` ̊ " P n ( dhgd( V  P l 4 & N r ȏ . J x 8 dhgd8 X  Ԓ 4  v   ڗ & H f    , 6 @ dh$Ifgddhgd@ X Z \ ^ b f j n r v xzkd=$$Ifl4fFg= 56    44 lapyt {h dh$Ifgd X Z ^ x Ÿ ğ Ɵ ȟ ʟ ̟ Ο П ҟ ԟ ֟ ؟ ڟ ܟ ޟ         ,h {hh B*KHOJQJ^JaJo(ph)h {hh B*KHOJQJ^JaJphh {hh KHOJQJaJNv x kd >$$Ifl4ִg= q ? 6    44 lapPyt {hx dh$Ifgd kdW?$$Ifl4ִg= q ? 6    44 lapPyt {h dh$Ifgd kd@$$Ifl4ִg= q ? 6    44 lapPyt {h Ÿ Ɵ ʟ Ο ҟ ֟ ڟ ޟ dh$Ifgdޟ kdB$$Ifl4ִg= q ? 6    44 lapPyt {h dh$Ifgd kdYC$$Ifl4ִg= q ? 6    44 lapPyt {h        dh$Ifgd      " $ & ( * , . 0 2 4 6 8 : < > @ L N P R T V X Z \ ^ ` b d f h j l n p r t v z | ~ h {hh KHOJQJaJ,h {hh B*KHOJQJ^JaJo(ph)h {hh B*KHOJQJ^JaJphM kdD$$Ifl4ִg= q ? 6    44 lapPyt {h " & * . 2 6 : > dh$Ifgd> @ kdF$$Ifl4ִg= q ? 6    44 lapPyt {h@ N R V Z ^ b f j dh$Ifgdj l kd[G$$Ifl4ִg= q ? 6    44 lapPyt {hl n r v | dh$Ifgd kdH$$Ifl4ִg= q ? 6    44 lapPyt {h dh$Ifgd kdJ$$Ifl4ִg= q ? 6    44 lapPyt {h   Ơ ʠ Π Ҡ dh$Ifgd   Ġ Ơ Ƞ ʠ ̠ Π Р Ҡ Ԡ ֠ ڠ ܠ ޠ             " $ & ( * , . 0 2 4 6 8 : < @ B D F H J L N P R T V X Z \ ^ b d h {hh KHOJQJaJ,h {hh B*KHOJQJ^JaJo(ph)h {hh B*KHOJQJ^JaJphMҠ Ԡ kd]K$$Ifl4ִg= q ? 6    44 lapPyt {hԠ ֠ ܠ dh$Ifgd kdL$$Ifl4ִg= q ? 6    44 lapPyt {h      dh$Ifgd  kd N$$Ifl4ִg= q ? 6    44 lapPyt {h  $ ( , 0 4 8 dh$Ifgd8 : kd_O$$Ifl4ִg= q ? 6    44 lapPyt {h: < B F J N R V Z dh$IfgdZ \ kdP$$Ifl4ִg= q ? 6    44 lapPyt {h\ ^ d h l p t x | dh$Ifgdd f h j l n p r t v x z | ~ ʡ ڡ ܡ            " $ & ( , . 0 2 8 : < > D F H J L N P R V X Z \ b d h {hh KHOJQJaJ)h {hh B*KHOJQJ^JaJph,h {hh B*KHOJQJ^JaJo(phN| ~ kd R$$Ifl4ִg= q ? 6    44 lapPyt {h~ ġ ȡ xzkdaS$$Ifl4fFg= 56    44 lapyt {h dh$Ifgd ȡ ʡ kdbT$$Ifl4ִg= q ? 6    44 lapPyt {hʡ ܡ dh$Ifgd kdU$$Ifl4ִg= q ? 6    44 lapPyt {h      $ dh$Ifgd$ & kdW$$Ifl4ִg= q ? 6    44 lapPyt {h& ( . 2 : > F J N dh$IfgdN P kdiX$$Ifl4ִg= q ? 6    44 lapPyt {hP R X \ d h p t x dh$Ifgdd f h n p r t v x z | ¢ Ģ ʢ ̢ Ң Ԣ ڢ ܢ ޢ             " $ & ( , . 0 2 h {hh KHOJQJaJ)h {hh B*KHOJQJ^JaJph,h {hh B*KHOJQJ^JaJo(phNx z kdY$$Ifl4ִg= q ? 6    44 lapPyt {hz | dh$Ifgd kd[$$Ifl4ִg= q ? 6    44 lapPyt {h Ģ ̢ Ԣ ܢ dh$Ifgdܢ ޢ kdk\$$Ifl4ִg= q ? 6    44 lapPyt {hޢ  dh$Ifgd  kd]$$Ifl4ִg= q ? 6    44 lapPyt {h      $ dh$Ifgd$ & kd_$$Ifl4ִg= q ? 6    44 lapPyt {h& ( . 2 6 : > B F dh$Ifgd2 4 6 8 : < > @ B D F H J N P T V X Z ^ ` d f h j l n p r v x | ~ £ Σ У ԣ ֣ أ ڣ ܣ ޣ h {hh KHOJQJaJ)h {hh B*KHOJQJ^JaJph,h {hh B*KHOJQJ^JaJo(phNF H kdm`$$Ifl4ִg= q ? 6    44 lapPyt {hH J P V Z ` f j n dh$Ifgdn p kda$$Ifl4ִg= q ? 6    44 lapPyt {hp r x ~ dh$Ifgd kdc$$Ifl4ִg= q ? 6    44 lapPyt {h dh$Ifgd £ kdod$$Ifl4ִg= q ? 6    44 lapPyt {h£ У ֣ ڣ ޣ dh$Ifgd kde$$Ifl4ִg= q ? 6    44 lapPyt {h    dh$Ifgd             " $ & ( * , . 0 2 4 6 : < > @ B D F H J L N P R T V X \ ^ ` b d f h j l n p r t v x Ķh OJQJaJo(h {hh OJQJaJo(h {hh KHOJQJaJ,h {hh B*KHOJQJ^JaJo(ph)h {hh B*KHOJQJ^JaJph@  kdg$$Ifl4ִg= q ? 6    44 lapPyt {h    " & * . 2 dh$Ifgd2 4 kdqh$$Ifl4ִg= q ? 6    44 lapPyt {h4 6 < @ D H L P T dh$IfgdT V kdi$$Ifl4ִg= q ? 6    44 lapPyt {hV X ^ b f j n r v dh$Ifgdv x kdk$$Ifl4ִg= q ? 6    44 lapPyt {hx z ؤ B  ,  ب ĩ x Ԭ ڭ 4 X ڮ & z b Բ < dhgd< l ص ̶ < ^ ʹ  ` غ ` N J  8 b ȿ dhgd & j l           ziziziZizizizizizizizih {hh KHOJQJaJ h {hh KHOJQJ^JaJ#h {hh KHOJQJ^JaJo(#h {hh CJOJPJQJaJo(h {hh 5CJOJQJo(#h {hh CJ OJPJQJaJ o(h {hOJQJaJo(h OJQJaJo(h {hh OJQJaJh {hh OJQJaJo(h {hh {hOJQJaJo(#ȿ ʿ F . 0 \  L 0 @  h r L  dhgd " D ` ,  p t N B  dhgd  & 8 ` v $dha$gdt!dhgd  @ z H  d    0 D Z t  2 * dhgd* r 0 `  : d  8 ` > d |  2 B dhgdB f @ j l pzkdsl$$Ifl4 F &&<6    44 lapyt {h dh$Ifgddhgd       & , 2 8 > D F P T X \ n Ff/o dh$Ifgd    $ & * , 0 2 6 8 < > B D F N P R T V X Z \ l n ~ h {hh KHOJQJaJ h {hh KHOJQJ^JaJ#h {hh KHOJQJ^JaJo(Q FfzFft dh$Ifgd              " $ & ( * , . 0 2 4 6 8 : @ B D F H J L N P R T V X Z \ ^ ` b d f h j l n p r t v x z #h {hh KHOJQJ^JaJo( h {hh KHOJQJ^JaJh {hh KHOJQJaJQ       $ ( , . 0 4 8 < > @ D H L Ffi dh$IfgdL P T X \ ` d h l n p t x | ~ FfFf' dh$Ifgd             " $ & ( * , . 0 2 4 6 8 : < > @ B D F L N P R h {hh KHOJQJaJ#h {hh KHOJQJ^JaJo( h {hh KHOJQJ^JaJQ      Ff dh$Ifgd  $ ( , 0 4 8 : < @ D H J L P T X \ ` d h l p t x z FfFfa dh$IfgdR T V X Z \ ^ ` b d f h j l n p r t v x z | ~ h {hh KHOJQJaJ#h {hh KHOJQJ^JaJo( h {hh KHOJQJ^JaJQz | Ffݢ dh$Ifgd        $ ( , 0 4 8 < > FfYFf dh$Ifgd             " $ & ( * , . 0 2 4 6 8 : < > @ D F H J L R T V X Z \ ^ ` b d f h j l n p r t v x z | ~ h {hh KHOJQJaJ h {hh KHOJQJ^JaJ#h {hh KHOJQJ^JaJo(Q> @ F J N P R V Z ^ b f j n r v z ~ Ff dh$Ifgd   FfFfչ dh$Ifgd           " $ & ( * , . 0 2 4 6 8 : < > @ B D F R T X Z \ ^ ` f h j l n p h {hh KHOJQJaJ#h {hh KHOJQJ^JaJo( h {hh KHOJQJ^JaJQ       $ ( , 0 4 8 < @ D F T Z ^ b d f j n r FfQ dh$Ifgdp r t v x z | ~             h {hh KHOJQJaJ#h {hh KHOJQJ^JaJo( h {hh KHOJQJ^JaJQr v z ~ FfFf dh$Ifgd        $ ( * , 0 4 8 Ff dh$Ifgd " $ & , . 0 2 4 6 8 : < > @ B D F H J L N P R T V X Z \ ` b d f h n p r t v x z | ~ h {hh KHOJQJaJ h {hh KHOJQJ^JaJ#h {hh KHOJQJ^JaJo(Q8 < @ D H L P T X Z \ b f j l n r v z ~ FfFfI dh$Ifgd  Ff dh$Ifgd              " $ & * , . 0 2 8 : < > @ B D F H J L N P R T V X Z \ ^ ` b d f h l n p r t z | ~ h {hh KHOJQJaJ h {hh KHOJQJ^JaJ#h {hh KHOJQJ^JaJo(Q       " $ & , 0 4 6 8 < @ D H L P T X \ ` d f FfAFf dh$Ifgdf h n r v x z ~ Ff dh$Ifgd p r h {hh {hOJQJaJo(h {hh OJQJaJo(h {hh KHOJQJaJ#h {hh KHOJQJ^JaJo( h {hh KHOJQJ^JaJF  8 r dhgdFf dh$Ifgd    xxxxxxxxxxxx dh$IfgdzkdQ$$Ifl4XF &&<6    44 lapyt {h           $ & * , . > @ D F H J L N ^ ` p r t v x z | ~ h {hh KHOJQJaJ#h {hh KHOJQJ^JaJo( h {hh KHOJQJ^JaJQ   & , . @ F J N ` r v z ~ Ff Ff dh$Ifgd    FfC dh$Ifgd              " $ & * , . 0 2 8 : < > @ B D F H J L N P R T V X Z \ ^ ` b d f h l n p r t z | ~ #h {hh KHOJQJ^JaJo(h {hh KHOJQJaJ h {hh KHOJQJ^JaJQ     " $ & , 0 4 6 8 < @ D H L P T X \ ` d f h n r FfFf dh$Ifgdr v x z ~ FfS! dh$Ifgd              " $ & ( * , . 2 4 6 8 : @ B D F h {hh KHOJQJaJ h {hh KHOJQJ^JaJ#h {hh KHOJQJ^JaJo(Q        " & * , . 4 8 Ff,Ff' dh$Ifgd8 < > @ D H L P T X \ ` d h l n p v z ~ Ffc2 dh$IfgdF H J L N P R T V X Z \ ^ ` b d f h j l n p t v x z | h {hh KHOJQJaJ#h {hh KHOJQJ^JaJo( h {hh KHOJQJ^JaJQ Ff=Ff8 dh$Ifgd            " $ & ( * , . 0 2 4 6 : < > @ B H J L N P R T V X Z \ ^ ` b d f h j l n p r t v x | ~ h {hh KHOJQJaJ h {hh KHOJQJ^JaJ#h {hh KHOJQJ^JaJo(Q         " & * . 2 4 6 < @ D F H L P T X \ ` FfsC dh$Ifgd` d h l p t v x ~ dhgdFfNFf#I dh$Ifgd @ B f h  % % *% ,% D% L% N% d% f% h% l% n% r% t% v% x% z% |% ~% % % % % % % % % % % % % % % }h {hhkZROJQJaJo(h OJQJaJo(hkZROJQJaJo(#h@h CJOJPJQJaJo(h {hh OJQJaJo(h {hh OJQJaJh {hh KHOJQJaJ#h {hh KHOJQJ^JaJo( h {hh KHOJQJ^JaJ1  @ B X 8 \ F  ( J b  Z   dhgd @   ~ D    b  n           l   , dhgd, . X t r   R  $     V 2 P   : ^   f h    $dha$gdt!dhgd   N    F   " d       & > Z      B l  dhgd    D $! d! ! ! ! " J" l" " " " # :# n# # # $ d$ $ $ % dhgd% % % "% $% &% (% *% ,% D% N% f% h% j% l% bkdgR$$Ifl4p0 u644 lapytkZR dh$Ifgddhgdl% n% p% r% t% v% -bkd T$$Ifl4p0 u644 lapytkZR dh$Ifgdbkd:S$$Ifl4p0 u644 lapytkZRv% z% ~% % % % % % % % % % % % % % % % % % % % % % % % % % FfV dh$Ifgd% % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % & & & & & & & & & & & & & & & & & "& $& && (& *& ,& .& 0& 2& 4& 6& 8& :& <& >& @& B& D& F& H& h {hh KHOJQJaJ h {hh KHOJQJ^JaJ#h {hh KHOJQJ^JaJo(Q% % % % % & & & & & & & & & "& && *& .& 2& 6& :& >& B& D& H& L& P& T& FfqaFf$\ dh$IfgdH& J& L& N& P& R& T& V& X& Z& \& ^& `& b& d& f& h& j& l& n& p& r& t& v& x& z& |& ~& & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & & h {hh KHOJQJaJ h {hh KHOJQJ^JaJ#h {hh KHOJQJ^JaJo(QT& X& \& `& d& h& l& p& t& x& |& & & & & & & & & & & & & & & & & & Fff dh$Ifgd& & & & & & & & & & & & & & & & ' ' ' ' ' ' ' "' &' *' .' 2' FfXqFf l dh$Ifgd& & & & & & ' ' ' ' ' ' ' ' ' ' ' ' "' $' &' (' *' ,' .' 0' 2' 4' 6' 8' :' <' >' @' B' D' F' H' J' L' N' P' R' T' V' X' Z' \' ^' `' b' d' f' h' j' l' n' p' r' t' v' x' z' |' ~' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' h {hh KHOJQJaJ#h {hh KHOJQJ^JaJo( h {hh KHOJQJ^JaJQ2' 6' :' >' B' F' J' N' R' V' X' \' `' d' h' l' p' t' x' |' ' ' ' ' ' ' ' ' Ff{Ffv dh$Ifgd' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ( ( Ff? dh$Ifgd' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( "( $( &( (( *( ,( .( 0( 2( 4( 6( 8( :( <( >( @( B( h {hh KHOJQJaJ#h {hh KHOJQJ^JaJo( h {hh KHOJQJ^JaJQ( ( ( ( ( ( ( ( "( &( *( .( 2( 6( :( >( B( F( J( N( R( V( Z( ^( `( f( j( n( FfًFf dh$IfgdB( D( F( H( J( L( N( P( R( T( V( X( Z( \( ^( `( d( f( h( j( l( n( p( r( t( v( x( z( |( ~( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( h {hh KHOJQJaJ h {hh KHOJQJ^JaJ#h {hh KHOJQJ^JaJo(Qn( r( v( z( ~( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( Ff& dh$Ifgd( ( ( ( ( ( ( ( ( ( ) ) ) ) ) ) ) ) ") &) *) ,) 2) 6) :) >) B) F) FfFfs dh$Ifgd( ( ( ( ( ( ( ( ( ( ( ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ") $) &) () *) ,) 0) 2) 4) 6) 8) :) <) >) @) B) D) F) H) J) L) N) P) R) T) V) X) Z) \) ^) `) b) d) f) h) j) l) n) p) t) v) x) z) |) ~) ) ) ) ) ) ) ) ) ) h {hh KHOJQJaJ h {hh KHOJQJ^JaJ#h {hh KHOJQJ^JaJo(QF) J) N) R) V) Z) ^) b) f) j) n) p) v) z) ~) ) ) ) ) ) ) ) ) ) ) ) ) ) Ff  dh$Ifgd) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) * * * * * * * * * * * * * * * * * "* $* &* (* ** ,* .* 0* 2* 4* 6* h {hh KHOJQJaJ#h {hh KHOJQJ^JaJo( h {hh KHOJQJ^JaJQ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) * * * * * * * * Ff dh$IfgdFfZ* "* &* ** .* 2* 6* :* <* B* F* J* N* R* V* Z* ^* b* f* j* n* r* v* z* ~* * * * FfAFf dh$Ifgd6* 8* :* <* @* B* D* F* H* J* L* N* P* R* T* V* X* Z* \* ^* `* b* d* f* h* j* l* n* p* r* t* v* x* z* |* ~* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * L+ Ϳh {hh OJQJaJo(h {hh KHOJQJaJ h {hh KHOJQJ^JaJ#h {hh KHOJQJ^JaJo(F* * * * * * * * * * * * * * * * * * + L+ N+ f+ + + 2, N, , dhgdFf dh$IfgdL+ N+ (5 b5 5 5 6 H6 G G G G G G G G G >W LW NW ZW \W ʿxjXGXG hoh KHOJQJ^JaJ#hoh KHOJQJ^JaJo(hoh OJQJaJo(hoh OJQJaJh|\oh 5CJOJQJo(#h|\oh CJ OJPJQJaJ o(h3ht!CJOJQJh|\oCJOJQJo(ht!CJOJQJo(h CJOJQJo(h {hh OJQJ^JaJo(h {hh OJQJaJo(h {hh OJQJaJ, 2- - - . &/ > > $? &? P? l? `@ @ @ PA A B B C dhgdC C C TD *E HE E E .F RF F :G G G G G G G G G G G G G G G G G G dhgdG G G G G G G G G G G ,H fH H H I .I ZI I I I vJ J J K hK K K $dha$gdt!dhgdK K K `L L L L $M RM M M N *N PN bN N N O LO tO O O O O P 6P FQ \Q R dhgdR R S ZS $T T T U 0U U U rV V $W &W >W NW \W dh$Ifgddhgd\W ^W `W dW hW lW pW tW xW |W dh$Ifgdbkd$$Ifl40@  644 lapyto \W ^W `W bW dW fW hW jW lW nW pW rW tW vW xW zW |W ~W W W W W W W W W W W W W W W W W W W W W W W W W W W W W W X X X X X X X X X X X X X X X "X $X &X (X *X ,X hX jX lX nX pX rX tX vX xX zX |X ~X X X #hoh KHOJQJ^JaJo( hoh KHOJQJ^JaJhoh KHOJQJaJQ|W ~W kd$$Ifl4ִ@Q  6    44 lapPyto~W W W W W W W W W W W W W W W W W W W W W W W X X X X X FfFf9 dh$IfgdX X X "X &X *X ,X jX nX rX vX zX ~X X X X X X X X X X X X X X X X FfgFf dh$IfgdX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y >Y @Y BY DY FY HY JY LY NY PY TY VY ZY \Y ^Y `Y bY dY fY hY jY Y Y Y Y Y Y Y Y Y Y Y hoh KHOJQJaJ hoh KHOJQJ^JaJ#hoh KHOJQJ^JaJo(QX X X X X Y Y Y Y Y Y Y Y @Y DY HY LY PY VY \Y `Y dY hY jY Y Y Y FfFf dh$IfgdFf Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y *Z .Z 2Z 8Z Z @Z BZ DZ FZ HZ JZ LZ NZ PZ RZ tZ vZ xZ zZ |Z ~Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z hoh KHOJQJaJ#hoh KHOJQJ^JaJo( hoh KHOJQJ^JaJQHZ LZ PZ RZ vZ zZ ~Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Ff/FfvFf dh$IfgdZ Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z [ [ [ [ [ [ [ [ [ [ [ [ [ [ d[ f[ h[ j[ l[ n[ p[ r[ t[ v[ x[ z[ |[ ~[ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ \ \ \ \ \ \ \ \ "\ $\ &\ (\ hoh KHOJQJaJ hoh KHOJQJ^JaJ#hoh KHOJQJ^JaJo(QZ Z Z [ [ [ [ [ [ [ [ f[ j[ n[ r[ v[ z[ ~[ [ [ [ [ [ [ [ [ [ [ FfFf dh$Ifgd[ [ \ \ \ \ "\ &\ *\ .\ 2\ 6\ :\ >\ B\ F\ H\ b\ f\ j\ r\ v\ z\ ~\ \ \ \ FfFfZ dh$Ifgd(\ *\ ,\ .\ 0\ 2\ 4\ 6\ 8\ :\ <\ >\ @\ B\ D\ F\ H\ `\ b\ d\ f\ h\ j\ p\ r\ t\ v\ x\ z\ |\ ~\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] 8] :] hoh KHOJQJaJ#hoh KHOJQJ^JaJo( hoh KHOJQJ^JaJQ\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ ] ] ] ] ] ] ] ] ] :] >] B] Ff>Ff dh$IfgdFf:] <] >] @] B] H] J] L] N] P] R] T] V] X] Z] \] ^] `] b] d] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ "^ $^ B^ D^ F^ H^ J^ L^ N^ P^ R^ T^ V^ X^ Z^ \^ ^^ `^ f^ h^ n^ p^ hoh KHOJQJaJ hoh KHOJQJ^JaJ#hoh KHOJQJ^JaJo(QB] J] N] R] V] Z] ^] b] d] ] ] ] ] ] ] ] ] ] ] ] ] ] ^ ^ ^ ^ ^ ^ Ff Ff  dh$Ifgd^ ^ "^ $^ D^ H^ L^ P^ T^ X^ \^ `^ h^ p^ r^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ FfFf"Ffi dh$Ifgdp^ r^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ _ _ _ _ _ _ _ _ "_ $_ &_ (_ *_ ,_ 2_ 4_ 6_ 8_ :_ <_ >_ ^_ `_ b_ d_ f_ h_ j_ l_ n_ p_ r_ t_ x_ z_ _ _ _ hoh KHOJQJ^JaJ#hoh KHOJQJ^JaJo(hoh KHOJQJaJQ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ _ _ _ _ $_ (_ ,_ 4_ 8_ <_ >_ `_ d_ h_ l_ p_ t_ FfM Ff dh$Ifgdt_ z_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ ` ` ` ` ` ` ` Ff'Ff$ dh$Ifgd_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ ` ` ` ` ` ` ` ` ` ` ` ` ` ` ~ ~ ~ ~ ~ hoCJOJQJo(ht!CJOJQJo(h CJOJQJo(h3h CJOJQJo(hoh OJQJaJo(hoh KHOJQJaJ#hoh KHOJQJ^JaJo( hoh KHOJQJ^JaJ3` ` ` P` l` ` ` a ~a a b c rc c d d d 8e e f ^f f f f >g g `h h h dhgdFfx+h h vi i j k k hl l m fm m n zo p q :r lr bs t Xt t u 4u Vu xu u u hv dhgdhv v *w bw w w x y py \z z { { @| } } ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ dhgd~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ : ` |   , b Ҁ * n J $dha$gdt!dhgd~ ~ ~ ~ ~ ~  N P t v ߻q`RD6hhCJOJQJo(hh CJOJQJo(hh OJQJaJo(!hh 5CJOJQJ\o(&hoh CJ OJPJQJ\aJ o(h3h CJOJQJo(h3h CJOJQJhoh OJQJaJhoh OJQJaJo(hoh 5CJOJQJo('hoh CJ OJPJQJ^JaJ o(#hoh CJ OJPJQJaJ o(h3hoCJOJQJo(   t B ȅ t  d  N P v $dha$gd!Ydhgdv  $ & Љ ҉    & ( N ^ ` j l | ~ ҋ ԋ ܌ ތ * . ɾyyyyyyyyyy)h!Yh!YB*KHOJQJ^JaJph,h!Yh!YB*KHOJQJ^JaJo(phh!Yh!YCJOJQJo(hCJOJQJo(h!YCJOJQJo(h CJOJQJo()hh B*KHOJQJ^JaJph,hh B*KHOJQJ^JaJo(ph*v  & ҉ Pkd-$$If4\\ <|)$6 @  0622 l4a f4yt7 dh$Ifgd    " $ & PHHHCCgd!Ydhgdkd.$$If4M\\ <|)$6 @  0622 l4a f4yt7 dh$Ifgd& ( N ` l ~ Fkd/$$If4\ `'$6@  0622 l4a f4yt1$d$1$Ifa$gd1gd!Y B ԋ $ V ތ , $d$1$If`a$gd1$d$1$Ifa$gd1 , . T f r \THHHH dh$Ifgddhgdkd0$$If4M\ `'$6@  0622 l4a f4yt1. R T d f p r 4 6 h j “ ” Ɣ Ȕ ʔ < @ J N R ̷̷̷̷̷̷̷̷̷㪖}p^O^hWCJ OJPJQJaJ o(#hWh7CJ OJPJQJaJ o(h3h7CJOJQJh3h7CJOJQJo(h!YCJOJQJo(&hg'Eh`5CJ,OJPJQJaJ,o(h3h CJOJQJ)hh B*KHOJQJ^JaJph,hh B*KHOJQJ^JaJo(phhh OJQJaJo(h3h CJOJQJo( 6 j “ Ĕ YMMMMMM dh$Ifgdkd1$$If4\ l`'$6  0622 l4a f4yt7Ĕ Ɣ Ȕ ʔ  < WOODODD $dha$gd!Ydhgdkd2$$If4M\ l`'$6  0622 l4a f4yt7< @ R ޕ  X ė ʗ F j * x  8  dhWD`gd"? $dha$gd!YdhgdR ܕ ޕ — ė ȗ ʗ  ʞ ̞ z | V X v " ǹٹr`RhQh7OJQJaJo(#hQh7CJOJPJQJaJo(h7clh7clOJQJaJh7clh7OJQJaJh7clh7OJQJaJo(#h7clh7CJOJPJQJaJo(hph7OJQJaJhph7OJQJaJo(#hph7CJ OJPJQJaJ o(h"?OJQJaJo(hWh7OJQJaJhWh7OJQJaJo(  l H ʞ ̞ | V X v $ *    f dhWD`gd $dha$gd!Y dhWD`gd"?dhgd" $ ( *        f h j l Z \ ` b     h j n Ⱥږwh3h7CJOJQJ#hQh7CJ OJPJQJaJ o(hQhOJQJaJo(h7OJQJaJo(hQOJQJaJo(h3h7CJOJQJo(#hQh7CJOJPJQJaJo(hOJQJaJo(hQh7OJQJaJo(hQh7OJQJaJ.f h j l \ b   (  j p  z @ dhWD`gd $dha$gd!Ydhgdn p  > @ D F 0 2 6 8 l n r t : < Z        2 4  ̺ٺrh"P6h7OJQJaJh"P6h7OJQJaJo(#h:h7CJ OJPJQJaJ o(h:h7OJQJaJh:h7OJQJaJo(#hQh7CJOJPJQJaJo(hQhQOJQJaJhQh7OJQJaJhQh7OJQJaJo(hOJQJaJo(,@ F 2 8 n t : < Z    \   2 4 $dha$gd!Y dhWD`gddhgd4  B ڹ L  H N  H N     j l dhWD`gd $dha$gd!Ydhgd ع ڹ ޹   F H L N   F H L N         j l \ ^ b d   2 x z ~ ˹櫞櫞h_Rh7OJQJaJh_Rh7OJQJaJo(#h_Rh7CJ OJPJQJaJ o(h3h7CJOJQJo(h"P6h7OJQJaJhOJQJaJo(h"P6h7OJQJaJo(>l ^ d   2 z | ~ d j $dha$gd!Y dhWD`gddhgd | ~ h j N P ^    Z \ ^ f h r ͻ孢ylyh_Rh!YOJQJaJh_Rh75CJOJQJo(h3h_RCJOJQJo(h!YCJOJQJo(h7CJOJQJo(h3h7CJOJQJo(#h_Rh7CJ OJPJQJaJ o(h3h7CJOJQJhOJQJaJo(h_Rh7OJQJaJo(h_Rh7OJQJaJ& N P ^   X Z \ ^ ` b d f h r dhgd $dha$gd!Y dhWD`gddhgd . 0 4 6 R T f h   p r 2 4 ( *    $ & R T b Ǽthp1hp15CJOJQJo(&hh`5CJ,OJPJQJaJ,o(h3hm7CJOJQJo(hm7CJOJQJo(h!YCJOJQJo(h7CJOJQJo(h3h7CJOJQJo(hm7h75CJOJQJo(hm7h7OJQJaJo(hm7h7OJQJaJ*  ( l . 0 B  & n <  J  j ^ dhgd 6 z 4 6 H x  8 R T f f h | dhgd|  8    : > & D ~ J X dhgd " 6  p r  t 2 4 N L $ j $dha$gd!Ydhgdj " x D X v ( * B 0 Z z dhgd               " $ & R T f $dha$gdp1dhgdb d f > @ B ( * . 0 | ~ 2 4 2 4 & ( yyyygXgyyhCJ OJPJQJaJ o(#hh7CJ OJPJQJaJ o(h~QOJQJaJo(hh7OJQJaJhh7OJQJaJo(h'CJ OJPJQJaJ o(#h'h7CJ OJPJQJaJ o(h3hp1CJOJQJo(h7CJOJQJo(h3h7CJOJQJo(h3h7CJOJQJhp1CJOJQJo(" @ B * 0 ~ 2 j . 4 dhWD`gd~Q dhWD`gddhgd $dha$gd' $dha$gdp1  4 2 4 ( . .  b B b dhWD`gd~Q dhWD`gddhgd( , . (<NR\^jlfǵm_R_hi3]h7OJQJaJhi3]h7OJQJaJo(#hi3]h7CJOJPJQJaJo(h3h7CJOJQJh#rh7OJQJaJh#rh7OJQJaJo(h3h7CJOJQJo(#h#rh7CJOJPJQJaJo(#h#rh7CJ OJPJQJaJ o(hh7OJQJaJh~QOJQJaJo(hh7OJQJaJo( &(<N8\^jlfh&( $dha$gdp1 dhWD`gddhgdfh&(xz  N P j   HJtvhj fh̺|nh3hX7_CJOJQJo(hX7_CJOJQJo(h7CJOJQJo(h3h7CJOJQJhX7_h7OJQJaJhX7_h7OJQJaJo(#hX7_h7CJOJPJQJaJo(hi3]hp1OJQJaJo(hX7_OJQJaJo(hi3]h7OJQJaJo(hi3]h7OJQJaJ+xz   N P j   v l  HJtv $dha$gdp1dhgdX7_ dhWD`gdX7_dhgdhj zfh dhWD`gdX7_ $dha$gdp1dhgd|~xz  np*!,!!!!<">"""##>$@$$$$%T%X%j%((h)j)++P,R,,,,0111ų#h*pMh7CJ OJPJQJaJ o(h*pMh7OJQJaJh*pMh7OJQJaJo(#h qh7CJ OJPJQJaJ o(h3h7CJOJQJo(hX7_h7OJQJaJo(#hX7_h7CJ OJPJQJaJ o(hX7_h7OJQJaJ4|~xz  np, *!,!!!!<">" $dha$gdp1 dhWD`gdX7_dhgd>"""##Z###>$@$$$$%V%X%j%%h&&&'>'''( $dha$gdp1 dhWD`gd qdhgd((((&)h)j)(*h***J+++P,R,,,,,D----.*. $dha$gdp1 dhWD`gd*pMdhgd*.d.../ 0l0011111x2z2436383:3<3>3@3J3z3J44 dWDd`gdu $dha$gdugdudhgd111x2z263>3@3F3H3J3z33333344H4J4T4X4̺xqh[OChChuCJaJo(hc7huCJaJo(h"ehu5>*CJo(hu>*OJo( huCJo(hhuCJo(hc7huCJOJaJo(huCJOJaJo(h]]huCJ$OJ PJ aJ$o(h4CJ OJPJQJaJ o(#h4huCJ OJPJQJaJ o(hp1CJOJQJh3h7CJOJQJo(h*pMh7OJQJaJh*pMh7OJQJaJo(X4\4^4b4d4h4l4n4|444444444444444444444n5Ĵ昦抦zgzYNhc7huCJaJhc7huCJOJaJo($h46hu5>*CJOJ\aJo(h46hu>*CJOJaJo(hs2huCJOJaJo(h-huCJ\aJo(h-huCJOJaJo(h-huCJOJ\aJo(huCJOJ\aJo(huCJaJo(hChuCJaJo(huCJOJaJo(hChuCJOJaJo(4n5z5555555 $1$Ifgd1h$IfWD8^h`gd1 $Ifgd1 ZWD2`Zgdun5v5x5~555555555555555555555555555555666666J6L6N6P6T6V6X6f6h6p6r6t6ŷŬŷѡі(jhc7huCJUaJmHnHuhuCJOJaJo(hu>*CJaJo(hs2huCJaJhs2huCJOJaJo(hs2huCJaJo(hc7huCJOJaJo(hc7huCJaJhuCJaJo(hc7huCJaJo(2555 $Ifgd1kdr3$$Iflֈiy {F",O A 0,4 lap<yt1556X666F7\kd4$$IflFi9 , V 0,    4 lapyt1 $Ifgd1t6v6666666667 7(7*7D7F7H7N7X7j7l77777777±}thttt\S\huCJaJo(h6huCJaJo(h.JhuCJaJo(huCJaJo(h:huB*CJaJph#h<hu>*B*CJaJo(ph$h<huB*CJOJaJo(ph h<huB*CJaJo(phhc7huCJaJhuCJOJaJo(hc7huCJaJo(hu>*CJOJaJo(hc7huCJOJaJo(F7H7N7X7b7l7x777777777Ff7 $$Ifa$gd1okd5$$Ifli~,,0, 4 lagZ&p yt177777777777 8 8888(8*8,8.8<8>8@8P8R8T8f8h8j888888888888888۸۬ۉ}uۣ}huCJaJh!-\huCJaJo(hc7hu5CJaJhc7hu5CJaJo(huCJaJo(hTdPhuCJaJo( hc7hu5B*CJaJph#hc7hu5B*CJaJo(phhc7huCJaJhc7huCJaJo( *h6huCJaJo(*777777777777777777777788Ff? $$Ifa$gd1 $$Ifa$gd1Ff; $Ifgd1 $$1$Ifa$gd18888 8 888888 8"8$8&8(8*8,8.80828486888:8FfG $Ifgd1 $$Ifa$gd1FfC $$1$Ifa$gd1:8<8>8@8B8D8F8H8J8L8N8P8R8T8j88 d$Ifgd1FfOFfK $Ifgd18888}tt $Ifgd1kdR$$Ifl0i~,0, 4 lapyt188889999999$9*9,989<9>9J9R9T9X9\9^99999999999999 : ::::,:.:0:X:^:r:x:|::ӹ蠔܈}}}h!-\huCJaJh!-\huCJaJo(h%6huCJaJo(hu>*CJaJo(hd huCJOJaJo(hd huCJaJo(hc7huCJOJaJo(huCJaJo(hc7huCJaJo(hc7huCJaJh;whuCJaJo(1889.:zd$IfWD`gd1 $Ifgd1jkdR$$Ifli~,,0, 4 lap yt1.:0::; d$Ifgd1jkdeS$$Ifli~,,0, 4 lap yt1:::::::::::::;; ;";0;2;@;B;R;T;b;d;f;h;z;~;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;<<< < <<<<<"<$<ݺԺݺݺݺݺݺݺݺԺݺݺݺݺݺݺhc7huCJaJo(hc7huCJOJaJo(huCJaJo(hc7huCJaJh!-\huCJaJh!-\huCJaJo(F;;f;h;jkdT$$Iflxi~,,0, 4 lap yt1 d$Ifgd1jkdT$$Ifli~,,0, 4 lap yt1h;t;;&<(<4<@<z<e\\ $Ifgd1kd?U$$IflF0i~,%0, 4 lapyt1 d$Ifgd1 $$Ifa$gd1$<&<(<2<4<><J<L<N<P<T<V<X<Z<^<b<d<l<n<x<z<|<<<<<<<<<<<<<<<<<<<<<<<<<= = ==&=(=0=2=B=D=L=P=R=Z=b=d=l=v=x=źŬߤźźźźhuCJaJhc7hu>*CJaJo(huCJOJaJo(hc7huCJOJaJo(hc7huCJaJo(huCJaJo(hc7huCJaJh#huCJaJo(@z<|<~<<<cWNN $Ifgd1 $$Ifa$gd1kdU$$Ifl4Fi~, g0,     4 lapyt1<<<<<< =cWNNNN $Ifgd1 $$Ifa$gd1kdV$$Ifl40Fi~,0,     4 lapyt1 ===(=5)) $$Ifa$gd1kdW$$Iflri!~, 8 0, 4 lap2yt1x=============>>>??????????????"@,@A(A&Bϸ롭tttftftftftftfttth3h7CJOJQJ\h3h7CJOJQJ\o(!h3h75CJOJQJ\o(hc7huCJaJo(h6huCJaJo(hc7huCJaJhrhuCJaJo(hu>*CJaJo(hc7hu>*CJaJo(hc7huCJOJaJo(huCJaJo(huCJOJaJo("(=====th $$Ifa$gd1kdX$$Ifl60i~,%0, 4 lapyt1 $Ifgd1===>>&>D>z>>>>??}xppppppppppdhgdgdukdY$$Ifl(0i~,%0, 4 lapyt1 ?"@,@d@@A(A$B&B(B*B,B.B8BTB`BlBxB dh$Ifgd $dha$gdjkbdhgd&B(B,B.B4B6B8BTBDDDDEFFּ}e}e}OBh3h7CJOJQJ+hjkbh75B*CJOJQJ^Jo(ph/h3h7B*CJKH$OJQJ\^Jo(ph/h3h7B*CJKH$OJQJ\^Jo(phhjkbh7CJ$OJ PJ aJ$o(-hjkbB*CJ KH$OJPJQJ\aJ o(ph3hjkbh7B*CJ KH$OJPJQJ\aJ o(phh3h8CJOJQJ\o(h8CJOJQJ\o(h7CJOJQJ\o(xBzBBBB\PPP dh$IfgdkdcZ$$Ifl:F0$ (# \  t0%6    44 lapyt7BBB.C\PP dh$IfgdkdA[$$Ifl:F0$ (# \  t0%6    44 lapyt7.C0C:CBCJCTC^ChCrCtCvCxCvjjjjjjjejjFf+^ dh$Ifgdkd\$$Ifl:00,(# t0%644 lapyt7 xCzC|C~CCCCCCCCCCCCCCCCCCCCCCCCFfWhFfdFfa dh$IfgdCCCCCCCCCCCCCCCCCCCCCCCCCDFfrFfoFfk dh$IfgdDDDD-!! dh$Ifgdkdt$$Ifl4:r0L$ d(# @ bb t0%644 lap2yt7DD D D dh$Ifgd DDDD* dh$Ifgdkdu$$Ifl4:r0L$ d(#  @ bb t0%644 lap2yt7DDDD dh$IfgdDDDrD* dh$Ifgdkdv$$Ifl4:r0L$ d(#  @ bb t0%644 lap2yt7rDtDDDDDrffff dh$Ifgdkdw$$Ifl4:00L(# # t0%644 lapyt7DDD dh$Ifgdskdx$$Ifl:0(#% t0%644 lap yt7DDDD dh$Ifgdskd'y$$Ifl0(#% t0%644 lap yt7DDDREthh dh$Ifgdkdy$$IflV00(#X t0%644 lapyt7RETEbEEthh dh$Ifgdkd}z$$Ifl'00(#X t0%644 lapyt7EEFF F0F2F4FGGtlllalllU dh$Ifgd $dha$gdjkbdhgdkd5{$$Ifl'00(#X t0%644 lapyt7 FF F F0F4F GGGG&G(G>G@GLGNGZG\GhGjGrGtG|G~GGGGGGGGGGGGGGGGGG HH,H0Hⷨpppppppppppppppppp h3h7CJKHOJQJ^J)h3h75CJKHOJQJ\^Jo(#h3h7CJKHOJQJ^Jo(hjkbCJKHOJQJ^Jo(hjkbh7CJ$OJ PJ aJ$o(4hjkb@B*CJ KH$OJPJQJ\aJ ho(ph:hjkbh7@B*CJ KH$OJPJQJ\aJ ho(ph,G(G@GNG\GjGtG~GGGGGGGGGGGGGGGGGGGGGFfN~ dh$IfgdGGGGGGGGGGGGGGGGGGHHHHH H HHHHFfFf. dh$IfgdHHHHHHH H"H$H&H(H*H,H.H0H2H4H6H8H:HH@HBHDHFHHHFf dh$IfgdHHJHLHNHPHRHTHVHXHZH\H^H`HbHdHfHhHjHlHnHpHrHtHvHxHzH|H~HFfFfΕ dh$Ifgd0HLHPHlHpHHHHIIJJ,J.Jތ.2gd8.2rv>B6<>DFLNdfprtŷۈzhZh}2yh$OJQJaJo(#h}2yh$CJ OJPJQJaJ o(h3h#CJOJQJo(h#CJOJQJo(h#h#5CJOJQJo(&h}2yh`5CJ,OJPJQJaJ,o(h3h&CJOJQJo(h&CJOJQJo(h$CJOJQJo(h3h$CJOJQJo(h3h$CJOJQJh8 h8o(ҍ"rvƎf ZN>B2ғ"r”bgd8bVF6:<>@BDFHJLNdft $dha$gd#dhgdgd8H ^ "(|hО$dhgd $dha$gd# "tv <>Хҥ8:@F`XZ:<\ κк ֻػձh3h$CJOJQJhh$OJQJaJhh$OJQJaJo(#hh$CJ OJPJQJaJ o(#h}2yh$CJ OJPJQJaJ o(h}2yh$OJQJ^JaJo(h}2yh$OJQJaJo(h}2yh$OJQJaJ6$>Zx؟ڟ@$tv £<>(Хҥ8:Φ $dha$gd# dhWD`gd}2ydhgdΦbLTԫjL®DF`XZΰ $dha$gd#dhgdΰ:<\ֲ \ȳʴ,N κк $dha$gd#dhgd ֻػ02ܼNNPBZp $dha$gd# dhWD`gddhgdػ026NP`bJLln24BD XZ |$&TV  ַh3h$CJOJQJh3hCJOJQJ#hh$CJ OJPJQJaJ o(h3h$CJOJQJo(hh$OJQJaJhh$OJQJaJo(A`bJL&ln 8Z|24BDl $dha$gd#dhgdl XZ z|r dhWD`gd $dha$gd#dhgd$&TV  "bddhgd $dha$gd#"bd  (*:<HJtvɹrheHheHOJQJaJo(h#OJQJaJo(heHh$H*OJQJaJo(heHh$OJQJaJo(heHh$5OJQJaJo(hh$5CJOJQJo(#hh$CJ OJPJQJaJ o(h3h$CJOJQJo(h#CJOJQJo(h$CJOJQJo(,(*,:<x{kd$$Ifl40# 064 laf4yt dh$Ifgd<>HJxx dh$Ifgd{kd$$Ifl40# 064 laf4ytJLVXxx dh$Ifgd{kdC$$Ifl40# 064 laf4ytXZfhxx dh$Ifgd{kd$$Ifl410# 064 laf4ythjtvxx dh$Ifgd{kd$$Ifl40# 064 laf4ytvxz{{{{ dh$IfgdxkdD$$IflA0# 064 layt{{{{ dh$Ifgdxkd$$Ifl0# 064 layt{{ dh$Ifgdxkd$$Ifl!0# 064 layt{{{ dh$Ifgdxkd'$$Ifl0# 064 laytsss dh$Ifgddhgdxkd̰$$Ifl0# 064 layt .0DF 68Nbdf (*<>NP\^ ҩҩheHh$5OJQJaJheHh#OJQJaJo(heHh$OJQJaJheHh$5OJQJaJo(heHh$OJQJaJo(heHh$H*OJQJaJo(>DFxxx dh$Ifgd{kdq$$Ifl40x d$ 064 laf4yteHFHRxxx dh$Ifgd{kd$$Ifl40x d$ 064 laf4yteHxxx dh$Ifgd{kdDz$$Ifl40x d$ 064 laf4yteHxxx dh$Ifgd{kdr$$Ifl40x d$ 064 laf4yteH xxx dh$Ifgd{kd$$Ifl40x d$ 064 laf4yteH  "{{{{ dh$Ifgdxkdȴ$$IflA0x d$ 064 layteH{{{ dh$Ifgdxkdm$$IflC0x d$ 064 layteH{{{ dh$Ifgdxkd$$Ifl0x d$ 064 layteH{{{ dh$Ifgdxkd$$Ifl0x d$ 064 layteH68{{{ dh$Ifgdxkd\$$Ifl0x d$ 064 layteH8:BNb{{{ dh$Ifgdxkd$$Iflm0x d$ 064 layteHbdf.<>ss dh$Ifgddhgdxkd$$IflJ0x d$ 064 layteH>@NPxx dh$Ifgd{kdK$$Ifl40# 064 laf4yteHPR\^xx dh$Ifgd{kd$$Ifl40# 064 laf4yteH^`jlxx dh$Ifgd{kd$$Ifl40# 064 laf4yteHlnz|xx dh$Ifgd{kdL$$Ifl410# 064 laf4yteH|~xx dh$Ifgd{kd$$Ifl40# 064 laf4yteH{{{{ dh$Ifgdxkd$$IflA0# 064 layteH{{{{ dh$IfgdxkdG$$Ifl0# 064 layteH{{ dh$Ifgdxkd$$Ifl!0# 064 layteH{{{ dh$Ifgdxkd$$Ifl0# 064 layteH{{ dh$Ifgdxkd*$$Ifl0# 064 layteH {{{ dh$IfgdxkdϿ$$Iflm0# 064 layteH  "$&(dhgdxkdt$$Ifl0# 064 layteH>BDPtvJdhrê~iUA~i&heHB*CJKHOJQJ^Jo(ph&h#B*CJKHOJQJ^Jo(ph)heHh$B*KHOJQJ^JaJph)h3h$B*CJKHOJQJ^Jph,heHh$5B*CJKHOJQJ^Jph1heHh$B*CJ KHOJPJQJ^JaJ phh3heHCJOJQJheHCJOJQJo(h#CJOJQJo(h$CJOJQJo(h3h$CJOJQJo((*,.02468:<>@BDPt`LNPdhgd# dh`gd# $dha$gd#dhgdPRTVXZ\^`bdfhrFrTBdhgd $dha$gd#dhgd# $dha$gd#dhgd:<vx,.RTrtNPZ\dfBD<>b̼~l[ heHh$CJ OJPJQJaJ #heHh$CJ OJPJQJaJ o(heHheHOJQJaJheHOJQJaJo(h$OJQJaJo(heHh$OJQJaJo(heHh$OJQJaJheHh$5CJOJQJo(1heHh$B*CJ KHOJPJQJ^JaJ ph4heHh$B*CJ KHOJPJQJ^JaJ o(ph#:<bvx,.PRTrtNPRTVXZ\fdhgdfBDd.<>`bdj Jdhgd $dha$gd#bdJL .8TVXz|LNhj  v LNheHh$5CJOJQJheHh$5CJOJQJo(#heHh$CJ OJPJQJaJ o(heHCJOJQJo(h#CJOJQJo(h3h$CJOJQJo(heHh$OJQJaJo(heHh$OJQJaJ9JL   "$&(*,.8dhgd8Vz|LNjdhjN 4dhgd $dha$gd#T 8vxz|~$ $dha$gd#dhgd B<LNT$ "zl&dhgd "VXZ\df      < > 6 8 0>FH<>wheHCJOJQJo(h#CJOJQJo(heHh$5CJOJQJo( heHh$CJ OJPJQJaJ #heHh$CJ OJPJQJaJ o(h3h#CJOJQJh$CJOJQJo(h3h$CJOJQJheHh$OJQJaJo(heHh$OJQJaJ.zVXZ\f       < >   $dha$gd#dhgd 6 8   @   @   "$&(*,.02dhgd2468:<>Ht<>\:4~ $dha$gd#dhgd>~ NPNP46 "VX:!$j$$$$$$$$$$%%%%% % %%%%% $dha$gd#dhgd%%%$%F%H%R%\%f%|% dh$Ifgd# $dha$gd#dhgd %%$%D%H%P%R%Z%\%d%f%z%|%~%&&&&((z)|)**~,,--//00"2$233L5N5B6D6667777*8,888v:x:Ͽh3h$CJOJQJo(h#hDLPCJOJQJo(h#h$CJOJQJo(h#h$5CJOJQJo(h3h$5CJOJQJo(heHh$5CJOJQJo(#heHh$CJ OJPJQJaJ o(h3h#CJOJQJo(2|%~%%%%&\PPPP dh$Ifgd#kd$$If\c  tV0644 layteH&&&4&&&^RRRR dh$Ifgd#kd$$If\c  tV0644 layteH&&&&&B'z''(^RRRRRRR dh$Ifgd#kd$$If\c  tV0644 layteH(( ( ((v((( )0)^RRRRRRRR dh$Ifgd#kdW$$If\c  tV0644 layteH 0)z)|)~)))8*j***Rkd$$If\c  tV0644 layteH dh$Ifgd# **** +f++++2,^RRRRRRRR dh$Ifgd#kd$$If\c  tV0644 layteH 2,~,,,,,>-p---Rkd$$If\c  tV0644 layteH dh$Ifgd# --...l.../6/^RRRRRRRR dh$Ifgd#kdO$$If\c  tV0644 layteH 6///// 0200Rkd $$If\c  tV0644 layteH dh$Ifgd#00000B111"2^RRRRRRR dh$Ifgd#kd$$If\c  tV0644 layteH"2$2&2(26222,3N3t3^RRRRRRRR dh$Ifgd#kd$$If\c  tV0644 layteH t333344l444L5RkdG$$If\c  tV0644 layteH dh$Ifgd# L5N5P5R5`5556B6^RRRRRRR dh$Ifgd#kd$$If\c  tV0644 layteHB6D6P6b666^RRRR dh$Ifgd#kd$$If\c  tV0644 layteH6667F77^RRRR dh$Ifgd#kd$$If\c  tV0644 layteH777777^RRRR dh$Ifgd#kd?$$If\c  tV0644 layteH77778*8^RRRR dh$Ifgd#kd$$If\c  tV0644 layteH*8,8.8088889|9:x:\TTTTTTTTdhgdkd$$Ifo\c  tV0644 layteH x::::::h;<>b>d>>>?P@@@@jDpDF.GHI dhWD`gd#dhgd`@ dh`gd`@dhgd $dha$gd#x::::b>d>>@@@@nDpDDNN:N6O8OOO8R:R^RtSvSSTTTT0U2UUUU*V,VJV[[ŸŭŸŸœwjwjwjwjwjwwhYh$OJQJaJhYh$OJQJaJo(h`@h#OJQJaJo(h3h$CJOJQJh`@h`@OJQJaJh$OJQJaJo(h`@h$OJQJaJh`@h$OJQJaJo(h3h$CJOJQJo(h#CJOJQJo(&h`@h`5CJ,OJPJQJaJ,o((IJKKTLLN6NN8OJOOOOPrPP]@]n]p]r]t]]]]]]]]]]]º~tntnjh h0Jjh0JUhYb@hUjhUU hUo(h@ h6qHh6qHmHnHsHuh6jh6U h6o(hR0jhR0UhYOJQJaJo(h#OJQJaJo(hYh$OJQJaJhYh$OJQJaJo(hYhYOJQJaJ)\\\\\\\\\\\\\\\\\\\\\\\\\6]8]:]$a$gd6dhgd:]<]]]]]]]]]]>^@^B^D^V^X^Z^^^^^^$a$gd-g &`#$gd7$a$gd*h]hgdj[9 &`#$gdh$a$gdU]]]]]]]]]]]"^$^*^,^<^>^@^B^D^F^R^T^V^Z^\^^^`^^^^^^^^^^^^^^^^^^^_______ _,_._0_4_6_ǹܦÙǹܡÙܕǹܦh}Djh-gU h-go(j *h<U* h0Jjh0JUh-gh@ h*jh*U h*o(hh6qHh6qHmHnHsHuhYb@jhYb@U hYb@o(:^^^_____0_2_4_____dhgd$a$gd}D &`#$gd1$a$gd-g6_8_:_<_>_l_n_t_v_____ĹhYOJQJaJo(hR0hh6qHh6qHmHnHsHuh}Djh}DU h}Do(j *h<U*hmHsH 6182P:p{. A!"#$%S C0P182P:pU. A!"#$%S Dp9182P0:pA .!"#$%S 0182P. A!"#$%S =&P 182P0:puA .!"#$%S 0182P. A!"#$%S 9182P0:p A .!"#$%S 6&P1:pu/ =!"#$% 6&P1:p8/ =!"#$% 218:p8. A!"#$%S 5180:puA .!"#$%S 218:pDLP. A!"#$%S $$If!vh555\5#v#v#v\#v:V l t76555\5yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l t76555\5-5 yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l t76555\5-5 yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l t76555\5-5 yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l4 t76+555\5-5 yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l4 t76+555\5-5 yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l4 t76+555\5-5 yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l t76555\5-5 yt7$$If!vh555\5#v#v#v\#v:V l t76555\5yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l t76555\5-5 yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l t76555\5-5 yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l t76555\5-5 yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l t76555\5-5 yt7$$If!vh555\5#v#v#v\#v:V l t76555\5yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l t76555\5-5 yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l t76555\5-5 yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l t76555\5-5 yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l t76555\5-5 yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l t76555\5-5 yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l t76555\5-5 yt7$$If!vh555\5#v#v#v\#v:V l t76555\5yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l t76555\5-5 yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l t76555\5-5 yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l t76555\5-5 yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l t76555\5-5 yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l t76555\5-5 yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l t76555\5-5 yt7$$If!vh555\5#v#v#v\#v:V l t76555\5yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l t76555\5-5 yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l t76555\5-5 yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l t76555\5-5 yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l t76555\5-5 yt7$$If!vh55t55#v#vt#v#v:V l t76m55t55yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh555\5#v#v#v\#v:V l t76555\5yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l t76555\5-5 yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh555\5#v#v#v\#v:V l t76555\5yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l t76555\5-5 yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh555\5#v#v#v\#v:V l t76555\5yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l t76555\5-5 yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh555\5#v#v#v\#v:V l t76555\5yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l t76555\5-5 yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55t55#v#vt#v#v:V l t76m55t55yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh555\5#v#v#v\#v:V l t76555\5yt7$$If!vh555\5-5 #v#v#v\#v-#v :V l t76555\5-5 yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55t55*5#v#vt#v#v*#v:V l t76m55t55*5yt7$$If!vh55 5e 5] #v#v #ve #v] :V l4 t06+++,585u 5 5 ayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l4 t06+++,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh5!#v!:V l t065&/ ayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55n/ aytr$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh5!#v!:V l t065&/  ayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh55 5e 55}#v#v #ve #v#v}:V l t06,585u 5 55nayt$$If!vh555#v#v#v:V 0065w 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh555#v#v#v:V 0065w 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V Z006505G 5S5yt$$If!vh555#v#v#v:V 0065w 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh555#v#v#v:V K0065w 5S5yt$$If!vh5555#v#v#v#v:V J006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh555#v#v#v:V K0065w 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5555#v#v#v#v:V 006505G 5S5yt$$If!vh5V55#vV#v#v:V l406+,555I/ / 4f4yt|$$If!vh5V55#vV#v#v:V l4F06+,,555I/ / 4f4yt|$$If!vh5V5#vV#v:V l4[06,554f4yt|$$If!vh5V555E5#vV#v#v#vE#v:V l4N06+,555 55/ 4f4yt|$$If!vh5V55#vV#v#v:V l4N06+,555I/ 4f4yt|$$If!vh5V55555#vV#v#v#v#v#v:V l406,55 5f54f4yt|$$If!vh5V5 55g #vV#v #v#vg :V l4M06,555f54f4yt|$$If!vh5V5 5555#vV#v #v#v#v#v:V l406,55O55f54f4yt|$$If!vh5$5>5555#v$#v>#v#v#v#v:V l4M06,55?55f54f4yt|$$If!vh5V5 5555#vV#v #v#v#v#v:V l406,55O55f54f4yt|$$If!vh5V5 5555#vV#v #v#v#v#v:V l406,55O55f54f4yt|;$$If!vh5V555j5;555#vV#v#v#vj#v;#v#v#v:V l406,55V555555/ 4f4yt|$$If!vh5V55f5;55#vV#v#vf#v;#v#v:V l4k06,555W5554f4yt|$$If!vh5f 55j5;555#vf #v#vj#v;#v#v#v:V l4"06,55V555554f4yt|$$If!vh5f 55j5;555#vf #v#vj#v;#v#v#v:V l406,55V555554f4yt|$$If!vh5f 5f5 5#vf #vf#v #v:V l406,55W554f4yt|$$If!vh5+5#v+#v:V l406,5F5B/ 4f4yt|$$If!vh555S5 #v#v#vS#v :V lp06,55u55n4yt|$$If!vh55e#v#ve:V l4306,554f4yt|$$If!vh55p#v#vp:V l06,5o5/ 4yt|$$If!vh55p#v#vp:V l 06,5o5/ 4yt|$$If!vh5J!#vJ!:V l0654yt|$$If!vh55 5 #v#v #v :V l4r06+,555(/ 4f4yt|$$If!vh55 5 #v#v #v :V l406+,555(/ 4f4yt|$$If!vh55 5 #v#v #v :V l4g06+,555(/ 4f4yt|$$If!vh55p#v#vp:V l06,5o5/ 4yt|$$If!vh55p#v#vp:V l 06,5o5/ 4yt|$$If!vh5J!#vJ!:V lU 0654yt|$$If!vh55+ 5#v#v+ #v:V l4r06+,555/ 4f4yt|$$If!vh55+ 5#v#v+ #v:V l406+,555/ 4f4yt|$$If!vh55+ 5#v#v+ #v:V l4g06+,555/ 4f4yt|$$If!vh5j5#vj#v:V l06,554yt|$$If!vh5j5#vj#v:V lm06,554yt|$$If!vh5j5#vj#v:V l06,554yt|$$If!vh5j5 5 5#vj#v #v:V l406,555'4f4yt|$$If!vh5j5#vj#v:V lh06,554yt|$$If!vh55o#v#vo:V l4506,5o5/ 4f4yt|$$If!vh55o#v#vo:V l406,5o5/ 4f4yt|$$If!vh55o#v#vo:V l 06,5o54yt|$$If!vh55o#v#vo:V l 06,5o54yt|$$If!vh5W 5 5L #vW #v #vL :V l4_ 0655@54f4yt|$$If!vh55555m#v5#v#v#vm:V l406+++,55 554f4ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l406+++55 5m54f4ytv$$If!vh5J!#vJ!:V l40654f4ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5J!#vJ!:V l40654f4ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh555#v5#v:V l406554f4ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l 0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l 0655 5m54ytv$$If!vh555#v5#v:V l406554f4ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh555#v5#v:V l406554f4ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh5555]5`5m#v5#v#v]#v`#vm:V l0655 5m54ytv$$If!vh505^5W5e#v0#v^#vW#ve:V l406+++,55h 57564f4ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l406+++,,55h 55564f4ytv$$If!vh505#v0#v:V l406554f4ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh5J!#vJ!:V l40654f4ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh5J!#vJ!:V l40654f4ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505#v0#v:V l406554f4ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh505^5~55e#v0#v^#v~#v#ve:V l0655h 55564ytv$$If!vh55w55 #v#vw#v#v :V l406++,55r 554f4ytv$$If!vh55w5`5c5 #v#vw#v`#vc#v :V l406++,,55r 5n54f4ytv$$If!vh5J!#vJ!:V l40654f4ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh5J!#vJ!:V l40654f4ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh5J!#vJ!:V l40654f4ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh5J!#vJ!:V l40654f4ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh505N5`5c5 #v0#vN#v`#vc#v :V l0655] 5n54ytv$$If!vh5455V5r 5o #v4#v#vV#vr #vo :V l406++++,5!555d5c/ /  f4yt7$$If!vh545555r 5o #v4#v#v#vr #vo :V l406++++,5!555d5c/ / f4yt7$$If!vh545555r 5o #v4#v#v#vr #vo :V l06,5!555d5c/ yt7$$If!vh545555r 5o #v4#v#v#vr #vo :V l06,5!555d5c/ yt7$$If!vh545555r 5o #v4#v#v#vr #vo :V l06,5!555d5c/ yt7$$If!vh545555r 5o #v4#v#v#vr #vo :V l06,5!555d5c/ yt7$$If!vh545555r 5o #v4#v#v#vr #vo :V l06,5!555d5c/ yt7$$If!vh545555r 5o #v4#v#v#vr #vo :V l06,5!555d5c/ yt7$$If!vh545555r 5o #v4#v#v#vr #vo :V l06,5!555d5c/ yt7$$If!vh545555r 5o #v4#v#v#vr #vo :V l06,5!555d5c/ yt7$$If!vh545555r 5o #v4#v#v#vr #vo :V l06,5!555d5c/ yt7$$If!vh545555r 5o #v4#v#v#vr #vo :V l06,5!555d5c/ yt7$$If!vh555a#v#v#va:V l46++,55+5>/  / / / / pyt {h$$If!v h555555555 5 5 #v#v#v#v#v#v #v :V l46+++++++++ + , 55+555 5 /  / /  / / / / /  /  /  pnyt {hrkd$$Ifl4 ~}) +/ +6,,,,44 lapnyt {h5$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46++++++++ + + , 55+5 5 5 5 /  /  / /  / /  / / / pւyt {hkd!$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkd,$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkdҝ$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkdx$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkd$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkdī$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkdj$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkd$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkd$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkd\$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkd$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkd$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkdN$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkd$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!vh555a#v#v#va:V l46++,55+5>/ /  / / / / pyt {h$$If!v h555555555 5 5 #v#v#v#v#v#v #v :V l46+++++++++ + , 55+555 5 / /  / / / / /  /  /  pnyt {hrkd$$Ifl4 ~}) +/ +6,,,,44 lapnyt {h'$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46++++++++ + + , 55+5 5 5 5 /  / /  / /  / / / pւyt {hkd"$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkd$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkd$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkdk$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkd$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkd$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkd]$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkd$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkd$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkdO$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkd $$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkd$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkdA$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkd$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkd$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkd3!$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkd%$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkd*$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkd%/$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkd3$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!v h555555555 5 5 5 5 #v#v#v#v #v #v #v :V l46+, 55+5 5 5 5 /  / /  / /  pւyt {hkdq8$$Ifl4" ~}) +,/ +6444444 lapւyt {h$$If!vh555#v#v#v:V l4f6++,5555/  / / / / pyt {hK$$If!vh55555555#v#v#v#v:V l46++,5555/  / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {h$$If!vh555#v#v#v:V l4f6++,5555/ /  / / / / pyt {hY$$If!vh55555555#v#v#v#v:V l46++,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {hT$$If!vh55555555#v#v#v#v:V l46+,5555/  / / / /  pPyt {h$$If!vh555_#v#v#v_:V l4 6++,5&5</  / / / / pyt {h$$If!vh555555555 5 5 5 5 5 555#v#v#v:V l46++,5&/  / / /  p֪yt {hkd^m$$Ifl4zti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h($$If!vh555555555 5 5 5 5 5 555#v#v#v:V l46+++,5&/  / / / /  /  / / / /  p֪yt {hkdr$$Ifl4zti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h($$If!vh555555555 5 5 5 5 5 555#v#v#v:V l46+++,5&/  / / / /  /  / / / /  p֪yt {hkdx$$Ifl4zti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h($$If!vh555555555 5 5 5 5 5 555#v#v#v:V l46+++,5&/  / / / /  /  / / / /  p֪yt {hkd?~$$Ifl4zti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h($$If!vh555555555 5 5 5 5 5 555#v#v#v:V l46+++,5&/  / / / /  /  / / / /  p֪yt {hkd$$Ifl4zti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h($$If!vh555555555 5 5 5 5 5 555#v#v#v:V l46+++,5&/  / / / /  /  / / / /  p֪yt {hkd$$Ifl4zti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h($$If!vh555555555 5 5 5 5 5 555#v#v#v:V l46+++,5&/  / / / /  /  / / / /  p֪yt {hkdy$$Ifl4zti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h($$If!vh555555555 5 5 5 5 5 555#v#v#v:V l46+++,5&/  / / / /  /  / / / /  p֪yt {hkd7$$Ifl4zti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h($$If!vh555555555 5 5 5 5 5 555#v#v#v:V l46+++,5&/  / / / /  /  / / / /  p֪yt {hkd$$Ifl4zti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h($$If!vh555555555 5 5 5 5 5 555#v#v#v:V l46+++,5&/  / / / /  /  / / / /  p֪yt {hkd$$Ifl4zti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h($$If!vh555555555 5 5 5 5 5 555#v#v#v:V l46+++,5&/  / / / /  /  / / / /  p֪yt {hkdq$$Ifl4zti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h($$If!vh555555555 5 5 5 5 5 555#v#v#v:V l46+++,5&/  / / / /  /  / / / /  p֪yt {hkd/$$Ifl4zti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h($$If!vh555555555 5 5 5 5 5 555#v#v#v:V l46+++,5&/  / / / /  /  / / / /  p֪yt {hkd$$Ifl4zti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h($$If!vh555555555 5 5 5 5 5 555#v#v#v:V l46+++,5&/  / / / /  /  / / / /  p֪yt {hkd$$Ifl4zti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h($$If!vh555555555 5 5 5 5 5 555#v#v#v:V l46+++,5&/  / / / /  /  / / / /  p֪yt {hkdi$$Ifl4zti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h($$If!vh555555555 5 5 5 5 5 555#v#v#v:V l46+++,5&/  / / / /  /  / / / /  p֪yt {hkd'$$Ifl4zti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h($$If!vh555555555 5 5 5 5 5 555#v#v#v:V l46+++,5&/  / / / /  /  / / / /  p֪yt {hkd$$Ifl4zti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h($$If!vh555555555 5 5 5 5 5 555#v#v#v:V l46+++,5&/  / / / /  /  / / / /  p֪yt {hkd$$Ifl4zti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h($$If!vh555555555 5 5 5 5 5 555#v#v#v:V l46+++,5&/  / / / /  /  / / / /  p֪yt {hkda$$Ifl4zti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h($$If!vh555555555 5 5 5 5 5 555#v#v#v:V l46+++,5&/  / / / /  /  / / / /  p֪yt {hkd$$Ifl4zti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h($$If!vh555555555 5 5 5 5 5 555#v#v#v:V l46+++,5&/  / / / /  /  / / / /  p֪yt {hkd$$Ifl4zti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h($$If!vh555555555 5 5 5 5 5 555#v#v#v:V l4w6+++,5&/  / / / /  /  / / / /  p֪yt {hkd$$Ifl4wzti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h($$If!vh555555555 5 5 5 5 5 555#v#v#v:V l4w6+++,5&/  / / / /  /  / / / /  p֪yt {hkdY$$Ifl4wzti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h($$If!vh555555555 5 5 5 5 5 555#v#v#v:V l4h6+++,5&/  / / / /  /  / / / /  p֪yt {hkd$$Ifl4hzti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h($$If!vh555555555 5 5 5 5 5 555#v#v#v:V l4J6+++,5&/  / / / /  /  / / / /  p֪yt {hkd$$Ifl4Jzti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h($$If!vh555555555 5 5 5 5 5 555#v#v#v:V l46+++,5&/  / / / /  /  / / / /  p֪yt {hkd$$Ifl4zti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h$$If!vh555_#v#v#v_:V l4X6++,5&5</ /  / pyt {h$$If!vh555555555 5 5 5 5 5 555#v#v#v:V l4X6++,5&/ / /  p֪yt {hkd $$Ifl4Xzti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h$$If!vh555555555 5 5 5 5 5 555#v#v#v:V l4X6+++,5&/ / / / / / / / /  p֪yt {hkdw$$Ifl4Xzti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h$$If!vh555555555 5 5 5 5 5 555#v#v#v:V l4X6+++,5&/ / / / / / / / /  p֪yt {hkd'$$Ifl4Xzti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h$$If!vh555555555 5 5 5 5 5 555#v#v#v:V l4X6+++,5&/ / / / / / / / /  p֪yt {hkd$$Ifl4Xzti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h$$If!vh555555555 5 5 5 5 5 555#v#v#v:V l4X6+++,5&/ / / / / / / / /  p֪yt {hkd$$Ifl4Xzti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h$$If!vh555555555 5 5 5 5 5 555#v#v#v:V l4X6+++,5&/ / / / / / / / /  p֪yt {hkd7$$Ifl4Xzti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h$$If!vh555555555 5 5 5 5 5 555#v#v#v:V l4X6+++,5&/ / / / / / / / /  p֪yt {hkd$$$Ifl4Xzti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h$$If!vh555555555 5 5 5 5 5 555#v#v#v:V l4X6+++,5&/ / / / / / / / /  p֪yt {hkd*$$Ifl4Xzti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h$$If!vh555555555 5 5 5 5 5 555#v#v#v:V l4X6+++,5&/ / / / / / / / /  p֪yt {hkdG0$$Ifl4Xzti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h$$If!vh555555555 5 5 5 5 5 555#v#v#v:V l4X6+++,5&/ / / / / / / / /  p֪yt {hkd5$$Ifl4Xzti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h$$If!vh555555555 5 5 5 5 5 555#v#v#v:V l4X6+++,5&/ / / / / / / / /  p֪yt {hkd;$$Ifl4Xzti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h$$If!vh555555555 5 5 5 5 5 555#v#v#v:V l4X6+++,5&/ / / / / / / / /  p֪yt {hkdWA$$Ifl4Xzti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h$$If!vh555555555 5 5 5 5 5 555#v#v#v:V l4X6+++,5&/ / / / / / / / /  p֪yt {hkdG$$Ifl4Xzti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h$$If!vh555555555 5 5 5 5 5 555#v#v#v:V l4X6+++,5&/ / / / / / / / /  p֪yt {hkdL$$Ifl4Xzti^ S H =2' &&&&&&&&&&&&&&&&&6DDDD44 lap֪yt {h$$If!vh5|5#v|#v:V l4p6++,5u5/ / / / / pytkZR$$If!vh5|5#v|#v:V l4p6++,5u5/ / / / / pytkZR$$If!vh5|5#v|#v:V l4p6++,5u5/ / / / / pytkZR$$If!vh5|5 5 555 5 5 5  5 5 5 5 5 55#v|#v #v#v#v #v :V l46+,5u53555 45 553/  / / /  p֠ytkZRbkdT$$Ifl4d$2A N [hu u3355444455555536@@@@44 lap֠ytkZR$$If!vh5|5 5 555 5 5 5  5 5 5 5 5 55#v|#v #v#v#v #v :V l6,5u53555 45 553/ / / /  p֠ytkZR_kd8Z$$Ifld$2A N [hu u3355444455555536@@@@44 lap֠ytkZR$$If!vh5|5 5 555 5 5 5  5 5 5 5 5 55#v|#v #v#v#v #v :V l6,5u53555 45 553/ / / /  p֠ytkZR_kd_$$Ifld$2A N [hu u3355444455555536@@@@44 lap֠ytkZR$$If!vh5|5 5 555 5 5 5  5 5 5 5 5 55#v|#v #v#v#v #v :V l6,5u53555 45 553/ / / /  p֠ytkZR_kdd$$Ifld$2A N [hu u3355444455555536@@@@44 lap֠ytkZR$$If!vh5|5 5 555 5 5 5  5 5 5 5 5 55#v|#v #v#v#v #v :V l6,5u53555 45 553/ / / /  p֠ytkZR_kdj$$Ifld$2A N [hu u3355444455555536@@@@44 lap֠ytkZR$$If!vh5|5 5 555 5 5 5  5 5 5 5 5 55#v|#v #v#v#v #v :V l+6,5u53555 45 553/ / / /  p֠ytkZR_kdlo$$Ifl+d$2A N [hu u3355444455555536@@@@44 lap֠ytkZR$$If!vh5|5 5 555 5 5 5  5 5 5 5 5 55#v|#v #v#v#v #v :V l6,5u53555 45 553/ / / /  p֠ytkZR_kdt$$Ifld$2A N [hu u3355444455555536@@@@44 lap֠ytkZR$$If!vh5|5 5 555 5 5 5  5 5 5 5 5 55#v|#v #v#v#v #v :V l6,5u53555 45 553/ / / /  p֠ytkZR_kdz$$Ifld$2A N [hu u3355444455555536@@@@44 lap֠ytkZR$$If!vh5|5 5 555 5 5 5  5 5 5 5 5 55#v|#v #v#v#v #v :V l6,5u53555 45 553/ / / /  p֠ytkZR_kdS$$Ifld$2A N [hu u3355444455555536@@@@44 lap֠ytkZR$$If!vh5|5 5 555 5 5 5  5 5 5 5 5 55#v|#v #v#v#v #v :V l6,5u53555 45 553/ / / /  p֠ytkZR_kd$$Ifld$2A N [hu u3355444455555536@@@@44 lap֠ytkZR$$If!vh5|5 5 555 5 5 5  5 5 5 5 5 55#v|#v #v#v#v #v :V l6,5u53555 45 553/ / / /  p֠ytkZR_kd$$Ifld$2A N [hu u3355444455555536@@@@44 lap֠ytkZR$$If!vh5|5 5 555 5 5 5  5 5 5 5 5 55#v|#v #v#v#v #v :V l6,5u53555 45 553/ / / /  p֠ytkZR_kd:$$Ifld$2A N [hu u3355444455555536@@@@44 lap֠ytkZR$$If!vh5|5 5 555 5 5 5  5 5 5 5 5 55#v|#v #v#v#v #v :V l6,5u53555 45 553/ / / /  p֠ytkZR_kd$$Ifld$2A N [hu u3355444455555536@@@@44 lap֠ytkZR$$If!vh5|5 5 555 5 5 5  5 5 5 5 5 55#v|#v #v#v#v #v :V l6,5u53555 45 553/ / / /  p֠ytkZR_kdԙ$$Ifld$2A N [hu u3355444455555536@@@@44 lap֠ytkZR$$If!vh5|5 5 555 5 5 5  5 5 5 5 5 55#v|#v #v#v#v #v :V l6,5u53555 45 553/ / / /  p֠ytkZR_kd!$$Ifld$2A N [hu u3355444455555536@@@@44 lap֠ytkZR$$If!vh5|5 5 555 5 5 5  5 5 5 5 5 55#v|#v #v#v#v #v :V l6,5u53555 45 553/ / / /  p֠ytkZR_kdn$$Ifld$2A N [hu u3355444455555536@@@@44 lap֠ytkZR$$If!vh5|5 5 555 5 5 5  5 5 5 5 5 55#v|#v #v#v#v #v :V l6,5u53555 45 553/ / / /  p֠ytkZR_kd$$Ifld$2A N [hu u3355444455555536@@@@44 lap֠ytkZR$$If!vh5|5 5 555 5 5 5  5 5 5 5 5 55#v|#v #v#v#v #v :V l6,5u53555 45 553/ / / /  p֠ytkZR_kd$$Ifld$2A N [hu u3355444455555536@@@@44 lap֠ytkZR$$If!vh5|5 5 555 5 5 5  5 5 5 5 5 55#v|#v #v#v#v #v :V l6,5u53555 45 553/ / / /  p֠ytkZR_kdU$$Ifld$2A N [hu u3355444455555536@@@@44 lap֠ytkZR$$If!vh5|5 5 555 5 5 5  5 5 5 5 5 55#v|#v #v#v#v #v :V l6,5u53555 45 553/ / / /  p֠ytkZR_kd$$Ifld$2A N [hu u3355444455555536@@@@44 lap֠ytkZR$$If!vh55#v#v:V l46+,5 5/  / /  / pyto$$If!vh555g55555#v#v#vg#v#v:V l46+++++++,5 5555/  / / / /  / / / pPyto$$If!v h555555555 5 #v#v#v#v#v :V l46+++++++ , 5 5555 /  / / / / /  /  / / pdytoBkd[$$Ifl4 @Q  6((((44 lapdytov$$If!v h555555555 5 #v#v#v#v#v :V l6,, 5 5555 / /  / /  pdyto?kd}$$Ifl @Q  6((((44 lapdytov$$If!v h555555555 5 #v#v#v#v#v :V lY6,, 5 5555 / /  / /  pdyto?kd6$$IflY @Q  6((((44 lapdytov$$If!v h555555555 5 #v#v#v#v#v :V lI6,, 5 5555 / /  / /  pdyto?kd$$IflI @Q  6((((44 lapdytov$$If!v h555555555 5 #v#v#v#v#v :V l6,, 5 5555 / /  / /  pdyto?kd$$Ifl @Q  6((((44 lapdytov$$If!v h555555555 5 #v#v#v#v#v :V l6,, 5 5555 / /  / /  pdyto?kda$$Ifl @Q  6((((44 lapdytov$$If!v h555555555 5 #v#v#v#v#v :V lY6,, 5 5555 / /  / /  pdyto?kd$$IflY @Q  6((((44 lapdytov$$If!v h555555555 5 #v#v#v#v#v :V lh6,, 5 5555 / /  / /  pdyto?kd$$Iflh @Q  6((((44 lapdytov$$If!v h555555555 5 #v#v#v#v#v :V lY6,, 5 5555 / /  / /  pdyto?kd$$IflY @Q  6((((44 lapdytov$$If!v h555555555 5 #v#v#v#v#v :V l6,, 5 5555 / /  / /  pdyto?kdE$$Ifl @Q  6((((44 lapdytov$$If!v h555555555 5 #v#v#v#v#v :V l6,, 5 5555 / /  / /  pdyto?kd$$Ifl @Q  6((((44 lapdytov$$If!v h555555555 5 #v#v#v#v#v :V l6,, 5 5555 / /  / /  pdyto?kd$$Ifl @Q  6((((44 lapdytov$$If!v h555555555 5 #v#v#v#v#v :V lY6,, 5 5555 / /  / /  pdyto?kdp$$IflY @Q  6((((44 lapdytov$$If!v h555555555 5 #v#v#v#v#v :V lv6,, 5 5555 / /  / /  pdyto?kd)$$Iflv @Q  6((((44 lapdytov$$If!v h555555555 5 #v#v#v#v#v :V lv6,, 5 5555 / /  / /  pdyto?kd$$Iflv @Q  6((((44 lapdytov$$If!v h555555555 5 #v#v#v#v#v :V lJ6,, 5 5555 / /  / /  pdyto?kd$$IflJ @Q  6((((44 lapdytov$$If!v h555555555 5 #v#v#v#v#v :V lw6,, 5 5555 / /  / /  pdyto?kdT$$Iflw @Q  6((((44 lapdytov$$If!v h555555555 5 #v#v#v#v#v :V lY6,, 5 5555 / /  / /  pdyto?kd $$IflY @Q  6((((44 lapdytov$$If!v h555555555 5 #v#v#v#v#v :V lh6,, 5 5555 / /  / /  pdyto?kd$$Iflh @Q  6((((44 lapdytov$$If!v h555555555 5 #v#v#v#v#v :V lh6,, 5 5555 / /  / /  pdyto?kd$$Iflh @Q  6((((44 lapdytov$$If!v h555555555 5 #v#v#v#v#v :V l;6,, 5 5555 / /  / /  pdyto?kd8 $$Ifl; @Q  6((((44 lapdytov$$If!v h555555555 5 #v#v#v#v#v :V lX6,, 5 5555 / /  / /  pdyto?kd$$IflX @Q  6((((44 lapdytov$$If!v h555555555 5 #v#v#v#v#v :V lw6,, 5 5555 / /  / /  pdyto?kd$$Iflw @Q  6((((44 lapdytov$$If!v h555555555 5 #v#v#v#v#v :V l6,, 5 5555 / /  / /  pdyto?kdc$$Ifl @Q  6((((44 lapdytov$$If!v h555555555 5 #v#v#v#v#v :V l6,, 5 5555 / /  / /  pdyto?kd$$Ifl @Q  6((((44 lapdytov$$If!v h555555555 5 #v#v#v#v#v :V l,6,, 5 5555 / /  / /  pdyto?kd$$Ifl, @Q  6((((44 lapdytov$$If!v h555555555 5 #v#v#v#v#v :V lY6,, 5 5555 / /  / /  pdyto?kd"$$IflY @Q  6((((44 lapdytov$$If!v h555555555 5 #v#v#v#v#v :V l;6,, 5 5555 / /  / /  pdyto?kdG&$$Ifl; @Q  6((((44 lapdytov$$If!v h555555555 5 #v#v#v#v#v :V l;6,, 5 5555 / /  / /  pdyto?kd*$$Ifl; @Q  6((((44 lapdyto$$If!vh5 55@ 5 #v #v#v@ #v :V 406,5 55@ 5 / 22 l4 a f4yt7$$If!vh5 55@ 5 #v #v#v@ #v :V 4M065 55@ 5 / 22 l4 a f4yt7$$If!vh5@ 5 55#v@ #v #v#v:V 406,5@ 5 55/ 22 l4 a f4yt1$$If!vh5@ 5 55#v@ #v #v#v:V 4M065@ 5 55/ 22 l4 a f4yt1$$If!vh5 55 5#v #v#v #v:V 406,5 55 5/ 22 l4 a f4yt7$$If!vh5 55 5#v #v#v #v:V 4M065 55 5/ 22 l4 a f4yt7<$$If!vh5O55 555A #vO#v#v #v#v#vA :V l0,,5O55 555A 4ap<yt1$$If!vh5 5V 5#v #vV #v:V l0,,5 5V 54apyt1$$If!vh5,#v,:V l0, ,5,4agZ&p yt1$$If!v h5555U55555 #v#v#v#vU#v#v#v#v#v :V l0, , 5555U55555 4apZyt1Qkd66$$Ifl i o r="'~,U0, $$$$4 lapZyt1$$If!v h5555U55555 #v#v#v#vU#v#v#v#v#v :V l40, +, 5555U55555 4apZyt1Tkd':$$Ifl4 i o r="'~,U0, $$$$4 lapZyt1$$If!v h5555U55555 #v#v#v#vU#v#v#v#v#v :V l40, +, 5555U55555 4apZyt1Tkd#>$$Ifl4 i o r="'~,U0, $$$$4 lapZyt1$$If!v h5555U55555 #v#v#v#vU#v#v#v#v#v :V l40, +, 5555U55555 4apZyt1TkdB$$Ifl4 i o r="'~,U0, $$$$4 lapZyt1$$If!v h5555U55555 #v#v#v#vU#v#v#v#v#v :V l40, +, 5555U55555 4apZyt1TkdF$$Ifl4 i o r="'~,U0, $$$$4 lapZyt1$$If!v h5555U55555 #v#v#v#vU#v#v#v#v#v :V l40, +, 5555U55555 4apZyt1TkdJ$$Ifl4 i o r="'~,U0, $$$$4 lapZyt1$$If!v h5555U55555 #v#v#v#vU#v#v#v#v#v :V l40, +, 5555U55555 4apZyt1TkdN$$Ifl4 i o r="'~,U0, $$$$4 lapZyt1$$If!vh55#v#v:V l0, ,554apyt1$$If!vh5,#v,:V l0, 5,4ap yt1$$If!vh5,#v,:V l0, ,5,4ap yt1$$If!vh5,#v,:V l0, ,5,4ap yt1$$If!vh5,#v,:V lx0, ,5,4ap yt1$$If!vh55%#v#v%:V lF0, ,55%4apyt1$$If!vh55 5g#v#v #vg:V l40, +,55 5g4apyt1$$If!vh555#v#v#v:V l400, +,5554apyt1$$If!vh55 5585 #v#v #v#v8#v :V l0, ,55 5585 4ap2yt1$$If!vh55%#v#v%:V l60, ,55%4apyt1$$If!vh55%#v#v%:V l(0, ,55%4apyt1$$If!vh5 5\ 5 #v #v\ #v :V l: t0%6,5 5\ 5 apyt7$$If!vh5 5\ 5 #v #v\ #v :V l: t0%6,5 5\ 5 apyt7$$If!vh55#v:V l: t0%6,5apyt7_$$If!vh55855@ 5855#v#v8#v#v@ #v8#v#v:V l4: t0%6+,55855@ 5855apFyt7kd\$$Ifl4:֞0L$ d<(#8@ 8 t0%644 lapFyt7_$$If!vh55855@ 5855#v#v8#v#v@ #v8#v#v:V l4: t0%6+,55855@ 5855apFyt7kd.`$$Ifl4:֞0L$ d<(# 8@ 8 t0%644 lapFyt7_$$If!vh55855@ 5855#v#v8#v#v@ #v8#v#v:V l4: t0%6+,55855@ 5855apFyt7kdc$$Ifl4:֞0L$ d<(# 8@ 8 t0%644 lapFyt7_$$If!vh55855@ 5855#v#v8#v#v@ #v8#v#v:V l4: t0%6+,55855@ 5855apFyt7kdf$$Ifl4:֞0L$ d<(# 8@ 8 t0%644 lapFyt7_$$If!vh55855@ 5855#v#v8#v#v@ #v8#v#v:V l4: t0%6+,55855@ 5855apFyt7kdZj$$Ifl4:֞0L$ d<(# 8@ 8 t0%644 lapFyt7_$$If!vh55855@ 5855#v#v8#v#v@ #v8#v#v:V l4: t0%6+,55855@ 5855apFyt7kdm$$Ifl4:֞0L$ d<(# 8@ 8 t0%644 lapFyt7_$$If!vh55855@ 5855#v#v8#v#v@ #v8#v#v:V l4: t0%6+,55855@ 5855apFyt7kd"q$$Ifl4:֞0L$ d<(# 8@ 8 t0%644 lapFyt7$$If!vh55 5@ 5b5b#v#v #v@ #vb:V l4: t0%6+,55 5@ 5bap2yt7$$If!vh55 5@ 5b5b#v#v #v@ #vb:V l4: t0%6+,55 5@ 5bap2yt7$$If!vh55 5@ 5b5b#v#v #v@ #vb:V l4: t0%6+,55 5@ 5bap2yt7$$If!vh55##v#v#:V l4: t0%6+,55#apyt7$$If!vh5%#v%:V l: t0%65%ap yt7$$If!vh5%#v%:V l t0%65%ap yt7$$If!vh55X #v#vX :V lV t0%6,55X apyt7$$If!vh55X #v#vX :V l' t0%655X apyt7$$If!vh55X #v#vX :V l' t0%655X apyt7_$$If!vh5>5C5t555555 5 ,5 b5 5 5 5#v>#vC#vt#v#v#v#v#v#v #v ,#v b#v #v #v #v:V l906,5555A5-5(5l5k5 5 5 X5 5 5 5// p֖ytjkb}kd{$$Ifl9N v<"%(-0=3/8K?A-(lkX/06<<<<44 lap֖ytjkb_$$If!vh5>5C5t555555 5 ,5 b5 5 5 5#v>#vC#vt#v#v#v#v#v#v #v ,#v b#v #v #v #v:V l06,5555A5-5(5l5k5 5 5 X5 5 5 5// p֖ytjkb}kd́$$IflN v<"%(-0=3/8K?A-(lkX/06<<<<44 lap֖ytjkb_$$If!vh5>5C5t555555 5 ,5 b5 5 5 5#v>#vC#vt#v#v#v#v#v#v #v ,#v b#v #v #v #v:V l06,5555A5-5(5l5k5 5 5 X5 5 5 5// p֖ytjkb}kd$$IflN v<"%(-0=3/8K?A-(lkX/06<<<<44 lap֖ytjkb_$$If!vh5>5C5t555555 5 ,5 b5 5 5 5#v>#vC#vt#v#v#v#v#v#v #v ,#v b#v #v #v #v:V l06,5555A5-5(5l5k5 5 5 X5 5 5 5// p֖ytjkb}kd$$IflN v<"%(-0=3/8K?A-(lkX/06<<<<44 lap֖ytjkb_$$If!vh5>5C5t555555 5 ,5 b5 5 5 5#v>#vC#vt#v#v#v#v#v#v #v ,#v b#v #v #v #v:V l06,5555A5-5(5l5k5 5 5 X5 5 5 5// p֖ytjkb}kdm$$IflN v<"%(-0=3/8K?A-(lkX/06<<<<44 lap֖ytjkb_$$If!vh5>5C5t555555 5 ,5 b5 5 5 5#v>#vC#vt#v#v#v#v#v#v #v ,#v b#v #v #v #v:V l06,5555A5-5(5l5k5 5 5 X5 5 5 5// p֖ytjkb}kdM$$IflN v<"%(-0=3/8K?A-(lkX/06<<<<44 lap֖ytjkb_$$If!vh5>5C5t555555 5 ,5 b5 5 5 5#v>#vC#vt#v#v#v#v#v#v #v ,#v b#v #v #v #v:V l06,5555A5-5(5l5k5 5 5 X5 5 5 5// p֖ytjkb}kd-$$IflN v<"%(-0=3/8K?A-(lkX/06<<<<44 lap֖ytjkb_$$If!vh5>5C5t555555 5 ,5 b5 5 5 5#v>#vC#vt#v#v#v#v#v#v #v ,#v b#v #v #v #v:V l06,5555A5-5(5l5k5 5 5 X5 5 5 5// p֖ytjkb}kd $$IflN v<"%(-0=3/8K?A-(lkX/06<<<<44 lap֖ytjkb$$If!vh55#v#v:V l406,554f4yt$$If!vh55#v#v:V l406,554f4yt$$If!vh55#v#v:V l406,554f4yt$$If!vh55#v#v:V l4106,554f4yt$$If!vh55#v#v:V l406,554f4yt$$If!vh55#v#v:V lA06,554yt$$If!vh55#v#v:V l06554yt$$If!vh55#v#v:V l!06554yt$$If!vh55#v#v:V l06,554yt$$If!vh55#v#v:V l06,554yt$$If!vh5 5f#v #vf:V l406,5d5$ 4f4yteH$$If!vh5 5f#v #vf:V l406,5d5$ 4f4yteH$$If!vh5 5f#v #vf:V l406,5d5$ 4f4yteH$$If!vh5 5f#v #vf:V l406,5d5$ 4f4yteH$$If!vh5 5f#v #vf:V l406,5d5$ 4f4yteH$$If!vh5 5f#v #vf:V lA06,5d5$ 4yteH$$If!vh5 5f#v #vf:V lC06,5d5$ 4yteH$$If!vh5 5f#v #vf:V l06,5d5$ 4yteH$$If!vh5 5f#v #vf:V l06,5d5$ 4yteH$$If!vh5 5f#v #vf:V l06,5d5$ 4yteH$$If!vh5 5f#v #vf:V lm06,5d5$ 4yteH$$If!vh5 5f#v #vf:V lJ06,5d5$ 4yteH$$If!vh55#v#v:V l406,554f4yteH$$If!vh55#v#v:V l406,554f4yteH$$If!vh55#v#v:V l406,554f4yteH$$If!vh55#v#v:V l4106,554f4yteH$$If!vh55#v#v:V l406,554f4yteH$$If!vh55#v#v:V lA06,554yteH$$If!vh55#v#v:V l06554yteH$$If!vh55#v#v:V l!06554yteH$$If!vh55#v#v:V l06,554yteH$$If!vh55#v#v:V l06,554yteH$$If!vh55#v#v:V lm06,554yteH$$If!vh55#v#v:V l06,554yteH$$If!vh5-55 5 #v-#v#v #v :V 065t555VyteH$$If!vh5-55 5 #v-#v#v #v :V 065t555VyteH$$If!vh5-55 5 #v-#v#v #v :V 065t555VyteH$$If!vh5-55 5 #v-#v#v #v :V 065t555VyteH$$If!vh5-55 5 #v-#v#v #v :V 065t555VyteH$$If!vh5-55 5 #v-#v#v #v :V 065t555VyteH$$If!vh5-55 5 #v-#v#v #v :V 065t555VyteH$$If!vh5-55 5 #v-#v#v #v :V 065t555VyteH$$If!vh5-55 5 #v-#v#v #v :V 065t555VyteH$$If!vh5-55 5 #v-#v#v #v :V 065t555VyteH$$If!vh5-55 5 #v-#v#v #v :V 065t555VyteH$$If!vh5-55 5 #v-#v#v #v :V 065t555VyteH$$If!vh5-55 5 #v-#v#v #v :V 065t555VyteH$$If!vh5-55 5 #v-#v#v #v :V 065t555VyteH$$If!vh5-55 5 #v-#v#v #v :V 065t555VyteH$$If!vh5-55 5 #v-#v#v #v :V 065t555VyteH$$If!vh5-55 5 #v-#v#v #v :V 065t555VyteH$$If!vh5-55 5 #v-#v#v #v :V o065t555VyteHb4 xxxpppppp000h002 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XVxPJ_HmH nHsH tHJ`J cke $1$a$ CJKH_HaJmH nHsH tHVV h 1$$dBTJ@&5CJKH,OJQJ\aJ,VV h 2$$d@&56CJOJQJ\aJ RR h 3$$d@&5CJ OJQJ\aJ $A`$ ؞k=W[SOBi@B nfh*B*ph"W1" `p5\&_A& 0HTML )Q0@0 pvU_ 1% OJQJaJ<@< pvU_ 2&VD^ OJQJaJ<< pvU_ 3'HVD^H OJQJaJ<< pvU_ 4(VDX^ OJQJaJ<< pvU_ 5)VD ^ OJQJaJ<< pvU_ 6*4VD^4 OJQJaJ<< pvU_ 7+ VD^ OJQJaJ<< pvU_ 8,| VDx^| OJQJaJ<< pvU_ 9- VD@^ OJQJaJ,B, / ckee,g.xaJ22 . ckee,g CharCJKHnn $nf(Web),nf (Web)0$dd1$[$\$a$B*CJKHOJQJph8Y8 2ech~gV1-D M J!J 1 ech~gV CharCJKHaJfH q d d \pTOC h3$d1$@& a$!B*KHOJPJQJ^JaJph6_PK![Content_Types].xmlj0Eжr(΢Iw},-j4 wP-t#bΙ{UTU^hd}㨫)*1P' ^W0)T9<l#$yi};~@(Hu* Dנz/0ǰ $ X3aZ,D0j~3߶b~i>3\`?/[G\!-Rk.sԻ..a濭?PK!֧6 _rels/.relsj0 }Q%v/C/}(h"O = C?hv=Ʌ%[xp{۵_Pѣ<1H0ORBdJE4b$q_6LR7`0̞O,En7Lib/SeеPK!kytheme/theme/themeManager.xml M @}w7c(EbˮCAǠҟ7՛K Y, e.|,H,lxɴIsQ}#Ր ֵ+!,^$j=GW)E+& 8PK!mQtheme/theme/theme1.xmlYMoE#F{oc'vGuرhF[x=ޝzvg53NjHHzZ $ʯI)*E_N&IA!>Ǽ3xN>UWL0Č߫߿z}rx{h9T8T/χ?xY'~3S~O_|w)ӈHt=a+d NG1-RlƁ1RJwT蠯M1K"o he˓ێ½PL-|%EhY7'qP.\L=dqķ3Iofi.ñBRb-JP_pG ݢiKtdӌhFio7;7Q2ȾD>a/Q>XW ˔M_uHq)h +:Viw4rBqϫ"r!2laCbU|!8^8>ܠ,AбVt׎~ls14_=,ɬožTV G"ѦbH'.4x޵w-ϷE|F;v`b3"G 'e\fHO '$i_wp >*8i&LY%\,xҕ= r6f 3Tʅ):ªZKLs&C Mܛ0 [˫p@ע`j۽7 YHxHicT5Ar@HZAZC}i' RQ\m,zo,gQu{Y\,Nר/=L _.̇Y7C6-fSh62"5NHT[X65̫4X%Yֳ2fkhi~tCKF#b +w1m|4`!:U!p5a:~{4mmio ήc8mDJpSǹ橠V1?#Si?3E'pS2W`qB]( 08w nA[s)k8= Aa?R dڒɾcUӽ˲d)#Queb}C!&i0>4S7{z F} 4sKvUKoȳh~1jYUVH5U8Vk;֜L9ŰD ?*|FL "A3>g]dm2iVֵ褽mg b% F m l 8l }l l l )m [m m m n :n qn 222244ZZZZ\g####%0[[[[[[[[[[[[[[[[[[[[[^\" h :$"6%'z*-14T7(;<?I,R\[fTlDvT~l7D,7Ruߛ#t7|@,N\^2}Ѝf8@,&L&7H&UdBw@*0\hR/49RGU\Z\^JeJpy}nҎ< v Ħ   # , B P } v~   f X V H X  d d 2  R p F % H& & ' B( ( ) 6* L+ \W X Y Z (\ :] p^ _ ~ v . R " n b ( f1X4n5t678:$<x=&BF0HrPfjHzػb>%x:[]6__ !$&),/147:<>AIUfo~ !#%')5@IT\`dioqtwz}/BGNv !&1<GR]hrz|          $ ( 9 > B F I M Q U Z ^ i  ~#,b9<EOX^fp:xJLZn~ŭ:ش;7(c98R.cowd>XVCR])7<IlIJJXKLL%MUM{MN^PPbRRS:SSU VVW"X\X%YUZ}[*\"]R]x]]k^"_E``a,bgcddde1fg,hohhh]iijklllm!n op}qqqrst}tuu8v3wtwxSy,z|z?{o{{||}~ Lҥ<fJx<j :%6,\158<EJfOVX^^^^v___``Naa0bbcddeefLg(hhihii.jLjkk4lBmmnn>oopXppq2rr2sst4uu8vvwfww4xXxJyyJzzzD{{{{}\Ph8px.tDr*`2X>n$^Fl@d  &+2|7:GIQ[Ldk.sxxX8@d '"/|/4b99@IR\Z\_ ``8`F`p`````aaDa\atavaaab,bXbrbbcceXefeveeff\gjgzg"hh6iiiijjDjRjjj>kkkkklFllll2mZmmmm$n`nnnnoBonoooop(pNppppp(qRq|qqqq.r^rrrr$sNsss tHtttuNuuuvBv|vv.www"xzxx0yyyzLzjzzz{{{{|@|r||| }<}}}~j~~~~$VtD؀pj‚tH\H$Hև">~VtLf֋DҌJp4tȎ<t܏F`ސDlȑD~8V2nĔ:•LjږH|*jژJL48Z4PН(hȞ<vڟ6dʠVơ @ x ( J z & V ̞   P ğ  Z ֠ 2 B d Ρ d  V z < R ֤ r  ؼ > , 6  > \  f& , 5 Z; B @ j l Ҡ Ԡ   8 : Z \ | ~ ȡ ʡ $ & N P x z ܢ ޢ   $ & F H n p £   2 4 T V v x < ȿ  * B L  z >  r 8  f   r 8 `  ,   % l% v% % T& & 2' ' ( n( ( F) ) * * , 9 C G K R \W |W ~W X X Y HZ Z [ \ B] ^ ^ t_ ` h hv ~ v & , Ĕ <  f @ 4 l | j >"(*.455F778:888.:;h;z<< =(==?xBB.CxCCDD DDDrDDDDREEGGHHH~HIOV \ahj"lqdxD:b$Φΰl<JXhvF 8b>P^l| (PfJ8 2#%|%&&(0)*2,-6/0"2t3L5B6677*8x:IT?ABCDEFGHJKLMNOPQRSUVWXYZ[]^_abcefghjklmnprsuvxy{|~      !"#$%&'()*+,-.0123456789:;<=>?@ACDEFHIJKLMOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuwxyz{|}~     "#$%'()*+,-./023456789:;=>?@ABCDEFHIJKLMNOPQSTUVWXYZ[\^_`abcdefgijklmnopqstuvwxy{}~                 ! " # % & ' ) * + , - . / 0 1 2 3 4 5 6 7 8 : ; < = ? @ A C D E G H J K L N O P R S T V W X Y [ \ ] _ ` a b c d e f g h j k l m n o p q r s t u v w x y z { | } ~  3qtvSWt#&C# ' ) f i  ! ŕǕr.1L[_zƢբע.2M\_pM\^HWYȥʥ1@Bfuwɧ˧ ":IKjy{Ԩ ^moϫѫZik³۳%46O^azmXXXXXXXXXXXXXXX"""t"t"t"t"t"t"t"t"t"t"t"t"t"t"t"t"t"t"t"t"t"t"t"t"t"t"t"t"t"t"t"t"t"t"t"t"t"t')5MO\ch%,4LP^!!! !!! !! !! !t  ,b$#ѩD'Tb'ij@ (  bB  S Dg #" ?B S  ?H0(  m.. t OLE_LINK1 OLE_LINK22 OLE_LINK9 OLE_LINK10 OLE_LINK11 OLE_LINK12SumNumffK : :  nggK @ @  n{PQRTSTUVTWXYZ<[\<]^<_`|ab|cd|ef|gh|ij|kl|mn|op|qr|st|uvw|xy|z{||<}<~|<<<<<<<|<<<DĝDĞDğDĻDĺDĹDĸDķDĶDĴDˆijÈDĈIJňDƈLjȈɈʈlczczcadpdddd?.@AAzAAAoBB*CCbDDDDFF G!HHHH IBIsIII JAJJJ5KKL?LL M3MMM?NO6OTOWYZ\\_d hXhh|^p-mB  >7I(~v~Ó*d~5 Hj"7b%R>ScuY 5Tn      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyzqcccfd}dddd?4@GAAABuBB0CChDDDEFFG'HHHHIHIyIIIJGJJJ;KK LELLM9MMMEN OBI2~~͓5o@O#q)>i,YEZj|d 5Tn  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz9z*urn:schemas-microsoft-com:office:smarttagsplaceB{*urn:schemas-microsoft-com:office:smarttagscountry-region>1*urn:schemas-microsoft-com:office:smarttags PersonName;s*urn:schemas-microsoft-com:office:smarttagschsdate -010204050708091101215171899191984199922020002001200220042005200720082010201123283304579DayFalse IsLunarDate IsROCDateMonth ProductIDYeareVgbNT~l{z{{{{z{s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s&$%$#' ) s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s&$%$#' ) s&$%$#' ) s&$%$#' ) s&$%$#' ) s&$%$#' ) s&$%$#' ) s&$%$#' ) s&$%$#' ) s&$%$#' ) s&$%$#' ) s&$%$#' ) s&$%$#' ) s&$%$#' ) s&$%$#' ) s&$%$#' ) s&$%$#' ) s&$%$#' ) s) ' #%$&$s) ' #%$&$s&$%$#' ) s&$%$#' ) s) ' #%$&$s) ' #%$&$s&$%$#' ) s&$%$#' ) s&$%$#' ) s&$%$#' ) s&$%$#' ) s) ' #%$&$s&$%$#' ) s&$%$#' ) s&$%$#' ) s) ' #%$&$s&$%$#' ) s&$%$#' ) s&$%$#' ) s&$%$#' ) s&$%$#' ) s&$%$#' ) s) ' #%$&$1(+s&$%$#')s)'#%$&$s)'"#%$&$1(*1(*s)' #%$&$s)'# %$&$s)'"# %$&$s)'# %$&$s)'# %$&$s)'#%$&$s)'#%$&$s)'#%$&$s)'#%$&$s)'#%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s) ' #%$&$s)'#%$&$1(,s)'!#%$&$s)'#%$&$s)'# %$&$s)'#%$&$s)'#%$&$s)'# %$&$s)'#%$&$/0QRbcijpq$%HI_`yz./FG`atu-.@ASTefyzFGtu jrt  "'3]^`aefht$&,-/0457Co p t u w + , I K M N ]y"#*59:;>@EIRThnrt}*+=>OPBCNOY[\]^_lq~   01WXlnopqrxy   3568oqrt    o q r t %!'!)!+!>!@!B!D!b!d!f!h!!!!!!!!!!""")"+"-"/"""""""""""""""""J#L#N#P#######################$$$$N$P$Q$S$$$$$$$$$$$$$$$% % %%%%%%%%%%%%%%&&&&;&<&I&J&`&&&&&&&&&&&&&&&&&&&&&' '''(')'8'9'h'i'v'w'''''''''''''''''''''(((((("(#(_(b(d(o(u(w(x(z((((((((((((((((((( ))")#)G)I)J)L)M)N)W)])o)p)v)w)))))))))))))))))))))))))****.*0*1*3*4*5*O*P*v*x*y*{*********++++%+&+A+C+D+F+G+H+O+P++++ , ,,,-,/,0,2,3,4,;,=,,,,,,,,,/-1-2-4-5-6-G-H---------{.}.~.......................... / / ///!/"/$/7/9/:/>6>8>b>d>>>>>>>>> ?#?%?)?*?D?H?L?M?j?l?z?|???????????m@n@@@@@@@@@@@AA3A5AEAFAMANAtAvAAAAAAAAAAAAA B B$B&BABCB[B]B{B}BBBBBBBBBCC-C.C8C9C\C^CvCwCCCCCCCCC(D*DIDJDQDRDoDqDDDDDDDDDDDDDEEEEEYE[EkEmEEEEEEEEE`FbFFFFF GG7G9GPGRGXGYGGGGGGGGH HHHH$H&H5H7HDHFHSHUH}HHnIpIIIIIII4J6JfJhJ}JJJJJJJJ(K*KkKmKKKKKKKKKKK L L+L-L>L@LgLiL{L}LLLLLLLLLLLLMMM&M;MBMDMQMRMMMMMPPP P*P+P8P9PEPFPQPRPfPgPrPsP~PPPPPPPPPPPPQQQQQQ&Q'Q0Q1Q8Q9QBQCQIQJQ_QaQjQkQ}Q~QQQQQQQQQQQQQQQQQRR"R$R5R6R@RARRRSR`RaRnRoRRRRRRRRRRRRRRRRRSS!S"SCSESvSwSSSSSSSSSSSSSSSSSSSSSTT"T#T'T(TLTMTQTRTjTkToTpT}T~TTTTTTTTTTTTTTTTTTT UUUU%U&U*U+U=U>UBUCUyUzU~UUUUUUUUUUUUUUUUUUUUUU V VVV(V)V-V.VsVtVxVyV}V~VVVVVVVVVVVVVVVVVVVVV W WWW'W(W,W-WIWJWNWOWZW[W_W`WWWWWWWWWWWWW'X(X+X,X=X>XAXBXhXiXlXmXxXyX|X}XXXXXXXXXXXXXXXXXYYY Y$Y%Y(Y)YBYCYFYGYbYcYfYgYYYYYYYYYYYYYYYYYYYZZ3Z4Z8Z9ZYZZZ[Z]ZeZfZiZjZZZZZZZZZZZZZZZZZ[[!["[9[:[=[>[][^[a[b[[[[[[[[[[[[[[\\\/\0\4\5\\\\\\\\\\\\\\\\\ ] ]]]]]!]"](])]-].]<]=]A]B]q]r]v]w]]]]]]]]]]]]]]]^^^^^^:^;^>^?^L^M^P^Q^v^w^z^{^^^^^^^^^^^^^^^^^__ _ _0_1_5_6_=_>_B_C_d_e_i_j_________________________$`%`(`)`5`6`9`:`F`G`H`J`````````````````)a-a9a;a?a@aWac c cccccdddddielemeefff f!f$f%f:fBfDfEf^f'h0h1hMhiiiiiiiikkkllll&l)l,l-lQlSlVlWlollllllllmmmmnnnn nxo{o|ooooooooooooopAB]cpq&'*+-.PQUVgÜǜȜӜ՜؜ٜ #$8,018:<=^Ҡ֠נǢϢѢ)-.=?BCWVZ[prtu/'MQRitvw&8<=Oadex˫իݫޫ­EHIbҮڮۮ012A39:P589S³ֳ !#Ifijz|~$'(=>WX]^5HIghuvθϸ,ڹݹ޹|ϼԼռCFG\]`av467C~'`cdzRTUh?Z\_`x [^_iknoHRTi ]ghz+,67G3befz#$'(IKNOqs}~1367M jmn!$%? #\^_rEMNZ'*+EGMNa^abz|.Mbcefu}!"@KNOi #ruv-^abr@EFTACDP8<=Q$-01G"#?(+,G;twxuxy; %         & @ A D E V         . 1 2 > S V W u    !;.12EGJKe #$Lenohlm{ !1367Q    :!>!?!W!o!{!|!"""$$$4$<%>%?%U%&&&&&&&&'''''''''''')))0)@*G*H*Y*****++++++++,,,,>-A-B-Z-----V.Y.Z.k.m.p.q...... ///0/@/U/X/Y/e/h/k/l//000011111111222244444p444444[5d5e5s55555Z6b6c6t66666777#7/78797I777778!8"8488888u9x9y99d:f:g::;;;;Y<w<y<|<}<<===-= ???%????@@ @ @ @AAAA!C$C%C:C;CgChCjCkC|C,DADBDDDED[D\DzD{D}D~DDDDDDDD`EcEdEsEEEEFF F FF~FFFFFFFFGGGGHHHHIII$I&I)I*I>IIIIIIIIIKKKKKKKKK L LLL!LPLQLRLiLLLLM-NGNINKNLNbNOOOPPPPPPQQQ RRR$RRRRRRRRSTTTTV V V-VVVVVWWWW?YCYDYZYxY{Y|YYYYYZZZZZ\\\]]]I]Q]R]g]^ ^^^^^^^8_L_M_Q_R_a_____aaeafasauaxayaaxb{b|bbFcJcKc]c_cbcccycccccddddee e eeeeeefffffYg]g^ghgjgqgrgugvgggggggggggg;h>h?hMhhhhhi i ii/i7i8iOiiii jjjjj kkk%k:n=n>nVnoo o&o'o2oUoqoso|o}ooppppppppCqGqHqfqqqqqqqVrZr[rlrrrrrssssssstNtVtWtlt$u,u-uBuuuuuvvvvw w w#w+w4w5wJwwwwwoxwxxxxyyy y!y1yyyyyyyyyyzjzpzqzz{{{{l{u{v{{|||}}}}}}}1~E~G~T~U~h~"#-/23K]dewր؀߀ׁځہ]abgikl|ςւ؂ۂ܂mpq'*+@,=@AZňƈ܈#'(57DEW1ɋˋ̋֋Ǎ  )=>AB[ "O\]u̓  "$,-H]acvږޖߖrvxCJK]٘ܘޘ /01DÙʙ˙י!"6 (9CDU˛̛͛%'*+BٜڜۜܜOPQc*JKX[cfghz?BCWҟӟԟQ_`rĠϠР4¡ġߡ"$+,Ez ?FGWmpq̣ϣѣ$>?Z˥ΥХ)hkmjmnħƧǧȧڧ7:;MUXYn|ĩȪ˪̪cgiyѬլ֬ܬެ!"3EIJaclm}˭̭ڭ+ܮݮ߮  *aef~')./359:Lǽֽ׽þݾ?DEPRTUc-57Spqr\^_xgjk#$12IJ\]  "#CDHI\]uv_bct +,89:;I  !./0>Yuv  +,-.D[\]sl{|/;<Bw|} %j~nrs3cfgrJe"k|}RWXkbefyNPQm 5Z[]^xFg      4 5 ]$!;!&H&I&L&M&V&W&Z&[&`&a&d&e&m&n&q&r&{&|&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&'''' ' '''''''$'%'(')'+','0'1';'<'@'B'I'N'O'S'T'^'_'c'd'u'v'z'{'''''''''''''''''''''''''''''''''''''''''(((( ( ((((((( (!(%(&()(*(2(3(6(7(<(=(@(A(F(G(J(K(P(Q(T(U(W(X(\(](g(h(l(m(v(w({(|((((((((((((((((((((((((((((((((((((((((((((((()) ) )))))")/);)<)=)@)))**8*9*^*`*a*b*d*e*h*i*t*u*****(+++E+G+J+K+S+T+++++++++++++++,, , ,!,#,1,2,O,R,X,[,o,q,t,u,w,x,,,,,,,,,,,,,,,,,- - - --- -"-&-'-)-*-w-y-}-~-------------.'.(.>.@.D.E.N.O.f.................// /$/&/*/+/-/./w/y/}/~///////////0 0 0000000000000000000 11111+1,1w1y1}1~111111111'202L2P2Q2^2_222;3@3B3F3G3K3L333333333333334444#4$44444444444445 5$5%5(5)5l5n5r5s5{5|5555555555555556666 6 6-6.686<6P6R6V6W6[6\6i6|6666666666666666667777 7 777777 7$7%7)7*7t777777777777777777788-8/838487888]8_8c8d8h8i8{888888888888888889999"9;9=9A9B9E9F9999999::(:*:.:/:2:3:B:J:V:Z:[:b:c:::::::;; ; ;;;=;M;^;d;f;j;k;r;s;;;;;;;;;;;;;;;;;;<<8<Q<T<n<p<t<u<y<z<H=J=W=X=k=m=n=q=x=y=|=}============>>>>?>A>D>E>b>d>g>h>>>>>>>>>>>????#?$?J?L?P?Q?z?|???????????????????-@.@D@F@@@AAAA A!A.A/A0A1A@AAAyAzAAAAAnBoBBB/C0C7C_CCCCCCCCCCCCCCCCCCCDDDDDFDGDaDbDgDhDDDDDDDDDDD2E3EOEQETEUEWEXEsEuEEEEEEEEE F F8F9FFFFFFFGG/G1GKGLGjGlGzG|GGGGGGGGGGGG H HHHHHH H!H&H'HHHHHHHHHHHHH I III6I8I;IL?LDLELyL|L}LLLLL M MMM2M3M8M9MhMMMMMMMMMMMMMMMMMMM>N?NDNENNNOO O O5O6O;OT?TITKTSTTTjTkTTTTTTTTTTTUU#U%U@UAUVUWUUUVV?V@VpVqVVVVVVVVVVV^W_WeWfWWWWW0X1XSXTXvXwXzX{XXXXXXXXXXX0Y1Y7Y8YYYYYYY2Z3Z8Z9ZYZZZ_Z`Z,[-[}[~[&\'\L\M\\\\\\\\\]]]]]]%]&]]]]][^\^`^a^i^j^____m_n_______``````` `)`*``````a8a9afffffffgggggg9h:hHhIh`hahhhhhhhhhhhhhhi~iiiiiiiiiiDjEjIjJjjjjjkkkkkkkkkkkk%l&lHlIlMlNl_l`lflglllll!m"m(m)mJmKmmmmmmmmnnn#n$ncndnnnoo.o/o`oao{o|ooooopppp p pppcpdppppppppppp"q#q'q(q0q1q7q8qvqwqqqqqqqqqqqqqqqrrPrQr_r`rrrrrsssssstt`tatotptttttttttuu!u"u>u?upuquuuuuuuuu vvKvLv{v}vvvvvvvwwwwww)x*x\x]xxxxxxxyyyy!y"y;yGH`akn1278uw{|-;STefghtuvw     !2356KLNObcef~#&01BCEFUVXY~   ;<>?XYabjkmn !#%&1579;<IJLM[\^_pqst:;BC45<=*+23pqxyVW_`ijx{#$,-@CFGPQ%&ijstghpq|MNWX45>?RS\]|}./89`c%&/0$%./ajmoz                          > A k o v x 5 9 @ B z |   SW^`imuw@BKM=AIKhltv%)13W[dfUYbd  >@CEJLdhqs 6:CErvgksuCGPR $-/hluw    !!!!!!!!N"P"X"Z"""""=#A#J#L#####$$$$m%n%%%%% &&&&&&&&i'm'v'x'(( ((p(t(}((((((((H)L)U)W))* * *L*P*Y*[*****J+N+W+Y+++++,",+,-,*-.-7-9-y-{--- ........7/;/D/F///0000j0n0w0y0/131;1=1111172;2D2F22222333333334!4*4,4l4p4y4{4)5-565855555566 66667777788888888T:X:a:c:;;!;#;;;;;S<W<`<b<<<<<<<<<&='=)=*=c=e=h=j=m=o=J>N>X>Z>u>y>>>>>>>>>>>>??? ? ?%?'?,?-???wDxDHHII+I-I6I7IEIhIkImItIuIIIII$J&JeJgJjJlJuJyJKKKK)L.LLLLLMMMM?NENLNMNNNNN#O)O0O1OOOOOPPPPQQQQSSSS>TDTLTMTUUUUUUUU1V7V?V@VVVVVW!W+W/WWWWWXXXXXY^YgYhYYYYYZZZZZZZZ=[C[L[M[$\&\+\/\\\\\^]d]l]m];^A^J^K^________>`?`C`D`M`N`````aaaabbbbc cccccd dtdzddddddd7e=eFeGef fff[f]fefifffff}gggggg8h9hhIhMhhhhhfiliiiii5j;jDjEjjjjj6l?PQPQÛśLNoLP!"!#)*8;>?CEǼ˼μϼ   _cfgýƽǽ$(+,mnpqtuptxy/378"#aeijlpuv!%*+[_delpuvvz gkpq*.34lpuv<?y{x|#',-X\ab%&+-    GHJKPQPTYZ$',-#$tx|}W[`a9=BC`dij;?DE15:;mn|}!&'bfkl*.34@DIJ!&'knJNST!'(>BHIGHKLTV  y}  %&~?CJK '(vwyz"&-.15<=mqxy58eipq26=>  vzJKWY  26=>nosu:>EF+/67y}RSUV]^OSZ[ '(\]bd     ! ( )     1 5 < =           4 7 > ?       59@ATX_`xztv((,,,, 9"9DDXXXXXXXX[[\\]]>^A^^^bbeeggsivigqjq^sasuuBvEvvvvv z z4|>|Չ؉:=j֐ِ ̮ͮOP  "%45CFNQtx{|  QRUVac.267oswxټܼ߼SW[\ڿ޿#',-&(x{\`ef159:%)./IMRS15:; %&quz{34?A"##$X[`a  &')*/0TZnr$(&9IPXYgiqrwx:>AB  =@CD9=@Axy  !"%&46;<   34hioq+,UV[]  @FIKLM            yz~469:OP"#,>  \+^+m+~+++++p,s,5555555555559999";#;,;.;LAMAVAXAGBHBTBVBII#J$J.J0J`LaLpLrLNNNNOOPPPPPPRRSSSSSSTTUUUUXWYWqWsW|WW/XHX_XbXYYYYYYYY|]]]]]]M_T_W_Y_p_t_bbbbbbggggghPmRmSmTmWmYmlmmm{m}mmmmmunxnnnnnnn?oDoopppppppppuvv vvvf{m{q{s{{{|2|d|e|j|k|||||}}}}c~e~!$ghopLODŽȄ̈́΄gj ݋ދÐAD_c#&>AȔ˔:=>?@DE`cdghwxØĘԘ՘  (+,/0CDadehikn xzdg\_""R#U#Y%\%@'C')),,%2'2D7G799>>DD1F3FFFFFvGxGHHIIIIIIOO[[ubbBfVgSlllmooo9pMpppqv?wXww yey{{~~%/Ɖ/DԐBƖS ڙqx')+-RU՜:ϠǢ&rJt{aIQhuϸTZ,;Cb$IKrsnxt~&.ce+-(rtu  jt""'')):9s99:<<AA?CNChCjCBDDD{D}DDDIIzRRZZ]^#d-deeff oroppqqVrrr~s$uuvww)woxxl{{|}} ~ ~F~чۇ%;ER\SZƐАƑΑ $ZOW٘-Ù  7tz˛ȜڜMOKY[dfҞҟOQ Ġ͡"=?kmɣ̣ڣ˥ڥhwhjħ'0ѨSUz|coެ7j-/u?D?y)o~L\AjQ[a(d(++E-I-3262V3X33377Q8T8z9}999::>;@; ==>>>>CCoDsDDDKK{O|OQQ5Q8QQQQQQQQQ_RbRRRRR'S*SDSGSdSgSkSnSSSSSSSSSSTUUaVdVVVWW.W1WWWCXFXVYYYYY*Z-ZTZVZ\\]]``b```1d4ddddegg+i.i4k7kCkGkhkjkoo{p~prrtttt;x>xzz}}džʆGJ"TUgh VZ؜ܜРӠMRפڤ:;HI"%mq~ù_b03or ru6;GKPUX]8>#&GJeh OR      ) , : = F I U X g j s v }    y | ?BBE,/!!M"P"##k(m((())))**--!-#-x-{-111111}5~55555g=j= K KKLOOP!PHQJQ{U}UWWoXqX$_'_m_p_``2a5affffhgkgkk*p,pKpMpppvv\w_wwwwwwy}yJzLz{{g~k~ik'*BE+-(*PSVY     ~25`cآۢ36`c(+gj05Ǻʺ#)=@DGlr~KNEHIKlo 8;ps35'*cepr}jl          ce9<    &")":&=&''=<A<AA.A5A=A@A$B'BKBNBhBkBBBBBCCBCECvCyCCCcDfDDDEEFFFF)M,MQQ2R6RSSWW;X>X\\llmm1m2momtmmmqqsstt܁26^c-2]`uxJN>B  ACeh&*ĺǺ RT<?  ru%(CForXZmu{~RUkn!$$$ &&& ''''E'M'N'T'U'['\'j'''''''''''''''' (5(=(>(D(E(K(L(Z(((()#)$)')C))))****5****+++ +'+,,f--.-...L/q//0001121W111v223 333@3H3I3O3P3V3W3e33333333333333334048494?4@4F4G4U44445"5G5J5h5n5o5r555588G<M<<< ??@@NCPCoCqCDDDDEE^E`EEEEEMM,N.N.O0OQPSPiUmUWWc#ceegghhkkmm[p^puuu|y|||)}-}Y}Z}|}}}}D~H~~~~~~~;?'+STw{€GKŁɁ)-ILтՂfjƒރ#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 N CI##,,..,21244668889*;1;`;f;%?*?DERGYGIIKKM0MMMOPP+PFPgPPPQaQ~QQQRwSSfBfiimnxooooqrrrttuvBwXwwwx yhyyzBzzz||}~~~~~ Ɖ2YČ1DSt ˒v3BƖ48S#Ü՜,:ҠǢ)?VrMtf|'G^|.G3''++V.m.U/h/?@EFI&IaauaFc_cdeYgrgii ~G~/]i#7O $٘˛'Kf̣˥hƧ7fEcܮ )5ǽ?R$J 9,jctk}!x!&' u]yO[/+<     2  TpIl1OYT~TAXupRk*6 ?? ?UU~ddg~u~с*Ḃѓғ&×֗.C,O#Q˚EśӛIN^wӜ (.CGW]qڝ#žўמ <WouΠԠ 17QWsyˡϡAGouBHУ6<kʤФ/5nߥ (BU̦Ҧbߧ :djΨԨ X^ҩ)<TkqϪ 5;U[v$6<Pc~̬Ҭ39Oĭʭ'-HNdͮ28`yү +1F[nðɰ(.GMjpб8<NThnŲ߲26GUyгֳ DJouƴݴ$DXrxĵ޵+1HNek}Ŷ28U[qwͷ"(;j}ظ (;OUpvԹڹ"/;Ljmٺܺ$3cfƻһnqju x<(F(U())S,,,19F9U9o:~:;DDXXXX2^A^^^ __$_bc ccevvH|M|a| ΐِ;sە5F[iϖ6Ylʗח#6CXkȘߘ#0EVl}ͮPr %4'*Z_PXR]FK]k~Jl~Z`{    >      P W   - : F  tz"  2+n+x+~+++g3355NOTT3UUUUVXWsWWW/XHXNXYY]]T_Y_bbggTmYmppv vm{s{2|8|J|Y|e|u|||hpȄׄ…:@DE`hwxĘӘ՘  (1@Daikn FGtu+ I K ]_x  :E`lwxȘИ՘ (5=Dakn%w"o>v\!){jXkvSz @0Y<p;}0:bEKC =Ȕ pOd'~UB 'Yk/)2<WC/J78h_|u:.;B]0=a\>*po@`PaRCFP6Gpl5GRpbH"jvSz pOd'7NG;poHSaRCP~KC Hy){5G/)%%                ^                NJ                        ^        .                        ^                                d                        تj                                                D        ^        6Zmr85:dt}Z~QX9bdrf?(U!Y]TyU$r%{K8_R\uL`+p1z . 4 Q [s )}  3 ?t > 4 W zX e t "> G Q U f 6L(= =Y  N^a<Kqyc)k:2AM[ '67\ e}{,s-c+\`@WjWEw::NA[eeHKZZc!~MQR75 8RYd[YaM l X!t!"$",>"c"R##,#%$6A$/i$~$%<%[%mc%&-#&8&/'@'m' (%()0@)L)])Zi)~***\*c*f*++$+%&+T5+t+D),m2,H,\,a -*8-o-*{-K&.B.*565D56 6N6F6"P6t6(7v;7J7m7 88h88s>8md8 99B9U9j[9^9f9t9w9z::';0;8u;Dz<=M=m=>!j> ?"?>?c?!Z@Yb@c@&~@%C(CDWDEg'E/EAENE^EXGtGHPHTH6qHrHI@IoI+~I #J&K-hK!qK{KOL%VLhMyM)#M*M2M*pMNCCNIN;NFFO~P*P4PrFPHPDLP;VPXPqCv!7.eOlzW{v9UAWa]rL;@QN#}DMb%P"w#G^v|7LS`cO{8R;z-P'/jnptx@BUCU(vd*ZaK,t6wL#raPD-mvx8KoP& [U|*m^y9QO04A?0FNqyMA %/ANB$I",JX,8q`Y^4E?OO3P9!r}wGS;qdr`A>L2X$~EMie"lD;h3wy{<` s_ ,1 ~=TZ#BT^RpsMbaknt<$'@6is#lvqzn&B'x ?l#qt37@iv,<X!03cDBLq{A+X*#z$[9]@AzU=XFH JLUC+8_.(LRGvWh_jqyW|31Y=g8#).:xS\@Uu> % Q "[HTQll;%My.<Kew|3uC@DF#\n+r.:YD#ABD'X@ Fk=DYbekf-0o4jg}YEfd [4fi2 3|>gr; 0FS&L;\0k OfS"aDu]z'H40@ Z<FkLM%eZnrs;W['cmu e"b+yUW c1 J@O-v'lHuNt$)%`@\nkbqMty|R#*6ZPk^2 !N"+_j JAgUeYnzJ)^0DPZg^;PRUc-g7%Bexz%R8H+T[nt"(,|'rt$C>Ixx-Qujp=ABY_iTMXckqry~mXsix4r.<S]zj'#QQXMAl A(9>G>\gbwij$g*v2 5#{1'"(pCYU'S~>gzx\-I<\@Hh HN%EFG]jpq.>Ubmm`````````>``H@`N`@`~````````X`b`|`````(``````L```f`p`r`z`|`~````````` UnknownwangdanG*Ax Times New Roman5Symbol3. *Cx Arial;= |8ўSOSimHei;([SOSimSun-= fN-= |8wiSO7.@ Calibri7K@CambriaMCentury Schoolbook;Wingdings7MarlettWKingsoft Phonetic PlainAE  eck\h[_GBKўSOG=  jMS Mincho-3 fgA BCambria Math 1 hi}O1'YS' S' !-!),.:;?]}    & 6"0000 0 0 00000 =@\]^([{  0 0 00000;[i55 3qHX ?8&2!xxhp322%                           ! " # $ Oh+'0`   ( 4@HPXhpNormal32289Microsoft Office Word@|@d @B9S՜.+,D՜.+, X`x www.xunchi.com' 5  8@ _PID_HLINKSAtZ[t*F:\?Qz&Ot\13 NSOuir;Sf[xvzVE&OtcWS.docA'%http://baike.baidu.com/view/3299.htmA $%http://baike.baidu.com/view/4005.htmA !%http://baike.baidu.com/view/2398.htmA %http://baike.baidu.com/view/9027.htmAR&http://baike.baidu.com/view/36470.htmAY&http://baike.baidu.com/view/42485.htmA %http://baike.baidu.com/view/2535.htmA %http://baike.baidu.com/view/2607.htmA %http://baike.baidu.com/view/3784.htmA  %http://baike.baidu.com/view/8345.htmA  %http://baike.baidu.com/view/1554.htmA [&http://baike.baidu.com/view/19319.htmAS&http://baike.baidu.com/view/20509.htmAT&http://baike.baidu.com/view/30777.htmA  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~                           ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~                            ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~                            ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~                            ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~                            ! " # $ % & ' ( ) * + , - . / 0 2 3 4 5 6 7 8 : ; < = > ? @ ] Root Entry FpCN9_ Data  }1Table WordDocumentnSummaryInformation(1 DocumentSummaryInformation89 CompObju  F#Microsoft Office Word 97-2003 ĵ MSWordDocWord.Document.89q

百度 搜狗 360搜索 陈德容说你们骂我骂轻点 警方通报男子地铁内虚假搭讪 港口航运板块短线拉升,凤凰航运、北部湾港涨停 经济学家:世界正在摆脱美元 2月鞋服配饰品牌TOP15,点击查看通勤美学|世研消费指数品牌榜

      <code id='5074a'></code><style id='1e363'></style>
      • <acronym id='fd0aa'></acronym>
        <center id='f92f7'><center id='acbe5'><tfoot id='0ddce'></tfoot></center><abbr id='537be'><dir id='4ea47'><tfoot id='ed419'></tfoot><noframes id='a287e'>

      • <optgroup id='1b876'><strike id='efc5a'><sup id='4847f'></sup></strike><code id='89b1d'></code></optgroup>
          1. <b id='a2ca6'><label id='ed5c6'><select id='31a24'><dt id='f7732'><span id='9a34f'></span></dt></select></label></b><u id='8b78c'></u>
            <i id='18d73'><strike id='c827c'><tt id='a4cb3'><pre id='72461'></pre></tt></strike></i>